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Abstract 
Objectives 
To determine 1) mortality and morbidity in people with bipolar disorder, and 2) the impact 
of maintenance medication on relapse/reoccurrence and adverse events.  
 
Methods 
Objective 1: I conducted a meta-analysis of studies examining mortality in bipolar disorder 
populations. I then carried out a cohort study in United Kingdom primary care electronic 
health records to understand rates of mortality and morbidity in bipolar disorder relative to 
the general population.  
 
Objective 2: I completed a network meta-analysis of the efficacy of maintenance mood 
stabiliser medications (lithium, valproate, olanzapine and quetiapine) in preventing relapse. 
I then carried out a series of cohort studies in primary care electronic health records. These 
studies examined 1) the effectiveness and tolerability of these medications, 2) the rates of 
renal, endocrine, hepatic and metabolic adverse events, and 3) the rates of self-harm, 
accidental injury and suicide. Propensity score methods were used to address issues of 
confounding.  
 
Results 
Objective 1: All-cause and cause specific mortality was elevated in people with bipolar 
disorder (summary standardised mortality ratio 2.05; 95% CI 1.89 to 2.23). In a cohort of 
17,341 with bipolar disorder, mortality rates increased from the mid-2000s relative to the 
general population (hazard ratio increased by 0.14 per year; 95% CI 0.10 to 0.19).  
 
 4 
Objective 2: Trials comparing lithium, valproate, olanzapine, quetiapine and placebo did 
not show superiority of one drug. In the electronic health records cohort studies individuals 
prescribed lithium went for longer before treatment failure (for example valproate had 
hazard ratio 1.20; 95% CI 1.10 to 1.32 compared with lithium), had increased mild (but not 
severe) renal failure (hazard ratio for valproate: 0.56; 95% CI 0.45 to 0.69 compared with 
lithium), hypo- and hyperthyroidism and hypercalcemia rates. However, they had lower 
rates of clinically significant weight gain (hazard ratio for >15% weight gain with valproate: 
1.62; 95% CI 1.31 to 2.01 compared with lithium) and there was no difference in 
hepatotoxicity, cardiovascular events or diabetes mellitus rates. Additionally, people taking 
lithium had lower self-harm (hazard ratio for alternatives: 1.51; 95% CI 1.21 to 1.88 
compared to lithium) and accidental injury rates. 
 
Conclusions 
Bipolar disorder is associated with increased mortality and morbidity, and the mortality gap 
with the general population has widened in recent years. Despite limited trial evidence, 
lithium appears to offer the best opportunity for mood stabilisation. Lithium is associated 
with increased renal and endocrine dysfunction, but these risks are offset by the potential 
of more frequent weight gain with alternative drugs. Furthermore, lithium may be 
associated with specific anti-suicidal effects.  These risk and benefits should be considered 
when individual treatment decisions are made. 
  
 5 
Acronyms 
ACEi – angiotensin converting enzyme 
inhibitor 
ACU – acceptable computer usage 
ALT - alanine transaminase  
AMR – acceptable mortality reporting 
APC – annual percentage change 
AST - aspartate aminotransferase 
BMI – body mass index 
BPD – bipolar disorder 
CKD – chronic kidney disease 
CVD – cardiovascular disease 
CVE – cerebrovascular event 
CI – confidence interval 
COPD – chronic obstructive pulmonary 
disease 
CPRD – Clinical Practice Research Datalink 
DSM – Diagnostic and Statistical Manual of 
Mental Disorders 
ECT – electroconvulsive therapy 
EHR – electronic health record 
EMIS – Egton Medical Information Systems 
FDA – Food and Drug Administration 
FGA – first generation antipsychotic 
GP – general practitioner 
HR – hazard ratio 
HES – Hospital episode statistics  
ICD –International Classification of Diseases 
IHD – ischemic heart disease 
IPTW – inverse probability treatment 
weighting 
IQR – interquartile range 
MI –myocardial infarction 
NHS – National Health Service 
NICE – National Institute for Health and Care 
Excellence 
NMA – network meta-analysis 
NSAID – non-steroidal anti-inflammatory drug 
ONS – Office for National Statistics 
PS – propensity score 
PYAR – person-years at risk 
QOF – Quality and Outcomes Framework 
RCT – randomised controlled trial 
RR – risk ratio 
SES – socioeconomic status 
SGA – second generation antipsychotic 
SMI – severe mental illness 
SMR – standardised mortality ratio 
T2DM – type 2 diabetes mellitus 
THIN – The Health Improvement Network 
TSH – thyroid stimulating hormone 
UCL – University College London 
UK – United Kingdom 
US – United States
 
  
 6 
Contents 
Thesis summary ________________________________________________________ 16 
Chapter 1 Introduction ____________________________________________ 17 
1.1 Summary _______________________________________________________ 17 
1.2 Bipolar disorder __________________________________________________ 18 
1.2.1 ICD-10 and DSM-5 criteria for bipolar disorder diagnosis _______________________ 18 
1.3 Research priorities in bipolar disorder ________________________________ 24 
1.3.1 What are the rates of negative outcomes for people with bipolar disorder? ________ 24 
1.3.2 Which medications reduce long-term adverse outcome rates in bipolar disorder? ___ 25 
1.4 Important long-term outcomes in bipolar disorder ______________________ 25 
1.4.1 Mortality in bipolar disorder ______________________________________________ 26 
1.4.2 Physical comorbidity in bipolar disorder _____________________________________ 28 
1.5 Maintenance treatment in bipolar disorder ___________________________ 30 
1.5.1 Prescription rates for bipolar disorder in the UK ______________________________ 31 
1.5.2 Lithium for the treatment of bipolar disorder ________________________________ 33 
1.5.3 Valproate _____________________________________________________________ 40 
1.5.4 Olanzapine and Quetiapine _______________________________________________ 43 
1.5.5 Head-to-head comparisons of lithium, valproate, olanzapine and quetiapine as 
maintenance mood stabilisers in bipolar disorder ____________________________________ 47 
1.6 Limitations of randomised controlled trials in bipolar disorder ____________ 48 
1.6.1 Problems with trial designs in bipolar disorder _______________________________ 48 
1.6.2 Recruitment problems in pharmacological trials for bipolar disorder ______________ 49 
1.6.3 Length of follow-up in pharmacological trials for bipolar disorder maintenance 
treatment ____________________________________________________________________ 49 
1.6.4 Choosing meaningful outcomes for maintenance treatment trials ________________ 50 
1.6.5 Lack of trials with active comparator groups in bipolar disorder maintenance treatment
 50 
1.6.6 Overcoming the limitations of trials of maintenance treatment __________________ 51 
1.7 Addressing the gaps in our understanding about long-term outcomes in bipolar 
disorder with observational data __________________________________________ 51 
1.7.1 Data Source: Primary care electronic health records ___________________________ 51 
1.7.2 Mortality and morbidity in bipolar disorder __________________________________ 52 
1.7.3 Effectiveness and tolerability of maintenance medication ______________________ 52 
1.7.4 Adverse events associated with maintenance medication in bipolar disorder _______ 53 
1.7.5 Self-harm rates with different maintenance medications _______________________ 54 
 7 
1.8 Objectives of the studies included in this thesis ________________________ 54 
1.8.1 Long-term outcomes in bipolar disorder ____________________________________ 54 
1.8.2 Effectiveness and adverse effects of maintenance treatments ___________________ 55 
Chapter 2 Methods – justification and overview ________________________ 56 
2.1 Summary _______________________________________________________ 56 
2.2 Systematic review and meta-analysis ________________________________ 57 
2.2.1 Summarising studies of mortality in people with bipolar disorder ________________ 57 
2.2.2 Network meta-analysis for comparing the efficacy and tolerability of maintenance 
mood stabilisers ______________________________________________________________ 57 
2.3 Data Source for cohort studies – primary care electronic health records ____ 58 
2.3.1 Comparison of The Health Improvement Network with other primary care electronic 
health records ________________________________________________________________ 58 
2.3.2 Coverage of The Health Improvement Network database _______________________ 59 
2.3.3 Data recording in The Health Improvement Network __________________________ 59 
2.3.4 Ethical approval for the cohort studies ______________________________________ 60 
2.4 Code lists for defining exposures, outcomes and covariates ______________ 60 
2.5 Inclusion criteria for the cohort studies _______________________________ 61 
2.5.1 Primary care practice inclusion criteria ______________________________________ 61 
2.5.2 Bipolar disorder and schizophrenia inclusion criteria___________________________ 62 
2.5.3 General population frequency matching for the study of mortality and morbidity ___ 63 
2.6 Data extraction from The Health Improvement Network database _________ 64 
2.7 Definition of exposures, outcomes and other covariates _________________ 64 
2.8 Benefits of using The Health Improvement Network for bipolar disorder 
outcomes and medication response research ________________________________ 66 
2.8.1 Size, variable recording, reliability, validity and generalisability of available data ____ 66 
2.9 Potential problems with the use of THIN for bipolar disorder outcomes and 
medication response research ____________________________________________ 67 
2.9.1 Causal inference in observational data ______________________________________ 67 
2.9.2 Using propensity scores to achieve conditional exchangeability __________________ 68 
2.9.3 Confounding by indication in observational studies____________________________ 69 
2.9.4 Other types of bias in studies using routine data ______________________________ 69 
2.9.5 Lack of recording of important covariates ___________________________________ 70 
2.10 Study design to minimise bias and confounding ________________________ 73 
2.10.1 Mortality and morbidity studies _________________________________________ 73 
2.10.2 Maintenance mood stabiliser studies _____________________________________ 74 
 8 
2.11 Approach to analysis to minimise bias and confounding _________________ 75 
2.11.1 Propensity score estimation ____________________________________________ 76 
2.11.2 Survival analyses regression techniques ___________________________________ 81 
Chapter 3 A systematic review and meta-analysis of mortality in individuals 
with bipolar disorder ________________________________________________ 84 
3.1 Summary _______________________________________________________ 84 
3.1.1 Objective _____________________________________________________________ 84 
3.1.2 Method _______________________________________________________________ 84 
3.1.3 Results _______________________________________________________________ 84 
3.1.4 Conclusion ____________________________________________________________ 85 
3.2 Introduction _____________________________________________________ 86 
3.3 Methods ________________________________________________________ 87 
3.3.1 Identification of studies __________________________________________________ 88 
3.3.2 Inclusion and exclusion criteria ____________________________________________ 88 
3.3.3 Data extraction _________________________________________________________ 90 
3.3.4 Statistical methods ______________________________________________________ 90 
3.4 Results _________________________________________________________ 91 
3.5 Discussion ______________________________________________________ 99 
3.5.1 Main findings __________________________________________________________ 99 
3.5.2 Potential limitations ____________________________________________________ 101 
3.5.3 Conclusions __________________________________________________________ 103 
3.5.4 Implications of the findings from this systematic-review and meta-analysis _______ 103 
Chapter 4 Mortality and morbidity in individuals with bipolar disorder and 
schizophrenia, compared to the general population ______________________ 104 
4.1 Summary ______________________________________________________ 104 
4.1.1 Objective ____________________________________________________________ 104 
4.1.2 Method ______________________________________________________________ 104 
4.1.3 Results ______________________________________________________________ 104 
4.1.4 Conclusion ___________________________________________________________ 105 
4.2 Introduction ____________________________________________________ 106 
4.3 Methods _______________________________________________________ 108 
4.3.1 Study design and setting ________________________________________________ 108 
4.3.2 Participants___________________________________________________________ 109 
4.3.3 Outcomes ____________________________________________________________ 110 
4.3.4 Statistical analyses _____________________________________________________ 110 
 9 
4.4 Results ________________________________________________________ 112 
4.4.1 Clinical and demographic features ________________________________________ 112 
4.4.2 All-cause mortality _____________________________________________________ 113 
4.4.3 Cardiovascular disease mortality and cardiovascular disease diagnoses __________ 117 
4.4.4 Suicide and self-harm___________________________________________________ 120 
4.5 Discussion _____________________________________________________ 122 
4.5.1 Main findings _________________________________________________________ 122 
4.5.2 Comparison with existing literature _______________________________________ 122 
4.5.3 Potential explanations for these findings ___________________________________ 123 
4.5.4 Strengths and limitations ________________________________________________ 124 
4.5.5 Conclusions __________________________________________________________ 126 
4.5.6 Implications of the findings from this study _________________________________ 126 
Chapter 5 Systematic review and network meta-analysis comparing the 
effectiveness and tolerability of lithium, valproate, olanzapine and quetiapine as 
maintenance medication in bipolar disorder ____________________________ 127 
5.1 Summary ______________________________________________________ 127 
5.1.1 Objective ____________________________________________________________ 127 
5.1.2 Method ______________________________________________________________ 127 
5.1.3 Results ______________________________________________________________ 127 
5.1.4 Conclusion ___________________________________________________________ 128 
5.2 Introduction ____________________________________________________ 129 
5.3 Methods _______________________________________________________ 132 
5.3.1 Identification of studies _________________________________________________ 132 
5.3.2 Inclusion and exclusion criteria ___________________________________________ 132 
5.3.3 Data extraction ________________________________________________________ 133 
5.3.4 Statistical analysis _____________________________________________________ 133 
5.4 Results ________________________________________________________ 134 
5.5 Discussion _____________________________________________________ 142 
5.5.1 Main findings _________________________________________________________ 142 
5.5.2 Strengths and limitations ________________________________________________ 143 
5.5.3 Conclusions __________________________________________________________ 144 
5.5.4 Implications of the findings of this network meta-analysis _____________________ 144 
Chapter 6 Comparison of the effectiveness and tolerability of lithium, 
valproate, olanzapine and quetiapine as maintenance medication in bipolar 
disorder 146 
 10 
6.1 Summary ______________________________________________________ 146 
6.1.1 Objective ____________________________________________________________ 146 
6.1.2 Methods _____________________________________________________________ 146 
6.1.3 Results ______________________________________________________________ 146 
6.1.4 Conclusion ___________________________________________________________ 147 
6.2 Introduction ____________________________________________________ 148 
6.3 Methods _______________________________________________________ 149 
6.3.1 Study design & setting __________________________________________________ 149 
6.3.2 Participants___________________________________________________________ 149 
6.3.3 Main outcome ________________________________________________________ 151 
6.3.4 Observed pre-treatment variables for propensity score estimation ______________ 151 
6.3.5 Statistical Analysis _____________________________________________________ 152 
6.4 Results ________________________________________________________ 153 
6.5 Discussion _____________________________________________________ 161 
6.5.1 Main findings _________________________________________________________ 161 
6.5.2 Comparison with previous literature ______________________________________ 161 
6.5.3 Strengths and limitations ________________________________________________ 162 
6.5.4 Conclusions __________________________________________________________ 165 
6.5.5 Implications of the findings of this study ___________________________________ 165 
Chapter 7 Comparison of the adverse renal, endocrine, hepatic and metabolic 
events during treatment with different maintenance mood stabiliser medications 
for bipolar disorder ________________________________________________ 167 
7.1 Summary ______________________________________________________ 167 
7.1.1 Objective ____________________________________________________________ 167 
7.1.2 Methods _____________________________________________________________ 167 
7.1.3 Results ______________________________________________________________ 167 
7.1.4 Conclusions __________________________________________________________ 168 
7.2 Introduction ____________________________________________________ 170 
7.3 Methods _______________________________________________________ 171 
7.3.1 Study design & Setting __________________________________________________ 171 
7.3.2 Participants___________________________________________________________ 171 
7.3.3 Exposure _____________________________________________________________ 171 
7.3.4 Main outcomes _______________________________________________________ 172 
7.3.5 Propensity score estimation using observed pre-treatment variables ____________ 173 
7.3.6 Statistical Analysis _____________________________________________________ 174 
 11 
7.4 Results ________________________________________________________ 174 
7.5 Discussion _____________________________________________________ 188 
7.5.1 Main findings _________________________________________________________ 188 
7.5.2 Comparison with previous literature ______________________________________ 188 
7.5.3 Strengths and limitations ________________________________________________ 190 
7.5.4 Conclusions __________________________________________________________ 191 
7.5.5 Implications of the findings of this study ___________________________________ 192 
Chapter 8 Comparison of self-harm, accidental injury and suicide in individuals 
with bipolar disorder during treatment with different maintenance mood 
stabiliser medications for bipolar disorder ______________________________ 193 
8.1 Summary ______________________________________________________ 193 
8.1.1 Objective ____________________________________________________________ 193 
8.1.2 Methods _____________________________________________________________ 193 
8.1.3 Results ______________________________________________________________ 193 
8.1.4 Conclusions __________________________________________________________ 194 
8.2 Introduction ____________________________________________________ 195 
8.3 Method _______________________________________________________ 197 
8.3.1 Study design, setting and participants _____________________________________ 197 
8.3.2 Exposure _____________________________________________________________ 197 
8.3.3 Outcomes ____________________________________________________________ 197 
8.3.4 Propensity score estimation _____________________________________________ 197 
8.3.5 Statistical analysis _____________________________________________________ 198 
8.4 Results ________________________________________________________ 199 
8.4.1 Self-harm ____________________________________________________________ 200 
8.4.2 Accidental injury ______________________________________________________ 202 
8.4.3 Suicide ______________________________________________________________ 202 
8.5 Discussion _____________________________________________________ 203 
8.5.1 Main findings _________________________________________________________ 203 
8.5.2 Comparison with previous literature ______________________________________ 203 
8.5.3 Strengths and limitations ________________________________________________ 204 
8.5.4 Conclusions __________________________________________________________ 206 
8.5.5 Implications of the findings of this study ___________________________________ 206 
Chapter 9 Discussion, implications and conclusions ____________________ 208 
9.1 Summary ______________________________________________________ 208 
9.2 Key findings ____________________________________________________ 209 
 12 
9.2.1 Mortality and morbidity in bipolar disorder _________________________________ 210 
9.2.2 Maintenance treatment for bipolar disorder ________________________________ 212 
9.3 Implications of findings from my mortality and morbidity studies_________ 214 
9.3.1 Key points for clinicians and patients ______________________________________ 214 
9.3.2 Key points for policy makers _____________________________________________ 215 
9.3.3 Key points for researchers _______________________________________________ 215 
9.3.4 All-cause mortality in people with bipolar disorder ___________________________ 216 
9.3.5 Cause-specific mortality in people with bipolar disorder _______________________ 217 
9.3.6 Why is there a still “mortality gap”? _______________________________________ 219 
9.3.7 What should be done to address the “mortality gap”? ________________________ 221 
9.4 Implications of findings from my maintenance treatment studies _________ 224 
9.4.1 Key points for clinicians and patients ______________________________________ 224 
9.4.2 Key points for policy makers _____________________________________________ 225 
9.4.3 Key points for researchers _______________________________________________ 225 
9.4.4 Effectiveness and tolerability of maintenance mood stabiliser medications _______ 226 
9.4.5 Adverse events during maintenance mood stabiliser treatment_________________ 227 
9.4.6 Self-harm, accidental injury and suicide during treatment with maintenance mood 
stabiliser medications _________________________________________________________ 232 
9.5 Strengths and limitations of studies making up this thesis _______________ 234 
9.5.1 Use of electronic health records __________________________________________ 234 
9.5.2 Diagnostic validity of bipolar disorder in THIN _______________________________ 235 
9.5.3 Comparing characteristics of my cohort of people with bipolar disorder with other 
cohort studies _______________________________________________________________ 237 
9.5.4 Defining drug exposure using EHR ________________________________________ 238 
9.5.5 Using drug monotherapy to investigate effects ______________________________ 239 
9.5.6 Follow-up time for patients with bipolar disorder in THIN _____________________ 240 
9.5.7 Validity of outcomes used in this thesis ____________________________________ 240 
9.5.8 Comparing bipolar disorder mortality with general population rates _____________ 241 
9.5.9 Approach to handling missing data in THIN _________________________________ 242 
9.5.10 Unmeasured and residual confounding __________________________________ 244 
9.5.11 Are propensity score approaches superior to traditional techniques? __________ 246 
9.5.12 Limitations related to study design _____________________________________ 246 
9.6 Bipolar disorder now and in the future ______________________________ 247 
9.6.1 Is bipolar disorder becoming more common? _______________________________ 247 
9.6.2 Underfunded and under researched _______________________________________ 248 
9.7 Future questions for bipolar disorder research ________________________ 249 
9.7.1 Can early diagnosis improve functioning and reduce adverse long-term outcomes? 249 
 13 
9.7.2 Can staging models improve outcomes? ___________________________________ 249 
9.7.3 How do we better use the drugs that we have? ______________________________ 250 
9.7.4 Could a better understanding of mechanism of lithium help develop new treatments?
 251 
9.8 Other research directions _________________________________________ 252 
9.8.1 Study design __________________________________________________________ 252 
9.8.2 Electronic health records ________________________________________________ 253 
9.9 Dissemination __________________________________________________ 254 
9.10 Conclusions ____________________________________________________ 255 
 
Figures 
Figure 1.i Example of a possible trajectory of mood episodes in bipolar disorder ................................... 19 
Figure 1.ii ICD-10 criteria for the diagnosis of hypomania or mania ........................................................... 20 
Figure 1.iii ICD-10 categories for manic episodes and bipolar disorder ...................................................... 22 
Figure 1.iv Prescribing for bipolar disorder in the UK: Proportion of time spent on treatment with 
lithium, valproate and any second generation antipsychotic .......................................................................... 32 
Figure 1.v Percentage of patients with clinically significant weight gain (>7%) in short-term (3-8 
weeks) placebo-controlled RCTs. ................................................................................................................................. 45 
Figure 2.i Flow diagram of included patients for each study ........................................................................... 65 
Figure 2.ii Potential distribution of propensity scores for two drugs ........................................................... 79 
Figure 3.i Flow diagram of the published articles evaluated for inclusion in this meta-analysis ...... 89 
Figure 3.ii SMR of all-cause mortality ....................................................................................................................... 96 
Figure 4.i Flow diagram of included patients ...................................................................................................... 109 
Figure 4.ii All-cause mortality rate in bipolar disorder and schizophrenia 2000-2014 ..................... 114 
Figure 4.iii All-cause mortality adjusted hazard ratio for bipolar disorder and schizophrenia 
compared to the general population 2000-2014 ............................................................................................... 116 
Figure 5.i Flow diagram of the trials evaluated for inclusion in this systematic review and NMA 135 
Figure 5.ii Network plot of included trials: Relapse and reoccurrence ..................................................... 138 
Figure 5.iii Network plot of included trials: Discontinuation ........................................................................ 138 
Figure 5.iv Forest plot for relapse or reoccurrence ........................................................................................... 140 
 14 
Figure 5.v Forest plot for all-cause discontinuation ......................................................................................... 141 
Figure 5.vi Cumulative probability of ranking .................................................................................................... 142 
Figure 6.i Flow diagram of included patients ...................................................................................................... 150 
Figure 6.ii Flow diagram of included patients..................................................................................................... 154 
Figure 6.iii Time to treatment failure (stopped treatment or addition of mood stabiliser, 
antipsychotic, antidepressant or benzodiazepine) (unadjusted) ................................................................ 156 
Figure 6.iv Propensity score distribution before matching ............................................................................ 158 
Figure 6.v Propensity score distribution after pairwise matching with lithium .................................... 158 
Figure 6.vi Time to treatment failure (excluding failures in the first 3 months of treatment) 
(unadjusted) ...................................................................................................................................................................... 160 
Figure 7.7.i Flow diagram of included patients .................................................................................................. 175 
Figure 7.7.ii Cumulative incidence estimates of adverse renal and hepatic event rates .................... 179 
Figure 7.7.iii Cumulative incidence estimates of adverse endocrine event rates ................................... 181 
Figure 7.7.iv Cumulative incidence estimates of adverse metabolic event rates ................................... 183 
Figure 8.i Flow diagram of included patients ...................................................................................................... 199 
Figure 8.ii Cumulative self-harm rate in patients prescribed lithium vs. valproate, olanzapine or 
quetiapine (unadjusted, with 95% confidence intervals) ............................................................................... 202 
 
Tables 
Table 1.i Studies of lithium’s effects on eGFR published since 2012 .............................................................. 35 
Table 1.ii Summary of recognised adverse effects from long-term use ........................................................ 38 
Table 2.i Diagnostic stability of bipolar disorder and schizophrenia ........................................................... 63 
Table 3.i Studies include in the meta-analysis ........................................................................................................ 93 
Table 3.ii Summary standardised mortality ratios for all-cause and cause specific mortalities ....... 97 
Table 3.iii Summary SMRs by subgroup for all-cause mortality, and natural and unnatural death 98 
Table 4.i Cohort characteristics ................................................................................................................................ 112 
Table 4.ii All-cause mortality ..................................................................................................................................... 115 
Table 4.iii Cardiovascular disease mortality and cardiovascular disease diagnoses .......................... 119 
 15 
Table 4.iv Suicide and self-harm ............................................................................................................................... 121 
Table 5.i Included trials ................................................................................................................................................ 136 
Table 5.ii Relative risk of relapse or reoccurrence (orange) and all-cause discontinuation (green) 
according to NMA ........................................................................................................................................................... 139 
Table 5.iii Probability of each treatment being ranked best-worst; for preventing 
relapse/reoccurrence, and for lowest all-cause discontinuation ................................................................. 142 
Table 6.i Characteristics of patients with bipolar disorder prescribed lithium, valproate, olanzapine 
or quetiapine monotherapy ........................................................................................................................................ 155 
Table 6.ii Rates of treatment failure by drug ....................................................................................................... 156 
Table 6.iii Supplementary analyses using PS adjusted model ....................................................................... 160 
Table 7.i Patient characteristics ............................................................................................................................... 176 
Table 7.ii Patients included for each outcome, N (%) ...................................................................................... 177 
Table 7.iii Adverse effects during maintenance treatment ............................................................................ 177 
Table 7.iv Median number (and interquartile range) of tests per year of drug exposure in patients 
included in analyses ....................................................................................................................................................... 185 
Table 7.v Sensitivity analyses to account for missing blood tests by 1) including all individuals and 
2) performing inverse probability weighting ...................................................................................................... 185 
Table 8.i Patient characteristics ............................................................................................................................... 200 
Table 8.ii Rates of self-harm, accidental injury, and suicide by mood stabiliser.................................... 201 
 
  
 16 
Thesis summary 
This thesis has two overarching aims: To define the mortality and morbidity in people with 
bipolar disorder (BPD), relative to other individuals with schizophrenia and the general 
population, and to understand the longer-term effects of maintenance medication on 
relapse/reoccurrence and adverse events in individuals with BPD.  
 
These aims were refined through completion of a systematic review and meta-analysis of 
premature mortality in BPD, and a network meta-analysis of efficacy of maintenance 
medication for BPD. Findings from these reviews informed a number of cohort studies 
using longitudinal data from United Kingdom (UK) primary care electronic health records 
(EHRs). Completed studies examine rates of all-cause and cause specific (suicide, 
cardiovascular) mortality in BPD relative to people with schizophrenia and the general 
population and compare rates of cardiovascular disease (CVD) diagnosis, and self-harm in 
these groups. Further studies examine rates of monotherapy treatment failure, rates of 
adverse physical health events and rates of self-harm, accidental injury and suicide in 
patients with BPD prescribed one of the four most common maintenance medications for 
mood stabilisation (lithium, valproate, olanzapine or quetiapine). EHRs provide ways of 
addressing these questions that have not been previously possible, with long follow-up 
times, and large, generalisable cohorts of individuals with BPD. 
 
Finally, the implications of findings from these studies in terms of clinical practice, policy 
and patient impact are explored, set in the context of previous research.  Overall strengths 
and limitations are discussed, and directions for future research are set out.  
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Chapter 1 Introduction 
1.1 Summary 
This chapter sets out the context for my thesis. It provides an overview of the 
characteristics of BPD, including potential international diagnostic differences and 
comparisons with other mental disorders, such as depression and schizophrenia. It goes on 
to outline the key research priorities that are addressed by this thesis and the current 
United Kingdom context in which these sit. Aims and objectives for each study are 
introduced, and existing literature relating to each objective is described and discussed. 
Previous literature on mortality and morbidity in BPD is summarised. Commonly used drug 
treatments in BPD are discussed, including the potential benefits and harms of each. 
Limitations of randomised controlled trials (RCTs) of maintenance treatments are examined 
in this context. 
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1.2 Bipolar disorder  
BPD is a life-long, recurrent, episodic illness with high rates of hospitalisation, suicide and 
comorbidity (Saunders and Goodwin, 2010). It affects at least 1% of the UK population (Das 
Gupta and Guest, 2002). In 2013 BPD was the sixteenth most common cause of years lived 
with disability in the world; similar to more prevalent conditions such as asthma or 
Alzheimer’s disease (Ferrari et al., 2016). It is projected to cost the UK over £6.5 billion per 
year by 2017 (McCrone et al., 2008). Despite this, BPD research is significantly 
underfunded, even when compared to other severe mental illness (SMI) such as 
schizophrenia  (Young, 2006). 
1.2.1 ICD-10 and DSM-5 criteria for bipolar disorder diagnosis 
The World Health Organisation’s International Classification of Disease, 10th revision (ICD-
10) and the American Psychiatric Associations Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition (DSM-5) are the most commonly used diagnostic classification 
systems in psychiatry (American Psychiatric Association, 2013, World Health Organisation, 
1992).  Both define BPD, previously known as manic depressive illness, as a severe chronic 
mood disorder characterised by episodes of mania, hypomania and alternating (or 
intertwining) episodes of depression (Figure 1.i). 
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Figure 1.i Example of a possible trajectory of mood episodes in bipolar disorder 
 
 
1.2.1.1 Manic and hypomanic episodes 
Mania and hypomania are states of elevated mood and increased motor drive (Grande et 
al., 2015) (Figure 1.i). ICD-10 criteria for hypomania are that the mood is elevated (or 
irritable) to a degree that is abnormal for the individual concerned for at least four 
consecutive days. At least three of the symptoms shown in Figure 1.ii must be present, 
leading to some interference in personal functioning. Mania is defined by similar, though 
more severe, symptoms (Figure 1.ii). In mania the mood change must be sustained for a 
least seven days (unless it is severe enough to result in hospitalisation) and lead to severe 
interference with personal functioning.   
 
 
 
 
 20 
Figure 1.ii ICD-10 criteria for the diagnosis of hypomania or mania 
 
From (World Health Organisation, 1992) .  
 
Psychotic symptoms in mania will most commonly be mood congruent, such as grandiose 
delusions or auditory hallucinations telling the individual that they have superhuman 
powers. However mood incongruent psychotic symptoms also occur, such as affectively 
neutral topics, persecutory delusions or delusions of reference. 
1.2.1.2 Depressive episodes 
Patients with BPD spend a substantial proportion of time suffering from syndromal or sub-
syndromal depressive symptoms (Grande et al., 2015) (Figure 1.i). Major depressive 
episodes in BPD are similar to those experienced in unipolar major depression (National 
Institute for Health and Care Excellence, 2014). Patients suffer depressed mood and 
experience profound loss of interest in activities, coupled with other symptoms such as 
fatigue, weight loss or gain, difficulty sleeping or staying awake, psychomotor slowing, 
feelings of worthlessness, excessive guilt and suicidal thoughts or actions (World Health 
Organisation, 1992). For patients presenting with a first episode of depression, it may not 
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be possible to distinguish between those who will go on to suffer recurrent unipolar 
depression and those who will develop BPD. However, evidence suggests there may be 
subtle differences between bipolar and unipolar depression. In particular, depression in the 
course of BPD may be more likely to show signs of psychomotor retardation, to have 
melancholic features (such as feelings of worthlessness and marked anhedonia), to show 
features of atypical depression (such as hypersomnia and weight gain) and to show 
psychotic features – especially in young people (Bowden, 2005, Forty et al., 2008, Goldberg 
et al., 2001). Patients experiencing a first episode of depression who display these features 
and have a family history of BPD may be at increased risk of developing BPD (McGuffin et 
al., 2003). 
Sub-syndromal depressive symptoms are common in patients with BPD and are often 
associated with significant interpersonal or occupational disability (Bonnin et al., 2012). The 
management of these chronic, low-grade depressive symptoms is therefore of major 
importance, but is also a substantial treatment challenge. 
1.2.1.3 Differences in diagnostic criteria between ICD and DSM 
Some key differences exist in the ICD and DSM diagnostic criteria for BPD (American 
Psychiatric Association, 2013, World Health Organisation, 1992). The most notable is the 
DSM’s differentiation of the disorder into bipolar I and bipolar II subtypes. DSM requires at 
least one manic episode to have occurred for a diagnosis of bipolar I and at least one 
hypomanic episode for bipolar II. Although major depressive episodes will typically occur, 
they are not needed for the diagnosis to be made. Conversely ICD does not include the I/II 
differentiation, although clinicians using ICD will commonly refer to the diagnosis in these 
terms, and much of the research literature is based on this differentiation (National 
Institute for Health and Care Excellence, 2014). It is likely that the I/II nomenclature will be 
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adopted in ICD-11 (de Dios et al., 2014).  ICD-10 requires that an individual experiences two 
mood episodes (with at least one being hypomania or mania) before a diagnosis of BPD be 
made. As such ICD criteria are stricter (Figure 1.iii).  Criteria for defining mania versus 
hypomania are also stricter in ICD-10. In DSM mania describes all elevated mood states 
“with functional impairment” and is qualified by severity, i.e., mild, moderate or severe 
(with or without psychosis). Hypomania is defined as any elevated mood state “without 
social or occupational dysfunction” lasting at least four days (American Psychiatric 
Association, 2013), with a number of researchers suggesting that this period should be 
shortened to two days (Angst et al., 2003). In ICD-10 the boundary between hypomania and 
mania is defined by the effect on social functioning. The threshold for a diagnosis of mania 
is made when the individual experiences a “severe or complete” disruption of work and 
social activity (World Health Organisation, 1992).  
Figure 1.iii ICD-10 categories for manic episodes and bipolar disorder 
 
From (World Health Organisation, 1992) .  
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These differences will clearly lead to more individuals being diagnosed under DSM criteria 
than ICD, and this may partially explain worldwide differences in prevalence and incidence 
estimates of BPD (Ferrari et al., 2011, Hardoon et al., 2013, Merikangas et al., 2007). Data 
for this thesis are from the UK, and as such, individuals identified as having BPD should be 
regarded as fulfilling ICD criteria for diagnosis.  Additionally, codes available in primary care 
EHR do not specifically identify bipolar I versus bipolar II.    
1.2.1.4 Bipolar disorder, depression and schizophrenia as separate diagnostic entities 
BPD appears to share more similarities with schizophrenia than major depressive disorder, 
despite the commonality of depressive symptoms. There is growing evidence of an 
aetiological and prognostic overlap between BPD and schizophrenia (Laursen et al., 2007). 
Genetic evidence supporting non-independence of BPD and schizophrenia has come from 
family, twin and linkage studies and from studies of individual genes (Craddock et al., 2006, 
2009).  BPD and schizophrenia also share neurotransmitter dysfunction similarities and 
there is a treatment overlap in terms of response to second generation antipsychotic (SGA) 
medication (dopamine receptor antagonists) (Möller, 2003).  
Traditionally, individuals with BPD have been considered to have better outcomes than 
those with schizophrenia. This appears to be due to assumptions about seemingly normal 
inter-episode function and an absence of significant cognitive impairment (Zarate Jr et al., 
2000). However, more recent studies have highlighted problems with psychosocial 
dysfunction in euthymic individuals with BPD, suggesting there is a discontinuity between 
clinical and functional outcomes (Martinez‐Aran et al., 2007).  The complex presentation 
of BPD may have hindered the identification of this impairment. Reduced health related 
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quality of life and functioning is now apparent, however, the impact of this impairment on 
adverse outcomes relative to schizophrenia is still not well understood.     
1.3 Research priorities in bipolar disorder 
There is remarkably little epidemiological evidence regarding the prognosis and treatment 
of bipolar disorder. A number of fundamental epidemiological questions about BPD, its 
treatment, and the resultant outcomes remain poorly answered. This thesis aims to 
address two key unanswered questions: 1) what are the rates of negative outcomes in 
BPD? And 2) which medications reduce adverse outcome rates? Getting answers to these 
questions is important to individuals with BPD and to clinicians providing their care and will 
facilitate informed decision making about available treatment options. Answers will also be 
important to the National Health Service (NHS) in informing the best use of resources.  
These clinical research questions are identified as priorities by the National Institute for 
Health and Care Excellence (National Institute for Health and Care Excellence, 2014), and 
the James Lind Alliance Priority Setting Partnership (Robotham et al., 2016) in the UK. For 
example, included in the James Lind Alliance top 10 for BPD are questions about effective 
medication, managing suicide risk, side-effects and adverse effects. They have also been 
identified as priorities by patients, clinicians and researchers in North America (Crowley et 
al., 2014, Michalak et al., 2012), Australia (Banfield et al., 2011) and across Europe (van Os 
and Wahlbeck, 2014). 
1.3.1 What are the rates of negative outcomes for people with bipolar disorder? 
There have been very few studies of the rates of mortality and comorbidities in BPD using 
nationally representative community based cohorts. Existing studies have relied mainly on 
hospital discharge data or case-control designs. The availability of primary care data 
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reflecting outpatient diagnoses is important as it allows inclusion of people not in contact 
with secondary care; this might be because of milder or more stable illness, or because of a 
refusal to engage with psychiatric services. This will result in more generalisable rate 
estimates.   
1.3.2 Which medications reduce long-term adverse outcome rates in bipolar disorder? 
The NICE guidelines identify a need to understand the relative benefits in terms of quality 
of life of individuals with BPD whilst taking different maintenance medications (National 
Institute for Health and Care Excellence, 2014). Lithium, valproate, olanzapine and 
quetiapine appear to reduce the risk of relapse when used long-term, but these four 
medications are also associated with a number of side effects, some of which can adversely 
affect physical health and may contribute to premature mortality (Correll et al., 2015, 
Joukamaa et al., 2006). Current research investigating the relative effectiveness and 
tolerability of these drugs and their impact on quality of life is insufficient due to both its 
scarcity and low quality.  
1.4 Important long-term outcomes in bipolar disorder  
There are a limited number of studies that examine long-term outcomes. We know patients 
with BPD are frequently hospitalised (between 10% and 50% per year (Adler et al., 2012, 
Tohen et al., 1990)), 15% die by suicide, and approximately half will attempt suicide 
(Baldessarini and Tondo, 2003, Tondo et al., 2003). Patients with BPD are also more likely to 
suffer medical and psychiatric comorbidities and have excess all-cause mortality (Crump et 
al., 2013, Krishnan, 2005). However, limited numbers of participants and follow-up periods 
in these studies mean that we have little understanding regarding long-term outcomes for 
people with bipolar disorder in the UK. 
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1.4.1 Mortality in bipolar disorder 
Research has suggested that BPD is associated with premature mortality. Where previously 
it was believed this was mostly attributable to unnatural causes such as suicide, homicide 
and accidents, it has also been shown that patients with BPD are at risk of premature death 
from a range of medical illnesses (Roshanaei-Moghaddam and Katon, 2009). In 1998, Harris 
and Barraclough reviewed mortality in all mental disorders (Harris and Barraclough, 1998); 
six studies contributed to their meta-analysis of mortality in BPD. A more recent review 
published in 2009 included 13 studies of mortality from general medical illnesses 
(Roshanaei-Moghaddam and Katon, 2009). Since these publications, a number of large 
database studies have derived elevated mortality estimates for BPD; however, there are no 
recent estimates from the UK.  
I conducted a systematic review and meta-analysis of all-cause and cause specific 
mortalities (Chapter 3). Cause specific mortalities were grouped as natural and unnatural. 
Natural deaths were then further divided into circulatory causes (for example myocardial 
infarction (MI) and cerebrovascular events (CVE)), respiratory causes (such as chronic 
obstructive pulmonary disease (COPD)), infectious causes (such as pneumonia or sepsis) 
and deaths from cancer. Unnatural deaths were divided into deaths by suicide and other 
violent causes. 
The most commonly used measure of effect in assessing mortality is the standardised 
mortality ratio (SMR). In general, SMRs remove confounding by age and sex only, and so 
they may be limited when comparing a patient group (such as those with BPD) who do not 
match the general population structure in terms of social deprivation or physical health at 
baseline. In addition, the SMR does not allow direct comparisons between study groups: for 
example comparisons of mortality between BPD and schizophrenia. 
 27 
From this systematic review, particular areas were identified for further investigation and 
are addressed in Chapter 4 of the thesis: all-cause mortality, CVD mortality, suicide, CVD 
and self-harm. 
1.4.1.1 All-cause mortality in bipolar disorder 
Whilst it there is a recognition that mortality is elevated in BPD (Hoang et al., 2011, 
Roshanaei-Moghaddam and Katon, 2009), we do not have contemporary information 
regarding mortality trends in people with BPD. In recent years, in the UK, a number of 
attempts have been made to understand and address the disparity in mortality between 
individuals with SMI (including BPD) and the general population. These include target 
setting for general practitioners (Colton and Manderscheid, 2006), establishing early 
intervention in psychosis services (Edwards and McGorry, 2002), independent review 
(Schizophrenia Commission, 2012), and Government policy and spending initiatives 
(Department of Health, 2011, 2014). It remains unclear if these changes have resulted in 
improved life expectancy for individuals with BPD relative to the general population.  
1.4.1.2 Cardiovascular disease mortality in bipolar disorder 
CVD has previously been shown to be the leading cause of death in individuals with BPD 
(Laursen et al., 2013, Roshanaei-Moghaddam and Katon, 2009, Weiner et al., 2011). 
However there are few estimates of CVD mortality compared to other SMIs, such as 
schizophrenia, and studies that investigate the potential role of medication, lifestyle factors 
and other comorbidities are even more limited (Osborn et al., 2007). Studies that do exist 
suggest that elevated rates of CVD death are not explained only by medication, smoking or 
physical inactivity (Kilbourne et al., 2009, Osborn et al., 2007). One previous UK EHR study 
has investigated rates of CVD death in SMI up until 2002, including people with  BPD and 
schizophrenia (Osborn et al., 2007). This study found a 3-fold increase in CVD deaths in 
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those aged 18 to 49 and a 2-fold increase in those aged 50 to 75 for any SMI diagnosis. 
Overall rates for specific SMI were not reported. However, in the 18 to 49 year old group 
the point estimate suggested BPD patients had elevated CVD mortality, but this could not 
be confirmed because of wide confidence intervals (CIs), due to a low event rate (HR 2.13; 
95% CI 0.77 to 5.93). In the 50 to 75 year age group individuals with BPD had an elevated 
CVD rate, similar to those with schizophrenia (HR 1.52; 95% CI 1.18  ̶1.95 and HR 1.96; 95% 
CI 1.63 to 2.35 respectively). 
1.4.1.3 Suicide in bipolar disorder 
Suicide is a leading public health priority in BPD; 10 to 15% of individuals with BPD will die 
by suicide (Hawton et al., 2005). However, it remains unclear if BPD conveys a bigger risk 
than other SMI, with previous research inconsistent in this regard (Mortensen et al., 2000, 
Osborn et al., 2008, Tidemalm et al., 2008). Contemporary estimates of suicide rate in BPD 
are also rare.   Until recently, research has also been limited by relatively small sample 
sizes, short follow-up periods and lack of data from representative community samples, 
and because of the rarity of suicide, identifying risk factors in BPD has been challenging  
(Schaffer et al., 2015).  
1.4.2 Physical comorbidity in bipolar disorder 
As with studies of mortality, BPD has been relatively neglected in terms of describing and 
quantifying morbidity risks (McIntyre et al., 2007, Weiner et al., 2011). Studies of physical 
comorbidities in representative population based cohorts of individuals with BPD have only 
recently begun to be carried out (Crump et al., 2013, McIntyre et al., 2007, Weiner et al., 
2011), but gaps in the knowledge around specific comorbidities remain. The longitudinal 
cohort study by Crump et al. is the only one to have examined the association between BPD 
and physical comorbidities in a representative sample, rather than relying on psychiatric 
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inpatient data (Crump et al., 2013). Patients with BPD have been found to have more 
physical health problems than the general population (Smith et al., 2013) and reduced 
access to appropriate treatment (Crump et al., 2013).  
1.4.2.1 Cardiovascular disease in bipolar disorder 
Evidence from a 2011 review suggests MI, CVE and ischemic heart disease (IHD) risk are all 
elevated in BPD (Weiner et al., 2011), however included studies are now dated (i.e., cover 
time before the introduction of atypical antipsychotic medication), and involve populations 
limited in size and generalisability. It is unclear if the high prevalence of CVD is related 
solely to increased traditional risk factors (such as smoking, obesity and type 2 diabetes 
mellitus (T2DM)), or if it is related to unrecognised emerging risk factors such as 
inflammation, abnormal metabolism and renal insufficiency (Joynt et al., 2003, Kupfer, 
2005).  There is evidence for reduced appropriate treatment for individuals with BPD and 
CVD (Laursen et al., 2009, Smith et al., 2013), but it is unclear if this remains the case 
following a number of high profile healthcare interventions (Department of Health, 2011, 
Doran et al., 2011, Roland, 2004).  
1.4.2.2 Self-harm and accidental injury in bipolar disorder 
In UK based research, self-harm refers to self-poisoning or self-injury regardless of apparent 
intent (Kapur et al., 2013). ‘Deliberate self-harm’ superseded previously used terms for 
non-fatal suicidal behaviour such as ‘parasuicide’ and ‘attempted suicide’ in the 1970s, and 
more recently the ‘deliberate’ prefix has been dropped because motivation or intent is not 
always clear. In the United States, research commonly refers to non-suicidal self-injury 
(NSSI) and this was formalised as a distinct disorder in DSM-5 (American Psychiatric 
Association, 2013). Concerns have been raised about the prefix ‘non-suicidal’ as NSSI is a 
risk factor for suicide, and the diagnosis excludes self-poisoning (i.e., all self-poisoning is 
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assumed to have suicidal intent) (Kapur et al., 2013). This thesis therefore uses the UK 
definition of self-harm. Self-harm is a major cause of morbidity in BPD (Singhal et al., 2014), 
and is strongly associated with suicide (Owens et al., 2002). As with suicide, rates have 
been poorly defined, relative to the general population and other SMI.  
Risk of accidental injury has also been understudied in BPD, despite deaths from 
unintentional injury being approximately six times higher in BPD than in the general 
population (Hoang et al., 2011).  Although unintentional injuries are often recorded in drug 
trials of BPD, they are rarely reported as important outcomes (Matson et al., 2006). 
Observational studies (i.e., studies where the exposure allocation is not under the control 
of the researcher) of accidental injury are rare (Khalsa et al., 2008). Accidental injury is 
thought to be associated with mania or hypomania, whereas self-harm may be related to 
depressive episodes (Khalsa et al., 2008).   
1.5 Maintenance treatment in bipolar disorder 
“Maintenance treatment” is not well defined in the literature (Goodwin et al., 2016, Grunze 
et al., 2013, National Institute for Health and Care Excellence, 2014). NICE state 
maintenance treatment means “long-term” treatment (National Institute for Health and 
Care Excellence, 2014), and there is no guidance on when to stop treatment. As such, it is 
often taken to mean anything from post-remission to lifetime prescribing (depending on if 
you are planning an RCT or treating a patient clinically). Guidelines suggest maintenance 
treatment should be considered after each mood episode, and especially for all patients 
experiencing a manic episode (including their first manic episode) (Goodwin et al., 2016, 
National Institute for Health and Care Excellence, 2014). Therefore, the large majority of 
patients with bipolar I and a number with bipolar II should receive maintenance treatment. 
The aim of maintenance treatment is to prevent re-emergence of symptoms, including 
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subsyndromal symptoms, and to limit illness progression (Grunze et al., 2013). Until 
September 2014 NICE recommended three drugs as possible first-line treatments for BPD 
maintenance: lithium, valproate and olanzapine, with quetiapine being recommended in 
predominantly depressive BPD (National Institute for Health and Care Excellence, 2006). In 
the updated guideline (National Institute for Health and Care Excellence, 2014), lithium is 
now first-line. This change was based on expert consensus and a number of trials 
conducted since 2006 (Amsterdam and Shults, 2010, Geddes et al., 2010, Licht et al., 2010, 
Weisler et al., 2011). This change is also supported by two recent meta-analyses (Miura et 
al., 2014, Severus et al., 2014) and more recently by the updated British Association for 
Psychopharmacology guidelines for treating BPD (Goodwin et al., 2016). In Chapter 5 I 
complete a systematic review and network meta-analysis of all maintenance treatment 
trials that include comparisons of lithium, valproate, olanzapine, quetiapine and placebo.   
NICE continue to highlight the need for further evidence about effective maintenance 
medication (National Institute for Health and Care Excellence, 2014), and evidence 
regarding effectiveness and safety of long-term maintenance treatment of BPD remains 
sparse (Goodwin, 2009, Goodwin et al., 2016). Head-to-head comparisons of maintenance 
medications are rare. There is also no clear evidence that any one of the recommended 
medications will prove more effective for a particular patient with a particular illness 
pattern.  
1.5.1 Prescription rates for bipolar disorder in the UK 
Lithium, valproate, olanzapine and quetiapine are the most commonly prescribed in the UK 
(Hayes et al., 2011) and are the four maintenance medications investigated in Chapter 6, 
Chapter 7 and Chapter 8. Patterns of prescribing up to 2009 reflected previous NICE 
guidance (National Institute for Health and Care Excellence, 2006). After their introduction, 
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there was a rapid increase in the use of valproate, olanzapine and quetiapine, whereas 
lithium has remained relatively stable (Figure 1.iv).    
 
Figure 1.iv Prescribing for bipolar disorder in the UK: Proportion of time spent on 
treatment with lithium, valproate and any second generation antipsychotic  
 
Adapted from (Hayes et al .,  2011) .  
 
Increasing age and an earlier date of starting treatment were the only factors that were 
associated with being treated with lithium rather than other drugs, suggesting that 
individuals with new prescribing for BPD in recent years will most likely receive valproate or 
an antipsychotic medication. Guidelines around avoiding valproate in women of 
childbearing potential were not being followed, with almost one in three being prescribed 
this drug (Hayes et al., 2011). This guidance was reinforced by NICE and the Medicines and 
Healthcare products Regulatory Agency in 2016.  
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1.5.2 Lithium for the treatment of bipolar disorder 
1.5.2.1 Effectiveness of lithium as a maintenance mood stabiliser  
Lithium was introduced by John Cade in 1949 and has been in clinical use for more than 50 
years (Abou-Saleh and Coppen, 1986). Lithium is widely used in the long-term treatment of 
affective disorders and its use has been considered well established (Geddes and Miklowitz, 
2013, Licht, 2012). However, its efficacy has been repeatedly questioned (Blackwell and 
Shepherd, 1968, Moncrieff, 1997), there are few trials that compare it with an alternative 
active treatment (Miura et al., 2014), and its benefits are restricted by its side effect profile 
and a narrow therapeutic window (Geddes and Miklowitz, 2013). Because of these factors, 
alternative maintenance treatments have become commonly used (Hayes et al., 2011). 
Overall, RCT evidence with up to 2 years follow-up suggests lithium is superior to placebo in 
treating both manic and depressive polarities of relapse, but it is poorly tolerated (Goodwin 
et al., 2016, Miura et al., 2014). 
1.5.2.2 Adverse effects from long-term use of lithium 
A number of long-term adverse effects of lithium have been identified since its use as a 
mood stabiliser became established in the 1970s (Bech, 2006), but it is only recently that 
they have begun to be characterised and quantified (Clos et al., 2015, Close et al., 2014, 
Kessing et al., 2015, McKnight et al., 2012, Murru et al., 2015, Shine et al., 2015). Lithium’s 
adverse effects include renal, thyroid, and parathyroid dysfunction. Lithium is also 
recognised to cause weight gain, but the risk of weight gain relative to other potential 
maintenance therapies has not been widely investigated (McKnight et al., 2012).  
1.5.2.3 Renal effects of long-term lithium use 
In 2012, McKnight et al. identified 30 studies (no RCTs) which investigated lithium effect on 
estimated glomerular filtration rate (eGFR) or urine concentrating ability. Only nine case-
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control studies could be used in the meta-analysis, the remainder being uncontrolled 
cohort studies with no data on within-patient changes over follow-up. The pooled estimate 
from these studies was a 6.22 mL/min (95% CI -14.65 to 2.20) reduction in eGFR for people 
prescribed lithium (which is not statistically or clinically significant). Since publication of this 
meta-analysis, large cohort and case-control studies have suggested that whilst lithium use 
appears to result in a decline in eGFR, clinically significant severe or end-stage chronic 
kidney disease (CKD) remains rare (Aiff et al., 2015, Castro et al., 2015, Clos et al., 2015, 
Close et al., 2014, Shine et al., 2015). Table 1.i describes the main characteristics of these 
studies.  
Often these studies have been limited by lack of active comparator groups, confounding by 
indication (that is; the chance of receiving treatment is related to severity and other 
baseline factors), surveillance biases (follow-up is differential and is related to exposure or 
outcome), and little information on potential confounders. It has been argued by others 
that modern lithium treatment regimens, involving regular and frequent monitoring and 
individually adjusted dosing, have eradicated lithium induced renal failure by avoiding 
toxicity, and keeping plasma levels below 0.8 mmol/L (Aiff et al., 2014b). Lithium has a very 
narrow therapeutic range where the majority of patients will experience toxic effects above 
1.5 mmol/L (Goodwin et al., 2016). The theory that toxicity alone causes renal failure is  
based on evidence that periods of toxicity are related to decline in eGFR (Table 1.i) and 
end-stage renal disease (Aiff et al., 2014a). 
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Table 1.i Studies of lithium’s effects on eGFR published since 2012 
Authors N Comparison group  Follow-up Controlled for confounding Key limitations Statistically 
significant  
decline in eGFR 
compared to 
comparison  
Toxicity 
related to 
decline in 
eGFR 
 
Aiff et al. 
(2015) 
630 lithium 
exposed 
Cohort/case-series – 
no comparator group 
Max=30 years, 
min=10 years 
No No adjustment, no 
comparison group, 
missing exposure 
data 
Decline 
observed 
Yes  
Castro et 
al. (2015) 
1145 cases, 
4306 controls 
Case-control – CKD 
stage 3 vs. no CKD 
stage 3  
Max=9 years, 
min=1 day 
(median 178 
days) 
Age, sex, ethnicity, Charlson 
index, insurance, hypertension, 
smoking, diabetes, schizophrenia 
Case-control, no 
report of change in 
eGFR, short follow-up 
Not reported  Yes  
Clos et al. 
(2015) 
305 lithium 
exposed, 815 
comparator 
drugs 
Cohort – patients 
prescribed mood 
stabiliser or 
antipsychotic 
Max=12 years 
(mean=55 
months) 
Age, sex, baseline eGFR, 
genitourinary disease, 
hypertension, diabetes, NSAID, β-
blocker, ACEi, toxicity 
Potential confounding 
by indication, 
surveillance bias, 
young cohort (<65), 
short follow-up 
No Yes  
Close et al. 
(2014) 
2496 lithium 
exposed, 3864 
unexposed 
Patients with BPD 
with no lithium 
exposure 
Max=18 years 
(median 5.4 
years) 
Age, sex, alcohol, smoking, BMI, 
IMD, CVD, liver failure, diabetes, 
cancer, hypertension, 
antipsychotics, mood staiblisers, 
β-blocker, diuretics, ACEi, 
paracetamol, NSAID 
Potential confounding 
by indication, 
surveillance bias  
Yes Yes  
Shine et al. 
(2015) 
4678 lithium 
exposed, 
689228 
unexposed 
All individuals 
receiving eGFR tests 
not taking lithium 
Max=28 years 
(median 3 
years) 
Age, sex, diabetes Potential confounding 
by indication, 
surveillance bias, 
heterogeneous 
population,  limited 
adjustment 
Yes Yes  
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1.5.2.4 Endocrine effects of long-term lithium use 
Regarding the effects of lithium on thyroid function, four RCTs with thyroid outcomes were 
identified by McKnight et al. (2012). These reported that, during up to a year of follow-up, 
4% of patients prescribed lithium developed hypothyroidism, compared to none taking 
placebo. Their meta-analysis of case-controls studies found an odds ratio (OR) of 5.78 (95% 
CI 2.00 to 16.67) for individuals prescribed lithium compared to placebo. The quality of 
evidence is limited by lack of active comparator groups and low power. Observational 
studies had similar limitations to those examining renal outcomes. Studies published since 
2012 have been equally limited. There has been one major high-quality US EHR study which 
found similarly elevated rates of hypothyroidism across all commonly used mood stabiliser 
medication, including lithium, at 4 years treatment duration (Lambert et al., 2016). Four  
case-control studies reported  increased thyroid function in those taking lithium, but meta-
analysis of all studies measuring TSH showed no difference between lithium and placebo 
(McKnight et al., 2012). 
Lithium may also affect parathyroid function and calcium levels, but again the evidence is 
limited, inconsistent and tends to be of poor quality. McKnight et al. identified 4 cohort 
studies, 14 case-control studies and 6 cross-sectional studies. Meta-analysis of case-control 
studies suggested calcium and parathyroid hormone were increased by 10% in those taking 
lithium, however results were highly heterogeneous (McKnight et al., 2012). The source of 
this heterogeneity was not investigated statistically, but studies included mixed groups in 
terms of diagnosis and control group health status. These studies were also relatively small 
(maximum 142 cases). Of the cohort studies, sample size was small (maximum 53 people) 
and follow-up short (maximum 24 months). To date, there have been two additional cohort 
studies. One which found no association between lithium and adjusted calcium 
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concentration (Shine et al., 2015), the limitations of which are described in the renal effects 
section. The other found new hypothyroidism occurred at a rate of 12.9% in those taking 
lithium, however the cohort was small, had no comparison group and did not account for 
potential confounders (Albert et al., 2015). 
1.5.2.5 Other physical health effects of lithium treatment 
Treatment with lithium may induce weight gain. From 14 RCTs, clinically significant weight 
gain (>7%) was more common in those receiving lithium compared to placebo (OR 1.89, 
95% CI 1.27 to 2.82) but lower than olanzapine (OR 0.32, 95% CI 0.21 to 0.49) (McKnight et 
al., 2012). Head-to-head comparisons of weight gain with mood stabiliser medications are 
rare and of short duration (one trial of lithium vs. valproate (Bowden et al., 2010), two trials 
of lithium vs. olanzapine (Niufan et al., 2008, Tohen et al., 2005), one trial of lithium vs. 
quetiapine (Sachs et al., 2004)). Additionally, none of these trials were powered (or set up) 
to test whether there were differences in weight gain.  Other adverse effects that may be 
associated with weight gain, such as CVD, hypertension, and T2DM have not been widely 
investigated in lithium treated patients, and RCTs will not last long enough for these 
adverse outcomes to develop. Small, poor quality cohort studies have suggested that 
patients taking lithium have lower CVD mortality than other patients with BPD, and similar 
CVD mortality to the general population (Ahrens et al., 1995, Bocchetta et al., 2007). One 
cross-sectional study of 40 patients taking lithium monotherapy found no relationship 
between duration of treatment and hypertension risk (Klumpers et al., 2004). I am aware of 
only one RCT examining metabolic abnormalities, which found no association with lithium 
(McIntyre et al., 2011). A cross-sectional study found that patients taking lithium had lower 
metabolic syndrome prevalence than those taking SGAs (Yumru et al., 2007). A meta-
analysis of case-control and cohort studies of patients with BPD found that prevalence of 
metabolic syndrome was higher than the general population and highest in those exposed 
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to antipsychotic medication, however it did not address the issue of lithium (Vancampfort 
et al., 2013a). Table 1.ii summarises these adverse effects. 
Table 1.ii Summary of recognised adverse effects from long-term use 
Adverse effect  Lithium Valproate Olanzapine Quetiapine 
Renal      
Hyponatremia +    
Renal failure + +? ? ? 
Renal replacement therapy ?    
Hepatic      
Increased transaminase + ++ +? +? 
Hepatitis + + ? ? 
Endocrine      
Hypothyroidism ++ +  +? 
Hyperthyroidism +?    
Hypercalcemia +    
Hyperprolactinemia - - + + 
Metabolic      
Weight gain + ++ ++ ++ 
Hypertension ? ? ++ + 
T2DM +? +? ++ + 
CVD +? +? ++ + 
Neurological      
Sedation  + + + 
Tremor ++ +   
Cognitive problems +/- + + + 
Gastrointestinal      
Pancreatitis  +   
Haematological      
Leukopenia  + + + 
Thrombocytopenia  +   
Sexual      
Decreased libido/function + + + + 
Infertility  + + + 
Teratogenic + ++ +? +? 
+ effect present, ++ strong effect,  -  protective effect,  ?  unclear effect. Adapted from (Calkin 
et al.,  2013,  Correl l  et a l.,  2015, Goodwin et al.,  2016, Lambert et a l.,  2016, McKnight et al .,  
2012, McLaren and Marangell,  2004, Murru et al .,  2015, Shine et  al.,  2015, Terrana et al.,  
2015).  
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Other adverse effects are likely to be important to patients and modify treatment 
adherence, but are unlikely to be well recorded by clinicians. For example, studies suggest 
that around one third of those taking lithium experience sexual dysfunction (Elnazer et al., 
2015, Grover et al., 2014), however it is unclear how rates compare to those in individuals 
with untreated bipolar depression or treated with antidepressants. The teratogenic risk 
associated with lithium is low in absolute terms, but is elevated relative to placebo (Nguyen 
et al., 2009).  
1.5.2.6 Suicide risk in patients taking lithium 
Because RCTs often exclude those with a history of suicidal behaviour, drug effects on self-
harm and suicide have been difficult to quantify due to low event rates (Perlis, 2011). The 
findings of a meta-analysis suggested that suicide was less likely in individuals prescribed 
lithium than placebo (4 trials, including no suicides in those treated with lithium and 6 in 
those treated with placebo – OR 0.13; 95% CI 0.03 to 0.66) (Cipriani et al., 2013a). However 
lithium did not reduce suicide compared to active comparator groups, and there was no 
difference in self-harm rates (Cipriani et al., 2013a). The results of observational studies 
have suggested that lithium use may reduce fatal and non-fatal self-harm compared with 
maintenance treatment alternatives, most commonly anticonvulsant medication 
(Baldessarini et al., 2006b, Goodwin et al., 2003, Schou, 1998, Smith et al., 2009, 
Søndergård et al., 2008). Baldessarini and colleagues used data from a number of sources 
to demonstrate that individuals with BPD not treated with lithium had 10 times the risk of 
suicide and almost 4 times the risk of suicide attempts, than those treated with lithium 
(Baldessarini et al., 2006a). However, these studies are similarly limited by low event rates, 
confounding by indication, and have often been designed to investigate the effects of 
medication adherence on suicide, rather than comparing individual drugs (Smith et al., 
2009, Søndergård et al., 2008). In addition, the findings have not always been consistent, 
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with a number of studies suggesting there is no difference between mood stabilisers 
(Ahearn et al., 2013, Bowden et al., 2000, Marangell et al., 2008). A recent large Swedish 
cohort study (unpublished PhD thesis (Song, 2017))  found a reduced rate of suicide-related 
events (self-harm and suicide) in people prescribed lithium, compared to those prescribed 
valproate. The study also found a reduced rate during periods on lithium compared to off-
lithium, such that (if the association were causal) 12% (95% CI 4-20) of suicide-related 
events could be prevented if all patients had taken lithium for the entire follow-up period. 
1.5.3 Valproate 
1.5.3.1 Effectiveness as a maintenance mood stabiliser  
Valproate has become increasingly used over the last two decades in the UK as prophylaxis 
against further affective episodes (Hayes et al., 2011), despite a lack of robust evidence for 
its effectiveness (National Institute for Health and Care Excellence, 2014).  Although RCT 
meta-analysis suggests valproate is favoured over placebo for prevention of a composite 
outcome of “any new mood episode”, this is not the case when individual manic or 
depressive relapses are the outcome of interest (Miura et al., 2014). This is potentially due 
to low powered studies examining these specific outcomes. It is also not superior to 
placebo in terms of tolerability or acceptability measures (Miura et al., 2014). There is more 
positive evidence from naturalistic studies that compare hospital admission rates on and 
off treatment over a number of years. These suggest valproate is associated with more 
hospitalisations than lithium, but fewer than other maintenance mood stabiliser options 
(Goodwin et al., 2016). Combination treatment with lithium plus valproate has been shown 
to be better than lithium monotherapy (Geddes et al., 2010), however this ignores the 
potential for additive untoward effects. The risk of teratogenic effects has meant that 
valproate has been contraindicated in women of child-bearing age since the mid-2000s 
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(Vajda et al., 2004) but this is not reflected in the prescribing trends (Figure 1.iv) (Hayes et 
al., 2011). 
1.5.3.2 Adverse effects from long-term use of valproate 
A number of adverse physical health events have been reported during treatment with 
valproate. Studies of these effects are rarer than those investigating the potential adverse 
outcomes for people taking lithium.  Whilst, to some extent, the adverse effects of 
valproate have been compared with other antiepileptic medication in individuals with 
epilepsy, comparisons with other mood stabilisers in BPD are lacking (Greenwood, 2000). 
The most commonly reported adverse effects include gastrointestinal disturbance, tremor, 
weight gain and transaminase abnormalities (see Table 1.ii). 
1.5.3.3 Weight gain during maintenance treatment with valproate 
Weight gain appears to be a particular issue with valproate relative to other 
anticonvulsants (Cramer et al., 2010). RCTs suggest incident weight gain during valproate 
treatment may be as high as 59% – 12 times higher than in those treated with 
carbamazepine (Richens et al., 1994). A systematic review of cohort studies suggests up to 
71% of adults with epilepsy treated with valproate will experience weight gain, with 47% 
gaining greater than 10% of baseline bodyweight (Jallon and Picard, 2001). Among trials in 
BPD populations, weight gain appears to be lower in people taking valproate than those 
taking antipsychotics, but higher than in lithium-treated patients. For example, a 12 week 
trial of manic patients found 10% of valproate-treated patients gained weight compared to 
25% of olanzapine-treated patients (Zajecka et al., 2002). However, in an extension of this 
RCT to 47 weeks it became apparent that this was an early effect of olanzapine and after 
week 19 there was no difference between groups in terms of weight gain from baseline 
(Tohen et al., 2003). In a large maintenance treatment RCT comparing valproate, lithium 
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and placebo weight gain occurred in 21%, 13% and 7% respectively (P=0.004 for the 
difference between valproate and placebo)(Bowden et al., 2000). The physiological 
mechanism behind valproate associated weight gain remains unclear, but is potentially 
related to hyperinsulinemia (Rakitin et al., 2015). 
1.5.3.4 Hepatic Effects of valproate 
Asymptomatic elevation of transaminases occurs in approximately 40% of individuals 
prescribed valproate (Murru et al., 2015). Severe liver toxicity is rare, but fatal hepatic 
failure occurs in 1 in 10,000 exposures, and appears to be non-dose-related (Perucca and 
Gilliam, 2012).  
1.5.3.5 Other effects of long-term valproate use 
Given the association between valproate and weight gain, we might expect increases in 
metabolic syndrome, hypertension, CVD and T2DM. Comparative studies of these longer-
term outcomes in BPD are rare or non-existent. I could identify three cross-sectional 
studies of metabolic syndrome and hypertension; two found no association between 
metabolic syndrome or hypertension and valproate (Correll et al., 2008, Elmslie et al., 
2009), one found no difference in risk between valproate and lithium (Yumru et al., 2007). 
However, these studies were of small numbers of patients, were not longitudinal in nature 
and took place in potentially non-representative samples, without appropriate comparison 
groups. No studies looked specifically at CVD or T2DM. Other notable adverse effects 
include encephalopathy symptoms, platelet disorders, pancreatitis and teratogenicity 
(including a 1% to 3% risk of neural tube defects) (Perucca, 2002, Perucca and Gilliam, 
2012).  Unlike lithium, there is no evidence that valproate is associated with renal or 
thyroid abnormalities.  
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1.5.3.6 Suicide risk in patients taking valproate 
In 2008, a warning was issued from the US Food and Drug Administration (FDA) (US Food 
and Drug Administration, 2009) that anticonvulsant medications carry an increased risk of 
suicidal self-harm. The FDA conducted a meta-analysis of 199 RCTs (27,863 patients) and 
found four suicides in those treated with anticonvulsants vs. none treated with placebo. 
Interestingly, the overall risk of suicidal ideation or behaviour was 3.5 times higher than 
placebo in epilepsy trials and 1.5 times placebo in psychiatric trials.  Of these RCTs, 14 were 
of valproate and found an OR for suicidal behaviour or ideation of 0.72 (95% CI 0.29 to 
1.84). Since then a number of studies have investigated this issue in BPD. A meta-analysis of 
RCTs of valproate (Redden et al., 2011)  and several observational studies that included 
only patients with BPD  (Arana et al., 2010, Gibbons et al., 2009, Leon et al., 2014, Reid, 
2011) did not support this concern. A recent Swedish cohort study suggests that self-harm 
and suicide occur at similar rates on and off valproate and more frequently than in lithium-
treated patients (Song, 2017). 
1.5.4 Olanzapine and Quetiapine 
1.5.4.1 Effectiveness as maintenance mood stabilisers 
The antipsychotic olanzapine has been shown to be one of the most potent treatments for 
acute mania, with a standardised mean difference compared to placebo of -0.43 (95% CI -
0.54 to -0.32) (Cipriani et al., 2011). In many clinical situations, it would seem reasonable to 
continue this after remission from the acute episode (National Institute for Health and Care 
Excellence, 2006). However, there are few long-term trials of olanzapine as maintenance 
treatment, most use enrichment designs (i.e., continuing treatment in those that have 
shown an initial response), and none have the same degree of independent replication of 
efficacy as lithium (Miura et al., 2014, Severus et al., 2014). However this lack of evidence 
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has not prevented its inclusion in guidelines as a first-line treatment (National Institute for 
Health and Care Excellence, 2006) and a rapid increase in use (Hayes et al., 2011).  
Quetiapine is the only monotherapy recommended as first-line treatment for acute bipolar 
depression (National Institute for Health and Care Excellence, 2014). Evidence for this 
recommendation comes from a meta-analysis of 11 trials which found a number needed to 
treat of 6 (95% CI 5 to 8) compared to placebo (Chiesa et al., 2012). Again, it would seem to 
be a rational treatment approach to continue this following mood stabilisation. This 
rationale is supported by one RCT with an active comparator group (lithium versus 
quetiapine (Weisler et al., 2011)). This trial suggested that individuals responding to 
quetiapine had an increased time to reoccurrence compared to those switched to lithium 
or placebo. This study design strongly favours quetiapine and was considered very low 
quality evidence by NICE (National Institute for Health and Care Excellence, 2014). Beyond 
this, RCTs of quetiapine as a longer-term maintenance treatment have not been carried 
out. 
1.5.4.2 Adverse effects of olanzapine and quetiapine 
Antipsychotic adverse effects have mostly been examined in the context of treatment for 
schizophrenia. Weight gain is a common adverse effect of antipsychotic medication and is 
associated with several diseases including CVD, hypertension, T2DM, respiratory problems 
and 11 different cancers (Kyrgiou et al., 2017, Must et al., 1999).  
1.5.4.3 Weight gain during treatment with olanzapine or quetiapine 
As can be seen, each drug in Figure 1.v is associated with more than twice as many patients 
experiencing >7% weight gain from baseline than individuals taking placebo, and weight 
gain with olanzapine and quetiapine appears to be particularly problematic. A recent meta-
analysis of weight gain in RCTs found, within a median duration of 3 months, olanzapine 
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and quetiapine were associated with a 2.4kg and 1.1kg weight gain respectively (Domecq et 
al., 2015).  As with some of the other outcomes studied in this thesis, only short-term 
weight gain has been well studied, so the trajectory of weight gain in individuals taking 
these drugs long-term is speculative. In addition, these are not head-to-head comparisons 
of olanzapine and quetiapine, so the relative weight gain on each drug is not known.  
Yearlong RCTs in BPD patients, with head-to-head comparisons of olanzapine vs. lithium 
(mean weight gain 1.8kg vs. -1.4kg; P<0.001) and olanzapine vs. valproate (mean weight 
gain 2.8kg vs. 1.2kg; P<0.001) suggest olanzapine may be particularly associated with 
weight gain (Tohen et al., 2005, Tohen et al., 2003). This is also reflected in the literature on 
schizophrenia treatment with SGAs. Risk of dyslipidaemia with SGAs appears to mirror their 
propensity to cause weight gain (De Hert et al., 2012, Haddad and Sharma, 2007).   
Figure 1.v Percentage of patients with clinically significant weight gain (>7%) in short-
term (3-8 weeks) placebo-controlled RCTs. 
 
Adapted from (Haddad, 2005) .   
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1.5.4.4 Metabolic and cardiac effects of olanzapine and quetiapine  
As stated, weight gain and dyslipidaemia are risk factors for adverse metabolic and cardiac 
outcomes. Studies of these longer-term outcomes are limited in number. Meta-analyses 
have found that SGAs are more strongly associated with T2DM than first generation 
antipsychotics (FGAs) (Smith et al., 2008). Observational studies have found that both 
olanzapine and quetiapine increase T2DM rates, relative to haloperidol (Lambert et al., 
2006) and untreated patients (Buse et al., 2003). However, these studies were in cohorts 
with schizophrenia and were not able to show differences between olanzapine and 
quetiapine because of the small numbers of people developing T2DM. One previous Danish 
population based cohort study has examined rates of CVD in patients prescribed olanzapine 
or quetiapine for all indications (Pasternak et al., 2014). This study found no difference 
between quetiapine and olanzapine in CVD rates, after adjustment for a number of 
sociodemographic and health variables (HR 0.86; 95% CI 0.50 ̶ 1.48). 
1.5.4.5 Other effects of olanzapine and quetiapine treatment 
Mild and transiently abnormal liver function tests (LFTs) are common in patients receiving 
antipsychotics (median 32% abnormal (Marwick et al., 2012)), but clinically significant 
elevations are rare (Correll et al., 2015). There is currently no clear evidence that either 
olanzapine or quetiapine convey a particular risk (see Table 1.ii). T2DM is associated with 
renal disease, and therefore theoretically olanzapine and quetiapine have the potential to 
increase renal failure via this route. However, I am aware of no studies that specifically 
examine CKD incidence.  
1.5.4.6 Suicide risk in patients taking olanzapine and quetiapine  
There are sparse data on the association between antipsychotic medication use and self-
harm or suicide in BPD. Small retrospective cohorts have shown no difference in self-harm 
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in patients taking olanzapine or quetiapine (Koek et al., 2012), but have demonstrated 
higher rates of suicide attempts in those prescribed SGAs (such as olanzapine or 
quetiapine) compared with lithium or valproate (Ahearn et al., 2013, Yerevanian et al., 
2007). In contrast, in schizophrenia, observational studies have shown that suicide risk is 
lower in those taking SGAs compared to individuals taking FGAs (Altamura et al., 2003). The 
findings of the study by Altamura et al. are limited by small sample size, potential bias and 
confounding. In RCTs, individuals prescribed olanzapine have been found to have lower 
suicide attempt rates than those taking risperidone (Tran et al., 1997) and haloperidol  
(Beasley et al., 1998, Glazer, 1998). However, these studies all have limited follow-up and 
were not powered to examine self-harm. 
1.5.5 Head-to-head comparisons of lithium, valproate, olanzapine and quetiapine as 
maintenance mood stabilisers in bipolar disorder  
As discussed, head-to-head comparisons of lithium, valproate, olanzapine and quetiapine in 
terms of effectiveness, tolerability, self-harm, accidental injury, suicide and adverse 
physical health effects when used long-term for mood stabilisation in BPD are rare. 
Comparisons of this nature, accounting as well as possible for potential confounders, are 
vital to inform clinical decision-making.   
From the potential adverse effects of these medicines (Table 1.iii), I chose to examine 
those which appear to be strongly related to a particular drug, commonly occurring (and 
well recorded in EHR), and/or having greatest impact on patient wellbeing and function.  
These can be divided into four types of adverse events: renal (chronic kidney disease), 
hepatic (hepatotoxicity), endocrine (thyroid disease, and hypocalcaemia) and metabolic 
(weight gain, hypertension, T2DM and CVD). 
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1.6 Limitations of randomised controlled trials in bipolar 
disorder 
Although RCTs are the gold standard for demonstrating the efficacy of medications, their 
applicability to individuals with BPD may be compromised by the complex, labile 
symptomatic presentations of the illness, patients’ tendency to deny illness or reject 
treatment, and diagnostic heterogeneity in routine practice. These concerns have been 
raised in other areas of medicine regarding RCTs where the disorder under investigation is 
chronic and relapsing-remitting and when the exclusion criteria of RCTs can often mean 
that external validity is low (i.e., people included in trials do not represent a real life sample 
of individuals receiving a bipolar disorder diagnosis) (Lancet Editors, 1992). Therefore 
applying  existing RCTs results to managing a lifelong illness of unpredictable course is not 
straightforward (Black, 1996). By definition, as soon as a clinical treatment lasts longer than 
the RCT that informed it, the treatment is no longer “evidence-based”. Necessary trials are 
also costly and difficult to run for sufficient periods in relation to the time-course of BPD 
(Hayes and Osborn, 2011). 
1.6.1 Problems with trial designs in bipolar disorder 
Many RCTs of maintenance treatment have been criticised because of enriched designs, 
which select patients who have responded to the treatment used in the acute phase. The 
network meta-analysis by Miura et al. found this to be the case in 19 of 33 included trials 
(Miura et al., 2014). It is recognised that this may be particularly problematic in the case of 
lithium, where withdrawal of the drug can prompt relapse (Moncrieff, 1997). However this 
is also true of valproate and olanzapine (Goodwin, 2009). The enrichment design can 
answer questions about the continued benefits of the investigational medicine, but is not a 
fair test of the comparator agent. 
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Of all existing trials, the study design for the ‘BALANCE’ RCT (Geddes et al., 2010) aimed to 
maximise the generalisability of the findings to a clinical population, by allowing clinicians 
to prescribe as they wished (beyond allocation to either lithium, valproate or lithium plus 
valproate). However, limitations inevitably remained in terms of including patients who had 
shown a differential previous response to either lithium or valproate, diagnostic 
heterogeneity within the sample population, and frequency of comorbidity compared with 
the general population.  
1.6.2 Recruitment problems in pharmacological trials for bipolar disorder 
Recruitment to trials of maintenance BPD medications has proved difficult and costly. 
Again, using the ‘BALANCE’ RCT (Geddes et al., 2010) as an example: it took seven years to 
recruit its 345 randomised subjects, compared to the original target of 3,000.  This also 
forced the investigators to change the primary outcome to provide sufficient statistical 
power (Geddes and Goodwin, 2001, Geddes et al., 2010). Other trials have had similar 
problems (Charlson and Horwitz, 1984, Jones et al., 2006, March et al., 2014, Nolen et al., 
2007). As such, further large comparative efficacy trials of “established” off-patent 
medications are unlikely to be funded. Therefore, alternative study designs are need to 
advance the evidence-base, such as quasi-experimental designs in routine cohorts. 
1.6.3 Length of follow-up in pharmacological trials for bipolar disorder maintenance 
treatment 
In the recent meta-analyses of maintenance treatment trials (including 33 studies) the 
longest follow-up was found to be 3.3 years, with the majority having only one year of 
follow-up and many of these risking bias because of high attrition rates (Miura et al., 2014). 
It is difficult to extrapolate conclusions of these RCTs to the longer-term maintenance 
treatment. Notably, given the recognised kindling effect of recurrent affective episodes 
(i.e., each new mood episode increases the risk of further episodes) it is unlikely that the 
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risk-benefit profile of a medication will be constant over time. In addition, none of the 
recognised long-term side effects of these medications will have the opportunity to 
develop. Much longer follow-up is needed to determine whether there is a timepoint when 
the benefits of the treatment cease or when the risks become unacceptable. 
1.6.4 Choosing meaningful outcomes for maintenance treatment trials 
BPD trials have tended to define their primary outcome for efficacy/effectiveness in terms 
of time to relapse or recurrence, measured by a mood disorder scale, meeting diagnostic 
criteria for a new mood disorder episode, hospitalisation, need for a change in medication 
or add-on of medication or ECT, or the investigator judging that medication was stopped 
due to a new mood episode. Often, these studies will include a measure of tolerability 
represented by time to stopping medication: i.e., staying on the drug means that the 
patient has no untoward side effects. Sometimes trials have used a combined efficacy and 
tolerability measure as their primary outcome which becomes more difficult to interpret, 
but may more accurately reflect real life use of the drugs (Hayes and Osborn, 2011).  
In the real world, treatment choice has multiple aims, including reducing hospital 
admissions, but also improving mood stability, reducing inter-episode residual symptoms, 
improving functioning and improving quality of life. Trials have struggled to assess these 
outcomes. 
1.6.5 Lack of trials with active comparator groups in bipolar disorder maintenance 
treatment 
Both placebo and active comparator trials are important for the full assessment of efficacy, 
effectiveness, tolerability and safety of medications. Active comparator studies have been 
identified as particularly important when 1) the medication may be associated with safety 
concerns for mortality or morbidity, and 2) a medication with inferior efficacy may 
  51 
conceivably lead to significant, long-term or irreversible harm (Committee for Medicinal 
Products for Human Use, 2011). Both of these issues are true in the case of lithium, 
valproate, olanzapine and quetiapine.    
1.6.6 Overcoming the limitations of trials of maintenance treatment 
In summary, trials are short in follow-up, limited in number, have few participants who are 
unrepresentative of the broader population with bipolar disorder diagnoses, and often 
biased because of their design. The following sections explain how this thesis aims to 
address the issues outlined above using observational data from primary care EHRs.    
 
1.7 Addressing the gaps in our understanding about long-
term outcomes in bipolar disorder with observational data 
1.7.1 Data Source: Primary care electronic health records 
The data source for each of the studies is The Health Improvement Network (THIN) an 
anonymised EHR primary care database in the United Kingdom.  It is described in detail in 
Section 2.3. At the time the cohorts were extracted for this thesis, THIN contained records 
of over 11 million people, with a median follow-up time of approximately six years 
(http://www.epic-uk.org/). Patients included in the database have been shown to be 
broadly representative of the UK population, and General Practitioners (GPs) contributing 
data are representative in terms of consultation and prescribing statistics (Blak et al., 2006, 
Blak et al., 2011). Approximately 98% of the population is registered with a GP (Lis and 
Mann, 1995). The reliability of THIN for research purposes has been validated against 
experimental and other observational evidence (Langley et al., 2010, Lewis et al., 2007). 
The validity of diagnoses of SMI (schizophrenia, BPD and other psychotic illnesses) in 
primary care has been shown (Nazareth et al., 1993) and the incidence rate of BPD in the 
database is similar to other European estimates (Hardoon et al., 2013). Although diagnosis 
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of BPD is mainly made in secondary psychiatric services, many patients will primarily be 
cared for by their GP (National Institute for Health and Care Excellence, 2014). This makes 
THIN an ideal data source for conducting representative, valid and generalisable research 
into the adverse outcomes and effects of drug treatment in BPD.  
1.7.2 Mortality and morbidity in bipolar disorder 
From the systematic review (Chapter 3), particular areas were identified for further 
investigation and are addressed in Study 1 (Chapter 4) of the thesis. Study 1 reports rates 
of all-cause mortality and mortality from cardiovascular events, and suicide in BPD, 
schizophrenia and a frequency matched general population comparator group. It also 
examines rates of CVD diagnoses, and self-harm in the three groups. It is hypothesised that 
all-cause mortality, CVD mortality, suicide, CVD diagnosis and self-harm rates are elevated 
relative to the general population, and in line with rates for schizophrenia. 
1.7.3 Effectiveness and tolerability of maintenance medication 
In the past, commentators have criticised observational studies of medications, suggesting 
they would overestimate treatment effects and that they therefore provide little value in 
assessing therapies; however, comparative studies with RCTs, across various branches of 
medicine, have now challenged this claim (Black, 1996). Study 2 (Chapter 6) is based on a 
similar complementary approach; attempting to reconfirm findings from RCTs, with larger 
patient numbers, over longer follow-up periods, and with patients who are more 
representative of a wider cross-section of those with a BPD diagnosis. This study compares 
the time to monotherapy treatment failure (defined as stopping the drug, swapping to a 
new drug or requiring add-on of a mood stabiliser, antipsychotic, antidepressant or 
benzodiazepine) in individuals prescribed lithium, valproate, olanzapine or quetiapine. This 
outcome was chosen as a proxy for combined effectiveness and tolerability, because it has 
  53 
been used in a number of drug trials in BPD (Miura et al., 2014). This study uses a quasi-
experimental design using a propensity score (PS) approach to balance baseline 
characteristics of patients prescribed different drugs. The PS approach is further described 
in Sections 2.9.2 and 2.11. It is hypothesised that all drugs will show similar rates of 
monotherapy treatment failure. 
1.7.4 Adverse events associated with maintenance medication in bipolar disorder 
Follow-up time in RCTs is usually short, relative to the time it may take to develop many 
drug side effects during long-term maintenance treatment. RCTs are also designed with 
sufficient sample size and statistical power to detect efficacy, rather than the power to 
determine the safety of the study medications (Wahab et al., 2013). Current methods of 
reporting chronic adverse events in routine surveillance, either by health professionals or 
patients are not felt to be adequate (Blenkinsopp et al., 2007). Use of routine EHRs is likely 
to be a more efficient way of identifying and quantifying the risk of adverse events, as they 
are likely to be complete for severe events, and do not require extra work of reporting 
events by the clinician (Honigman et al., 2001, von Euler et al., 2006).  
Lithium, valproate, olanzapine and quetiapine have been widely used across the world and 
so there should be many years of patient data available for side effect profiling. Despite this 
the risks of chronic adverse effects have only recently begun to be quantified and appraised 
(Close et al., 2014, McKnight et al., 2012, Shine et al., 2015) and there are no existing 
studies making head-to-head comparisons of adverse events associated with these drugs. 
Study 3 (Chapter 7) is a comparison of the major adverse events associated with lithium, 
valproate, olanzapine and quetiapine using a PS approach. These can be divided into four 
types of adverse events: renal (chronic kidney disease), hepatic (hepatotoxicity), endocrine 
(thyroid disease, and hypocalcaemia) and metabolic (weight gain, hypertension, T2DM and 
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CVD). It is hypothesised that lithium will be associated with more renal and endocrine 
adverse events, valproate with more hepatic adverse events, and olanzapine and 
quetiapine with more metabolic adverse events. However, given that there is some 
evidence that each of these drugs can potentially have hepatic, renal and metabolic effects, 
not all differences may be clinically significant.  
1.7.5 Self-harm rates with different maintenance medications   
Preventing self-harm and suicide are key aims in the effective management of BPD. Lithium 
is the only drug which has been consistently found to reduce self-harming behaviour in 
both observational (Baldessarini and Tondo, 2003, Baldessarini et al., 2003, Goodwin et al., 
2003) and trial data (Cipriani et al., 2013a).  However, existing cohort studies have tended 
to lack active comparator groups and results from RCTs are secondary analyses with small 
numbers of events. Study 4 (Chapter 8) is therefore a comparison of rates of self-harming 
behaviour in patients prescribed lithium, valproate, olanzapine or quetiapine using a PS 
approach. The study also examines accidental injury rates to test hypotheses about 
potential mechanisms of action.  It is hypothesised that patients prescribed lithium will 
have the lowest rates of self-harm. 
1.8 Objectives of the studies included in this thesis 
1.8.1 Long-term outcomes in bipolar disorder 
i) To summarise previous observational studies of long-term prognosis in individuals 
with a diagnosis of BPD by examining all-cause and cause specific mortality via 
systematic review and meta-analysis (Chapter 3) 
ii) To calculate recent time trends in all-cause mortality in the UK in individuals with 
BPD compared to individuals with schizophrenia and the general population (Study 
1: Chapter 4) 
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iii) To determine relative rates of i) CVD deaths, ii) suicide, iii) CVD diagnoses, iv) self-
harm in individuals diagnosed with BPD or schizophrenia compared to the general 
population, while accounting for sociodemographic factors (Study 1: Chapter 4) 
 
1.8.2 Effectiveness and adverse effects of maintenance treatments 
iv) To determine relative efficacy of the four most commonly used maintenance mood 
stabiliser medications (lithium, valproate, olanzapine and quetiapine) via a network 
meta-analysis of all head-to-head and placebo controlled RCTs (Chapter 5) 
v) To assess comparative effectiveness and tolerability of the four most common 
mood stabilisers by calculating rates of time to cessation of treatment, or add-on of 
another psychotropic medication in individuals prescribed lithium, valproate, 
olanzapine and quetiapine, while accounting for propensity to be prescribed one of 
these mood stabilisers (Study 2: Chapter 6)   
vi)  To calculate rates of adverse events on these four mood stabilisers, specifically 
chronic renal, hepatic, endocrine and metabolic effects, accounting for propensity 
to be prescribed one of these mood stabilisers   (Study 3: Chapter 7)   
vii) To determine rates of self-harm, unintentional injury and suicide on these four 
mood stabilisers, while accounting for propensity to be prescribed one of these 
mood stabilisers  (Study 4: Chapter 8)   
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Chapter 2 Methods – justification and 
overview 
2.1 Summary 
This chapter provides a rationale for decisions made about how to compete the systematic 
reviews and meta-analyses and the planning of the five completed cohort studies. THIN was 
identified as a suitable data source for the studies in this thesis, for the reasons outlined. 
The steps taken in the developing the hypotheses to be tested, the study design used and 
the analysis plans for each of the studies (with the aim of minimising confounding and bias 
and maximising the possibility of drawing conclusions related to causality) are described. 
The limitations of the chosen approach are considered in the discussion section of each 
chapter and more generally in Chapter 9. 
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2.2 Systematic review and meta-analysis 
2.2.1 Summarising studies of mortality in people with bipolar disorder 
There are a number of methods of reporting premature mortality; including death rates, 
life-expectancy, and measures of years of life lost. However, the most commonly used 
comparative measure is the SMR. The SMR is an indirect method of standardisation 
calculated by the ratio of observed deaths in the study group to expected deaths in the 
general population. Studies reporting SMR were the focus of the review to be reported in 
Chapter 3 because the large number of available SMR estimates allowed a meta-analysis 
and updated the highly cited work of Harris and Barraclough (Harris and Barraclough, 
1998). 
2.2.2 Network meta-analysis for comparing the efficacy and tolerability of maintenance 
mood stabilisers  
A key limitation of traditional meta-analysis techniques to examine treatment effects is that 
they compare only two interventions at a time (Cipriani et al., 2013b). This is a particular 
problem if several treatment options need to be compared, as the result will be a number 
of pairwise meta-analysis comparisons. This is an issue in the assessment of maintenance 
mood stabilisers for BPD, where multiple drugs may be effective. Network meta-analysis 
(NMA) is a method to summarises trial results of all treatments (Caldwell et al., 2005). NMA 
synthesises data from a network of trials about more than two competing interventions. 
The integration of direct evidence (from studies directly comparing interventions) with 
indirect evidence (information about two treatments derived via a common comparator) 
increases the precision in the estimates and can produce a relative ranking of all treatments 
for the studied outcome (Bucher et al., 1997, Salanti et al., 2011). As such, the relative 
effectiveness of two treatments can be estimated, even if no trials compare them directly. 
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However, the validity of the conclusions drawn relies on a number of assumptions about 
heterogeneity, transitivity and consistency (Chaimani et al., 2013).  
Chapter 5 of this thesis is a NMA of trials comparing any combination of lithium, valproate, 
olanzapine, quetiapine and placebo. These treatments are better connected in the NMA 
than all the drugs included in Miura et al. (Miura et al., 2014) and comparisons are less 
likely to violate the transitivity assumption (this is discussed in the introduction to Chapter 
5). Comparisons with findings from the NMA of Miura et al. are made in the discussion 
section of Chapter 5.  
2.3 Data Source for cohort studies – primary care electronic 
health records 
2.3.1 Comparison of The Health Improvement Network with other primary care 
electronic health records 
Three large primary care EHR systems exist in the UK: Clinical Practice Research Datalink 
(CPRD), QResearch, and THIN (Shephard et al., 2011). Both CPRD and THIN are descendants 
of the Value Added Information System (VAMP) which began extracting pseudonymised 
medical records from the Vision software platform (a frontend user EHR) in 1987 (Williams 
et al., 2012). Currently there is an overlap of data held in CPRD and THIN, with 
approximately 60% of GP practices contributing to both, because of their use of Vision 
(Carbonari et al., 2015). QResearch extracts from another commonly used EHR software; 
Egton Medical Information System (EMIS) (Coupland et al., 2016). A number of studies 
carried out across these three databases have suggested high levels of similarity (Hippisley-
Cox et al., 2014, Reeves et al., 2014). I chose THIN as the data source for the studies 
because of the extensive expertise that exists within UCL (in both the Division of Psychiatry 
and the Department of Primary Care and Population Health) and because UCL holds a 
licence to access all THIN data. 
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2.3.2 Coverage of The Health Improvement Network database 
The studies in this thesis use data up until the end of 2014, at which time, THIN covered 
641 GP practices, representing 6% of the UK population (13,816,680 total patients) 
(Personal correspondence with IMS Health, 2016). Patients in the database have been 
shown to be broadly representative of the UK population, and GPs contributing data have 
been shown to be representative in terms of consultation and prescribing statistics (Blak et 
al., 2006, Blak et al., 2011). Approximately 98% of the UK population is registered with a GP 
(Lis and Mann, 1995). 
2.3.3 Data recording in The Health Improvement Network 
Information in the THIN database is generated through routine record keeping of GPs for 
the purposes of clinical management of their patients. GPs use Read codes, a hierarchical 
coding system, to record information in THIN (Chisholm, 1990). These codes include 
diagnoses (which map onto ICD-10 codes), symptoms, examination findings, health 
indicators (for example smoking, alcohol intake, body mass index (BMI)), referrals, test 
results and information from hospital specialists, creating a longitudinal record for each 
patient (Davé and Petersen, 2009). GPs are responsible for issuing drug prescriptions if 
treatment is ongoing, and this information is available and essentially complete in THIN 
(Health and Social Care Informaiton Centre, 2012). Missing prescribing data may occur 
when prescriptions are handwritten or when a patient is in hospital for a prolonged period. 
Some drugs, such as clozapine and some depot antipsychotic medications are prescribed in 
secondary care but are not relevant to the studies in this thesis. Over the counter 
medications are also not included, but similarly are not important in the context of these 
studies. 
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THIN also contains a record of patient ethnicity. This was poorly recorded prior to 2006, but 
GPs were incentivised, via the Quality and Outcomes Framework (QOF), to add it to records 
from 2004. By 2010 over 90% of newly registered primary care patients were having 
ethnicity recorded (Mathur et al., 2014). There is no patient level measure of 
socioeconomic status (SES) or educational attainment recorded in THIN, but there is an 
area level measure which is associated with individual SES; the Townsend deprivation 
index. The Townsend score incorporates four variables: unemployment (as a percentage of 
those aged 16 and over who are economically active), non-car ownership (as a percentage 
of all households), non-home ownership (as a percentage of all households), and household 
overcrowding (Townsend, 1987).  In THIN a score is assigned to each lower super output 
area (an area of approximately 650 households) and is expressed in quintiles of Townsend 
score based on 2001 UK census data. 
2.3.4 Ethical approval for the cohort studies 
The scheme for THIN to provide anonymous patient data to researchers was approved by 
the National Health Service South-East Multicentre Research Ethics Committee in 2003, and 
scientific approval for the studies in this thesis was obtained from Cegedim Strategic Data 
Medical Research’s Scientific Review Committee in March 2015. A copy of the scientific 
approval application is included in Appendix 1. 
2.4 Code lists for defining exposures, outcomes and 
covariates 
Code lists were developed for each variable used in the studies using the method described 
by Davé and Petersen (Davé and Petersen, 2009). These were either Read code lists or drug 
code lists, but the essential technique for code list preparation is the same. Researchers at 
the Department of Primary Care and Population Health (UCL) and the Division of Psychiatry 
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(UCL), have previously developed a large number of code lists, and further lists are held at 
https://clinicalcodes.rss.mhs.man.ac.uk/ (Springate et al., 2014). However, on reviewing 
the Read code lists it became apparent that each study would require unique lists, often 
due to the sensitivity and specificity of the lists. Code lists for exposure and outcome 
variables would often need to be more sensitive than those used for confounder 
adjustment.  Where possible, existing code lists were used as the starting point for study 
specific code list development. Code lists were developed via an iterative process of 
refinements involving all supervisors.   Full code lists for BPD and schizophrenia are 
included in Appendix 2 as examples.  Code lists for outcomes and covariates are available 
on request. These have not been included as code lists for outcomes alone were greater 
than 400 pages long. 
2.5 Inclusion criteria for the cohort studies 
2.5.1 Primary care practice inclusion criteria 
Two measures of data quality have been developed for use with THIN: acceptable mortality 
reporting (AMR) (Maguire et al., 2009) and acceptable computer usage (ACU) (Horsfall et 
al., 2013). AMR is a measure comparing the standardised annual rates of all-cause mortality 
reporting for a GP practice with expected deaths using Office for National statistics (ONS) 
death data, accounting for the age and sex distribution of patients in the practice (Maguire 
et al., 2009). The ACU is the date at which a practice first entered an average of two or 
more therapy records, or one medical record and one additional data item into each 
patient record per year (Horsfall et al., 2013). For the studies in this thesis, practices are 
only included after they meet both these criteria. Combining ACU and AMR has been found 
to produce incident time trends consistent with external data sources (Horsfall et al., 2013). 
Furthermore, GP practices had to contribute at least three years of data to THIN, have a list 
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size of more than 2000 patients and have a measure of area level deprivation for at least 
80% of registered patients. These additional criteria have been used previously to ensure 
only high quality patient records are used for analysis. 
2.5.2 Bipolar disorder and schizophrenia inclusion criteria 
The code lists used as a starting point for BPD and schizophrenia case identification have 
been used previously (Hardoon et al., 2013, Osborn et al., 2011, Osborn et al., 2015). For 
BPD, 97 codes were identified. These codes denoted a range of episode severity and 
chronicity of disorder. Unfortunately, it was not possible to separate out subtypes of BPD 
using Read codes. However, patients with BPD diagnoses who attended GPs and were 
coded as having depression and or depression symptoms were identified. For 
schizophrenia, 92 codes were identified. A conservative approach was taken to code list 
generation to increase specificity. For example; individuals with codes suggestive of 
schizoaffective illness were excluded, as this disorder is an intermediate phenotype, which 
shares diagnostic and endophenotypic features with both BPD and schizophrenia. 
Individuals with schizotypal diagnoses were only included if they eventually were coded as 
schizophrenia. Other non-organic psychotic illness diagnoses were also excluded, as their 
aetiology was uncertain. 
Individuals were included if they were 16 years of age or over. Diagnosis start date was 
considered the first date at which any SMI or depression diagnosis code was entered into 
the patient record, in the case of BPD, and the first date at which any SMI code was 
entered, in the case of schizophrenia. If an individual received more than one SMI diagnosis 
in their longitudinal EHR, the most recent (latest) one was used. Most recent diagnosis was 
considered most accurate, as the clinician would have access to information about the 
patient’s full illness history. Previous research has shown that BPD and schizophrenia 
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diagnoses in THIN are relatively stable between first record of SMI and diagnosis ultimately 
assigned (Table 2.i) (Hardoon et al., 2013). 
Table 2.i Diagnostic stability of bipolar disorder and schizophrenia 
  Diagnosis ultimately assigned, % 
First SMI record BPD Schizophrenia Other SMI SMI register 
 BPD 98.5 1.5 0 0 
 Schizophrenia 1.5 98.5 0 0 
 Other SMI 3.4 8.0 88.5 0 
 SMI register 5.3 3.4 5.6 85.8 
Adapted from (Hardoon et a l.,  2013) .  
 
2.5.3 General population frequency matching for the study of mortality and morbidity 
For each individual with BPD or schizophrenia, up to six people without BPD or 
schizophrenia (but potentially with other mental health problems) were selected at random 
from the same GP practice. There are diminishing gains in increasing the ratio of unexposed 
(general population) to exposed (BPD or schizophrenia) in the study, and a ratio beyond 3:1 
or 4:1 is commonly seen as unnecessary (Strom, 2011). However, because of the size of 
THIN a ratio of 6:1 is feasible. Individuals from the general population were matched on 
sex, age (in five-year age bands) and index GP appointment attendance date (to ensure 
individuals in the comparator group were active in healthcare seeking in the same period as 
those with BPD and schizophrenia). This strategy for generating a comparison group 
partially removes potential confounding by age, sex, area level differences and cohort 
effects. By only excluding those with BPD or schizophrenia, it avoids rendering the 
comparison group an abnormally healthy sample, therefore biasing results. 
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2.6 Data extraction from The Health Improvement Network 
database 
Data extraction for the studies in this thesis was carried out on two separate occasions. The 
effectiveness/tolerability study (Study 2: Chapter 6), the adverse effects study (Study 3: 
Chapter 7) and the suicide/self-harm study (Study 4: Chapter 8) were completed first, and 
used data from 1 January 1995 until 31 December 2013. The mortality/morbidity study 
(Study 1: Chapter 4) used a later THIN extraction of data from 1 January 2000 until 31 
December 2014 (Figure 2.i).  Data extraction was completed using Stata version 13 or 14 
(StataCorp, 2013). I wrote or modified code to extract the required cohort and covariates of 
interest. All data cleaning and new variable generation was also completed using Stata 
(StataCorp, 2013). 
2.7 Definition of exposures, outcomes and other covariates 
Study specific exposures, outcomes and covariates are defined in each chapter, with code 
lists in Appendix 2 and available from the author on request.  
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Figure 2.i Flow diagram of included patients for each study 
 
  66 
 
2.8 Benefits of using The Health Improvement Network for 
bipolar disorder outcomes and medication response research 
2.8.1 Size, variable recording, reliability, validity and generalisability of available data 
THIN has been used extensively to examine outcomes for people with SMI (Petersen et al., 
2016), predict risk in SMI (Osborn et al., 2015) examine prescribing trends (Hayes et al., 
2011, McCrea et al., 2015), monitor health trends (Hardoon et al., 2016) and perform 
clinical effectiveness studies (Blackburn, 2016). Previous recent work has identified a cohort 
of over 10,000 individuals with BPD (Osborn et al., 2015) and the cohort used in this thesis 
was larger than this: benefiting from extra years of data and additional GP practices joining 
THIN (at which point historical records are added to the database).  This makes the cohort 
of BPD patients in THIN comparable in size to population based registries, such as those in 
Denmark (Medici et al., 2015) or Sweden (Ösby et al., 2016).  
The incidence rate of BPD in THIN has been shown to be similar to other European cohorts 
(Hardoon et al., 2013) and validity of severe mental illness diagnoses held in primary care 
has been established (Nazareth et al., 1993). NICE guidance recommends that any patient 
with suspected BPD should be referred to a psychiatrist for diagnosis and treatment 
planning (National Institute for Health and Care Excellence, 2014). As such, individuals in 
this cohort are considered to fulfil ICD-10 criteria for BPD. A number of the health 
outcomes and drug related adverse events examined in this thesis have also been validated 
in THIN, including mortality, suicide, CKD, thyroid disease, T2DM, hypertension, and CVD 
(Blak et al., 2011, Hall, 2009, Khan et al., 2010). THIN has also shown itself to be suitable for 
pharmacoepidemiological research, with a number of studies showing comparability 
between UK EHR prescribing and national dispensing data (Langley et al., 2010, Lewis et al., 
2007, Walley and Mantgani, 1997). 
  67 
THIN offers an opportunity to examine a number of outcomes experienced by individuals 
with BPD. The coverage of THIN should mean that findings are generalisable to individuals 
with BPD living in the UK. It should be noted that the approximately 1.5% of the population 
missing from any study of primary care might have higher rates of SMI, including BPD, 
because prisoners, illegal immigrants and homeless people are less likely to be registered 
with a GP. However, the majority of this unregistered group is likely to be young healthy 
men (Harvey et al., 2012). Since 2004, the QOF has meant that GPs are incentivised to 
record particular information about chronic health problems, including SMI (Roland, 2004). 
There is evidence that this has improved the quality and accuracy of GP EHR (Doran et al., 
2011). With regards to SMI, GPs are remunerated for keeping a register of individuals with 
SMI and carrying out an annual review (Osborn et al., 2011). Particular to individuals 
prescribed lithium, QOF indicators exist for having lithium levels checked six monthly and 
serum creatinine and thyroid stimulating hormone checked every 15 months. Beyond SMI, 
there are a number of measures of health (hypertension, T2DM, for example) that are used 
in this thesis and are well recorded due to QOF (Doran et al., 2011). Another particular 
strength of THIN for BPD research is the complete and accurate prescribing data available. 
Prescribing data are better quality and are available for longer, than prescribing data from 
the previously mentioned Nordic registers. The other advantage over these registers is the 
recording of blood tests and illness symptoms, which are vital for the studies proposed in 
this thesis. 
2.9 Potential problems with the use of THIN for bipolar 
disorder outcomes and medication response research 
2.9.1 Causal inference in observational data 
The limitations of RCTs in the area of BPD have been discussed in Section 1.6. The 
limitations of observational data and approaches to managing these must also be 
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considered. One particular problem is the potential to make causal inference in non-
experimental settings.  Causal inference based on counterfactual models has become 
increasingly standard in medical and epidemiological studies (Höfler, 2005). In its simplest 
form the counterfactual model considers the potential outcomes of the same individual, at 
the same time point, assigned to both treatment and no treatment. Clearly only one of 
these two states can be observed, be it in an RCT or observational study. Therefore, it is not 
feasible to examine the effects of a given treatment on a single individual, but estimating 
the average effect across equivalent individuals who receive different treatments is 
possible. 
2.9.2 Using propensity scores to achieve conditional exchangeability 
If we consider a perfectly designed and executed RCT (one that is adequately powered, 
appropriately randomised, no loss to follow-up), randomisation ensures exchangeability; 
that is, participants are equivalent because treatment assignment is not associated with the 
counterfactual outcome. Under these circumstances, the causal effect is not dependent on 
which group receives the intervention and the differences observed between treatment 
and control group are the same as the average difference in potential outcomes. Some 
RCTs, rather than randomly assigning on a one-to-one basis will randomise accounting for a 
particular baseline characteristic. In this case, the RCT is conditioned or stratified on a 
baseline variable, and whilst exchangeability is not maintained between treatment and 
control groups, there will be exchangeability within a particular strata (this is called 
conditional exchangeability). This provides a starting point to consider the design of 
observational studies, which aim to fulfil criteria for conditional exchangeability. The use of 
a PS is an approach that has been suggested to achieve conditional exchangeability. PS 
approaches are further discussed in Section 2.11.1 and are used in Studies 2 (Chapter 6), 3 
(Chapter 7) and 4 (Chapter 8).       
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2.9.3 Confounding by indication in observational studies 
A traditional concern about the validity of findings from epidemiologic studies, and one 
that is linked to lack of exchangeability, is the possibility of bias from uncontrolled 
confounding. Case-control and cohort studies compare outcomes between groups with 
different exposures, and confounding arises when the groups under comparison differ in 
other ways than the exposure alone. These differences may include demographic factors, 
behaviours, clinical characteristics, medical conditions, or treatments. Some exposures are 
more liable to confounding than others. When the outcome is an unintended or 
unanticipated effect of the exposure, for example rare adverse effects, confounding is less 
likely to occur than when the outcome is an intended effect of the exposure (Miettinen, 
1983). The potential problem of intended effects is likely to arise when the exposure of 
interest is a medication or a medical procedure, and it is often called confounding by 
indication (Walker, 1996). Confounding by indication may arise when a drug treatment 
serves as a marker for a clinical characteristic or medical condition that triggers the use of 
the treatment and that, at the same time, increases the risk of the outcome under study. 
Confounding by indication is not conceptually different from confounding by other factors, 
and the approaches to control for confounding by indication are the same: matching, 
stratification, restriction, and multivariable adjustment. However confounding by indication 
remains an often-intractable threat to validity in observational studies (Freemantle et al., 
2013).  
2.9.4 Other types of bias in studies using routine data 
Structural biases, such as the bias due to left truncation or censoring, can occur when the 
inclusion criteria for a study are related to a variable of primary study interest, either 
directly or indirectly (Cain et al., 2011). This is unlikely to be an issue for Study 1, which 
examines time to death, cause specific death and morbidity. In this study, the comparison 
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group is matched on index GP appointment attendance date and age to avoid this problem. 
However, it is a potential problem in the maintenance mood stabiliser studies (Studies 2, 3 
and 4). Individuals included in these studies may have previously been exposed to the 
mood stabiliser, but also (by definition) they would not be included if they had already 
experienced an outcome event of interest. For these studies, the possibility of working with 
an incident cohort was explored, but numbers of individuals taking each drug became too 
small to examine rare outcomes. Often information about previous use of mood stabilisers 
and BPD diagnosis before the start of follow-up was available and this was included in the 
statistical models used to minimise this problem. There is also a strong argument that 
although studies of prevalent exposures can involve left truncation, studies of incident 
exposures may involve right censoring and therefore may not be able to adequately assess 
the long-term effects of exposure (Vandenbroucke and Pearce, 2015). RCTs of these 
medications invariably face the same problem of prevalent exposure. In fact, a mix of 
prevalent and incident exposures might be the ideal situation as this allows exploration of 
the effects of different durations of exposure and enhances information on long exposure 
durations (Vandenbroucke and Pearce, 2015). 
2.9.5 Lack of recording of important covariates 
Because the EHR exists for the purposes of clinical management, rather than to run 
perfectly designed cohort studies, data on important confounders may not be recorded, 
and data at necessary time points may be missing.  
2.9.5.1 Proxy variables 
Proxy variables are known/measured variables that are associated with an unmeasured 
variable of interest. In the case of THIN, a proxy for body fat percentage (unrecorded) may 
be BMI (recorded), a proxy for individual level SES (unrecorded) may be Townsend score 
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(recorded) (Pickett and Pearl, 2001). Potential proxies for clinician prescribing choice and 
patient preference are discussed in Section 2.10.2. 
2.9.5.2 Missing data 
A number of approaches have been developed to manage missing data. Multiple 
imputation is a favoured approach (Schafer, 1999) and techniques have been specifically 
developed in THIN to manage missingness in longitudinal datasets (Welch et al., 2014). 
Before designing the studies presented in this thesis, a lot of thought was given to the 
analytical approach. Analysis using PS was favoured over other ways of managing 
confounding in the studies comparing mood stabiliser medication (for example 
instrumental variables, self-controlled case series). Currently there is no reliable strategy 
for incorporating multiple imputation and PS approaches (Mitra and Reiter, 2016) and thus 
other methods of managing missingness were considered. It was decided that the best 
approach was to consider the record as complete and perform sensitivity analyses as 
appropriate to each study. There are a number of examples where complete-case analysis 
is superior, or equal to, to multiple imputation. In particular, complete-case analysis has 
negligible bias when data is missing completely at random and when missingness is 
independent of outcome (White and Carlin, 2010). 
There are situations in EHR where variables are incompletely recorded. In some 
circumstances, this is not a major problem, for example if an individual does not have a 
record of T2DM; it is unlikely that they have T2DM. Blood tests that would have led to the 
diagnosis (in this case abnormal HbA1C results) may augment diagnostic codes, and this 
approach is used in the adverse effects study (Study 3). Obviously, this would not be a 
problem in a specially designed, prospectively followed up cohort, where the researchers 
may confirm that a participant did not have T2DM, but the EHR reflects real world events. 
  72 
Therefore, in all studies, outcomes should be regarded as having the prefix “GP recorded 
diagnosis/symptoms of…”. This approach may be more prone to error for other important 
variables, namely smoking status, alcohol intake and ethnicity. Potentially these variables 
are missing not at random (i.e., the missing observations are related to the values of the 
unobserved data) and if they are not included in a patients registration consultation with a 
GP they are less likely to be recorded. There is no method of data analysis that can fully 
account for missingness if this is the case  (Sterne et al., 2009). My approach is set out 
below. 
In the studies in this thesis, smoking status is coded as current smoker, ex-smoker, or non-
smoker (if there is no record of being a smoker at any time). Smoking status is recorded for 
84% of patients within a year of them registering with a THIN GP practice (Marston et al., 
2014). If the EHR states that an individual is a smoker, this is likely to be correct (low risk of 
false positive), but if there is no smoking record it cannot be guaranteed that this person 
truly doesn’t smoke (risk of false negative) (Lewis and Brensinger, 2004). Despite this 
concern, previous research has supported this approach with evidence that the vast 
majority of those with missing smoking records were ex- or non-smokers (Lewis and 
Brensinger, 2004, Marston et al., 2010, Marston et al., 2014). Alcohol consumption is coded 
as none (if there is no record of being a drinker at any time) /low or 
moderate/heavy/dependent. Of all newly registered patients, 76% have an entry for 
alcohol intake (Khadjesari et al., 2013). Comparisons with British Regional Heart Study and 
ONS Omnibus Survey on Drinking in Adults suggest that a large number of individuals 
consuming alcohol within UK recommended limits have missing alcohol consumption 
records, and that heavy, hazardous and dependent drinking is underreported to GPs 
(Khadjesari et al., 2013, Marston et al., 2010). Therefore, this approach to categorising 
alcohol consumption may reduce between group differences. For both smoking and alcohol 
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intake use of multiple imputation has been shown to fail because of violation of key 
assumptions, so there is no perfect solution to this problem (Marston et al., 2010). As 
noted above, ethnicity recording in GP EHRs has been found to be 78% complete after 2006 
(Mathur et al., 2014). For the studies in this thesis ethnicity was coded as White, Black, 
Asian, other (including mixed). Missing ethnicity was coded as White, in line with previous 
research using primary care data EHR, which suggests that more than 93% of individuals 
without ethnicity recorded are from a White ethnic group (Hippisley-Cox et al., 2008). 
In the adverse effects study (Study 3: Chapter 7) a number of adverse physical outcomes 
relied on the presence of blood test results. Approaches to managing missing data for these 
outcomes are discussed in Chapter 7. 
2.10  Study design to minimise bias and confounding 
2.10.1 Mortality and morbidity studies 
Study 1 (Chapter 4) compares BPD with schizophrenia; another SMI which has traditionally 
been considered more severe and resulting in worse outcomes (Kraepelin, 1921). It also 
compares these groups with a frequency matched comparison group. All-cause mortality 
has been identified as being well recorded in THIN, with 99.6% positive predictive value and 
99.7% sensitivity (Hall, 2009). However cause of death is less well recorded (Hall, 2009). To 
manage this, a number of algorithms for assigning cause of death have been developed. For 
example, studies of suicide using THIN have defined a suicide death as a code for self-harm, 
followed by a code for death in the following month and a final date of any activity in the 
patient record within 6 months (Arana et al., 2010). This approach has a positive predictive 
value of 97% for suicide (Arana et al., 2010).  Because of concerns about potential under 
identification, cause-specific mortality hazard ratios (HRs) in this study are likely to be 
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accurate, but rates may potentially be underestimates compared to the UK population (this 
is investigated in Chapter 4 and discussed in Chapters 4 and 9).  
As discussed in Chapters 1 and 3, the SMR typically accounts for only the age and sex 
distribution of the population. Study 1 (Chapter 4) examines all-cause mortality HRs in BPD 
and schizophrenia compared to the UK general population. The simplest model accounts 
only for age, sex and calendar period. Estimates derived from this model are therefore 
comparable with studies reporting SMR in the systematic review and meta-analysis 
(Chapter 3). Additionally, models adjust for sociodemographic factors (ethnicity and area 
level SES), median number of GP contacts per year and use a robust sandwich estimator for 
standard errors to account for clustering within GP practice. In the case of CVD diagnosis 
and mortality an adjunct model examining the potential confounding effects of smoking, 
BMI, hypercholesterolemia, hypertension and T2DM diagnosis was run.   
2.10.2 Maintenance mood stabiliser studies 
A key missing variable in the EHR is a measure of illness severity. The starting point for the 
design of Studies 2 (Chapter 6), 3 (Chapter 7) and 4 (Chapter 8) was the assumption that 
lithium, valproate, olanzapine and quetiapine were all similarly likely to be prescribed to 
people with BPD, who reached a threshold for maintenance treatment (i.e., likely to be of 
similar severity). Beyond this, the majority of reasons for differences in prescribing will be 
recorded in the EHR or represented by proxy variables. There was no untreated BPD 
comparison group as this was likely to produce highly biased estimates of treatment effect 
because the untreated population are likely to be a very different group in terms of a 
number of factors including illness severity and medication adherence. 
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During the bulk of the study period NICE recommended lithium, valproate or olanzapine as 
first-line maintenance mood stabilisers (for both polarities), and quetiapine in the case of 
bipolar depression (as discussed in Section 1.5). This suggests clinical equipoise between 
these drugs. Beyond this, clinicians prescribing choices are likely to depend on baseline 
patient characteristics (including potential for adverse effects), clinician preference and 
patient preference (Elwyn et al., 2003).  Many of the baseline characteristics that would 
influence drug choice will be recorded in the EHR. For example avoiding drugs known to 
cause weight gain in those that are already obese, avoiding prescribing in people with a 
pre-existing contraindication to a given drug, or avoiding drugs that interact with alcohol if 
a patient is known to be a heavy drinker. Clinician preference (beyond that based on a 
risk/benefit analysis based on what the treating clinician knows about the patient’s illness 
and general health) is unmeasured in the EHR, but proxies may exist. For example, most 
prescribing for BPD will be commenced in secondary care, each GP practice will be served 
by only one NHS Mental Health Trust, and therefore a limited number of psychiatrists, 
consequently including an identifier for GP practice will account for some of the variability 
in prescribing choice. Similarly, patient preference will not be explicitly recorded in the EHR, 
but it is likely to be associated with variables that are. For example, weight gain, a side 
effect of olanzapine in particular, might be less acceptable to women who are already 
overweight, than to men who are not (Regitz-Zagrosek et al., 2006); weight and sex will be 
well recorded in THIN.   
2.11  Approach to analysis to minimise bias and confounding 
Analyses are described in each chapter. The following is a summary and discussion of the 
main approaches used: 
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2.11.1 Propensity score estimation 
2.11.1.1 The propensity score: An approach to managing confounding in 
observational studies 
The concept of PS adjustment was developed by Rosenbaum & Rubin in 1983 with the 
intent of addressing residual confounding by simulating a randomised environment 
(Rosenbaum and Rubin, 1983).  In non-randomised observational studies, treatment 
assignment is not arbitrary; therefore, direct comparisons of outcomes in different 
treatment groups will be misleading. This problem is traditionally minimised by design (for 
example, matched sampling) or analysis (for example, stratification or covariance 
adjustment). These methods are limited because they can only employ a limited number of 
covariates for adjustment. However, PSs provide a scalar summary of the covariate 
information, and do not have this limitation. This is particularly relevant to 
pharmacoepidemiology where the focus of the study is often rare outcomes that occur in 
patients with multiple risk factors and many possible indications and contra-indications for 
drug use. For instance, it has been found that with fewer than eight events per confounder, 
analysis based on PSs yields less biased, more robust, and more precise estimates than a 
regression approach based on logistic regression (Cepeda et al., 2003). 
Therefore, the PS is an estimate of the likelihood of an individual receiving a particular 
treatment calculated using their covariate information (d’Agostino, 1998). It has even been 
argued that if unmeasured variables are associated with observed variables the approach 
can reduce bias from these unknown covariates (Austin et al., 2005, Joffe and Rosenbaum, 
1999).  PS methods derive from a formal model for causal inference, the potential 
outcomes framework, so that causal questions can be well defined, explicitly specified and 
not conflated with the modelling approach, as they are with traditional regression 
approaches.  
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2.11.1.2 Calculating the propensity score  
The PS approach, initially developed for studies comparing two treatment options 
(Rosenbaum and Rubin, 1983) has been generalised to address the issue of comparing 
multiple treatments. This approach was initially described by Imbens (Imbens, 2000), with 
practical examples provided by Spreeuwenberg et al. (Spreeuwenberg et al., 2010). The 
multiple treatments PS is defined as the conditional probability of receiving a particular 
treatment, given a set of observed pre-treatment variables. The score is calculated via 
multinomial logistic regression, where the probability of receiving each treatment is 
estimated. It has been shown that the multiple treatments PS is a balancing score, like the 
two treatments version and therefore can be used to correct for initial differences at 
baseline, and leads to valid estimates in multiple treatment comparisons (Imai and Van Dyk, 
2012, Imbens, 2000).  
2.11.1.3 Variable selection for the propensity score 
Clear guidance on variable selection for PS estimation is sparse (Brookhart et al., 2006). In 
the studies in this thesis, as recommended, specification of the model was guided by 
clinical knowledge. The following recommendations were followed in constructing the PS: 
i) Include all variables thought to be related to outcome, regardless of whether it 
is expected that they are related to the exposure, the inclusion of these 
variables will increase the precision of the estimated exposure effect without 
increasing bias (Rubin and Thomas, 1996),  
ii) Statistically non-significant associations between covariate and exposure are 
important in PS models, again these variables can increase precision without 
additional bias (Brookhart et al., 2006), 
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iii) Addition of a variable unrelated to the outcome, but related to the exposure 
will increase the variance of an estimated exposure effect, without reducing 
bias (Brookhart et al., 2006), however; 
iv) In medium/large studies covariates related to exposure should not be excluded 
unless it was known a priori that they are not related to outcome (Brookhart et 
al., 2013), 
v) Only variables unaffected by participation should be included in the model; 
that is variables should be fixed over time or measured at baseline (Caliendo 
and Kopeinig, 2008), 
vi) Covariates included in the model should have 8-10 (exposure) events per 
variable (Weitzen et al., 2004), 
vii) Over-parameterised models should be avoided; this will not bias the score or 
make it inconsistent, but it may increase variance (Caliendo and Kopeinig, 
2008), 
viii) Collinearity is not an issue, as this will only affect the precision of the estimated 
coefficients (and will not result in bias) (Harrell, 2002), 
ix) Interaction terms should be included if there is improvement in the resulting 
balance between treatment groups  (Weitzen et al., 2004). 
With these points in mind, the PS was built using a structured, non-parsimonious, iterative 
approach similar to that described by Rosenbaum and Rubin (Rosenbaum and Rubin, 1984). 
I only considered age and sex as potential interaction terms. The PSs therefore varied 
slightly for the effectiveness/tolerability, adverse effects and suicide/self-harm studies 
(Studies 2, 3 and 4).  
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2.11.1.4 Assessing the propensity score  
Plotting PSs can help to understand their distributions and areas of common support 
(Caliendo and Kopeinig, 2008). Figure 2.ii shows a simplified version of this for two drug 
treatments. This highlights the fact that there are some individuals who, given their PS, will 
always be prescribed drug A, or will always be prescribed drug B. There is a range of PSs 
where individuals have similar chances of receiving drug A or drug B. 
Figure 2.ii Potential distribution of propensity scores for two drugs 
 
Adapted from (Schneeweiss,  2010) .  
 
The performance of the PS can be assessed by evaluating the balance of covariates 
(Brookhart et al., 2013). However, thorough methods have not been developed for multiple 
treatments (McCaffrey et al., 2013). In this thesis, balance was checked following 
stratification of the score into deciles. For each drug ranges, mean (and standard deviation) 
and median (and interquartile range) of multiple PSs were compared (Caliendo and 
Kopeinig, 2008). The distribution of individual covariates within each decile for each drug 
was then compared (Spreeuwenberg et al., 2010).  
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2.11.1.5 Using the propensity score  
There are four common approaches to using the PS: adjustment, stratification, matching 
and inverse probability of treatment weighting (IPTW) (Austin, 2011). Adjusting for PS is the 
most commonly used approach in the clinical literature and is the method most similar to 
traditional regression modelling (Shah et al., 2005). Simulation studies have suggested that 
stratification by quintiles of PS will remove over 90% of the bias in each of the covariates 
that contributes to the PS (Cochran, 1968, d’Agostino, 1998, Rosenbaum and Rubin, 1984). 
Both adjusting and stratification techniques use all available data and as such make full use 
of the generalisability of the dataset. Stratification on the PS can be conceived as a set of 
quasi-RCTs, which are then combined, weighted by the proportion of subjects in each strata 
(Austin, 2011). Matching has been described as a more accurate way of estimating 
treatment effects than stratification or adjustment, because it compares patients with 
similar observed characteristics. However, it may produce a non-representative sample of 
patients receiving treatment, because of the patients that are unmatched and therefore 
dropped from the analysis  (d’Agostino, 1998, Rosenbaum and Rubin, 1985). Again, there is 
no consensus on which matching technique is superior (Caliendo and Kopeinig, 2008). IPTW 
uses PSs to form a weight, which creates a pseudo or synthetic population in which the 
covariates and treatment assignment are independent of each other. This approach is 
similar to the use of survey sampling weights so that results are representative of specific 
populations (Morgan and Todd, 2008). 
Studies 2 (Chapter 6), 3 (Chapter 7) and 4 (Chapter 8) report results adjusted for PS. In 
each case, this was shown to be preferable to stratification by quintiles or deciles of PS, 
tested formally using Akaike information criteria and Bayesian information criteria.  In the 
effectiveness/tolerability study (Study 2) and the suicide/self-harm study (Study 4), a 
matching technique is used. This was not used for the adverse events study (Study 3) 
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because a number of the outcomes were too rare. Given the aim of estimating treatment 
effects, and that results of matching were compared with adjustment, a strict matching 
regimen was employed. Patients taking each other drug were matched with lithium on a 
one-to-one basis, with their closest possible match, with a caliper (maximum permitted 
difference between matched subjects) of 0.01.  This caliper was used as it falls below the 
upper limit of 0.25 PS standard deviations recommended by Cochran and Rubin (Cochran 
and Rubin, 1973). Inverse probability of treatment weighting was not used, apart from as a 
sensitivity analysis, because there is no evidence that it is superior to other methods 
(Austin and Stuart, 2015). In addition, adjustment and matching were considered more 
transparent approaches to data analysis that could be easily communicated to the target 
audience of these studies: clinicians, patients and key stakeholders. 
2.11.2 Survival analyses regression techniques 
Survival analysis is a set of techniques for analysing data where the outcome is time until an 
event of interest. A survival approach is more appropriate than other regression methods, 
such as linear or logistic regression, because censoring can be handled appropriately.  
2.11.2.1 Cox Proportional Hazards model 
A commonly used regression model for the analysis of survival data is the Cox proportional 
hazards regression model (Cox, 1972). It allows testing for differences in survival times of 
two or more groups of interest, while allowing for adjustment of confounders. The Cox 
regression model is a semiparametric model, which makes fewer assumptions than typical 
parametric methods. In particular, it makes no assumptions about the shape of the so-
called baseline hazard function. The Cox regression model provides information regarding 
the relationship of the hazard function to predictors (Cleves, 2008). While a nonlinear 
relationship between the hazard function and the predictors is assumed, the HR comparing 
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any two observations is in fact constant over time in the setting where the predictor 
variables do not vary over time. This assumption is called the proportional hazards 
assumption and checking if this assumption is met is an important part of a Cox regression 
analysis. 
2.11.2.2 Kaplan-Meier curves & assessing the proportional hazards assumption 
For unadjusted survival analysis, Kaplan–Meier analyses are often applied, and provide a 
way of displaying results graphically. The Kaplan–Meier method estimates the probability 
of survival up until a certain time point in the presence of censored cases. For subjects 
whose data are censored, either because they left the cohort or because they reached the 
end of the study period without an outcome event, all information until their time of 
censoring is included in the analysis (Bland and Altman, 1998). Results can then be reported 
as survival probabilities (for example median survival, or 1-, 2-, and 5-year cumulative 
survival). However, when using the Kaplan–Meier method, the effect size cannot easily be 
quantified (Jager et al., 2008).  
The proportional hazards assumption can be informally checked via Kaplan-Meier curves: 
plotting survival function against survival time, the shape of the curves should be 
essentially the same and the separation between curves should remain proportional across 
analysis time (Hess, 1995). Formal tests of proportionality can be completed by plotting a 
scaled version of the Schoenfeld residuals (Grambsch and Therneau, 1994, Schoenfeld, 
1982). 
2.11.2.3 Competing risks regression 
In some circumstances, competing risks can be an important problem (Noordzij et al., 
2013). A competing risk is an event that hinders observation of the outcome of interest or 
modifies the likelihood that this event will occur, for example in the adverse events study 
  83 
(Study 3: Chapter 7); death competes with the physical health outcomes of interest. In this 
study cumulative incidence competing risk methods are used to display results graphically 
and provide survival probabilities, rather than traditional Kaplan-Meier plots, which are 
likely to be inaccurate in this circumstance and cannot adequately account for potential 
confounders. However, this approach generates sub-distribution HRs, rather than HRs, 
which cannot be interpreted in the same way as HRs (Noordzij et al., 2013). Therefore, 
alongside competing risk methods, HRs from Cox regression models are presented.   
2.11.2.4 Data analysis 
All data analysis was completed using Stata versions 13 and 14 (StataCorp, 2013). 
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Chapter 3 A systematic review and 
meta-analysis of mortality in individuals 
with bipolar disorder 
3.1  Summary 
3.1.1 Objective 
To summarises previous observational studies examining all-cause and cause specific 
mortality in individuals with a diagnosis of BPD via systematic review and meta-analysis. 
3.1.2 Method 
Cause-specific mortality was grouped into natural and unnatural causes. These subgroups 
were further divided into circulatory, respiratory, neoplastic, infectious causes, and suicide 
and other violent deaths. Summary SMRs were calculated using random-effects meta-
analysis. Heterogeneity was examined via subgroup analysis and meta-regression. 
3.1.3 Results  
Systematic searching found 31 studies meeting inclusion criteria. Summary all-cause SMR 
was 2.05 (95% CI 1.89 to 2.23) but heterogeneity was high (I2=96.2%). This heterogeneity 
could not be accounted for by date of publication, cohort size, mid-decade of data 
collection, population type or geographic region. Unnatural death summary SMR was 7.42 
(95% CI 6.43 to 8.55) and natural death 1.64 (95% CI 1.47 to 1.83). Specifically, suicide SMR 
was 14.44 (95% CI 12.43 to 16.78), other violent death SMR 3.68 (95% CI 2.77 to 4.90), 
deaths from circulatory disease SMR 1.73 (95% CI 1.54 to 1.94), respiratory disease SMR 
2.92 (95% CI 2.00 to 4.23), infection SMR 2.25 (95% CI 1.70 to 3.00) and neoplasm SMR 1.14 
(95% CI 1.10 to 1.21). 
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3.1.4 Conclusion 
Despite considerable heterogeneity, all summary SMR estimates and a large majority of 
individual studies showed elevated mortality in BPD compared to the general population. 
This was true for all causes of mortality studied.   
A modified version of this chapter was published as Hayes JF, Miles J, Walters K, King M, 
Osborn DP. A systematic review and meta‐analysis of premature mortality in bipolar 
affective disorder. Acta Psychiatrica Scandinavica. 2015; 131: 417-25 
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3.2 Introduction  
As described in Section 1.4.1, relative to major depression and schizophrenia, there is a 
limited understanding of the premature mortality associated with BPD. In 1998, Harris and 
Barraclough reviewed mortality in all mental disorders. Six studies totalling a population of 
4547 people contributed to their meta-analysis of mortality in BPD (Harris and Barraclough, 
1998). The pooled all-cause SMR was 2.02 (95% CI 1.88 to 2.17). Unnatural deaths SMR was 
9.18 (95% CI 8.01 to 10.46) and natural deaths 1.50 (95% CI 1.37 to 1.64). These SMRs 
estimates are all more elevated than those for schizophrenia from the same systematic 
review. The schizophrenia mortality meta-analysis was made up of 20 studies including 
over 35,000 patients (Harris and Barraclough, 1998), highlighting the relative paucity of BPD 
research. A more recent review, published in 2009, included 13 studies of death by natural 
causes (Roshanaei-Moghaddam and Katon, 2009). However, this review only searched one 
database and included patients without a clear diagnosis of BPD (such as mixed 
unipolar/bipolar groups, schizoaffective disorder or affective psychoses diagnoses). In 
addition, all-cause mortality and SMRs for unnatural deaths were not investigated. Of the 
included studies, five produced precise estimates due to reasonable sample size (greater 
than 2500 individuals). The authors did not perform a meta-analysis but concluded “higher 
mortality from natural causes among patients with bipolar spectrum disorders ranged from 
35% higher than a comparison group to twofold higher”. Since these publications, a 
number of large cohort studies have reported SMR estimates. Given the paucity of studies 
examining only BPD mortality before 2009, the systematic review and meta-analysis of 
these studies is likely to be an important addition to the evidence base. 
There is likely to be considerable heterogeneity among SMR estimates, because of both 
BPD mortality data source, and the data used to generate the expected number of deaths. 
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Overreliance on either inpatient data or community-based samples is an important 
limitation that will influence observed death recording. For example, sole use of inpatient 
data may potentially result in bias and poor generalisability by including only more severe 
cases, whereas community-based samples may be limited by insufficient sample sizes or 
loss to follow-up. Heterogeneity may also be introduced by period effects (that is; 
comparing estimates from different time periods, when different services or treatments 
were available), and by comparing treated and untreated groups. The choice of data source 
used to generate the expected number of deaths is also important, and will influence the 
effect estimate. Of particular impact is whether this is an internal comparison estimated 
from within the same data source, or data from another source. Internal comparisons may 
be more valid in terms of important confounders, but may produce an overly healthy 
comparator group. These factors and other reported study level characteristics will be 
considered in assessing the heterogeneity of SMR estimates. 
3.3 Methods 
Existing studies of SMR in BPD were systematically reviewed to examine the association 
between BPD and all-cause and cause-specific mortality.  Cause-specific mortality was 
grouped into natural and unnatural causes. These subgroups were further divided into 
suicide and other violent deaths, and deaths from circulatory, respiratory, neoplastic, and 
infectious causes. Heterogeneity was assessed by geographic region, population type, 
cohort size, mid-decade of cohort data collection (to account for cohort effects and 
potential changes in treatement) and decade of publication. I closely followed the guidance 
provided by the PRISMA statement and MOOSE proposal for reporting (Moher et al., 2009, 
Stroup et al., 2000). Quality checks were completed by a collaborator Dr Joseph Miles (JM). 
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3.3.1 Identification of studies 
To identify all studies examining mortality in BPD, the Medical Subject Heading (MeSH) 
terms and keywords for BPD and mortality were searched in PsychINFO, Medline and 
EMBASE. MeSH terms were: bipolar disorder, mortality, life expectancy, death, death and 
dying. Keywords searched were: bipolar illness, manic depression, bipolar disorder, bipolar 
affective disorder, life expectancy, mortality, death (see Appendix 3.1). All databases were 
searched from their inception until 30 July 2014. JM and I performed the searches 
individually and then compared results. The abstracts of potentially relevant articles were 
reviewed by JM and myself. Additional articles and conference papers including primary 
data were identified from citations in relevant studies and reviews, the Cochrane database 
of systematic reviews and Google Scholar. Emails were then sent to senior authors of 
articles that met inclusion criteria to attempt to identify all missing studies. One extra 
published study was identified by this method, no further unpublished data were made 
available (Figure 3.i). 
3.3.2 Inclusion and exclusion criteria 
Included studies met all of the following a priori defined criteria: 
i) Published between 1 January 1960 and 1 July 2014, 
ii) Reported deaths of individuals diagnosed with BPD; studies were included if BPD 
was diagnosed by any criteria, 
iii) Individuals included in the study were 16 years or older, 
iv) Primary data on all-cause mortality or cause specific mortality were included; 
specific sub-categories of mortality were: natural deaths, unnatural deaths, suicide, 
other violent deaths, infection, neoplasm, respiratory and circulatory system 
disease, 
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v) Reported data on observed and expected deaths, or SMR allowing the number of 
observed and expected deaths to be calculated. 
Figure 3.i Flow diagram of the published articles evaluated for inclusion in this meta-
analysis 
 
Studies were excluded if they: 
i) Involved cohorts that could not be defined as having BPD (i.e., studies which 
grouped together affective disorders), 
ii) Included a cohort of less than 50 patients (to avoid including cohorts in which there 
were no observed deaths), 
iii) Were not standardised by age, 
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iv) Reported mortality in a particular subgroup of the population with BPD (i.e., prison 
population), 
v) Reported duplicate data, or datasets from overlapping time periods at the same 
site, (if this occurred the most informative paper was then used as the 
representative mortality estimate for inclusion in the meta-analysis. I.e., larger 
samples and longer time periods were preferred). 
 
3.3.3 Data extraction 
Once a study was included, data were extracted and entered into a database that included 
the following variables: authors, country, year of publication, years of data collection, 
length of follow-up, which covariates the mortality was standardised by, the site of 
collection (i.e., multiple site or population level), population type  (i.e., recruited from 
inpatient or community), number of men and women in the cohort, deaths from all causes 
and specific causes for both men and women, and population level estimates of expected 
deaths.  JM and I individually extracted data used in the analysis using a standardised form I 
designed. If disagreements arose, these were resolved by consensus.  
3.3.4 Statistical methods 
The SMR gives the ratio of death in BPD compared to the general population. For each 
cause of death, SMRs and their 95% CIs were extracted from each publication or calculated 
(observed deaths/expected deaths).  
The statistical significance of the SMR is based on the Poisson distribution (two-tailed) using 
95% CIs. The SMR is significantly raised when the lower CI is greater than 1.00. For each 
study 95% CIs were calculated using the Rothman–Greenland method (Rothman et al., 
2008). Pooled SMRs with 95% CI for all-cause and cause-specific mortality were calculated 
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using the DerSimonian and Laird method, a random-effects model that incorporates both 
between-study and within-study variation (DerSimonian and Laird, 1986). Using this 
method assumes that significant heterogeneity exists between studies (Veroniki et al., 
2015).  
Statistical heterogeneity was assessed in a number of ways. First, the I2 index and χ2 test 
were used to investigate differences among studies with respect to SMRs. Additionally, 
meta-regression was performed for heterogeneity of the all-cause SMR because of decade 
of publication, cohort size, geographic region, mid-decade of cohort data collection and 
population type (i.e., inpatient or community).  Subgroup analyses were performed to 
assess potential sources of heterogeneity separately as a result of the following available 
patient-level and study-level factors: geographic region of study, patient population type, 
and decade of the middle year of patient observation. These were considered the key 
sources of potential bias in the included studies. Funnel plots and Egger’s regression were 
used to assess for publication and small-study bias in groups containing 10 or more studies 
(Sterne et al., 2008). All analysis was completed using metan and associated commands in 
Stata (StataCorp, 2013). 
3.4 Results 
The inclusion criteria were met by 31 published studies including unique datasets reporting 
either all-cause or cause-specific SMR (Ahrens et al., 1995, Ajetunmobi et al., 2013, 
Amaddeo et al., 2007, Angst et al., 2002, Black et al., 1987, Bratfos and Haug, 1968, Chang 
et al., 2010, Crump et al., 2013, Dutta et al., 2007, Hiroeh et al., 2001, Hiroeh et al., 2008, 
Hoang et al., 2013, Hoang et al., 2011, Innes and Millar, 1970, Jorgensen and Mortensen, 
1992, Kay and Petterson, 1977, Laursen et al., 2013, Newman and Bland, 1991, Nilsson, 
1995, Nordentoft et al., 2011, Norton and Whalley, 1984, Osborn et al., 2008, Osborn et al., 
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2007, Osby et al., 2001, Saku et al., 1995, Schneider et al., 2001, Sharma and Markar, 1994, 
Tsuang et al., 1980, Vestergaard and Aagaard, 1991, Weeke et al., 1987, Westman et al., 
2013)(Figure 3.i, Table 3.i). Of these, 64% were studies where patients were recruited from 
inpatient settings. A large number (45%) of studies came from Scandinavian countries 
(Norway, Sweden, Denmark and Finland). Overall, there were more than 83,919 individuals 
with a diagnosis of BPD (3 studies did not provide total numbers of patients (Hiroeh et al., 
2001, Hiroeh et al., 2008, Hoang et al., 2011)). Data collection ranged from 1935-2010.  
The reported SMRs for all-cause mortality in patients with BPD ranged from 1.24 (95% CI 
0.83 to 1.17) to 4.65 (95% CI 1.27 to 11.91). Within the 26 individual studies assessing all-
cause mortality, all SMR point estimates were elevated, but 4 out of 26 had CIs that 
overlapped one (Ahrens et al., 1995, Dutta et al., 2007, Schneider et al., 2001, Tsuang et al., 
1980) , these were all relatively small studies (N<440). The all-cause summary SMR for BPD 
was 2.05 (95% CI 1.89 to 2.23). There was significant heterogeneity between these studies 
(I2=96.2%, 95% CI 95.6 to 96.7, P<0.001) (Figure 3.ii). 
Sex-specific all-cause mortality showed similarly elevated summary estimates, but again the 
studies were highly heterogeneous (Table 3.ii). This was also true for mortality grouped as 
natural and unnatural. Studies had heterogeneous SMR estimates for suicide, other violent 
deaths, circulatory and respiratory disease mortality. SMR estimates for, infectious and 
neoplastic deaths were more homogenous. Summary estimates suggested increased rates 
of death from all causes in individuals with BPD (Table 3.ii). 
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Table 3.i Studies include in the meta-analysis 
 
 
Country Years of 
collection 
Total N N Men N Women   Standardised 
by 
Site of collection Population type Mortality outcome 
Bratfos & 
Haug (1968)  
Norway 1950-1963 207 N/A N/A Age, Sex Single site Inpatient All-cause, suicide 
Innes & 
Miller (1970)  
United 
Kingdom 
1964-1969 374 N/A N/A Age Population Inpatient & 
community 
All-cause 
Kay & 
Petterson 
(1977)  
Sweden 1961-1970 192 84 108 Age, sex Multiple site Inpatient All-cause 
Tsuang et al. 
(1980)  
United 
States 
1935-1974 100 45 55 Age, sex Single site Inpatient All-cause, unnatural, natural, 
infectious , neoplasm, circulatory 
Norton et al.  
(1984)  
United 
Kingdom 
1967-1976 791   Age, sex Population Inpatient & 
community 
All-cause, suicide, infectious, 
neoplasm, circulatory 
Black et al. 
(1987)  
United 
States 
1970-1981 586 266 320 Age, sex, time 
at risk 
Single site Inpatient All-cause, unnatural, natural 
Weeke et al. 
(1987)  
Denmark 1969-1976 417 185 232 Age, sex, time 
at risk 
Inception cohort Inpatient All-cause, unnatural, natural, 
suicide, other violent, neoplasm, 
circulatory 
Newman & 
Bland (1991)  
Canada 1976-1985 1429 N/A N/A Age, sex, time 
at risk  
Multiple site Inpatient & 
community 
All-cause, suicide 
Vestergaard 
& Aagaard 
(1991)  
Denmark 1981-1988 133 N/A N/A Age, sex Multiple site Inpatient All-cause, suicide, circulatory, 
respiratory 
Jorgensen & 
Mortensen 
(1992)  
Denmark 1970-1988 18293 N/A N/A Age, sex Inception cohort Inpatient All-cause 
Sharma et al. 
(1994)  
United 
Kingdom 
1970-1987 472 N/A N/A Age, sex Population Inpatient & 
community 
All-cause, suicide, circulatory, 
respiratory 
Ahrens et al. 
(1995)  
Denmark, 
Germany, 
Canada, 
Austria 
1962-1992 440 189 251 Age, sex Multiple site Inpatient & 
community 
All-cause, suicide, circulatory 
Continued overleaf  
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Country Years of 
collection 
Total N N Men N Women   Standardised by Site of collection Population type Mortality outcome 
Nilson (1995)  Sweden 1970-1991 362 N/A N/A Age, sex Single site Inpatient All-cause 
Saku et al. 
(1995)  
Japan 1948-1982 187 119 68 Age Single site Inpatient All-cause, neoplasm 
Hiroeh et al. 
(2001)  
Denmark 1973-1993 N/A N/A N/A Age, sex, time 
at risk 
Population Inpatient Unnatural, suicide, other violent 
Osby et al. 
(2001)  
Sweden 1973-1995 15386 6578 8808 Age, sex Population Inpatient All-cause, unnatural, natural, 
suicide, other violent, infectious, 
neoplasm, circulatory, respiratory 
Schneider et 
al. (2001)  
Germany 1983-1988 74 24 50 Age, sex Single site Inpatient All-cause, unnatural 
Angst et al. 
(2002)  
Switzerland 1959-1997 220 N/A N/A Age Single site Inpatient All-cause, unnatural, natural, 
suicide, other violent, neoplasm, 
circulatory 
Amaddeo et 
al. (2007)  
Italy 1982-2001 278 N/A N/A Age, sex Population Community All-cause 
Dutta et al. 
(2007)  
United 
Kingdom 
1965-1999 135 102 133 Age, sex Inception cohort Community All-cause, natural, suicide, 
neoplasm 
Osborn et al. 
(2007)  
United 
Kingdom 
1987-2002 10742 N/A N/A Age, sex Population Community Circulatory 
Hiroeh et al. 
(2008) 
Denmark 1973-1993 N/A N/A N/A Age, sex, time 
at risk 
Population Inpatient Natural, infectious, neoplasm, 
circulatory, respiratory 
Osborn et al. 
(2008)  
United 
Kingdom 
1987-2002 10742 N/A N/A Age, sex Population Community Suicide 
Chang et al. 
(2010)  
United 
Kingdom 
2007-2009 2700 N/A N/A Age, sex Inception cohort Community All-cause 
Hoang et al. 
(2011)  
United 
Kingdom 
1999-2006 N/A N/A N/A Age, sex Population Inpatient All-cause, unnatural, natural 
Nordentoft 
et al. (2011)  
Denmark 1970-2006 5927 2571 3356 Age, sex Inception cohort Inpatient & 
community 
Suicide 
Continued overleaf  
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Country Years of 
collection 
Total N N Men N Women   Standardised 
by 
Site of collection Population type Mortality outcome 
Ajetunmobi 
et al. (2013)  
 
United 
Kingdom 
1986-2010 3839 N/A N/A Age, sex, 
deprivation, 
time at risk 
Inception cohort Inpatient All-cause, unnatural, natural, 
suicide, infectious, neoplasm, 
circulatory 
Crump et al. 
(2013)  
Sweden 2003-2009 6618 2700 3918 Age, sex Population Inpatient & 
community 
All-cause, unnatural, natural, 
suicide, other violent, infectious, 
neoplasm, circulatory, respiratory 
Hoang et al. 
(2013)  
United 
Kingdom 
2006-2008 14017 N/A N/A Age, sex Population Inpatient All-cause 
Laursen et al. 
(2013)a  
Sweden 2000-2007 18355 7367 10988 Age, sex Population Inpatient All-cause, unnatural, natural, 
circulatory 
Laursen et al. 
(2013)b 
Finland 2000-2007 9919 4489 5430 Age, sex Population Inpatient All-cause, unnatural, natural, 
circulatory 
Laursen et al. 
(2013)c  
Denmark 2000-2007 11101 4280 6821 Age, sex Population Inpatient All-cause, unnatural, natural, 
circulatory 
Westman et 
al. (2013)  
Sweden 1987-2006 17101 8208 8893 Age, sex Population Inpatient All-cause, unnatural, natural, 
circulatory 
N/A, not available ; Hiroeh et al.  (2001)  and Hiroeh et al .  (2008)  presented person-years at r isk (PYAR) rather than individuals : men= 155,337 PYAR, women 
309,639 PYAR, Hoang et a l.  (2011) reported number of  hospital discharges (100,851) but did not identify number of patients that this  repr esented
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Figure 3.ii SMR of all-cause mortality 
SMR, standardised mortal ity ratio; CI,  confidence interval; % weight from random -effects 
analysis  
In univariable meta-regression all-cause mortality was not significantly associated with 
decade of publication (P=0.63), cohort size (P=0.75), geographic region (P=0.55) mid-
decade of cohort data collection (P=0.89) or population type (P=0.65). After accounting for 
all of these possible explanatory variables in multivariable meta-regression, residual 
variation due to heterogeneity amongst all-cause mortality SMRs remained (I2=88.3%, 95% 
CI 84.6-90.7, P<0.001).  
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Table 3.ii Summary standardised mortality ratios for all-cause and cause specific 
mortalities 
 No. of 
studies  
Number of 
individuals
Ϯ
 
Summary SMR (95% CI) I² (95% CI) Het P 
All-cause 26 220,134 2.05 (1.89–2.23) 96.2 (95.6–96.7) <0.001 
 men 15 34,636 2.17 (2.01–2.34) 83.6 (74.8–88.3) <0.001 
 women 15 46,075 2.11 (1.93–2.31) 84.4 (83.4–91.4) <0.001 
Natural 12 159,495 1.64 (1.47–1.83) 98.0 (98.0–98.5) <0.001 
 men 9 34,220 1.72 (1.54–1.93) 94.5 (92.5–95.8) <0.001 
 women 9 45,598 1.74 (1.51–1.99) 97.6 (97.1–98.0) <0.001 
Unnatural 12 159, 434 7.42 (6.43–8.55) 95.6 (93.9–96.2) <0.001 
 men 9 34,142 7.89 (7.05–8.81) 82.4 (68.1–88.6) <0.001 
 women 9 45,515 9.23 (7.14–11.94) 96.6 (95.6–97.2) <0.001 
Suicide 15 46,756 14.44 (12.43–16.78) 87.0 (80.4 - 90.7) <0.001 
 men 9 12,325 13.31 (10.62–16.69) 87.8 (78.7–91.9) <0.001 
 women 9 16,698 15.74 (12.84–19.31) 81.7 (63.4–88.7) <0.001 
Other violent 5 22,641 3.68 (2.77–4.90) 89.5 (77.2–93.8) <0.001 
 men  4 9,463 3.06 (2.19–4.03) 86.2 (57.6–92.8) <0.001 
 women 4 12,958 5.53 (1.60–19.14) 99.0 (98.7–99.2) <0.001 
Circulatory 14 153,948 1.73 (1.54–1.94) 95.2 (93.9 – 96.1) <0.001 
 men 9 34,041 1.81 (1.61–2.05) 90.3 (85.1–93.1) <0.001 
 women 9 45,396 1.72 (1.46 - 2.03) 96.0 (94.8–96.8) <0.001 
Respiratory 5 22,609 2.92 (2.00 – 4.23) 94.14 (89.8–96.1) <0.001 
 men 4 9,278 2.73 (1.76–4.24) 90.2 (75.9–94.5) <0.001 
 women 4 12,726 2.72 (1.78–4.20) 91.3 (80.0–95.0) <0.001 
Infection 5 22,895 2.25 (1.70 – 3.00) 45.4 (0.0–78.5) 0.12 
 men 4 9,323 2.76 (1.94–3.92) 43.1 (0.0–80.0) 0.15 
 women 4 12,781 1.77 (1.30 – 2.40) 20.9 (0.0–4.1) 0.29 
Neoplasm 10 27,693 1.14 (1.10–1.21) 20.7 (0.0–61.9) 0.25 
 men 7 9,729 1.11 (1.05–1.17) 0.0 (0.0–58.5) 0.47 
 women 7 13,214 1.19 (1.05–1.37) 56.3 (0.0–79.3) 0.03 
SMR, standardised mortal ity ratio: CI,  confidence interval; I
2
,  index of  heterogeneity; Het P 
from X
2
 test; Ϯnot including individuals in studies Hiroeh et al.  (2001),  Hiroeh et a l.  (2008)and 
Hoang et al.  (2011)   
 
Subgroup analyses were performed stratified by geographic region, population type and 
mid-decade of study (Table 3.iii). Stratifying by these covariates had little effect on 
heterogeneity in summary estimates for all-cause, natural and unnatural death SMRs, 
which remained high. 
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Table 3.iii Summary SMRs by subgroup for all-cause mortality, and natural and unnatural 
death 
  No. of 
Studies 
Summary SMR 
(95% CI) 
I
2 
(95% CI) Het P 
All-cause     
 Geographic region     
   Scandinavia 10 2.20 (2.01–2.41) 96.5 (95.2–97.5) <0.001 
   North America 3 1.77 (1.24–2.53) 81.4 (42.7–94.0) 0.005 
   UK 8 2.06 (1.74–2.34) 91.7 (86.0–95.1) <0.001 
   Other European 4 1.67 (1.18–2.38) 51.7(0.0–84.1) 0.1 
   Japan 1 1.93 (1.44–2.52) - - 
 Population type     
   Inpatient 17 2.05 (1.86–2.25) 97.3 (96.9–97.7) <0.001 
   Inpatient & 
community 
6 2.21 (1.79–2.73) 80.6 (49.1–89.4) <0.001 
   Community 3 1.85 (1.16–2.94) 77.6 (0.0–91.1) 0.01 
 Mid-point of study     
   1950s 2 1.86 (0.88–3.94) 90.9*  0.001 
   1960s 3 1.85 (1.58–2.17) 0.0 (0.0–72.9) 0.7 
   1970s 6 1.93 (1.67–2.24) 82.5 (60.8–89.8) <0.001 
   1980s 6 2.30 (1.84–2.87) 84.1 (62.3–90.9) <0.001 
   1990s 3 2.12 (1.42–3.14) 99.3 (99.0–99.4) <0.001 
   2000s 5 2.13 (1.90–2.39) 95.7 (93.9–96.8) <0.001 
Natural     
 Geographic region     
   Scandinavia 6 1.79 (1.56–2.05) 98.8 (98.6–99.0) <0.001 
   North America 2 1.34 (0.90–2.00) 64.9* 0.09 
   UK 3 1.42 (0.95–2.12) 98.7 (98.1–99.0) <0.001 
   Other European 1 1.40 (1.17–1.66) - - 
 Population type     
   Inpatient 10 1.67 (1.48–1.88) 98.5 (98.3–98.7) <0.001 
   Inpatient & 
community 
1 1.79 (1.68–1.91) - - 
   Community 1 1.03 (0.71–1.44) - - 
 Mid-point of study     
   1950s 1 1.10 (0.79–1.49) - - 
   1960s 0 - - - 
   1970s 3 1.36 (1.23–1.51) 0.0 (0.0–72.9) 0.43 
   1980s 3 1.51 (1.14–2.00) 99.1 (98.8–99.3) <0.001 
   1990s 2 2.06(2.00–2.12) 0.0* 0.62 
   2000s 3 1.75 (1.50–2.03) 97.1 (95.8–97.9) <0.001 
Continued overleaf  
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  No. of 
Studies 
Summary SMR 
(95% CI) 
I
2 
(95% CI) Het P 
Unnatural      
 Geographic region     
   Scandinavia 6 8.15(7.20–9.24) 94.0 <0.001 
   North America 2 3.12 (1.97–4.96) 0* 0.75 
   UK 2 7.90 (3.16–19.73) 99.2* <0.001 
   Other European 2 5.60 (2.42–12.95) 31.8* 0.23 
 Population type    - 
   Inpatient 11 7.56 (6.52–8.77) 95.4 (94.0–96.3) <0.001 
   Inpatient & 
community 
1 6.05 (5.14–7.12) - - 
   Community        0 -     -                - 
 Mid-point of study     
   1950s 1 2.93 (1.52–5.13) - - 
   1960s 0 - - - 
   1970s 3 5.46 (3.03–9.85) 84.3 (15.7–93.0) 0.002 
   1980s 3 8.75 (6.39–11.97) 97.3 (95.4–982) <0.001 
   1990s 2 6.93 (3.60–13.34) 98.9* <0.001 
   2000s 3 8.26 (6.53–10.44) 94.9 (91.6–96.6) <0.001 
SMR, standardised mortal ity ratio: CI,  confidence interval; I
2
,  index of  heterogeneity; Het P 
from X
2
 test; *95% CI cannot be calculated due to 1 degree of freedom.  
 
For all-cause mortality SMR Eggers test did not suggest significant publication bias (P=0.63). 
The same was true for SMR of unnatural deaths (P=0.55) and suicide (P=0.40). However, 
given the high heterogeneity, publication bias cannot be ruled out with certainty in these 
groups. It is even more likely to be present in studies of natural deaths (P=0.05), and 
circulatory disease (P=0.17) where P-values are closer to the established threshold of 
P<0.05. 
3.5 Discussion 
3.5.1 Main findings 
This review of mortality in patients with BPD highlights the increased risk of death from all 
causes. Summary SMR estimates from random effects meta-analysis showed that all-cause 
mortality in BPD is double that expected in the general population. Natural deaths are over 
1.5 times greater in BPD than the general population; these natural deaths are made up of 
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an almost double risk of deaths from circulatory illnesses (heart attacks, strokes, etc.) and 3 
times risk of deaths from respiratory illness (COPD, asthma, etc.).  Unnatural deaths are 
around 7 times more common, with increased risk of suicide of around 14 times and other 
violent deaths (accidents, homicide, etc.) almost 4 times as likely. Deaths by all causes were 
similarly elevated in both men and women. It is particularly concerning that having BPD in 
the 2000s has the same mortality risk, compared to the general population, as it did in the 
1950s. With the increased use of SGAs in these cohorts (Alexander et al., 2011, Hayes et al., 
2011) and associated elevated risk of CVD; the failure of smoking cessation policy to 
address the needs of the severely mentally ill, relative to the general population (Cassidy et 
al., 2001, Hert et al., 2011); and the continued lack of equality in access to healthcare for 
individuals with BPD (Hert et al., 2011), this gap in deaths from medical illness may widen 
unless it is directly addressed.  In terms of modifying the increased rate of unnatural 
deaths, particular attention needs to be paid to comorbid substance misuse, exploitation, 
receipt and perpetration of violence, and suicidal ideation (Cassidy et al., 2001, Gonda et 
al., 2012, Khalifeh and Dean, 2010). 
Heterogeneity across studies was high (less so for cancer, and infection deaths). 
Heterogeneity in all-cause mortality, natural and unnatural death SMRs could not be 
accounted for by year of publication, study size, mid-point of data collection, geographical 
region or population type. Whilst it is possible that some of these factors were imperfectly 
adjusted for in the analysis (for example some cohorts spanned many decades), the results 
suggest that there are unidentified factors that led to differences in outcomes for different 
cohorts of patients with BPD. It has been found that patients with BPD in the United States 
have worse physical health and greater comorbidity than those in Germany and the 
Netherlands (Post et al., 2014), however it may be the case that there are even more 
localised differences in BPD outcomes. This meta-analysis suggests that within the US or 
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Europe, mortality estimates for BPD are not homogenous.  Adjusting for cohort size did 
little to reduce the heterogeneity, despite the increased accuracy in SMR estimates larger 
studies should provide. Stratifying by decade of data collection did not affect 
heterogeneity, suggesting that the differences are not down to improvements in treatment 
over time. Studies of inpatient populations and community cohorts were also 
heterogeneous, suggesting these differences are not down to engagement with services or 
severity of illness.  
3.5.2 Potential limitations 
There are several limitations of studies included in this review. SMRs were often only age 
and sex adjusted; therefore, other characteristics of the study populations such as illness 
duration, treatment and lifestyle factors, may have contributed to the significant 
heterogeneity. For example, it was not possible to assess whether current or former 
smoking contributed to excess respiratory mortality. Disease severity was not assessed in 
all of the included studies, and therefore, it is not possible to assess heterogeneity in the 
overall mortality by severity. It has been recognised that patients with BPD accumulate 
numerous medical risk factors including smoking, poor nutrition, use of alcohol and other 
illicit drugs, prescribed medication and comorbid anxiety and eating disorders that lead to 
earlier disease onset, poor engagement with healthcare and poor long-term outcomes 
(Kilbourne et al., 2004). These risk factors may be assigned differentially, both 
geographically and temporally. In many of the included studies, cause of death was 
ascertained from death certificates and therefore may be subject to potential 
misclassification bias. Having a mental health diagnosis has been shown to increase the risk 
of a coroner’s verdict of suicide rather than accidental or undetermined death (Rosenberg 
et al., 1988) but may also reduce diagnosis of terminal illness leading to miscoding of 
physical cause of death (Hert et al., 2011).  
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It has been argued that in the event of high heterogeneity, meta-analysis is inappropriate 
as the pooled effect estimate represents the mean distribution of SMRs from included 
studies, rather than a potentially “true” effect estimate (Hedges and Vevea, 1998).  One 
aims of this analysis was to attempt to identify reasons for this heterogeneity and so a 
random-effects approach was taken. A random-effects meta-analysis model involves an 
assumption that the effects being estimated in the different studies are not identical, but 
follow some distribution. The model represents the lack of knowledge about why real, or 
apparent, SMRs differ by considering the differences as if they were random.  
Additionally, it was not possible to fully assess study quality.  I considered assessing 
methodological quality via a tool such as the Newcastle–Ottawa Scale (Stang, 2010). 
However, many of the points included in this tool are not applicable to the studies in 
question, for example the definition of outcome does not vary; it is always death, nor does 
the definition of control population; it is always overall mortality in the general population. 
I also considered adding that studies needed to have explicit inclusion/exclusion criteria 
and operationalised diagnostic criteria to be considered ‘high quality’. However, this 
tended to make scores more similar; single site studies of inpatient populations score well 
on these criteria, whereas population-based cohorts score badly (despite population-based 
cohorts clearly being more generalisable). Universally reported factors that could introduce 
biased estimates were assessed, these included the following: country of study, year of 
publication, years of data collection, factors for standardisation, site of data collection 
(population, single site and multisite), population type (inpatient or community). I did not 
feel combining these factors into a ‘score’ would have improved the analysis or its 
interpretation. 
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3.5.3 Conclusions 
This meta-analysis highlights differential mortality in patients with BPD and the general 
population. Similarly to schizophrenia, patients with BPD have over twice the all-cause 
mortality (Saha et al., 2007). Mortality from all physical conditions and unnatural causes is 
elevated. Variation in all-cause mortality is considerable across time and place. There is no 
evidence that all-cause mortality for patients with BPD has improved over time relative to 
the general population. 
3.5.4  Implications of the findings from this systematic-review and meta-analysis 
Generalisable and timely measures of mortality in BPD will become more available with the 
development of EHRs. The numbers of patients in these datasets will provide sufficient 
power to analyse mortality and other negative outcomes in BPD, whereas previously 
opportunities have been limited because of the low prevalence of the disorder and the 
tendency to focus only on follow-up of inpatient samples. Subgroup analysis, by treatment 
received or illness severity will also be possible. Study 1 (Chapter 4) partially addresses this 
research need using a population-based cohort from THIN, which is representative of the 
UK population, and examines all-cause mortality HRs and cause specific HRs for CVD deaths 
and suicide.   
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Chapter 4 Mortality and morbidity in 
individuals with bipolar disorder and 
schizophrenia, compared to the general 
population  
4.1 Summary 
4.1.1 Objective 
To calculate trends in all-cause mortality in the UK in individuals with BPD compared to 
individuals with schizophrenia and the general population, and to calculate rates of i) CVD 
deaths, ii) suicide, iii) CVD diagnoses, iv) self-harm in individuals diagnosed with BPD or 
schizophrenia compared to the general population, while accounting for sociodemographic 
factors. 
4.1.2 Method 
A longitudinal cohort study conducted in a nationally representative UK sample using 
primary care EHR data collected between January 1, 2000, and December 31 2014. All 
patients diagnosed as having BPD or schizophrenia and a frequency matched comparison 
group of the general population were included.  The primary outcome was all-cause 
mortality. Secondary outcomes were cardiovascular deaths, CVD diagnoses, suicide and 
self-harm. 
4.1.3 Results 
Among 17,341 individuals with BPD and 22,497 with schizophrenia, 1,266 and 2,061 
respectively died during follow-up. Individuals with BPD had an all-cause mortality 1.79 
times (95% CI 1.67 to 1.88) and those with schizophrenia 2.08 times (95% CI 1.98 to 2.19) 
that of the general population, accounting for sociodemographic characteristics. Adjusted 
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HRs were stable in BPD between 2000 and 2006, and then increased by 0.14 per year (95% 
CI 0.10 to 0.19). HRs for schizophrenia fell until 2004 (-0.29 per year; 95% CI -0.48 to -0.10), 
increased gradually between 2004 and 2010 (0.11 per year; 95% CI 0.04 to 0.17) and 
increased more rapidly after 2010 (0.34 per year; 95% CI 0.18 to 0.49). Cardiovascular 
mortality was elevated in those with schizophrenia (HR 1.39; 95% CI 1.12 to 1.73) and 
greatly so in those aged 50 years and under (HR 3.20; 95% CI 1.62 to 6.31), but not in BPD. 
The HR for CVD diagnosis suggests under-recording in those under 50 with schizophrenia. 
Suicide rates were elevated in both BPD (HR 12.66; 95% CI 7.79 to 20.58) and schizophrenia 
(HR 7.21; 95% CI 4.26 to 12.19) as were rates of self-harm (HR 25.24; 95% CI 22.37 to 28.29 
and HR 22.14; 95% CI 19.58 to 25.03 respectively).     
4.1.4 Conclusion 
Despite falling mortality rates in individuals with BPD and schizophrenia, the gap between 
BPD and schizophrenia mortality, and mortality in the general population became wider 
between the mid-2000s and 2014. Death from cardiovascular disease is markedly elevated 
in those younger than 50 with schizophrenia. Death from suicide is similarly elevated in BPD 
and schizophrenia relative to the general population. 
A modified version of this chapter was published as Hayes JF, Marston L, Walters K, King 
M, Osborn DP. Widening mortality gap for people with bipolar disorder and 
schizophrenia: UK based cohort study 2000-2014. British Journal of Psychiatry. 2017; DOI: 
10.1192/bjp.bp.117.202606 
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4.2 Introduction 
As discussed in Chapter 1, death rates are increased in people with severe SMI relative to 
the general population, and this translates to around 20-years of premature mortality 
(Laursen, 2011, Laursen et al., 2013). This has been found in a number of longitudinal 
studies (Hoang et al., 2013, Hoang et al., 2011, Saha et al., 2007, Tiihonen et al., 2009). It 
has been reported that the mortality gap has narrowed or plateaued since the mid-1990s 
(Bushe et al., 2010), but there are no studies examining this using UK data.  
Since the turn of the millennium, a number of strategies aimed at reducing the mortality 
gap between people with SMI and the general population have been implemented in the 
UK NHS (Colton and Manderscheid, 2006, Department of Health, 2011, 2014, Doran et al., 
2011, Edwards and McGorry, 2002, Roland, 2004, Schizophrenia Commission, 2012, 
Swinson et al., 2007). Additionally, the UK age-standardised mortality rate in the general 
population has declined. Between 2000 and 2014 the annual age-standardised mortality 
rate fell by approximately 20% (Office for National Statistics, 2016). Therefore, any 
intervention targeted at mortality in people with SMI would have to reduce mortality at a 
rate greater than this to reduce the mortality gap. Few previous studies cover SMI mortality 
during this period. It is therefore timely to review all-cause and cause-specific mortality 
rates in individuals diagnosed with BPD and schizophrenia relative to the general 
population. Schizophrenia has tended to be the “target” diagnosis in SMI, so it is important 
to understand how BPD mortality compares to a group that has been more commonly the 
focus of policy and research. I used CVD mortality and suicide as exemplars of natural and 
unnatural causes of death that have been targets of mental health policy. 
Evidence suggests that CVD is the leading cause of death in individuals with SMI (Laursen et 
al., 2013, Roshanaei-Moghaddam and Katon, 2009, Weiner et al., 2011). However, large 
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representative longitudinal studies remain limited in number. For example, the only 
previous population based study, of which I am aware, used data from 1987-2002 and 
found that people aged under 50 with schizophrenia had over three times the rate of CVD 
mortality (Osborn et al., 2007). Data from this study are now over 15 years old; it predates 
the increase in SGA use and the efforts to reduce mortality in the SMI population. Osborn 
et al. also found that HRs for CVD incidence were smaller than HRs for CVD death. This 
suggests that those with SMI may present less, get diagnosed less or receive correct 
treatment less frequently (Osborn et al., 2007). Although lack of access to appropriate 
treatment has also been reported elsewhere (Kurdyak et al., 2012, Laursen et al., 2009, 
Newcomer and Hennekens, 2007, Smith et al., 2013), an alternative has been postulated: 
individuals with SMI may truly be at greater risk of unheralded coronary events, potentially 
due to different pathology (e.g., more plaque rupture) (Leboyer et al., 2012).  
In the UK a number of initiatives have been targeted at improving physical health of those 
with SMI, particularly CVD, which are intended to lead to earlier diagnosis of CVD (Roland, 
2004), reducing CVD risk factors (Cormac, 2009, McCreadie, 2003) and effective treatment 
implementation (Miller, 2009). However, studies are yet to investigate if CVD deaths in 
people with SMI have fallen because of these interventions, and if inequalities in access to 
care have reduced. It is unclear if age and sex differences remain the same as previous 
studies. Also, as far as I am aware the contribution of lifestyle and presence of 
cardiovascular risk factors as an explanation for the potential increase in CVD mortality and 
CVD diagnosis has not been explored. 
As shown in Chapter 3, Suicide is the cause of death that is most elevated in individuals 
with BPD and this is also true in schizophrenia, compared to the general population (Brown, 
1997). It remains unclear if suicide is elevated in BPD compared to schizophrenia, as 
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previous studies have given inconsistent results (Mortensen et al., 2000, Osborn et al., 
2008, Tidemalm et al., 2008). Up-to-date estimates of suicide rates are important markers 
of the success of psychiatric care (Swinson et al., 2007). Self-harm is the major risk factor 
for suicide, with a large number of those dying by suicide having a history of self-harm 
(Owens et al., 2002). Self-harm is also a marker of quality of life and emotional distress in 
individuals with SMI (Singhal et al., 2014).   
This study compares rates of all-cause mortality, CVD death and CVD, suicide and self-harm 
in people with BPD, and schizophrenia and a general population comparator group from 
2000 to 2014.   
4.3 Methods 
4.3.1 Study design and setting 
This cohort study was completed using pseudonymised primary care EHRs from THIN, as 
discussed in Section 2.3. Data were included from January 1 2000, until December 31 2014 
(Figure 2.i, Figure 4.i).   
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Figure 4.i Flow diagram of included patients 
 
AMR, Acceptable Mortal ity Reporting;  ACU,  Acceptable Computer Usage  
 
4.3.2 Participants 
All individuals aged 16 or over, ever receiving a diagnosis of BPD or schizophrenia were 
included in the cohort. If individuals had multiple diagnoses they were classified by the 
diagnosis most recently assigned. Patients with schizoaffective disorders and unipolar 
depression were excluded. The validity of diagnoses of BPD and schizophrenia in primary 
care records is discussed in Section 2.5.2.  Individuals with BPD and schizophrenia were 
frequency matched with up to six individuals without these diagnoses to create a 
comparator group. The comparator group was matched on age (in 5-year age bands) and 
sex, from within the same primary care practice (Section 2.5.3). 
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4.3.3 Outcomes 
CVD was defined as any entry of myocardial infarction (MI), ischemic heart disease (IHD) or 
cerebrovascular event (CVE) in the longitudinal EHR. CVD diagnoses have previously been 
validated in THIN with positive predictive values greater than 90% (Hammad et al., 2008, 
Ruigómez et al., 2010). In line with other studies CVD mortality was defined as a death code 
with a CVD cause, or a CVD code, followed by a death code in the following sixty days and a 
final date of any activity in the EHR within six months (Ogdie et al., 2014). 
The definition for self-harm events included Read codes for intentional poisoning, 
intentional self-injurious behaviour, and self-harm acts of uncertain intent. This unitary 
definition of self-harm, where there is no distinction made between non-suicidal self-harm 
and self-harm with suicidal intent is consistent with UK research norms (Haw et al., 2015). 
The positive predictive value of this outcome in THIN has been shown to be 97% (Arana et 
al., 2010). Suicide was defined as a death code identified as suicide or a self-harm code 
followed by a death code in the following thirty days and a final date of any activity in the 
EHR within six months, in line with previous research (Arana et al., 2010). 
4.3.4 Statistical analyses 
Rates of all-cause, cause specific mortality (CVD deaths, suicide) and morbidity (CVD, self-
harm) were calculated. Annual rates were calculated for all-cause mortality. In order to 
assess trends in rates over time, a segmented regression analysis using joinpoint models 
was performed (Kim et al., 2000, Wagner et al., 2002). To complete this analysis the 
Surveillance Research Program of the United States National Cancer Institute Joinpoint 
software was used (Version 4.3.1.0 (Statistical Methodology and Applications Branch, 
2016)). This analysis identifies time points where there is a change in the linear slope of the 
trend. The optimum number of linear slopes and joinpoints is assessed using modified 
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Bayesian Information Criteria (Zhang and Siegmund, 2007). The models incorporate 
estimated variation for each data point using the standard error of the rate. After 
identification of a change in trend, segmented regression can be fitted and annual 
percentage change in rate (with 95% CIs) can be calculated. 
Cox proportional hazards regression analyses were conducted comparing rates of all-cause 
mortality, in individuals with BPD, schizophrenia and the matched comparison group. The 
assumption of proportional hazards was tested by analysis of Schoenfeld residuals 
(Schoenfeld, 1982). A number of multivariable models were tested. Firstly, the association 
between diagnosis and all-cause mortality was assessed, adjusting for age, sex and calendar 
year and clustering within primary care practices, then additionally adjusting for area level 
deprivation (defined as quintiles of Townsend score – a proxy for SES (Townsend, 1987), 
based on the patients lower super output area),  and ethnicity (categorised as White 
British, White other, Black, Asian, mixed and other). This fully adjusted model was stratified 
by sex, and age (16-50 years, over 50 years old). As with the rate, annual adjusted HRs were 
calculated for all-cause mortality and trends in HRs were assessed using joinpoint 
regression. In this instance, a change in HR per year (with 95% CIs) was calculated. 
The associations between diagnosis and CVD death, CVD diagnosis, suicide and self-harm 
were assessed using the same multivariable approach, additionally adjusting for area level 
deprivation, ethnicity and average number of visits to the physician per year of follow-up 
(to account for the likelihood of having a diagnostic code recorded in the EHR). For each 
outcome these models were stratified by sex, age (16-50 years, over 50 years old) and 
calendar period (start of 2000 until end of 2004, start of 2005 until end of 2009, start of 
2010 until end of 2014) to examine potential effect modification.  
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A further model additionally including smoking status (worst ever of: never, ex, current 
smoker), BMI (worst ever of: healthy weight, overweight, obese), and diagnoses of 
hypercholesterolemia (defined as total cholesterol ≥5.2mmol/L (Ford et al., 2003)), 
hypertension (defined as code for hypertension or two consecutive records of systolic 
blood pressure>140mmHg (National High Blood Pressure Education Program, 2004))  and 
T2DM during follow-up was tested to see if these covariates explained elevated rates of 
CVD death and diagnoses in individuals with BPD and schizophrenia relative to the 
comparison group.  
4.4 Results  
4.4.1 Clinical and demographic features 
17,314 people had a diagnosis of BPD and 22,497 had a diagnosis of schizophrenia with 
active records between the start of 2000 and the end of 2014. These were matched with 
219,387 individuals who never received BPD or schizophrenia diagnoses. There were 1,266 
deaths in total in the group with a BPD diagnosis, 2,061 in those with schizophrenia and 
6,279 in the comparison group (Table 4.i). 
Table 4.i Cohort characteristics 
  
General 
population 
comparison  
Bipolar disorder Schizophrenia  
N 219,387 17,341 22,497 
Female, N (%) 102,037 (46.51) 10,202 (58.83) 
8,499  
(37.78) 
Age at start of f/u years, median (IQR) 
41.35  
(31.75–54.20) 
42.76  
(32.59–56.43) 
42.51  
(32.34–56.51) 
Age at first mention diagnosis 
years, median (IQR) 
- 
38.00  
(28.14–50.47) 
30.00  
(23.12-41.00) 
Follow-up years, median (IQR) 
2.00  
(0.77–4.32) 
2.32  
(0.93–5.12) 
2.47  
(0.94–5.53) 
Died, N (%) 6,279 (2.74) 1,266 (7.30) 2,061 (9.16) 
Primary care contacts per year, median (IQR) 
7.19  
(2.39–18.89) 
14.59  
(7.86–27.13) 
11.36  
(5.98–20.84) 
Continued overleaf  
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General 
population 
comparison  
Bipolar 
disorder 
Schizophrenia  
Ethnicity, N (%)    
White British 180,690 (82.36) 15,024 (86.64) 18,648 (82.89) 
White Other 20,792 (9.48) 1,465 (8.45) 1,753 (7.79) 
Black 5,091 (2.32) 235 (1.36) 981 (4.36) 
Asian 8,464 (3.86) 330 (1.90) 635 (2.82) 
Other or mixed 4,350 (1.98) 287 (1.66) 480 (2.13) 
Social deprivation at baseline, quintiles of UK 
Townsend score, N (%) 
   
1 [least deprived] 38,404 (17.51) 2,696 (15.55) 2,142 (9.52) 
2 38,862 (17.71) 2,932 (16.91) 2,780 (12.36) 
3 45,679 (20.82) 3,742 (21.58) 4,127 (18.34) 
4 47,633 (21.71) 4,128(23.80) 5,932 (26.37) 
5 [most deprived] 41,971 (19.13) 3,416 (19.70) 6,695 (29.76) 
 missing 6,838 (3.12) 427 (2.46) 821 (3.65) 
Record during follow-up of:    
Smoking, N (%) 55,531 (25.31) 6,503 (37.50) 10,406 (46.26) 
Obesity, N (%) 45,447 (20.72) 5,911 (34.09) 7,801 (34.68) 
Hypercholesterolemia, N (%) 33,867 (15.44) 3,800 (21.91) 14,398 (19.55) 
Hypertension, N (%) 71,194 (32.45) 6,494 (37.45) 8,047 (35.77) 
Diabetes Mellitus, N (%)  14,061 (6.41) 1,851 (10.67) 2,986 (13.27) 
 
4.4.2 All-cause mortality 
The rate of all-cause mortality in individuals with BPD was 210.34 per 10,000 person years 
at risk (PYAR) (95% CI 199.07 to 222.25). Trends in BPD mortality rate suggested a reduction 
over follow-up time. Joinpoint regression fitted a linear model with a significant annual 
percentage change (APC) in rate of -4.1% (95% CI -5.1 to -3.1) (Figure 4.ii). In individuals 
with schizophrenia the mortality rate was 248.57 per 10,000 PYAR (95% CI 238.06 to 
259.53). Similarly, the rate of mortality in schizophrenia reduced between 2000 and 2014, 
with joinpoint regression fitting a model with no joinpoints, and an APC of -2.0% (95% CI -
3.0 to -0.9).  In the comparison population the mortality rate was relatively stable between 
2000 and 2003 (APC 4.2; 95%CI –7.6 to 17.6) and then decreased until the end of the study 
period (APC –8.1; 95%CI –9.6 to –6.5). 
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Figure 4.ii All-cause mortality rate in bipolar disorder and schizophrenia 2000-2014 
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Mortality was elevated in those with BPD (HR 1.77; 95% CI 1.67 to 1.88) and schizophrenia 
(HR 2.08; 95% CI 1.98 to 2.19) relative to the comparison group, after adjustment for age, 
sex, calendar year, area level deprivation and ethnicity (Table 4.ii).  Stratification by sex 
suggested that men and women with BPD had similarly elevated mortality rates (P=0.297), 
but in those with schizophrenia, men’s morality rate (HR 2.50; 95% CI 2.32 to 2.69) was 
more elevated than women’s (HR 1.78; 95% CI 1.66 to 1.90, test for interaction P<0.0001). 
Mortality rates in those aged 50 and under were more elevated, relative to the comparison 
group, than those over 50 (test for interaction in both groups p<0.0001). Individuals with 
BPD aged 50 or under had an adjusted HR of 3.22 (95% CI 2.77 to 3.75), individuals with 
schizophrenia had an adjusted HR of 4.69 (95% CI 4.16 to 5.29).  
Table 4.ii All-cause mortality 
  General 
population 
comparison
a
 
Bipolar disorder Schizophrenia 
All-cause mortality    
Deaths, n 6279 1266 2061 
PYAR (10,000s) 64.88 6.02 8.29 
Rate, per 10,000 PYAR (95% CI) 96.79  
(94.42–99.21) 
210.34  
(199.07–222.25) 
248.57  
(238.06–259.53) 
Age, sex, calendar period adjusted HR 
(95% CI) 
1  
(reference) 
1.79 (1.69–1.90) 2.14 (2.03–2.25) 
b
Sociodemographics adjusted HR (95% 
CI) 
1  
(reference) 
1.77 (1.67–1.88) 2.08 (1.98–2.19) 
Stratified fully 
b
adjusted model HR (95% 
CI) 
   
 Men 1 (reference) 1.85 (1.68–2.04) 2.50 (2.32–2.69) 
 Women 1 (reference) 1.73 (1.61–1.87) 1.78 (1.66–1.90) 
 Test for interaction   P=0.297 P<0.0001 
 16-50 1 (reference) 3.22 (2.77–3.75) 4.69 (4.16–5.29) 
 >50 1 (reference) 1.60 (1.50–1.70) 1.80 (1.71–1.91) 
 Test for interaction   P<0.0001 P<0.0001 
a
General population comparison group of up to 6 individuals without BPD or schizophrenia 
matched for sex,  age group,  and primary care practice,  
b
age, sex, calendar period, area level 
deprivation, ethnicity  
 
There was evidence of a change in HRs over the study period for groups with both BPD and 
schizophrenia diagnoses (Figure 4.iii). Joinpoint analysis fitted a model with one joinpoint 
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at 2006 for BPD. This model suggested that the HR decreased by 0.08 (95% CI -0.18 to 0.02) 
per year between 2000 and 2006, and significantly increased by 0.14 (95% CI 0.10 to 0.19) 
per year from 2006 to 2014 (Figure 4.iii). For schizophrenia, joinpoint regression fitted 
three linear models (two joinpoints); from 2000 to 2004 the HR reduced significantly by 
0.29 (95% CI -0.48 to -0.10) per year, from 2004 to 2010 the HR increased by 0.11 (95% CI 
0.04 to 0.17) per year, and from 2010 to 2014 increased by 0.34 (95% CI 018 to 0.49) 
(Figure 4.iii).  
Figure 4.iii All-cause mortality adjusted hazard ratio for bipolar disorder and 
schizophrenia compared to the general population 2000-2014 
 
Continued overleaf  
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4.4.3 Cardiovascular disease mortality and cardiovascular disease diagnoses 
There was evidence of an elevated HR for cardiovascular deaths in schizophrenia (HR 1.39; 
95% CI 1.12 to 1.73) after accounting for age, sex, calendar year, area level deprivation, 
ethnicity and average number of visits to the physician during follow-up (Table 4.iii). 
Following additional adjustment for smoking, hypercholesterolemia, hypertension, BMI and 
T2DM, there was no evidence that CVD deaths were elevated in people with schizophrenia 
relative to the general population (HR 1.22; 95% CI 0.98 to 1.52), suggesting that the excess 
CVD deaths are explained by increases in traditional CVD risk factors.  The HR for BPD was 
not elevated, relative to the comparison group and there was no evidence that this differed 
by sex or age (Table 4.iii). Stratification by five year periods suggested that cardiovascular 
deaths were elevated in people with BPD, relative to the general population after 2010 (HR 
1.92; 95% CI 1.24 to 2.98), but not before this. Amongst those individuals with 
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schizophrenia, sex was not an effect modifier (P=0.068). The HR for CVD mortality in people 
with schizophrenia aged 50 or under was 3.20 (95% CI 1.62 to 6.31), whereas in those over 
50 it was 1.29 (95% CI 1.03 to 1.63, test for interaction P=0.013) (Table 4.iii).  
 
Rates of new CVD were elevated in both BPD and schizophrenia groups compared to the 
comparison group after adjustment for age, sex, calendar year, area level deprivation, 
ethnicity and average number of visits to the physician during follow-up  (HR 1.41; 95% CI 
1.26 to 1.58, and HR 1.36; 95% CI 1.24 to 1.50 respectively) (Table 4.iii).  Records of 
smoking, hypercholesterolemia, hypertension, BMI, and T2DM in the patient notes did not 
explain the increased rates, though it did attenuate them (HR 1.26; 95% CI 1.12 to 1.41 in 
BPD, and HR 1.22; 95% CI 1.11 to 1.35 in schizophrenia after adjustment for these 
confounders). 
Men were significantly more likely to receive a CVD diagnosis than women in both BPD and 
schizophrenia groups (HR 1.55; 95% CI 1.31 to 1.82, and HR 1.37; 95% CI 1.20 to 1.57 
respectively). Women with either SMI diagnosis did not have elevated rates relative to 
women in the general population (Table 4.iii). Increased rates of CVD mortality in those 
with schizophrenia aged 16-50 were not reflected in equally increased rates of CVD 
diagnosis (HR 1.66; 95% CI 1.29-2.15). 
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Table 4.iii Cardiovascular disease mortality and cardiovascular disease diagnoses 
  General 
population 
comparison
a
 
Bipolar disorder Schizophrenia 
Cardiovascular disease death    
Events, n 437 59 106 
PYAR (10,000s) 64.88 6.02 8.29 
Rate, per 10,000 PYAR (95% CI) 6.74 (6.13–7.40) 9.80 (7.59–12.65) 12.78 (10.57–15.46) 
Age, sex, calendar period adjusted HR (95% 
CI) 
1 (reference) 1.11 (0.85–1.46) 1.43 (1.15–1.76) 
b
Sociodemographics adjusted HR (95% CI) 1 (reference) 1.10 (0.84–1.46) 1.39 (1.12–1.73) 
Stratified 
b
 adjusted model HR (95% CI)    
 Men 1 (reference) 1.28 (0.83–1.97) 1.74  (1.26–2.39) 
 Women 1 (reference) 1.00 (0.70–1.43) 1.16 (0.86–1.57) 
 Test for interaction   P=0.394 P=0.068 
 16-50 1 (reference) 1.13 (0.34–3.71) 3.20 (1.62–6.31) 
 >50 1 (reference) 1.10 (0.83–1.45) 1.29 (1.03–1.63) 
 Test for interaction   P=0.960 P=0.013 
 2000-2004 1 (reference) 1.06 (0.64–1.77) 1.61 (1.12–2.30) 
 2005-2009 1 (reference) 0.69 (0.42–1.14) 1.13 (0.80–1.60) 
 2010-2014 1 (reference) 1.92 (1.24–2.98) 1.57 (1.01–2.43) 
 Test for interaction   P=0.009 P=0.323 
c
Health and health behaviour adjusted HR 
(95% CI) 
1 (reference) 1.05 (0.80–1.39) 1.22 (0.98–1.52) 
Cardiovascular disease    
Events, n 2445 382 551 
PYAR (10,000s) 61.59 5.60 7.76 
Rate, per 10,000 PYAR (95% CI) 39.70  
(38.15–41.30) 
68.19  
(61.69–75.39) 
70.97  
(65.28–77.15) 
Age, sex, calendar period adjusted HR (95% 
CI) 
1 (reference) 1.46(1.31–1.63) 1.47 (1.34–1.61) 
b
Sociodemographics adjusted HR (95% CI) 1 (reference) 1.41 (1.26–1.58) 1.36 (1.24–1.50) 
Stratified 
b
 adjusted model HR (95% CI)    
 Men 1 (reference) 1.55 (1.31–1.82) 1.37 (1.20–1.57) 
 Women 1 (reference) 1.00 (0.86–1.17) 1.04 (0.90–1.20) 
 Test for interaction   P<0.0001 P=0.018 
 16-50 1 (reference) 2.30 (1.78–2.99) 1.66 (1.29–2.15) 
 >50 1 (reference) 2.45 (2.01–2.99) 2.60 (2.14–3.14) 
 Test for interaction   P=0.670 P=0.002 
 2000-2004 1 (reference) 1.22 (0.96–1.56) 1.45 (1.12–1.69) 
 2005-2009 1 (reference) 1.26 (1.03–1.54) 1.46 (1.24–1.71) 
 2010-2014 1 (reference) 1.57 (1.34–1.83) 1.35 (1.16–1.57) 
 Test for interaction   P=0.118 P=0.762 
c
Health and health behaviour adjusted HR 
(95% CI) 
1 (reference) 1.26 (1.12–1.41) 1.22 (1.11–1.35) 
a
General population comparison group of up to 6 individuals without BPD or schizophrenia 
matched for sex,  age group,  primary care practice,  
b
Adjusted for age, sex, calendar period, 
area level deprivation, ethnicity ,  number of primary care contacts,  
c
Adjusted for age, sex,  
calendar period, area level deprivation, ethnicity ,  smoking, high cholesterol,  high blood 
pressure, BMI, d iabetes mellitus and  primary care contacts   
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4.4.4 Suicide and self-harm 
After accounting for age, sex, calendar year, area level deprivation, ethnicity and average 
number of visits to the physician per year of follow-up, the rate of suicide in those with BPD 
was 12.66 (95% CI 7.79 to 20.58) times that of the comparison group (Table 4.iv). The 
similarly adjusted HR in the group with schizophrenia was 7.21 (95% CI 4.26 to 12.19). 
Increased suicide rates were observed in both BPD and schizophrenia irrespective of sex, 
age or calendar period.  However, whilst there were some differences in the point 
estimates, confidence intervals were wide and there was no evidence of significant  
differences by sex, age group or time period (Table 4.iv). 
Self-harm rates were elevated in both BPD (HR 25.24; 95% CI 23.63 to 29.96) and 
schizophrenia (HR 22.14; 95% CI 19.58 to 25.03) after adjusting for sociodemographic 
characteristics and physician visits (Table 4.iv). Rates of self-harm did not differ by sex in 
either BPD (P=0.096) or schizophrenia (P=0.735). Self-harm was dramatically elevated in 
those aged 50 or under with a diagnosis of BPD (HR 55.74; 95% CI 45.35 to 68.52) and 
schizophrenia (HR 52.07; 95% CI 42.43 to 63.92) and still increased, but to a lesser extent in 
those aged over 50 years old (Table 4.iv).   
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Table 4.iv Suicide and self-harm 
  General 
population 
comparison
a
 
Bipolar disorder Schizophrenia 
Suicide    
Events, n 33 36 33 
PYAR (10,000s) 64.88 6.02 8.29 
Rate, per 10,000 PYAR (95% CI) 0.51 (0.36–0.72) 5.98 (4.31–8.29) 3.98 (2.83–5.60) 
Age, sex, calendar period adjusted HR 
(95% CI) 
1 (reference) 12.94 (8.04–20.82) 7.90 (4.84–12.90) 
b
Sociodemographics adjusted HR (95% 
CI) 
1 (reference) 12.66 (7.79–20.58) 7.21 (4.26–12.19) 
Stratified fully 
b
adjusted model HR (95% 
CI) 
   
 Men 1 (reference) 11.10 (5.85–21.06) 6.91 (3.71–12.87) 
 Women 1 (reference) 15.27 (7.11–32.78) 7.90 (3.15–19.79) 
 Test for interaction   P=0.524 P=0.810 
 16-50 1  
(reference) 
13.20 (7.58–22.99) 8.17 (4.45–14.99) 
 >50 1  
(reference) 
8.79 (3.30–23.41) 5.47 (2.00–14.90) 
 Test for interaction   P=0.478 P=0.499 
 2000-2004 1 (reference) 6.60 (1.53–28.48) 10.18 (3.25–31.90) 
 2005-2009 1 (reference) 9.50 (4.74–19.07) 6.26 (3.05–12.88) 
 2010-2014 1 (reference) 18.88 (8.62–41.32) 7.50 (2.94–19.12) 
 Test for interaction   P=0.306 P=0.772 
Self-harm     
Events, n 390 950 1101 
PYAR (10,000s) 64.87 5.99 8.26 
Rate, per 10,000 PYAR (95% CI) 6.01  
(5.44–6.64) 
158.66  
(148.88–169.07) 
133.33  
(125.68–141.44) 
Age, sex, calendar period adjusted HR 
(95% CI) 
1 (reference) 26.61 (23.63–29.96) 24.04 (21.37–27.07) 
b
Sociodemographics adjusted HR (95% 
CI) 
1 (reference) 25.24 (22.37–28.49) 22.14 (19.58–25.03) 
Stratified fully 
b
adjusted model HR (95% 
CI) 
   
 Men 1 (reference) 22.21 (18.48–26.68) 22.32 (18.91–26.34) 
 Women 1 (reference) 27.31 (23.21–32.13) 21.43 (17.97–25.54) 
 Test for interaction   P=0.096 P=0.735 
 16-50 1 (reference) 55.74 (45.35–68.52) 52.07 (42.43–63.92) 
 >50 1 (reference) 13.99 (11.98–16.34) 9.99 (8.53–11.72) 
 Test for interaction   P<0.0001 P<0.0001 
 2000-2004 1 (reference) 20.56 (14.25–29.67) 23.69 (16.91–33.19) 
 2005-2009 1 (reference) 26.56 (21.96–32.13) 17.69 (14.60–21.43) 
 2010-2014 1 (reference) 26.69 (22.48–31.69) 24.68 (20.79–29.31) 
 Test for interaction   P=0.424 P=0.030 
a
General population comparison group of up to 6 individuals without  BPD or schizophrenia 
matched for sex,  age group,  primary care practice, 
b
Adjusted for age, sex, calendar period, 
area level deprivation, ethnicity ,  number of primary care contacts  
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4.5 Discussion 
4.5.1 Main findings 
In this cohort of over 17,000 people with BPD and over 22,000 people with schizophrenia, I 
found decreasing rates of all-cause mortality for both diagnoses. Despite this, due to an 
even steeper decline in the mortality rate in the general population, the rate of death 
relative to a matched general population comparison group increased from the mid-2000s. 
This suggests that the improvement in health in the general population is increasing more 
rapidly than in those with SMI, and health inequalities are growing.   
4.5.2 Comparison with existing literature 
After accounting for sociodemographic characteristics, over the fifteen-year follow-up 
period, the rate of all-cause mortality in those with BPD was 1.77 times that of the general 
population (95% CI 1.67 to 1.88) and in those with schizophrenia was 2.08 times greater 
(1.98 to 2.19). These results are slightly lower than those from meta-analyses of the 
existing literature (Chapter 3 and (Saha et al., 2007)), but are consistent with population 
based samples (Chapter 3). Deaths in those aged 50 and under were markedly elevated for 
both BPD and schizophrenia.  In individuals with schizophrenia, the risk of dying before 50 
of CVD is strikingly elevated and CVD is infrequently diagnosed in advance of the terminal 
event. This is in-line with the work of Osborn and colleagues that used a cohort ending in 
2002 (Osborn et al., 2007). Increased rates of CVD death in those with schizophrenia were 
explained by traditional risk factors (smoking, BMI, hypercholesterolemia, hypertension and 
T2DM). Suicide was rare in the cohort and as such, I could not state which of the SMI 
diagnoses has more elevated risk, relative to the general population.   
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4.5.3 Potential explanations for these findings 
During the study period, a number of factors could have differentially influenced mortality 
in people with BPD and schizophrenia compared to the general population. There is 
evidence that addressing negative health behaviours has been more effective in the general 
population, for example, population level smoking cessation programmes have had less 
impact on people with SMI (Lawrence and Kisely, 2010). Whilst SGAs have been shown to 
reduce mortality overall (Tiihonen et al., 2009), polypharmacy and higher drug dosages may 
increase it (Weinmann et al., 2009). Polypharmacy is increasingly common in BPD (Hayes et 
al., 2011) and may be contributing to the worsening CVD mortality compared to the general 
population in the 2010-2014 period. Wahlbeck and colleagues speculated that the reducing 
mortality gap seen in Nordic countries up until 2006 reflected the success of 
deinstitutionalisation (Wahlbeck et al., 2011).  Whilst deinstitutionalisation in the UK has 
been a success in terms of integrating people into wider society, it has been argued that 
there is now too little support for people living with BPD and schizophrenia in the 
community (Fakhoury and Priebe, 2007, Green and Griffiths, 2014) and this may be 
reflected in mortality rates. Research into the health effects of recession has suggested that 
consequences will be most severe for the poorest groups in society and will impact most 
where social safety-nets are lacking and public hardship grows rapidly (Cooper, 2011, 
Riumallo-Herl et al., 2014). Given this, I could hypothesise that policies made in the UK 
following the 2008 financial crash (i.e., austerity) have impacted hardest on those with SMI. 
A comprehensive understanding of the mechanisms by which SMI shortens life remains 
elusive, but potentially constitutes a syndemic including psychiatric and physical 
comorbidity, substance misuse, clustering of adverse social factors and lifestyle behaviours 
(Liu et al., 2017). 
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4.5.4 Strengths and limitations 
A major strength of this study, beyond its size and length of follow-up, is that the results 
are generalisable to individuals living with BPD and schizophrenia in the UK (whether or not 
they have been inpatients in psychiatric hospitals), because of the representativeness of 
the THIN database. The exposure groups (BPD and schizophrenia) (Hardoon et al., 2013, 
Nazareth et al., 1993) and the outcomes (mortality, CVD deaths, CVD, suicide and self-
harm) (Arana et al., 2010, Hammad et al., 2008, Ruigómez et al., 2010) have been well 
validated. Despite this, there is potential under-recording of cause specific deaths and 
morbidity, and potential for misclassification. Cause of death from death certificates would 
have improved the study, but this information was not available. In particular, suicide rates 
were lower than would be expected from ONS data (Office for National Statistics, 2016) and 
generally suicide deaths and self-harm events may be under recognised in the general 
population using EHRs (Thomas et al., 2013a). Additionally, suicide was a rare outcome and 
therefore the study was potentially underpowered to investigate differences by sex, age 
and calendar period. However, I would not expect these to be differential by diagnostic 
group and my HRs reflect recent standardised mortality ratio estimates from the UK (Brown 
et al., 2010, Hoang et al., 2013).  
There is no evidence that CVD death recording would be differential by diagnostic group 
(Denaxas et al., 2012), and the proportion of deaths from CVD in the general population 
comparison group (7%) is consistent with 2014 ONS data, where in a similar age range, CVD 
mortality represented 6% of all deaths (Office for National Statistics, 2016). There should be 
minimal under-recording of all-cause mortality (Maguire et al., 2009). 
I included only those individuals with a diagnosis code of schizophrenia, and excluded those 
with other non-affective psychosis codes. This was because previous literature on mortality 
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in people with SMI has tended to focus on schizophrenia, and non-affective psychosis is a 
highly heterogeneous group. Those receiving a schizophrenia diagnosis are likely to be at 
the more severe end of the psychosis spectrum – therefore it is an important finding that 
mortality rates are similar in both BPD and schizophrenia.     
There was a small amount of missing data for both ethnicity and SES. As discussed in 
Section 2.9.5, ethnicity was dealt with via agreed methods. Individuals with no measure of 
social deprivation were dropped from the analysis, there is good evidence that variables 
with less than 5% missing data will not generate bias (Bennett, 2001).  
The measure of social deprivation included in the multivariable model was one related to 
the area in which the individual lived, rather than their individual SES. As such, this may not 
be sensitive enough to capture the impact of socioeconomic status on the association 
between SMI and mortality. However, my study goes further than others in this area, which 
use age and sex adjusted SMRs, by adjusting for a number of other recognised 
confounders.  There are potential confounders that I did not include in the model that 
aimed to explain the elevated CVD rates in SMI, for example alcohol use and other lifestyle 
factors. Therefore, there remains the potential for unmeasured confounding. However, the 
covariates included are those used in CVD risk prediction models and are likely to partially 
mediate the relationship between SMI and CVD (rather than being true confounders).  
Recording of smoking status, BMI, hypercholesterolemia, hypertension and T2DM may be 
incomplete and therefore there is potential for residual confounding. However, recording 
of a number of these CVD risk factors has been incentivised by the QOF (Doran et al., 2011), 
and I have attempted to minimise missingness by defining these as ever recorded during 
follow-up. Although this incentivisation potentially improved CVD recording after 2004, 
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there is no evidence that this was differential with regards to BPD, schizophrenia or the 
comparison group. Limitations are discussed in more detail in Section 9.5. 
4.5.5 Conclusions 
Mortality trends in individuals with severe mental illness are important indicators of 
outcome and quality of psychiatric and medical care (Bushe et al., 2010, Ösby et al., 2000). 
This study suggests that despite important reductions in over-all mortality since 2000, 
interventions to improve health outcomes for those with BPD or schizophrenia have not 
reduced the mortality gap.  
4.5.6 Implications of the findings from this study 
My results underscore how continuous monitoring of mortality and morbidity in people 
with BPD and schizophrenia might guide us in evaluating the impact of interventions to 
manage physical comorbidity, reduce inequalities in medical care provision and prevent 
inequalities in their background risk factors. In Study 3 (Chapter 7) I continue to explore 
physical outcomes (such as CVD) in BPD when I assess  how commonly used maintenance 
treatments may influence rates of adverse effects, and in Study 4 (Chapter 8) where I 
examine the relative rates of suicide in people prescribed these medications. Implications 
for clinicians, patients, policy makers and for further research are discussed in Chapter 9. 
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Chapter 5 Systematic review and 
network meta-analysis comparing the 
effectiveness and tolerability of lithium, 
valproate, olanzapine and quetiapine as 
maintenance medication in bipolar 
disorder  
5.1 Summary 
5.1.1 Objective 
To summarises relative efficacy of commonly used maintenance mood stabiliser 
medications (lithium, valproate, olanzapine and quetiapine) via a NMA of all head-to-head 
and placebo controlled RCTs. 
5.1.2 Method 
The Cochrane Central Register of Controlled Trials was searched to identify trials of 
treatments for BPD (lithium, valproate, olanzapine or quetiapine), which involved head-to-
head comparisons or were placebo controlled, lasted for six months or longer, and included 
any measure of effectiveness to prevent any mood episode and/or discontinuation. 
Effectiveness and tolerability were assessed using a random-effects NMA within a Bayesian 
framework. 
5.1.3 Results 
I screened 382 trials, and 18 fulfilled inclusion criteria. All active medications were 
significantly more effective than placebo at preventing any mood episode and had 
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significantly lower all-cause discontinuation. It was not possible to distinguish between 
lithium, valproate, olanzapine or quetiapine statistically in terms of efficacy or tolerability.  
5.1.4 Conclusion 
All four medications examined are superior to placebo, but NMA does not clearly identify 
one treatment as superior. There is better quality evidence to support the use of lithium, 
notwithstanding its tolerability profile. 
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5.2 Introduction 
Recent meta-analysis (Severus et al., 2014), NMA (Miura et al., 2014) and guidelines 
updates (Goodwin et al., 2016, National Institute for Health and Care Excellence, 2014) 
concluded that lithium is the most appropriate first-line treatment for maintenance of 
euthymia in BPD. However, there are multiple limitations in evaluating the trials that 
contributed to this conclusion, and it is unclear how this recommendation should be 
applied clinically. Across the RCTs included in Miura et al. and Severus et al. there were a  
number of conceptual design differences. Inclusion criteria varied with trials including pure 
bipolar I or bipolar II samples, or combinations of both. It is likely that the diagnosis of BPD 
has been applied differently over time (trials form the early 1970s are included) and by 
Country (Geddes et al., 2004). Therefore, a group (at both study-level and individual-level) 
that appears homogenous may in reality include a range of illness severities. Further 
complicating this is the fact that many patients present with a similar polarity of illness 
during each relapse, therefore recruitment during a manic or depressive phase may 
obscure effectiveness of a drug for the other polarity. 
In traditional pairwise meta-analyses, comparing treatments is only appropriate when trials 
are similar in terms of methodological and clinical characteristics. The same holds true for 
indirect comparisons in NMA. This extension of homogeneity to indirect comparisons in 
NMA is known as transitivity (Cipriani et al., 2013b).  As such, it is only appropriate to 
perform NMA on studies that are clinically and methodologically transitive; this should 
include factors such as inclusion criteria, illness severity, and stage of illness. The plausibility 
of the transitivity assumption requires judgment to decide whether differences in the 
distributions of the effect modifiers across studies are large enough to make NMA invalid 
(Chaimani et al., 2013). Consistency is the statistical expression of transitivity. It is assessed 
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by statistically comparing direct and indirect summary effects in specific loops (Bucher et 
al., 1997). Until recently, NMA was limited by a need for advanced statistical software and 
computational knowledge. However, NMA is now possible through as suite of Stata 
commands (mvmeta) (StataCorp, 2013) and a number of authors have provided guidance 
on its methodology (Chaimani et al., 2013, Cipriani et al., 2013b, Salanti et al., 2011, Salanti 
et al., 2014).  
Miura et al. completed an NWA of all maintenance treatments for BPD (Miura et al., 2014). 
Interventions included monotherapies: aripiprazole; carbemazapine; fluoxetine; 
imipramine; lithium; lamotrigine; olanzapine; oxcabazepine; paliperidone; quetiapine; 
risperidone injection and valproate, and combination therapies: lithium and oxcarbazepine; 
lithium and imipramine; lithium and valproate; valproate and aripiprazole;  aripiprazole and 
lamotrigine; valproate and lamotrigine. Trials were parallel design with active or placebo 
comparator groups. Using the GRADE framework (Guyatt et al., 2011) the authors show 
that the quality of evidence (certainty of point estimate) was low or very low for all 
comparisons apart from lithium versus placebo and olanzapine versus placebo (which were 
both moderate). Transitivity is also a problem in this NMA. For example, a number of 
treatments (such as drug combinations or those given via injection) are systematically 
different from other comparator drugs. There are also fundamental differences in terms of 
illness severity, diagnostic criteria, illness polarity, enriched design, pragmatic design, 
outcome definition and duration. 
In some trials, participants were recruited and randomised to interventions whilst they 
were euthymic. In others, participants were recruited during an acute episode and 
prescribed a particular intervention drug, then responders to this drug would be 
randomised to continue this treatment or switch to a placebo or active comparator 
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(enriched design). This method tends to favour the investigational drug, and is more 
commonly found in pharmaceutical company sponsored trials (Goodwin et al., 2016). Of 
the trials included in Miura et al. 58% were enriched. In an attempt to overcome this 
limitation the authors completed a sensitivity analysis reducing the weight of these studies 
by 50%. This did not affect the summary estimates or conclusions, but may not have 
captured the full extent of the advantage given to the enriched design drugs.  
Another limitation when combining trial results is the range of outcome definitions chosen 
to represent relapse or reoccurrence. Whilst it is clear that a reoccurrence requiring 
hospitalisation is a clear failure in treatment, this was rare as a primary outcome. In 
addition, over time as services change, there is unlikely to be a consistent threshold for 
hospitalisation. Relapse as measured by rating scale, or addition of new medications 
(especially if these are short-term prescriptions of low dose antipsychotics or 
benzodiazepines) may not be considered treatment failures by clinicians or, more 
importantly by patients themselves. Often a composite measure of all of these outcomes 
has been used in a bid to increase outcome event frequency and power. The range of 
outcomes measured and the limited number of trials means that a sensitivity analysis by 
specific outcome would not be possible. 
 
The most commonly prescribed maintenance medications in the UK are lithium, valproate 
and olanzapine – having been recommended in the NICE guidelines from 2006 as first-line 
treatments (National Institute for Health and Care Excellence, 2006), and quetiapine – 
because of its effectiveness in bipolar depression (Calabrese et al., 2005a). It is unclear if 
the evidence presented in these reviews (Goodwin et al., 2016, Miura et al., 2014, National 
Institute for Health and Care Excellence, 2014, Severus et al., 2014) is strong enough to 
change prescribing practice in terms of new prescribing for patients with BPD, let alone 
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consider a change of prescribing in someone in which maintenance treatment is already 
established. Given the current clinical use of these drugs, this review and subsequent NMA 
aims to examine the existing evidence for preferable prescribing of one of these drugs over 
the other three. To do this I have examined trials that compare two of these drugs or trials 
of one of these drugs against a placebo control. Given the treatment aims of maintenance 
mood stabiliser medication (i.e., to protect against either polarity of illness) this review 
includes trials that used any measure of relapse or reoccurrence, with any pole (manic or 
depressive) as an outcome. It also examines discontinuation for any reason, as this measure 
most accurately reflects real world medication adherence and usage. 
5.3 Methods 
I systematically searched randomised controlled parallel group trials of one of the study 
drugs versus another as an active comparator or versus placebo. 
5.3.1 Identification of studies 
The Cochrane Central Register of Controlled Trials was searched to the end of June 2015. 
This database includes relevant studies from MEDLINE, PsycINFO and Embase. The search 
was completed using terms relating to BPD and maintenance treatment and lithium or 
valproate or olanzapine (see Appendix 3.2 for full search terms). Following this, reference 
lists of all identified RCTs and other relevant papers were checked for missing trials. The 
abstracts of potentially relevant articles were reviewed. Study-level information was 
filtered to identify trials reported in more than one location. 
5.3.2 Inclusion and exclusion criteria  
Included trials met all of the following a priori defined criteria: 
i) Published between 1 January 1960 and 1 June 2015 
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ii) Reported trials of lithium, valproate or olanzapine versus placebo or any of the 
study drugs versus each other 
iii) Individuals included in the trial were 16 years or older 
iv) Trial follow-up of at least 6 months 
v) Included any measure of effectiveness and/or discontinuation 
Studies were excluded if: 
i) Patients received adjunctive treatment as part of the intervention 
ii) An intention-to-treat analysis could not be completed from data in the trial 
manuscript or additional correspondence  
 
5.3.3 Data extraction 
Once a trial was included, data were extracted and entered into a database that included 
trial-level variables: authors, year of publication, decade in which trial was carried out, 
length of follow-up, intervention and comparator drug, number of participants in each arm, 
diagnosis, blinding status, if the trial had an enriched design for the drug of interest (i.e., 
patients were assigned to this drug prior to the start of the trial), reporting of previous 
maintenance treatment and outcome measure.  Individual-level variables were also 
extracted: number of individuals with relapse or reoccurrence in each arm and number of 
individuals who discontinued in each arm.  
5.3.4 Statistical analysis  
A NMA was completed using mvmeta commands in Stata (StataCorp, 2013). NMA 
synthesises data from a network of trials about more than two competing interventions. 
The integration of direct evidence (from studies directly comparing interventions) with 
indirect evidence (information about two treatments derived via a common comparator) 
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increases the precision in the estimates and produces a relative ranking of all treatments 
for the studied outcome. 
5.4 Results 
After duplicate removal, 105 full manuscripts were reviewed from a possible 382 trials 
(Figure 5.i). Eighteen trials met the inclusion criteria: three compared lithium with 
valproate (Bowden et al., 2000, Calabrese et al., 2005b, Geddes et al., 2010), one compared 
lithium with olanzapine (Calabrese et al., 2005b), one compared lithium and quetiapine 
(Weisler et al., 2011), one trial directly compared valproate and olanzapine for 
discontinuation only (Tohen et al., 2003); eleven trials compared lithium with placebo 
(Amsterdam and Shults, 2010, Bowden et al., 2003, Bowden et al., 2000, Calabrese et al., 
2003, Cundall et al., 1972, Dunner et al., 1976, Kane et al., 1982, Melia, 1970, Prien et al., 
1973a, Stallone et al., 1973, Weisler et al., 2011) (one of these had no discontinuation data 
(Dunner et al., 1976)), one compared valproate with placebo (Bowden et al., 2000) two 
olanzapine with placebo (Tohen et al., 2006) and two quetiapine and placebo (Weisler et 
al., 2011, Young et al., 2014). In total 4,515 individuals were included across all trials. 
Characteristics of included trials are shown in Table 5.i. 
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Figure 5.i Flow diagram of the trials evaluated for inclusion in this systematic review and 
NMA 
 
 
The mean duration of follow-up in included trials was 74.6 weeks (SD 27.3). There was 
considerable variation in mood state at recruitment and in treatments used to stabilise 
mood episodes prior to randomisation. Five trials were enriched for one of the study drugs 
(i.e., patients were selected who had responded acutely to that drug) (Table 5.i). 
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Table 5.i Included trials 
Author Year Intervention Control Duration 
(weeks) 
N 
intervention 
N 
control 
Effectiveness 
outcome 
Diagnosis Recruit 
mood 
Blinding enriched Drug before 
Melia et al. 1970 lithium placebo 104 5 6 hospitalisation BPD euthymic double no lithium 
Cundall et 
al. 
1972 lithium placebo 26 8 5 combination BPD unknown double yes lithium 
Prien et al. 1973 lithium placebo 104 101 104 combination BPD manic double yes lithium 
Stallone et 
al. 
1973 lithium placebo 121 25 27 combination BPD euthymic double no unknown 
Dunner et al. 1976 lithium placebo 69 16 24 supplementary 
drugs 
BPD euthymic double no unknown 
Kane et al. 1982 lithium placebo 104 4 7 clinical relapse BP-2 euthymic double no another mood 
stabiliser 
Bowden et 
al. 
2000 lithium valproate 52 91 187 combination BP-1 any double no either of study 
drugs 
Bowden et 
al. 
2000 valproate placebo 52 187 94 combination BP-1 any double no either of study 
drugs 
Bowden et 
al. 
2000 lithium placebo 52 91 94 combination BP-1 any double no either of study 
drugs 
Bowden et 
al. 
2003 lithium placebo 76 46 70 supplementary 
drugs 
BP-1 any double no another mood 
stabiliser 
Calabrese et 
al. 
2003 lithium placebo 76 121 121 combination BP-1 depressive double no another mood 
stabiliser 
Tohen et al. 2003 valproate olanzapine 47 126 125 N/A BPD manic double no unknown 
Calabrese et 
al. 
2005 lithium valproate 80 32 28 rating scale 
relapse 
BPD any double no combination of 
study drugs 
Tohen et al. 2005 lithium olanzapine 48 214 217 rating scale 
relapse 
BP-1 manic double no combination of 
study drugs 
Continued overleaf  
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Author Year Intervention control Duration 
(weeks) 
N 
intervention 
N 
control 
Effectiveness 
outcome 
Diagnosis Recruit 
mood 
Blinding enriched Drug before 
Tohen et al. 2006 olanzapine placebo 48 225 136 combination BP-1 manic double yes olanzapine 
Geddes et al. 2010 lithium valproate 104 110 110 combination BP-1 euthymic open no combination of 
study drugs 
Amsterdam 
et al. 
2010 lithium placebo 50 26 27 combination BP-2 depressive double no antidepressant 
Weisler et al. 2011 lithium placebo 104 364 404 combination BP-1 any double yes quetiapine 
Weisler et al. 2011 lithium  quetiapine 104 364 404 combination BP-1 any double yes quetiapine 
Weisler et al. 2011 quetiapine placebo 104 404 404 combination BP-1 any double yes quetiapine 
Vieta et al. 2012 olanzapine placebo 78 131 135 combination BP-1 any double no another 
antipsychotic 
Young et al. 2014 quetiapine placebo 52 291 294 combination BPD depressive double yes quetiapine 
N/A, not available; BPD, any bipolar d isorder diagnosis; Bowden et al.  (2000)  and Weisler et a l.  (2 011) are 3 arm tr ials
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Figure 5.ii shows the network of comparisons in the NMA for relapse and reoccurrence and  
Figure 5.iii shows the network for discontinuation. Each node represents a drug included in 
the analysis, with the node size proportional to the number of individuals who were 
assigned to that drug treatment. Each line represents direct comparisons between drug 
treatments. The width of the line is proportional to the number of trials in that comparison. 
All treatments were compared with at least two other treatments.  
Figure 5.ii Network plot of included trials: Relapse and reoccurrence 
 
Figure 5.iii Network plot of included trials: Discontinuation 
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For any mood episode relapse or reoccurrence each of the study drugs was better than 
placebo (Figure 5.iv), this was also true for all-cause discontinuation (Figure 5.v). There was 
no evidence of a difference between direct and indirect estimates (test of inconsistency 
was Chi2=1.45, df=5, P=0.918 for relapse/reoccurrence and Chi2=2.05, df=6, P=0.915 for all-
cause discontinuation).  
None of the active drugs was superior to other study drugs for either outcome. Relative risk 
estimates for all comparisons are shown in Table 5.ii.  
Table 5.ii Relative risk of relapse or reoccurrence (orange) and all-cause discontinuation 
(green) according to NMA 
Placebo 0.63 
(0.53–0.74) 
0.59          
(0.43–0.80) 
0.51       
(0.39–0.66) 
0.53         
(0.39–0.71) 
0.83          
(0.72–0.96) 
Lithium 0.94          
(0.71–1.24) 
0.80          
(0.61–1.07) 
0.84           
(0.61–1.15) 
0.77         
(0.62–0.96) 
0.93          
(0.76–1.13) 
Valproate 0.86           
(0.58–1.27) 
0.90          
(0.60–1.36) 
0.71          
(0.57–0.89) 
0.86         
(0.68–1.08) 
0.93           
(0.72–1.19) 
Olanzapine 1.05          
(0.71–1.55) 
0.66           
(0.51–0.85) 
0.79          
(0.60–1.04) 
0.85           
(0.61–1.18) 
0.92          
(0.66–1.28) 
Quetiapine 
Comparisons between treatments should be read from left to r ight and the estimate is in the 
cell  in common between the column -def ining treatment and the row -defin ing treatment. For 
relapse/reoccurrence, r isk ratios (RRs)  below 1 favour the column -def ining treatment. For 
discontinuation, RRs higher than 1 favour the column -defining treatment.  Emboldened values 
P<0.05 
 
The ranking of the study drugs for prevention of relapse or reoccurrence was 1) olanzapine, 
2) quetiapine, 3) valproate 4) lithium, (with placebo ranking last). The ranking for all-cause 
discontinuation was 1) quetiapine, 2) olanzapine, 3) valproate, 4) lithium (with placebo 
ranking last) (Table 5.iii; Figure 5.vi).  
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Figure 5.iv Forest plot for relapse or reoccurrence 
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Figure 5.v Forest plot for all-cause discontinuation 
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Table 5.iii Probability of each treatment being ranked best-worst; for preventing 
relapse/reoccurrence, and for lowest all-cause discontinuation 
 Preventing relapse/reoccurrence (% chance of rank) 
Rank Placebo Lithium Valproate Olanzapine Quetiapine 
Best 0.0 0.6 12.8 51.3 35.3 
2
nd
 0.0 7.0 25.1 32.4 35.6 
3
rd
 0.0 36.8 33.6 12.0 17.6 
4
th
 0.0 55.6 28.5 4.4 11.5 
Worst 100 0.0 0.0 0.0 0.0 
 Lowest all-cause discontinuation (% chance of rank) 
Rank Placebo Lithium Valproate Olanzapine Quetiapine 
Best 0.0 0.3 7.7 27.2 64.8 
2
nd
 0.0 5.5 26.6 47.0 20.9 
3
rd
 0.1 25.1 45.9 18.4 10.5 
4
th
 1.4 68.7 18.8 7.3 3.7 
Worst 98.5 0.4 1.0 0.1 0.0 
 
 
Figure 5.vi Cumulative probability of ranking 
 
                             Relapse/reoccurrence                                            Discontinuation  
 
5.5 Discussion 
5.5.1 Main findings  
Lithium, valproate, olanzapine and quetiapine were significantly more efficacious than 
placebo with regards to preventing relapse or reoccurrence of any mood episode in BPD. All 
drugs were also superior in terms of reduced all-cause discontinuation. Ranking of the 
interventions suggested olanzapine may be most effective in terms of preventing new 
mood episodes and quetiapine may be least associated with all-cause discontinuation. This 
is consistent with the results of the analysis of Miura et al. (Miura et al., 2014). However, 
these authors suggest lithium should be first line as it shows (relative to placebo) efficacy in 
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any mood episode and superiority for specific trials of emergent manic and depressive 
mood episodes. It also has the most robust and unbiased evidence. Whereas they state that 
olanzapine is not better than placebo for preventing depressive episodes, and quetiapine 
studies (though showing superiority at both polarities compared to placebo) were biased by 
using enrichment designs. In this analysis, although valproate was superior to placebo for 
preventing any mood relapse, it was not superior for specific manic or depressive relapses 
(Miura et al., 2014). However, as with the current analysis, the authors failed to find a 
significant risk ratio for any comparison of lithium, valproate, olanzapine or quetiapine with 
another of these drugs.  
5.5.2 Strengths and limitations 
This NMA only studies the commonly used maintenance mood stabilisers, and as such 
displays better transitivity and connectivity than the work of Miura et al. (Miura et al., 
2014). The evidence network in my NMA was relatively well connected, but often 
comparisons were formed of one or two trials. I did not attempt to examine specific 
polarities of relapse in this analysis, as this has been recently completed (Miura et al., 
2014). It was also not possible to separate trials by BPD type (bipolar II or rapid-cycling, for 
example). There are a number of important limitations to the RCTs included in the NMA.  
Trials lasted two years at most – therefore any more prolonged treatment regimen (as will 
typically be the case for maintenance treatment in BPD) goes beyond the evidence-base. 
RCTs have tended to look at emergence of new mood episodes, but the prevention of 
subsyndromal symptoms will also be important in clinical practice and will be more 
challenging to measure. Many of the studies included were funded by pharmaceutical 
companies, raising concerns about sponsorship bias, and 5 of the 18 trials were enriched, 
favouring patients who had already responded to one of the study drugs. This trial design 
can give an advantage to the drug in question (often this occurred when newer drugs were 
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compared with lithium). Additionally, many trials include patients who have been 
previously exposed to the study drugs, so their response may be predictable. Ideally, RCTs 
should involve incident treatment, but this is rarely possible.  
The RCT selection process discussed in Section 5.3.1 and Section 5.3.2, may have 
potentially missed trials, because of inadequate search terms or because they remain 
unpublished. I may also have excluded relevant RCTs because of the ‘intention-to-treat 
analysis’ criteria. Studies included in the NMA by Miura et al. (Miura et al., 2014), but 
excluded in my NMA were a trial that only lasted for 17.3 weeks (Prien et al., 1973b) and a 
study which appeared to overlap other reported RCT data (Fieve et al., 1976). My NMA 
included one RCT which was not in Miura et al. (Stallone et al., 1973).  
5.5.3 Conclusions 
From the results of this NMA, lithium was not convincingly superior to valproate, 
olanzapine or quetiapine. All of the drugs considered, which were recommended by NICE 
(National Institute for Health and Care Excellence, 2006), are superior to placebo for 
relapse and reoccurrence prevention and all-cause discontinuation, but none is superior to 
the others in direct or indirect comparison using all available RCTs.  
5.5.4 Implications of the findings of this network meta-analysis 
Given that there are unlikely to be trials making head-to-head comparisons of these 
medications in the future (because they are all now off-patent), further research into which 
drug is most appropriate for maintenance BPD treatment will only come from indirect 
comparisons (where one of these established drugs is used as the control treatment trials 
of a new drug) or via non-trial clinical effectiveness studies. In Chapter 6, I undertake such a 
study, comparing the time to stopping the study drug, switching to an alternative 
medication or add-on of another mood stabiliser, antipsychotic, antidepressant or 
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benzodiazepine. This outcome is similar to that used in a number of RCTs in this area and 
represents a combination of both effectiveness and tolerability.  
One of the major limitations of all trials of maintenance mood stabiliser medication 
considered is that not one has provided more than two years of follow-up (Miura et al., 
2014, Severus et al., 2014). However, when choosing a drug for long-term if not life-long 
treatment, efficacy and safety are important not only during the first years, but also 
thereafter. The use of lithium over longer time periods is associated with risk of kidney 
dysfunction (McKnight et al., 2012), the use of SGAs with metabolic syndrome and an 
increased mortality risk due to cardiovascular problems (Bobo et al., 2011, Vieta, 2004), 
and the use of valproate with weight gain, liver failure and  haematological abnormalities 
(Perucca, 2002). Although it has not yet been established how these late adverse effects 
have an impact on the long-term safety of these drugs, the assumption made by NICE is 
that over 10 or more years the safety of lithium is at least in balance with that of SGAs 
(National Institute for Health and Care Excellence, 2014). However, it is clear that longer-
term studies of effectiveness, tolerability and safety of these drugs, reflecting real world 
use are necessary. To address this I designed and conducted a longitudinal study using EHR, 
where longer follow-up data are available (Chapter 7), to study of some of the recognised, 
but previously poorly quantified, adverse effects of these maintenance medications. 
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Chapter 6 Comparison of the 
effectiveness and tolerability of lithium, 
valproate, olanzapine and quetiapine as 
maintenance medication in bipolar 
disorder  
6.1 Summary 
6.1.1 Objective 
To compare the effectiveness and tolerability of lithium, valproate, olanzapine and 
quetiapine using rates of time to cessation of treatment, or add-on of another psychotropic 
medication as a proxy measure, while accounting for propensity to be prescribed one of 
these mood stabilisers. 
6.1.2 Methods 
Cohort study using a representative, anonymous UK primary care data collected 1995-2013. 
5089 patients with BPD were prescribed lithium (N=1505), valproate (N=1173) olanzapine 
(N=1336) or quetiapine (N=1075) as monotherapy.  Treatment failure was defined as time 
to stopping medication, switching to another study drug, or add-on of another 
anticonvulsant, antipsychotic, antidepressant or benzodiazepine.  
6.1.3 Results 
Individuals prescribed lithium had a longer time to treatment failure than those prescribed 
the other study drugs. This remained the case after propensity score adjustment for key 
predictors of treatment allocation. Compared to lithium, valproate had an elevated HR 
(1.19; 95% CI 1.09 to 1.31) as did olanzapine (HR 1.16; 95% CI 1.05 to 1.28) and quetiapine 
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(HR 1.30; 95% CI 1.18 to 1.44). This relationship remained in a propensity score matched 
analysis, when treatment failure was defined as stopping, swapping or add-on of an 
anticonvulsant or antipsychotic, and when treatment failure was restricted to greater than 
3 months after commencing the study drug.  
6.1.4 Conclusion 
Lithium appears to be more successful as monotherapy maintenance treatment than 
valproate, olanzapine or quetiapine. People receiving valproate, olanzapine or quetiapine 
require alternative or additional treatments earlier, which may indicate worse outcomes 
and may cause additional side effects. 
A modified version of this chapter was published as Hayes JF, Marston L, Walters K, 
Geddes JR, King M, Osborn DP. Lithium vs. valproate vs. olanzapine vs. quetiapine as 
maintenance monotherapy for bipolar disorder: a population‐based UK cohort study 
using electronic health records. World Psychiatry. 2016; 15: 53-8 
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6.2 Introduction  
A number of drug treatments are recommended for maintenance in BPD (as discussed in 
Chapter 1 and Chapter 5). In the UK, the most commonly used medications are lithium, 
valproate, olanzapine and quetiapine (Hayes et al., 2011). This reflects previous National 
Institute for Health and Care Excellence (NICE) guidance on first-line monotherapy 
maintenance treatment, which suggested equivalence of these drugs (National Institute for 
Health and Care Excellence, 2006). An update of this guidance in September 2014 
suggested that lithium should be first-line (National Institute for Health and Care 
Excellence, 2014). Globally there is a range of prescribing advice, which includes 
additionally: lamotrigine, carbamazepine, oxcarbazepine, aripiprazole and other SGAs 
(Association and Kernberg, 2002, Goodwin et al., 2016, Mok et al., 2011, Yatham et al., 
2013). Recent meta-analyses and network meta-analyses have highlighted the superiority 
of lithium and these results have contributed to the change in NICE guidance (Miura et al., 
2014, Severus et al., 2014). However, no one randomised controlled trial (RCT) has 
conclusively proved the benefit of lithium over other drugs, and there are no trials that 
compare valproate with olanzapine, valproate with quetiapine or olanzapine with 
quetiapine directly (Chapter 5). The applicability of RCT results to people with BPD in the 
real world may be limited by diagnostic heterogeneity, diagnosis or treatment rejection, 
and complex, labile presentations of the illness that occur over the life-course (Baldessarini, 
2002, Reed et al., 2009).  
As discussed in Chapter 1 and Chapter 2, EHRs offer an opportunity to augment RCT 
findings with head-to-head comparison studies which include large numbers of patients, 
representative of real world clinical practice and long follow-up periods. Using data from 
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THIN, I aimed to compare rates of stopping, switch to, or add-on of, another psychotropic 
drug in individuals prescribed lithium, valproate, olanzapine or quetiapine as maintenance 
monotherapy for BPD. This outcome represents a combination of both effectiveness and 
tolerability of the study medication and is similar to that used in many RCTs of maintenance 
treatment for BPD (Miura et al., 2014, Severus et al., 2014).  
6.3 Methods 
6.3.1 Study design & setting 
For this study, I defined, extracted and analysed a large prospective cohort of patients in 
THIN from January 1st 1995 and December 31st 2013 (Figure 6.i). As discussed in Chapter 2 
in the UK, GPs are responsible for issuing all drug prescriptions if treatment is ongoing, 
following advice from a psychiatrist, and this information is well recorded in THIN, as 
prescriptions are issued electronically.  
6.3.2 Participants 
Patients with a diagnosis of BPD were included if they had 2 or more consecutive 
prescriptions for treatment lasting 28 days of lithium, valproate, olanzapine or quetiapine 
after 1 January 1995, or after the date at which the GP practice met quality assurance 
criteria for data entry (based on computer usage and mortality recording rates) (Horsfall et 
al., 2013, Maguire et al., 2009). Patients were excluded if they received a diagnosis of 
schizophrenia at any time. They were also excluded if they were prescribed another of the 
study drugs, or any other anticonvulsant, antipsychotic, antidepressant or benzodiazepine 
at the start of follow-up, or in the month before this. The cohort was therefore one in 
which the intention was to treat with lithium, valproate, olanzapine or quetiapine 
monotherapy. Last date of follow-up was date of death, leaving the GP practice or the end 
of the study period (December 31 2013). 
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Figure 6.i Flow diagram of included patients 
 
AMR, Acceptable Mortal ity  Reporting;  ACU,  Acceptable Computer Usage  
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6.3.3 Main outcome 
Patients were followed-up until they stopped the study drug, or had another study drug, an 
anticonvulsant, an antipsychotic, an antidepressant or a benzodiazepine added to their 
treatment regimen. Date of first prescription was taken as the start of exposure time, the 
end of the prescription was calculated from the prescription length and prescribing 
instructions coded by the GP. Patients were considered to have a period of continuous 
prescribing if another prescription for the same drug was issued within three months of the 
predicted end date. If this did not occur, the date of stopping the study drug was the end 
date of the final prescription. 
6.3.4 Observed pre-treatment variables for propensity score estimation 
Sociodemographic, psychiatric and physical health characteristics at baseline were 
extracted from each patient’s medical record. Psychiatric and physical health problems 
were considered present if referenced in the patient notes. If a patient had multiple entries 
of the same (or similar) Read codes, the start date of the condition was taken as the earliest 
date of entry.  
As discussed in Chapter 2 a PS for each individual was estimated using variables defined a 
priori, based on existing research (Holmes, 2013, Rosenbaum and Rubin, 1984). The PS 
attempts to account for all of the covariates that predict receiving a particular study drug 
(Holmes, 2013, Rosenbaum and Rubin, 1983). The PS was then checked by comparison of 
covariate balance across treatments, within strata. The included variables were: sex, age at 
start of treatment with the study drug, year of entry to the cohort, ethnicity (grouped as 
White, Black, Asian, mixed, other, with missing values coded as White), physical health 
history at baseline (ischemic heart disease, myocardial infarction, cerebrovascular event, 
hypertension, renal disease, thyroid disease, liver disease, T2DM, epilepsy, history of 
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alcohol dependence, history of illicit drug use), smoking status (grouped as never-smoker, 
ex-smoker, current smoker), BMI (grouped as healthy weight, overweight (BMI 25 to 30), 
obese (BMI over 30)), mental health history at baseline (history of anxiety symptoms, 
hypomania as most proximal diagnosis code, history of depressive symptoms, sleep 
disturbance, previous treatment with the study drug before baseline, incident diagnosis of 
BPD) and clustering by  GP practice. For demographic and health-related covariates, the 
entire medical record prior to baseline was reviewed (potentially including records 
anteceding 1988, when paper records were transposed to EHR). For BMI, alcohol use, and 
smoking status the most proximate data in the 5 years before baseline was used. These 
variables were selected because they represent factors influencing prescribing choice (such 
as risk factors for adverse effects with a particular study medication) (National Institute for 
Health and Care Excellence, 2014). 
 
Although PS estimation cannot remove all bias, it has been postulated to also reduce 
confounding from unmeasured variables, because of their association with measured 
covariates (Austin et al., 2005, Joffe and Rosenbaum, 1999). Therefore in this study, for a 
given PS, exposure to lithium, valproate, olanzapine or quetiapine is presumed to be at 
random (Becker and Ichino, 2002). 
6.3.5 Statistical Analysis 
Cox regression analyses were conducted comparing the rates of switch to, or add-on of, 
another psychotropic medication in the four treatment groups. Analyses were adjusted for 
sex, age, ethnicity and calendar year. Time to treatment failure was summarised by Kaplan-
Meier curves. The proportional hazards model was tested formally with analysis of 
Schoenfeld residuals (Schoenfeld, 1982). The PS was calculated using multinomial logistic 
regression using the covariates described as independent variables, with drug treatment as 
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the dependent variable. The PS was then used as a linear term in a Cox regression analysis 
that also included age and calendar year (d’Agostino, 1998). This model was shown to be 
superior to stratifying on PS using Akaike information criterion and Bayesian information 
criterion (Lin and Dayton, 1997), and was a more efficient use of data than PS matching, 
because it uses all patients.  
Analysis using PS matching was then completed. As discussed in Section 2.11.1, although 
matched analyses may include a non-representative sample of patients receiving 
treatment, they may provide a more valid estimate of treatment effect as they compare 
patients with similar observed characteristics (d’Agostino, 1998, Rosenbaum and Rubin, 
1985). Pairwise matching was performed for each patient in the valproate, olanzapine and 
quetiapine groups with individuals in the lithium treated group. Patients were matched on 
a one-to-one basis if their PS was within 0.01 of each other; all other patients were dropped 
from the analysis.  
Supplementary analyses excluding benzodiazepine and antidepressant add-on as a source 
of treatment failure were carried out. A supplementary analysis excluding patients who 
stopped, swapped or had psychotropic medication added-on within the first three months 
of follow-up was also performed.  
6.4 Results 
A total of 14,396 individuals had a diagnosis of BPD. Of these, 5,089 were prescribed 
monotherapy with one of the study drugs at the start of cohort follow-up: lithium was 
prescribed to 1,505 people, valproate to 1,173, olanzapine to 1,336 and quetiapine to 1,075 
people (Figure 6.ii). Individuals prescribed lithium tended to be older than other groups, 
with more years of follow-up data and fewer GP practice contacts during this period. They 
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were less likely to have a previous record of depression in their notes and less likely to be 
an incident case (Table 6.i). 
Figure 6.ii Flow diagram of included patients 
 
 
  
  155 
Table 6.i Characteristics of patients with bipolar disorder prescribed lithium, valproate, 
olanzapine or quetiapine monotherapy 
  lithium valproate olanzapine quetiapine 
Number 1505 1173 1336 1075 
Female, N (%) 860 (57.14) 631 (53.79) 733 (54.87) 735 (68.37) 
Age at entry to the 
cohort, median (IQR) 
44.94  
(35.45–58.66) 
41.56  
(31.40–53.69) 
40.86  
(31.88–52.74) 
38.46  
(29.31–49.77) 
Total years of follow-up, 
median (IQR) 
4.23  
(1.54–8.62) 
3.05  
(1.13–6.27) 
3.57  
(1.36–6.88) 
2.12  
(0.87–3.91) 
GP practice contacts per 
year of follow-up, median 
(IQR) 
12.07  
(7.10–19.74) 
14.81  
(8.69–23.75) 
14.33  
(8.84–24.60) 
17.95  
(11.76–26.92) 
Non-white ethnic 
background, N (%) 
44 (2.92) 
 
50 (4.26) 65 (4.87) 35 (3.26) 
Health at baseline, N (%)     
IHD, MI, CVE history 76 (5.05) 80 (6.82) 58 (4.34) 41 (3.81) 
Renal disease history 51 (3.39) 36 (3.06) 33 (2.47) 42 (3.91) 
Thyroid disease history 161 (10.70) 89 (7.59) 89 (6.66) 75 (6.98) 
Diabetes 77 (5.12) 87 (7.42) 42 (3.14) 71 (6.60) 
Epilepsy 29 (1.93) 82 (6.99) 37 (2.77) 34 (3.16) 
Obesity (BMI>30) 617 (41.00) 488 (41.60) 482 (36.08) 467 (43.44) 
Previous anxiety problems 98 (6.51) 102 (8.70) 133 (9.96) 154 (14.33) 
Previous alcohol 
dependence 
7 (0.47) 3 (0.26) 12 (0.90) 7 (0.65) 
Current smoker 518 (34.42) 462 (39.39) 571 (42.74) 425 (39.53) 
Bipolar disorder  
characteristics at baseline, 
N (%) 
    
Incident diagnosis 318 (19.62) 396 (33.99) 543 (41.71) 416 (40.82) 
Previous depressive 
episode 
845 (56.15) 701 (59.76) 826 (61.83) 788 (73.30) 
Hypomania as most 
recent diagnosis 
234 (15.55) 154 (13.13) 238 (17.81) 125 (11.63) 
Previous record of taking 
study drug   
936 (62.19) 507 (43.22) 463 (34.66) 328 (30.51) 
IQR, interquarti le range; IHD, ischemic heart disease ; MI, myocardial infarction; CVE, 
cerebrovascular event; BMI,  body mass index  
In unadjusted analyses, the duration of successful monotherapy was longest in individuals 
treated with lithium (Figure 6.iii, Table 6.ii). The median time to treatment failure (as 
defined by stopping, switching or add-on of medication) in the lithium monotherapy group 
was 0.28 years (95% CI 0.23 to 0.35) compared to 0.22 years (95% CI 0.19 to 0.27) in the 
valproate group, 0.24 years (95% CI 0.21 to 0.28) in the olanzapine group and 0.17 years 
(95% CI 0.14 to 0.21) in the quetiapine group. Treatment failure had occurred in 75% of 
those prescribed quetiapine by 0.76 years (95% CI 0.64 to 0.84) compared to lithium; 2.05 
years (95% CI 1.63 to 2.51), valproate; 0.98 years (95% CI 0.84 to 1.18) and olanzapine; 1.13 
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years (95% CI 1.00 to 1.31).  The differences between treatments became more apparent 
the longer the duration of treatment (Figure 6.iii).  
Table 6.ii Rates of treatment failure by drug 
 N 
events 
PYAR 
(100s) 
Rate, per 100 
PYAR (95% CI) 
Treatment failure, Hazard ratio (95% CI) 
    Crude Model 1
a
 Model 2
b
 Model 3
c
 
Lithium 1151 1570 73.31   
(65.55–81.78) 
1 1 1 1 
Valproate 909 777 116.93    
(102.95–132.39) 
1.25  
(1.14–  
1.37) 
1.22  
(1.11–
1.34) 
1.19  
(1.09–
1.31) 
1.20  
(1.10–
1.32) 
Olanzapine 977 893 109.36 
(96.30–123.67) 
1.19  
(1.08–
1.30) 
1.19  
(1.08–
1.30) 
1.16  
(1.05–
1.28) 
1.17  
(1.07–
1.29) 
Quetiapine 814 457 177.94     
(157.87–199.84) 
1.48  
(1.35–
1.62) 
1.31  
(1.19–
1.44) 
1.30  
(1.18–
1.44) 
1.32  
(1.20–
1.45) 
a
Adjusted for clustering by primary GP pract ice,  age, sex and calendar year,  
b
Adjusted for PS, 
clustering by GP practice, age and calendar year ,  
c
PS matched  (pairwise matching with 
lith ium) adjusted for c luster ing by GP practice, age and calendar year  
 
Figure 6.iii Time to treatment failure (stopped treatment or addition of mood stabiliser, 
antipsychotic, antidepressant or benzodiazepine) (unadjusted) 
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Lithium’s superiority remained after adjustment for clustering by GP practice, age, sex, 
calendar year, and ethnicity. It also remained after adjusting for PS, age and calendar year, 
and after matching by PS (Table 6.ii), with olanzapine having the least elevated HR (1.16, 
95% CI 1.05 to 1.28). Compared to olanzapine, quetiapine had an increased rate of 
monotherapy failure (HR 1.12, 95% CI 1.02 to 1.23) in the PS adjusted model. Compared to 
valproate, olanzapine and quetiapine had similar rates of treatment failure (HR 0.97; 95% CI 
0.89 to 1.06 and HR 1.09; 95% CI 0.99 to 1.19 respectively). The proportional hazards 
assumption held for all analyses. Before pairwise matching, PS scores were most different 
for lithium (median 0.45, IQR 0.25 to 0.61) and quetiapine (median 0.14, IQR 0.8 to 0.25) 
(Figure 6.iv). After matching the median PS was 0.21 (IQR 0.13 to 0.30) for lithium and 0.14 
for quetiapine (IQR 0.8 to 0.25), this comparison included 626 patients in each group 
(Figure 6.v). 
Individuals prescribed lithium or valproate were more likely to require antipsychotic add-on 
(19.53% and 18.41% respectively) than those prescribed olanzapine or quetiapine 
monotherapy (10.25% and 9.02% respectively). Conversely, individuals prescribed 
olanzapine and quetiapine were more likely to require mood-stabiliser add-on (14.07% and 
12.56% respectively) compared to lithium and valproate (6.71% and 5.20% respectively). 
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Figure 6.iv Propensity score distribution before matching 
 
 
Figure 6.v Propensity score distribution after pairwise matching with lithium 
 
Continued overleaf  
  159 
 
 
Supplementary analyses produced similar results to the primary analyses. If treatment 
failure was restricted to stopping medication, swapping to an alternative study drug or add-
on of a mood stabiliser or antipsychotic medication then PS adjusted HRs were elevated for 
all drugs compared to lithium (Table 6.iii). The same was true if patients failing in the first 
three months of follow-up were excluded from the analysis (Table 6.iii, Figure 6.vi). 
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Table 6.iii Supplementary analyses using PS adjusted model 
 Treatment failure, Hazard ratio (95% CI) 
 Excluding 
benzodiazepine add-
on
a
 
Excluding benzodiazepine 
and antidepressant add-
on
b
  
Excluding failures in the first 3 
months of treatment
c
 
Lithium 1 1 1 
Valproate 1.25 (1.14–1.37) 1.18  (1.08–1.29) 1.22 (1.06–1.40) 
Olanzapine 1.10 (1.00–1.22) 1.17 (1.07–1.28) 1.26 (1.09–1.45) 
Quetiapine 1.25 (1.13–1.38) 1.13 (1.03–1.25) 1.20 (1.04–1.40) 
a
Treatment fai lure represents stopping medication or requiring a m ood stabi liser or 
antipsychotic,  
b
Treatment failure represents stopping medication or requiring a mood 
stabil iser,  antipsychotic  or antidepr essant as add-on, 
c
Treatment fai lure after  a 3 month 
period of stabi lisation.  
 
Figure 6.vi Time to treatment failure (excluding failures in the first 3 months of 
treatment) (unadjusted) 
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6.5 Discussion 
6.5.1 Main findings  
As far as I am aware this study represents the only head-to-head comparison of the four 
most common maintenance treatments for BPD, and has the longest follow-up (up to 14.5 
years) and largest cohort (over 5000 patients) of any direct comparison of treatment for 
BPD. RCTs making these comparisons do not exist and are unlikely to be possible. The 
overall rate of treatment failure (represented by stopping index medication, swapping to an 
alternative study medication or requiring add-on of a mood stabiliser, antipsychotic, 
antidepressant or benzodiazepine) was increased for valproate, olanzapine and quetiapine 
when compared to lithium. This was also true if failures within the first three months were 
excluded (i.e., once the patient had been stabilised on the prescribed drug). This analysis 
may more closely capture the effectiveness of the drug, as tolerability and resolving mood 
episode issues are most likely to arise in the period directly after drug initiation. These 
results suggest that monotherapy with lithium may be more successful than the other 
recommended drugs. Monotherapy treatment failure appear to be common (often early in 
treatment), but this is consistent with other naturalistic studies (Kessing et al., 2007, 
Schumann et al., 1999). The rate of treatment failure was also elevated for quetiapine 
compared to olanzapine, but it was not possible to separate the other drugs from each 
other.  
6.5.2 Comparison with previous literature  
One previous study has used EHR to examine the comparative effectiveness of lithium and 
valproate (Kessing et al., 2011). This study found monotherapy with lithium before 
treatment failure to be longer than valproate monotherapy, and found greater difference 
between rates of treatment failure in those treated with lithium and valproate than my 
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study (HR 1.86, 95% CI 1.59 to 2.16). However, this study was limited by the small number 
of individuals prescribed valproate, and the potential for unmeasured confounding. I am 
not aware of other observational studies comparing effectiveness of maintenance mood 
stabilisers.  As described in Chapter 1 and Chapter 5, combined evidence from RCTs does 
not reliably separate one active drug from the others in terms of superior efficacy (Miura et 
al., 2014). 
6.5.3 Strengths and limitations  
The use of contemporaneous, representative medical records mitigated the risk of 
potential biases relating to selection into the study. Patients could still potentially have 
been misdiagnosed (this is discussed in Section 9.5.2); however, there is less risk of this 
occurring in this study compared to the mortality/morbidity study (Study 1) because 
patients had to be diagnosed with BPD and receive an appropriate mood stabiliser.  
Information bias should partially have been avoided by the use of prescribing data as 
exposure; in the UK GPs are responsible for on-going prescribing within the NHS (Health 
and Social Care Informaiton Centre, 2012), which is detailed and well recorded in THIN. 
However, exposure to the study drug was approximated through prescriptions issued to 
patients, and may not reflect how the patient used the medication. Poor adherence to 
prescribed drug regimens is a problem with all medications, and this is particularly true if 
side effects are unpleasant, as can be the case with all of the study drugs (Sajatovic et al., 
2007, Sajatovic et al., 2006). In this study, stopping the drug will be reflected in the 
outcome, but erratic adherence cannot be detected. It is possible that erratic adherence is 
more likely for drugs other than lithium (as this is more closely monitored through regular 
blood tests) and may have contributed to lithium’s perceived superiority, but other 
longitudinal cohort studies have not shown differential adherence (Sajatovic et al., 2007). 
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Treatment failure was defined as stopping the drug or initiation of any mood stabiliser, 
antipsychotic, antidepressant or benzodiazepine. It is likely that addition of a mood 
stabiliser or antipsychotic represents more serious treatment failure than addition of an 
antidepressant (which would only occur during a depressive relapse) or a benzodiazepine 
(which may be used short-term to avoid a relapse). A supplementary analysis excluding 
addition of these drugs had similar results. In my initial analysis plan, I had hoped to 
additionally use psychiatric hospitalisation as an outcome. It was expected that these data 
would be available via a linkage between THIN and the Hospital Episode Statistics (HES) 
database, which contains records of secondary care outpatient contacts and inpatient 
admissions (Sinha et al., 2013). However, by the time of writing up this thesis this linkage 
remains unavailable, in part because of the failure of the care.data project, which aimed to 
link numerous UK health data (Carter et al., 2015). 
It may be the case that both of these outcomes fail to capture what is important to patients 
in terms of relapse, reoccurrence, functioning and quality of life. These factors are not 
measured in the data. However, through examining monotherapy treatment failure I 
believe I have described a proxy for these important outcomes that captures both 
tolerability and effectiveness and highlights a very common need for adjunctive drug 
treatments. This outcome has also been used in a number of RCTs of maintenance drug 
treatment for BPD and therefore comparison with these results is possible. For example, 
the largest trial of lithium versus valproate treatment had a primary outcome of “time to 
new intervention for an emerging mood episode” (Geddes et al., 2010). This trial found 
similar results to my study (HR 1.41, 95% CI 1.00 to 1.92) but was not powered to directly 
compare lithium and valproate.       
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A limitation of interpretation of data from studies such as this is the inability to rule out 
important unmeasured confounding effects. I attempted to account for confounding by 
indication by building a PS model that included important clinical predictors of treatment 
allocation (Rosenbaum and Rubin, 1983). This included physical health variables that may 
lead a clinician to avoid a certain drug because of its side effect profile, for example renal 
disease with lithium or CVD with olanzapine. Characteristics such as sex, age, and BMI were 
also included as valproate is contraindicated in women of childbearing potential (Hayes et 
al., 2011), and olanzapine has the potential to cause rapid weight-gain (Eder et al., 2014). 
Adjusting for the GP practice should have accounted for physician preference for a 
particular drug. Once these covariates were adjusted for, there was a similar propensity for 
patients to be prescribed valproate, olanzapine or quetiapine, with patients prescribed 
lithium having slightly higher scores. Despite this, I cannot rule out the possibility that these 
confounders were imperfectly adjusted for or that other important confounders were not 
included in the PS model.  
Unfortunately, I was unable to separate treatment failure relating to emergent manic (or 
hypomanic) episodes from depressive episodes, and there is evidence that the study drugs 
may be differentially effective in preventing a particular polarity of illness (Miura et al., 
2014). However, an ideal “mood stabiliser” would protect against both polarities of relapse 
(Bauer and Mitchner, 2004), and this is what my study captures.  I was also unable to 
examine the physician’s reason for treatment initiation, and it may be that quetiapine’s 
apparent inferiority is because in some patients it is prescribed not as maintenance 
treatment, but for shorter-term indications (which I hoped to capture in the supplementary 
analysis). There were too few patients on monotherapy with other recommended 
maintenance treatments, such as lamotrigine or aripiprazole, to include these drugs in the 
analysis. 
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6.5.4 Conclusions 
This study provides necessary supplementary and complementary evidence to RCT findings 
for maintenance treatments for BPD. In clinical practice, lithium appears to be the most 
effective treatment to prevent any relapse or reoccurrence of BPD and may prolong the 
time before adjunctive prescribing is necessary. This finding echoes the results of recent 
meta-analyses that suggest lithium is superior to these drugs in protecting against both 
manic and depressive relapse (Miura et al., 2014, Severus et al., 2014). This is important as 
lithium is often avoided because of its side effect profile (Shine et al., 2015), but 
monotherapy with valproate, olanzapine or quetiapine is more likely to fail  sooner and 
may result in patients experiencing the additive side effects of multiple psychotropic drugs. 
6.5.5 Implications of the findings of this study 
As EHRs grow in size and number, it will become possible to run these sorts of comparative 
effectiveness and tolerability studies for a number of medications and indications. As 
stated, in terms of BPD treatments, THIN is currently too small to examine newer 
medications such as aripiprazole or lamotrigine, and combination treatments such as 
lithium and valproate.  These potential studies could powerfully augment RCT results, and 
there has been a move to elevate the level of evidence provided by such studies by the 
British Association for Psychopharmacology   (Goodwin et al., 2016). Alongside advances in 
the size of EHRs, analytical techniques will need to be developed further to manage 
concerns about residual confounding. Potential techniques are discussed in Chapter 9. 
Further implications for practice, policy and future research of the results of this study and 
the NMA (Chapter 5) are discussed in Section 9.4. I examine additional issues that need to 
be addressed in the selection of maintenance treatment in the next two chapters. Firstly, is 
the potential for adverse physical health outcomes related to the drug (Chapter 7)? Then, 
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what is the potential for adverse psychiatric outcomes, such as self-harm and suicide 
(Chapter 8)? 
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Chapter 7 Comparison of the adverse 
renal, endocrine, hepatic and metabolic 
events during treatment with different 
maintenance mood stabiliser 
medications for bipolar disorder 
7.1 Summary 
7.1.1 Objective 
To calculate rates of adverse chronic renal, hepatic, endocrine and metabolic effects in 
individuals prescribed lithium, valproate, olanzapine and quetiapine, accounting for 
propensity to be prescribed one of these mood stabilisers.  
7.1.2 Methods  
I conducted a propensity score adjusted cohort study using nationally representative 
United Kingdom electronic health records from January 1 1995 until 31 December 2013. 
Included patients had a diagnosis of BPD and were prescribed lithium (N=2148), valproate 
(N=1670) olanzapine (N=1477) or quetiapine (N=1376) as maintenance mood stabiliser 
treatment. Adverse outcomes were chronic kidney disease, thyroid disease, 
hypercalcaemia, weight gain, hypertension, T2DM, CVD and hepatotoxicity. The propensity 
score included important demographic, physical health and mental health predictors of 
drug treatment allocation. 
7.1.3 Results 
Compared to patients prescribed lithium, those taking valproate, olanzapine and quetiapine 
had reduced rates of chronic kidney disease stage 3 or more severe, following adjustment 
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for propensity score, age, calendar year and accounting for clustering by primary care 
practice (valproate HR 0.56; 95% CI 0.45 to 0.69; P<0.001, olanzapine HR 0.57; 95% CI 0.45 
to 0.71; P<0.001, quetiapine HR 0.62; 95% CI 0.47 to 0.80; P<0.001). Hypothyroidism was 
reduced in those taking valproate (HR 0.60; 95% CI 0.40 to 0.89; P=0.012) and olanzapine 
(HR 0.48; 95% CI 0.29 to 0.77; P=0.003), compared to those taking lithium. Rates of new 
onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09 to 0.61; P=0.003, olanzapine HR 
0.31; 95% CI 0.13 to 0.73; P=0,007) and hypercalcemia (valproate HR 0.25; 95% CI 0.10 to 
0.60; P=0.002, olanzapine HR 0.32; 95% CI 0.14 to 0.76; P=0.008, quetiapine HR 0.23; 95% 
CI 0.07 to 0.73; P=0.013) were also reduced relative to lithium. However, rates of greater 
than 15% weight gain on valproate, olanzapine and quetiapine were higher (valproate HR 
1.55; 95% CI 1.28 to 1.86; P<0.001, olanzapine HR 1.64; 95% CI 1.35 to 2.00; P<0.001, 
quetiapine HR 1.48; 95% CI 1.16 to 1.87; P<0.001) than in individuals prescribed lithium, as 
were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06 to 1.87; 
P=0.017). I found no significant difference in rates of chronic kidney disease stage 4 or more 
severe, T2DM, CVD or hepatotoxicity. Despite estimates being robust following sensitivity 
analyses, limitations include the potential for residual confounding and ascertainment bias, 
and an inability to examine dosage effects. 
7.1.4 Conclusions  
Lithium use is associated with more renal and endocrine adverse events, but less weight 
gain than commonly used alternative mood stabilisers. Risks need to be offset with the 
effectiveness and anti-suicidal benefits of lithium, and potential metabolic side effects of 
alternative treatment options.  
A modified version of this chapter was published as Hayes JF, Marston L, Walters K, 
Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events 
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during maintenance mood stabiliser treatment for bipolar disorder: a population-based 
cohort study. PLoS Med. 2016; 13: e1002058 
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7.2 Introduction 
As discussed in Chapter 1, a number of adverse effects of lithium have been identified since 
its use as a mood stabiliser became established in the 1970s (Bech, 2006), but it is only 
recently that they have begun to be characterised and quantified (Close et al., 2014, 
Kessing et al., 2015, McKnight et al., 2012, Murru et al., 2015, Shine et al., 2015). Lithium’s 
adverse effects include renal, thyroid, and parathyroid dysfunction. Lithium is also 
recognised to cause weight gain, but the risk of weight gain relative to other potential 
maintenance therapies has not been widely investigated (McKnight et al., 2012). 
Alternatives, such as SGAs and valproate, have been found to be obesogenic (Tarricone et 
al., 2010), especially olanzapine, which is the most commonly prescribed antipsychotic in 
BPD (Hayes et al., 2011). Weight gain is associated with a number of adverse events such as 
hypertension, T2DM and CVD (Haupt, 2006). Valproate, olanzapine and quetiapine are 
metabolised by the liver. Valproate has been found to be associated with a high risk of 
asymptomatic elevated transaminases and can cause idiosyncratic hepatic failure (Dols et 
al., 2013, Murru et al., 2015). Olanzapine and quetiapine have also been associated with 
rare cases of hepatotoxicity (Atasoy et al., 2007, El Hajj et al., 2004, Ozcanli et al., 2006). 
Therefore, the balance of risks associated with maintenance mood stabiliser selection is not 
straightforward, and I am aware of no studies that make these comparisons across 
treatment options.  
This study uses EHR to compare rates of major recognised adverse outcomes amongst 
individuals prescribed lithium, valproate, olanzapine or quetiapine for mood stabilisation in 
BPD. The adverse events examined are CKD, hypothyroidism, hyperthyroidism, 
hypercalcemia, weight gain, hypertension, T2DM, CVD and hepatotoxicity (Dols et al., 2013, 
Murru et al., 2015).   
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7.3 Methods 
7.3.1 Study design & Setting 
As with the previous study (Chapter 6), this study used a prospective cohort of patients in 
THIN from January 1st 1995 and December 31st 2013 (Figure 6.i).  See Section 2.5, Section 
4.3.1 and Section 6.3.1 for a full description of the data source. 
7.3.2 Participants 
As previously, patients with a diagnosis of BPD were included if they had 2 or more 
consecutive prescriptions for treatment lasting 28 days of lithium, valproate, olanzapine or 
quetiapine after 1 January 1995, or after the date at which the medical records met quality 
assurance criteria for data entry (based on computer usage and mortality recording rates). 
Patients were excluded if they were prescribed another study drug at the start of follow-up, 
or in the month before this. Diagnosis of BPD could occur at any time in the patient record. 
For each outcome requiring haematological or biochemical confirmation for diagnosis (CKD, 
thyroid disease, hypercalcemia, hepatotoxicity) patients were excluded from the primary 
analysis if they did not receive a specific blood test for the outcome, to reduce surveillance 
bias. For the weight gain outcome, patients were excluded if they did not have a baseline, 
or pre-treatment weight, and at least one other weight measurement.  For the outcome of 
hyperthyroidism, patients taking thyroxine were excluded, as this can result in thyroid 
stimulating hormone (TSH) suppression (Beastall et al., 2006).  Patients were also excluded 
if they had the outcome of interest at baseline (as I was interested in new/incident events). 
Therefore, each outcome has a different number of patients included. 
7.3.3 Exposure 
Date of first prescription was taken as the start of exposure time. The end of the 
prescription was calculated from the amount prescribed and dosage instructions coded by 
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the physician. Patients were considered to have a period of continuous prescribing if 
another prescription for the drug was issued within three months of the calculated end 
date. If this did not occur, the date of stopping the study drug was the end date of the final 
prescription. Three months was added to this end date to account for late development of 
the adverse event or delayed recording. Each patient could only contribute exposure time 
to one of the study drugs (the first they received) and did not re-enter the cohort if they 
restarted the drug after more than 3 months. In contrast to the effectiveness/tolerability 
study (Study 2: Chapter 6), patients could be prescribed other psychiatric medications but 
not combinations of the study drugs. If they commenced another study drug (i.e., lithium, 
valproate, olanzapine, quetiapine) they were censored (to ensure the outcome could be 
assigned to a particular drug). 
7.3.4 Main outcomes 
Outcomes of interest were: CKD stage 3 or above (or an estimated glomerular filtration rate 
[eGFR] of <60ml/min/1.73m2), CKD stage 4 or above (or an eGFR <30ml/min/1.73m2)  
(Crowe et al., 2008, Vassalotti et al., 2007), (if eGFR was unavailable I calculated it from 
available creatinine blood tests using the CKD-EPI equation (Levey et al., 2009)), 
hypothyroidism (or a TSH of >10mU/L) , hyperthyroidism (or a TSH<0.1mU/L) (Beastall et 
al., 2006), hypercalcemia (adjusted calcium>2.65mmol/L) (Smellie et al., 2008), >7% and 
>15% weight gain from baseline (Manu et al., 2015), hypertension, T2DM (or HBA1c 
>48mmol/mol) (John, 2012), CVD (defined as any of IHD, MI or CVE) and hepatotoxicity (or 
alanine transaminase [ALT] >200U/L, or aspartate aminotransferase [AST] >250U/L) (Sabin, 
2004).  CKD, thyroid disease, T2DM, hypertension, CVD and other chronic health condition 
diagnoses have been validated in THIN (Blak et al., 2006, Blak et al., 2011). 
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Patients were followed-up until the earliest of i) the first record of the adverse event of 
interest, ii) the date of stopping the study drug plus three months, iii) date of switching to 
another study drug, iv) date of death or date of leaving the primary care practice, v) 31 
December 2013. 
7.3.5 Propensity score estimation using observed pre-treatment variables 
A number of baseline patient characteristics were extracted from THIN. Physical and mental 
health conditions were considered present if referenced in patient notes and absent if they 
were not. If a patient had multiple entries of the same (or similar) codes, the start date of 
the condition was taken as the earliest date of entry.  
A PS for each individual was estimated, as described in Section 2.11.1 and Section 6.3.4. 
Included variables were: sex, age at start of treatment with the study drug, year of entry to 
the cohort, ethnicity (grouped as White, Black, Asian, mixed, other, with missing values 
coded as White [44]), IHD diagnosis before baseline, history of MI, history of CVE, 
hypertension, CKD at baseline, history of hypo or hyperthyroidism, history of liver disease 
or hepatotoxicity, T2DM, epilepsy, alcohol use (grouped as none/low, moderate, 
high/dependent), history of illicit drug use, smoking status (grouped as never-smoker, ex-
smoker, current smoker), BMI (grouped as healthy weight, overweight (BMI 25 to 30), 
obese (BMI over 30)), anxiety symptoms or diagnosis before baseline, depressive symptoms 
or diagnosis, sleep disturbance before baseline, treatment with one of the study drugs at or 
before baseline and clustering by practice in which the treating physician was working. The 
PS was checked by comparison of covariate balance across treatments, within strata. The 
variables in the PS excluded the outcome variable for that particular analysis.  
  174 
7.3.6 Statistical Analysis 
Cox regression analyses were conducted comparing the rates of adverse events in the four 
treatment groups. As in the effectiveness/tolerability study (Study 3: Chapter 6) the 
proportional hazards model was tested formally with analysis of Schoenfeld residuals 
(Schoenfeld, 1982).  The PS was calculated using multinomial logistic regression using drug 
treatment as the dependent variable and the covariates described as independent 
variables. The PS was then used as a linear term in a Cox regression analysis that also 
included age, calendar year and clustering by practice (d’Agostino, 1998). In all cases this 
model was shown to be superior to stratifying on PS using Akaike information criterion and 
Bayesian information criterion (Lin and Dayton, 1997), and was a more efficient use of data 
than PS matching (because no patients were excluded). To account for the competing risk 
of each outcome with death, I plotted graphs of cumulative incidence function, adjusted for 
PS and age, following competing-risks regression (Fine and Gray, 1999, Noordzij et al., 
2013).I conducted sensitivity analyses where individuals who did not receive blood tests or 
weight measurements were not dropped from the cohort, and where individuals were 
assigned inverse probability weights (IPTW) based on how likely they were to have blood 
test or weight records (Seaman and White, 2013). I used multiple demographic and clinical 
variables to predict missingness for the IPTW model.  
7.4 Results 
Of the 14,396 individuals with a diagnosis of BPD, 6671 were potentially included in the 
analysis; 2148 prescribed lithium, 1670 prescribed valproate, 1477 prescribed olanzapine 
and 1376 prescribed quetiapine (Figure 1.i).  
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Figure 7.7.i Flow diagram of included patients 
 
 
The characteristics of the potentially included cohort are shown in Table 1.ii.  Drug 
exposure ranged from 28 days to 17 years 11 days. People prescribed lithium tended to be 
older than those taking other study drugs, with more years of follow-up data. These 
individuals were less likely to have records of depression or anxiety prior to entry into the 
cohort. Individuals prescribed lithium had no more contacts with primary care services 
during follow-up than individuals prescribed other drugs. The number of individuals 
included for each outcome by treatment group is shown in Table 7.ii. 
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Table 7.i Patient characteristics 
 Lithium Valproate Olanzapine Quetiapine 
Total, N 2148 1670 1477 1376 
Female, N (%) 1287 (59.92) 911 (54.55) 791 (53.55) 959 (69.69) 
Age, median (IQR), years 46.28  
(35.70–60.67) 
42.31  
(31.95–54.80) 
41.01  
(32.03–53.08) 
38.08  
(29.30–48.71) 
Non-white ethnic background, N 
(%) 
55 (2.56) 85 (5.09) 78 (5.28) 43 (3.13) 
Follow-up, median (IQR), years 2.03  
(0.77–4.86) 
1.48  
(0.65–3.35) 
1.28  
(0.59–3.29) 
1.06  
(0.56–2.26) 
Primary care contacts per year, 
median (IQR) 
11.14  
(6.54–18.02) 
12.51  
(7.36–19.96) 
11.94  
(7.08–19.55) 
14.61  
(9.21–22.55) 
Health at baseline, N (%)     
  CVD history 124 (5.77) 121 (7.25) 68 (4.60) 53 (3.85) 
  ≥CKD3 (or eGFR<60 
ml/min/1.73m
2
) 
52 (2.42) 40 (2.40) 27 (1.83) 32 (2.33) 
  Hypothyroidism (or TSH>10mU/L) 183 (8.52) 105 (6.29) 60 (4.06) 61 (4.43) 
  Hyperthyroidism (or 
TSH<0.1mU/L) 
16 (0.74) 8 (0.48) 9 (0.61) 9 (0.66) 
  T2DM (or HBA1c>48mmol/mol) 108 (5.03) 140 (8.38) 45 (3.05) 86 (6.25) 
  Hepatic impairment (or 
ALT>200U/L or AST>250U/L 
34  (1.58) 41 (2.45) 37 (2.51) 19 (1.38) 
  Obesity (BMI>30) 896 (41.71) 716 (42.87) 509 (34.36) 609 (44.26) 
  Hypercalcemia (adjusted 
calcium>2.65mmol/L) 
10 (0.47) 4 (0.24) 2 (0.14) 3 (0.22) 
  Hypertension 184 (8.57) 173 (10.36) 103 (6.97) 130 (9.45) 
  Epilepsy 43 (2.00) 132 (7.90) 50 (3.39) 49 (3.56) 
  Previous anxiety problems 144 (6.70) 150 (8.98) 137 (9.28) 201 (14.61) 
Moderate/heavy alcohol use 1189 (57.00) 899 (54.75) 791 (53.55)  708 (52.21) 
  Current smoker 711 (33.10) 652 (39.04) 632 (42.79) 567 (41.21) 
Bipolar disorder characteristics at 
baseline, N (%) 
    
  Previous depressive episode 1238 (57.64) 990 (59.28) 915 (61.95) 1015 (73.76) 
  Previous record of taking study 
drug   
1731 (80.59) 1157 (69.28) 886 (59.99) 847 (61.56) 
CVD cardiovascular disease ;  CKD chronic kidney disease; eGFR estimated glomerular f i l tration 
rate; TSH thyroid stimulating hormone; T2DM type 2 diabetes mell itus;  ALT alanin e 
transaminase; AST aspartate aminotransferase; BMI body mass index  
In unadjusted analysis and after adjustment for PS, age, calendar year and clustering by 
practice in which the primary care physician worked, rates of CKD stage 3 or above in 
individuals prescribed valproate (HR 0.56; 95% CI 0.45 to 0.69; P<0.001) olanzapine (HR 
0.57; 95% CI 0.45 to 0.71; P<0.001) or quetiapine (HR 0.62; 95% CI 0.47 to 0.80; P<0.001) 
were reduced compared to lithium (Table 7.iii, Figure 7.7.ii).  
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Table 7.ii Patients included for each outcome, N (%) 
 Lithium Valproate Olanzapine Quetiapine 
Total potentially included, N 2148 1670 1477 1376 
≥CKD stage 3 1541 (71.74) 1116 (66.83) 964 (65.27) 939 (68.24) 
≥CKD stage 4 1642 (76.44) 1176 (70.42) 1016 (68.79) 983 (71.44) 
Hypothyroidism 1620 (74.95) 916 (54.85) 832 (56.33) 735 (53.42) 
Hyperthyroidism 1398 (65.08) 844 (50.54) 775 (52.47) 687 (49.93) 
Hypercalcemia 785 (36.55) 513 (30.72) 408 (27.62) 388 (28.20) 
T2DM 2040 (94.97) 1530 (91.62) 1432 (96.95) 1290 (93.75) 
CVD 2024 (94.23) 1549 (92.75) 1409 (95.40) 1323 (96.15) 
Weight gain 1426 (66.39) 1116 (66.83) 1004 (67.98) 912 (66.28) 
Hypertension 1964 (91.43) 1497 (89.64) 1374 (93.03) 1246 (90.55) 
Hepatotoxicity 1171 (54.52) 852 (51.02) 718 (48.61) 611 (44.40) 
CKD, chronic kidney disease; T2DM, type 2 d iabetes mellitus; CVD, cardiovascular d isease.  
Table 7.iii Adverse effects during maintenance treatment 
 Lithium Valproate Olanzapine Quetiapine 
≥CKD stage 3 (N=4560)     
Events, N 489 130 121 71 
 PYAR (100s) 51.97 29.85 25.64 16.89 
Rate, per 100 PYAR  9.41  
(8.61–10.28) 
4.35  
(3.67–5.17) 
4.72  
(3.95–5.64) 
4.20  
(3.33–5.31) 
Unadjusted HR (95% CI) 1 [reference] 0.46  
(0.38–0.55) 
0.50  
(0.41–0.61) 
0.43  
(0.33–0.55) 
 PS Adjusted HR (95% CI) 1 [reference] 0.56  
(0.45–0.69) 
0.57  
(0.45–0.71) 
0.62  
(0.47–0.80) 
P-value  <0.001 <0.001 <0.001 
≥CKD stage 4 (N=4817)     
Events, N 91 34 20 12 
PYAR (100s) 63.48 32.75 27.77 18.35 
Rate, per 100 PYAR  1.43  
(1.17–1.76) 
1.04  
(0.74–1.45) 
0.72  
(0.46–1.12) 
0.65  
(0.37–1.15) 
Unadjusted HR (95% CI) 1 [reference] 0.75  
(0.51–1.13) 
0.52  
(0.32–0.85) 
0.47  
(0.25–0.87) 
 PS Adjusted HR (95% CI) 1 [reference] 0.94  
(0.59–1.50) 
0.65  
(0.37–1.12) 
0.67  
(0.33–1.37) 
P-value  0.806 0.127 0.273 
Hypothyroidism (N=4093)     
Events, N 183 61 41 33 
PYAR (100s) 59.23 27.78 23.79 15.59 
Rate, per 100 PYAR  3.09  
(2.67–3.57) 
2.20  
(1.71–2.82) 
1.72  
(1.27–2.34) 
2.12  
(1.50–2.98) 
Unadjusted HR (95% CI) 1 [reference] 0.69  
(0.51–0.94) 
0.54  
(0.38–0.77) 
0.62  
(0.42–0.90) 
PS Adjusted HR (95% CI) 1 [reference] 0.60  
(0.40–0.89) 
0.48  
(0.29–0.77) 
0.63  
(0.38–1.05) 
P-value  0.012 0.003 0.074 
Hyperthyroidism (N=3704)     
Events, N 41 5 6 6 
PYAR (100s) 52.49 25.81 22.62 14.65 
Rate, per 100 PYAR  0.78  
(0.58–1.06) 
0.19  
(0.08–0.47) 
0.27  
(0.12–0.59) 
0.41  
(0.18–0.91) 
Unadjusted HR (95% CI) 1 [reference] 0.24  
(0.09–0.61) 
0.33  
(0.14–0.78) 
0.48  
(0.20–1.17) 
 PS Adjusted HR (95% CI) 1 [reference] 0.24  
(0.09–0.61) 
0.31  
(0.13–0.73) 
0.45  
(0.18–1.18) 
P-value  0.003 0.007 0.096 
Continued overleaf  
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 Lithium Valproate Olanzapine Quetiapine 
Hypercalcemia (N=2094)     
Events, N 55 6 6 3 
PYAR (100s) 36.29 17.1 13.44 8.99 
Rate, per 100 PYAR  1.52  
(1.16–1.97) 
0.35  
(0.16–0.78) 
0.45  
(0.20–0.99) 
0.33  
(0.11–1.03) 
Unadjusted HR (95% CI) 1 [reference] 0.24  
(0.10–0.56) 
0.31  
(0.14–0.68) 
0.24  
(0.07–0.76) 
 PS Adjusted HR (95% CI) 1 [reference] 0.25  
(0.10–0.60) 
0.32  
(0.14–0.76) 
0.23  
(0.07–0.73) 
P-value  0.002 0.008 0.013 
T2DM (N=6292)     
Events, N 150 86 88 51 
PYAR (100s) 69.11 36.52 34.01 21.28 
Rate, per 100 PYAR  2.17  
(1.85–2.55) 
2.35  
(1.91–2.91) 
2.59  
(2.10–3.19) 
2.40  
(1.82–3.15) 
Unadjusted HR (95% CI) 1 [reference] 1.21  
(0.94–1.55) 
1.31  
(0.99–1.74) 
1.32  
(0.95–1.82) 
PS Adjusted HR (95% CI) 1 [reference] 1.08  
(0.83–1.42) 
1.20  
(0.89–1.61) 
0.94  
(0.65–1.35) 
P-value  0.586 0.230 0.752 
CVD (N=6305)     
Events, N 94 32 26 21 
PYAR (100s) 69.49 37.56 33.41 22.17 
Rate, per 100 PYAR  1.35  
(1.11–1.66) 
0.85  
(0.60–1.20) 
0.78  
(0.53–1.14) 
0.95  
(0.62–1.45) 
Unadjusted HR (95% CI) 1 [reference] 0.67  
(0.44–1.04) 
0.61  
(0.38–0.98) 
0.79  
(0.47–1.35) 
PS Adjusted HR (95% CI) 1 [reference] 0.91  
(0.59–1.41) 
0.85  
(0.53–1.36) 
1.11  
(0.63–1.96) 
P-value  0.684 0.509 0.732 
>7% weight gain (N=4458)     
Events, N 467 410 396 299 
PYAR (100s) 63.20 33.28 30.56 19.05 
Rate, per 100 PYAR  7.39  
(6.75–8.09) 
12.32  
(11.18–13.57) 
12.96  
(11.74–14.30) 
15.70  
(14.02–17.58) 
Unadjusted HR (95% CI) 1 [reference] 1.90  
(1.64–2.20) 
1.99  
(1.72–2.30) 
2.72  
(2.33–3.16) 
PS Adjusted HR (95% CI) 1 [reference] 1.37  
(1.17–1.61) 
1.43  
(1.23–1.67) 
1.37  
(1.16–1.62) 
P-value  <0.001 <0.001 <0.001 
>15% weight gain (N=4458)     
Events, N 179 182 189 130 
PYAR (100s) 63.92 34.27 31.24 19.30 
Rate, per 100 PYAR  2.80  
(2.42–3.24) 
5.31  
(4.59–6.14) 
6.05  
(5.25–6.98) 
6.74  
(5.67–8.00) 
Unadjusted HR (95% CI) 1 [reference] 2.29  
(1.87–2.82) 
2.57  
(2.06–3.22) 
3.41  
(2.61–4.44) 
PS Adjusted HR (95% CI) 1 [reference] 1.62  
(1.31–2.01) 
1.84  
(1.47–2.30) 
1.67  
(1.24–2.20) 
P-value  <0.001 <0.001 <0.001 
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 Lithium Valproate Olanzapine Quetiapine 
Hypertension (N=6081)     
Events, N 174 85 89 33 
PYAR (100s) 64.25 35.66 32.30 20.65 
Rate, per 100 PYAR  2.71  
(2.33–3.14) 
2.38  
(1.93–2.95) 
2.76  
(2.24–3.39) 
1.60  
(1.14–2.24) 
Unadjusted HR (95% CI) 1 [reference] 0.98  
(0.75–1.26) 
1.11  
(0.84–1.46) 
0.75  
(0.50–1.12) 
 PS Adjusted HR (95% CI) 1 [reference] 1.19  
(0.90–1.58) 
1.41  
(1.06–1.87) 
0.89  
(0.59–1.34) 
P-value  0.274 0.017 0.590 
Hepatotoxicity (N=3352)     
Events, N 20 10 14 13 
PYAR (100s) 50.13 25.95 20.39 12.53 
Rate, per 100 PYAR  0.40  
(0.26–0.62) 
0.39  
(0.21–0.72) 
0.69  
(0.41–1.16) 
1.04  
(0.60–1.79) 
Unadjusted HR (95% CI) 1 [reference] 0.96  
(0.45–2.07) 
1.71  
(0.86–3.40) 
2.59  
(1.26–5.32) 
 PS Adjusted HR (95% CI) 1 [reference] 0.65  
(0.30–1.39) 
1.23  
(0.63–2.42) 
1.21  
(0.54–2.74) 
 P-value  0.274 0.558 0.658 
CKD, chronic kidney disease; T2DM, type 2 d iabetes mellitus; CVD, cardiovascular d isease; 
PYAR, person-years at r isk; HR, hazard ratio; PS,  propensity score. Unadjusted hazard ratio 
accounts for clustering by primary care practice, adjusted hazard ratio is adjusted for 
propensity  score age group and calendar period time varying variables and clustering by 
primary care practice. P -values for  PS adjusted HR.  
 
Figure 7.7.ii Cumulative incidence estimates of adverse renal and hepatic event rates 
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From PS and age adjusted competing-risks regression. Note dif ferences in scale of  y -axis  for 
each plot.  
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Compared to lithium, rates of hypothyroidism were reduced in those prescribed valproate 
(HR 0.60; 95% CI 0.40 to 0.89; P=0.012), olanzapine (HR 0.48; 95% CI 0.29 to 0.77; P=0.003), 
but not quetiapine (HR 0.63; 95% CI 0.38 to 1.05; P=0.074) after adjustment. Rates of 
hyperthyroidism were lower in those prescribed valproate (HR 0.24; 95% CI 0.09 to 0.61; 
0.003) and olanzapine (HR 0.31; 95% CI 0.13 to 0.73; 0.007), but not quetiapine (HR 0.45; 
95% CI 0.18 to 1.18; 0.096) compared to lithium. Hypercalcemia was less common in those 
prescribed valproate (HR 0.25; 95% CI 0.10 to 0.60; P=0.002), olanzapine (HR 0.32; 95% CI 
0.14 to 0.76; P=0.008), or quetiapine (HR 0.23; 95% CI 0.07 to 0.73; P=0.013) compared to 
lithium (Table 7.iii, Figure 7.7.iii). 
 
Figure 7.7.iii Cumulative incidence estimates of adverse endocrine event rates 
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From PS and age adjusted competing -risks regression. Note dif ferences in scale of  y -axis  for 
each plot.   
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After adjustment, rates of weight gain were higher in valproate, olanzapine and quetiapine 
than lithium (>15% weight gain: valproate HR 1.62; 95% CI 1.31 to 2.01; P<0.001, 
olanzapine HR 1.84; 95% CI 1.47 to 2.30; P<0.001, quetiapine HR 1.67; 95% CI 1.24 to 2.20; 
P<0.001). Rates of hypertension were higher in olanzapine (HR 1.41; 95% CI 1.06 to 1.87; 
P=0.017) than lithium (Table 7.iii, Figure 7.7.iv).  
   
Figure 7.7.iv Cumulative incidence estimates of adverse metabolic event rates 
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From PS and age adjusted competing -risks regression. Note dif ferences in scale of  y -axis  for 
each plot.  
 
I found no significant difference in rates of CKD stage 4 or above, T2DM, CVD, or 
hepatotoxicity between groups (Table 7.iii). The median number of eGFR/creatinine and 
TSH blood tests per year in treatment was higher in those taking lithium than the other 
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drugs (Table 7.iv). Weight measurement and blood tests for adjusted calcium and ALT/AST 
were less frequent in patients prescribed lithium, but not significantly so (Table 7.iv).  
Table 7.iv Median number (and interquartile range) of tests per year of drug exposure in 
patients included in analyses 
 Lithium Valproate Olanzapine Quetiapine 
eGFR or creatinine 1.84 (1.04–3.03) 1.10 (0.62–1.88) 1.00 (0.56–1.78) 1.20 (0.69–2.01) 
TSH 1.64 (1.05–2.47) 0.85 (0.49–1.46) 0.80 (0.45–1.50) 1.04 (0.62–1.70) 
Adjusted calcium 0.91 (0.38–2.18) 0.90 (0.41–2.12) 1.10 (0.43–2.99) 1.37 (0.62–2.99) 
ALT or AST 0.75 (0.36–1.51) 0.81 (0.40–1.57) 0.73 (0.37–1.40) 0.94 (0.49–1.70) 
Weight 0.98 (0.53–1.73) 1.19 (0.73–2.07) 1.20 (0.63–2.01) 1.44 (0.89–2.44) 
eGFR,  est imated glomerular f i l tration rate; TSH , thyroid  stimulating hormone; ALT , alanine 
transaminase; AST, aspartate aminotransferase. Type 2 diabetes mellitus, cardiova scular 
disease and hypertension  were not def ined by tests  
 
For outcomes in which patients had been excluded because of missing tests (CKD, hypo- 
and hyperthyroidism, hypercalcemia, weight gain and hepatotoxicity) sensitivity analyses 
including all patients resulted in reduced rate estimates compared to the primary analyses, 
but had little effect on HRs (Table 7.v). Sensitivity analyses using IPTW suggest results from 
the primary analyses are robust (Table 7.v). From Schoenfeld residuals, there was no 
evidence against the assumption of proportional hazards for any outcome. 
Table 7.v Sensitivity analyses to account for missing blood tests by 1) including all 
individuals and 2) performing inverse probability weighting 
 Lithium Valproate Olanzapine Quetiapine 
≥CKD stage 3 (N=6520)     
Events, N 
 
489 130 121 71 
 PYAR (100s) 
 
60.65 36.62 32.56 21.33 
Rate, per 100 PYAR  
(95% CI)  
8.06  
(7.38–8.81) 
3.55  
(2.99–4.22) 
3.72  
(3.11–4.44) 
3.33  
(2.64–4.20) 
Unadjusted HR  
(95% CI) 
P–value 
1 [reference] 0.44  
(0.37–0.54) 
<0.001 
0.46  
(0.38–0.57) 
<0.001 
0.41  
(0.32–0.53) 
<0.001 
 PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.54  
(0.44–0.67) 
<0.001 
0.55  
(0.44–0.70) 
<0.001 
0.55  
(0.42–0.72) 
<0.001 
IPTW PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.63  
(0.51–0.78) 
<0.001 
0.67  
(0.53–0.83) 
<0.001 
0.70  
(0.52–0.93) 
0.016 
Continued overleaf  
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 Lithium Valproate Olanzapine Quetiapine 
≥CKD stage 4 (N=6600)     
Events, N 91 34 20 12 
PYAR (100s) 72.26 39.58 34.70 22.81 
Rate, per 100 PYAR  
(95% CI) 
1.25  
(1.03–1.56) 
0.86   
(0.61–1.20) 
0.58  
(0.37–0.89) 
0.53 
(0.30–0.93) 
Unadjusted HR  
(95% CI) 
P-value 
1 [reference] 0.73  
(0.49–1.08) 
0.118 
0.49  
(0.30–0.79) 
0.003 
0.45  
(0.24–0.83) 
0.012 
 PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.90  
(0.57–1.43) 
0.666 
0.61  
(0.36–1.05) 
0.070 
0.58  
(0.28–1.18) 
0.138 
IPTW PS Adjusted HR 
 (95% CI) 
P-value 
1 [reference] 1.04  
(0.64–1.68) 
0.883 
0.70  
(0.40–1.21) 
0.208 
0.77  
(0.36–1.64) 
0.509 
Hypothyroidism (N=6262)     
Events, N 183 61 41 33 
PYAR (100s) 63.69 37.20 33.50 22.03 
Rate, per 100 PYAR  
(95% CI) 
2.87  
(2.49–3.32) 
1.64  
(1.28–2.10) 
1.22  
(0.90–1.66) 
1.50  
(1.06–2.11) 
Unadjusted HR  
(95% CI) 
P-value 
1 [reference] 0.56  
(0.41–0.76) 
<0.001 
0.41  
(0.29–0.59) 
<0.001 
0.48  
(0.33–0.70) 
<0.001 
PS Adjusted HR 
 (95% CI) 
P-value 
1 [reference] 0.59  
(0.42–0.84) 
0.003 
0.43  
(0.29–0.63) 
<0.001 
0.47  
(0.31–0.73) 
<0.001 
IPTW PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.54  
(0.38–0.78) 
<0.001 
0.42  
(0.28–0.63) 
<0.001 
0.49  
(0.32–0.78) 
0.002 
Hyperthyroidism (N=6220)     
Events, N 41 5 6 6 
PYAR (100s) 56.79 35.27 32.41 21.11 
Rate, per 100 PYAR  
(95% CI) 
0.72  
(0.53–0.98) 
0.14  
(0.06–0.34) 
0.19  
(0.08–0.41) 
0.28  
(0.13–0.62) 
Unadjusted HR  
(95% CI) 
P-value 
1 [reference] 0.19  
(0.07–0.49) 
<0.001 
0.25  
(0.11–0.59) 
0.001 
0.37  
(0.15–0.91) 
0.030 
 PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.19  
(0.07–0.51) 
<0.001 
0.25  
(0.11–0.59) 
0.001 
0.34  
(0.13–0.90) 
0.029 
IPTW PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.20  
(0.08–0.53) 
<0.001 
0.28  
(0.12–0.67) 
0.004 
0.34  
(0.14–0.99) 
0.030 
Hypercalcemia (N=6652)     
Events, N 55 6 6 3 
PYAR (100s) 72.59 40.23 35.03 23.12 
Rate, per 100 PYAR  
(95% CI) 
0.76  
(0.58–0.99) 
0.15  
(0.07–0.33) 
0.17  
(0.08–0.38) 
0.13  
(0.04–0.40) 
Unadjusted HR  
(95% CI) 
P-value 
1 [reference] 0.22  
(0.09–0.51) 
<0.001 
0.24  
(0.11–0.54) 
<0.001 
0.20  
(0.06–0.64) 
0.008 
 PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.23  
(0.09–0.56) 
<0.001 
0.28  
(0.12–0.66) 
0.003 
0.21  
(0.06–0.68) 
0.012 
IPTW PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.22  
(0.09–0.57) 
<0.001 
0.24  
(0.10–0.55) 
0.001 
0.22  
(0.06–0.76) 
0.019 
Continued overleaf  
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 Lithium Valproate Olanzapine Quetiapine 
>7% weight gain (N=6671)     
Events, N 467 410 396 299 
PYAR (100s) 73.36 39.54 35.96 23.09 
Rate, per 100 PYAR  
(95% CI) 
6.35  
(5.80–6.96) 
10.37  
(9.41–11.42) 
11.01  
(9.98–12.15) 
12.90  
(11.52–14.46) 
Unadjusted HR  
(95% CI) 
P-value 
1 [reference] 1.91  
(1.65–2.21) 
<0.001 
2.01  
(1.74–2.33) 
<0.001 
2.77  
(2.37–3.22) 
<0.001 
PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 1.37  
(1.17–1.61) 
<0.001 
1.46  
(1.25–1.71) 
<0.001 
1.28  
(1.09–1.52) 
0.004 
IPTW PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 1.23  
(1.08–1.41) 
0.002 
1.30  
(1.14–1.47) 
<0.001 
1.52  
(1.33–1.75) 
<0.001 
>15% weight gain (N=6671)     
Events, N 179 182 189 130 
PYAR (100s) 73.95 40.53 36.65 23.35 
Rate, per 100 PYAR  
(95% CI) 
2.43  
(2.10–2.82) 
4.49  
(3.88–5.19) 
5.16  
(4.47–5.95) 
5.57  
(4.69–6.61) 
Unadjusted HR  
(95% CI) 
P-value 
1 [reference] 2.28  
(1.85–2.81) 
<0.001 
2.57  
(2.05–3.22) 
<0.001 
3.44  
(2.63–4.47) 
<0.001 
PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 1.63  
(1.31–2.02) 
<0.001 
1.86  
(1.49–2.33) 
<0.001 
1.54  
(1.15–2.05) 
0.003 
IPTW PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 1.35  
(1.15–1.58) 
<0.001 
1.44  
(1.23–1.69) 
<0.001 
1.62  
(1.32–1.98) 
<0.001 
Hepatotoxicity (N=6540)     
Events, N 20 10 14 13 
PYAR (100s) 72.08 39.57 34.13 22.86 
Rate, per 100 PYAR  
(95% CI) 
0.28  
(0.18–0.43) 
0.25  
(0.14–0.47) 
0.41  
(0.24–0.69) 
0.57  
(0.33–0.98) 
Unadjusted HR  
(95% CI) 
P-value 
1 [reference] 0.94  
(0.44–2.02) 
0.883 
1.53  
(0.77–3.06) 
0.229 
2.22  
(1.07–4.57) 
0.031 
 PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.63  
(0.30–1.34) 
0.228 
1.05  
(0.53–2.08) 
0.897 
0.98  
(0.45–2.16) 
0.963 
IPTW PS Adjusted HR  
(95% CI) 
P-value 
1 [reference] 0.58  
(0.27–1.26) 
0.166 
0.97  
(0.48–1.94) 
0.938 
1.12  
(0.48–2.59) 
0.804 
CKD, chronic kidney disease ; PYAR, person-years at r isk; HR, hazard ratio; PS, propensity 
score; IPTW, inverse probability weighted;  outcomes for  cardiovascular disease, type 2 
diabetes mellitus and hypertension had no missing data. N for each outcome var ies because 
of potential d iagnoses pre-baseline. Unadjusted HR accounts for c lustering by primary care 
practice,  PS adjusted HR is adjusted for  propensity score, age group and calendar period time 
varying variables and clustering by primary care practice, IPTW PS adjusted HR accounts for 
probability of being a complete record, adjusted for propensity score,  ag e group and calendar 
period t ime varying variables and clustering by primary care practice.  
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7.5 Discussion 
7.5.1 Main findings 
In a large dataset of nearly 7000 individuals treated for BPD with lithium, valproate, 
olanzapine or quetiapine, with follow-up times of up to 17 years, I found differential rates 
of a number of adverse events.  Those prescribed lithium were significantly more likely to 
have a decline in renal function and develop hypo- or hyperthyroidism, and hypercalcemia. 
However, they were less likely to gain significant weight. Individuals prescribed olanzapine 
had the highest rate of weight gain and new onset hypertension. I did not find any 
differences in the rate of new T2DM, CVD or hepatotoxicity across drug treatment groups.   
7.5.2 Comparison with previous literature 
Severe CKD (stage 4 or above) was uncommon in the cohort (approximately 1 in 100 PYAR) 
and I did not find differences by drug treatment, but less severe CKD (stage 3 or above) 
occurred most frequently in patients prescribed lithium. Whilst many of these patients (i.e., 
those with CKD stage 3) would not progress to a clinically relevant decline in renal function, 
a number of them would be at increased risk of doing so. It remains unclear if this result is 
due to 1) lack of power to determine a true difference in rates of severe CKD, 2) 
surveillance bias due to increased monitoring of renal function in those taking lithium, 
which would lead to apparent increased rates of asymptomatic CKD stage 3, or 3) lithium 
treatment truly increasing the risk of reduced renal function without increasing severe CKD 
risk. Previous studies have found similar results and have not been able to account for this 
potential bias (Aiff et al., 2014a, Close et al., 2014, Kessing et al., 2015, Shine et al., 
2015)[12-14,56].  Clos et al. found no decline in eGFR in individuals taking lithium, using a 
similar active comparator design, but were also limited by potential ascertainment bias 
(Clos et al., 2015).  
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Rates of both hypothyroidism and hyperthyroidism were increased in individuals prescribed 
lithium compared to valproate and olanzapine (but not quetiapine). Increased 
hypothyroidism has been shown previously (Kibirige et al., 2013, McKnight et al., 2012) but 
literature on the association between lithium and hyperthyroidism is inconsistent (Shine et 
al., 2015) and lithium induced hyperthyroidism is considered rare (Lazarus, 2009). 
Monitoring thyroid dysfunction in BPD is vital because of evidence that abnormalities are 
associated with longer time to remission and more symptoms during the maintenance 
period (Fagiolini et al., 2006). Thyroid function potentially normalises on cessation of 
lithium, but only one study has investigated this (Souza et al., 1991). Hypercalcemia is also 
recognised to be associated with lithium prescribing (Khandwala and Uum, 2006, Lehmann 
and Lee, 2013, McKnight et al., 2012, Shine et al., 2015). Calcium monitoring in patients 
prescribed lithium was rare in my representative sample of primary care (37% had one or 
more calcium blood test result), despite it being recommended in the 2006 NICE guidance 
(National Institute for Health and Care Excellence, 2006).  
The rate of individuals gaining more than 7%, and more than 15% of their baseline weight 
was greater in those prescribed olanzapine, quetiapine or valproate than those prescribed 
lithium. This degree of weight gain represents a significant risk factor for a number of 
adverse physical health outcomes including CVD and T2DM (Manu et al., 2015).  I may not 
have captured increased rates of CVD or T2DM because of the relatively brief median 
follow-up time, in relation to the time taken to develop these diseases.  Olanzapine had the 
highest adjusted rate of greater than 15% weight gain compared to lithium, and the highest 
rate of new onset hypertension.  This has been shown previously in comparisons of 
antipsychotic drugs (Newcomer, 2005), and in trials of olanzapine versus lithium or 
valproate (Nashed et al., 2011).  
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Hepatotoxicity was rare in the cohort, and before PS adjustment rates appeared to be 
elevated in the quetiapine group, compared to lithium. This association has been identified 
previously (Atasoy et al., 2007). After PS adjustment, there was no evidence of between 
group differences.  
7.5.3 Strengths and limitations 
As with the study of comparative effectiveness and tolerability (Study 2) the major strength 
of this study, beyond size and length of follow-up, is the direct comparison between BPD 
maintenance mood stabiliser treatment options for a number of adverse effects. The use of 
electronic health records also means it is possible to adjust for a number of demographic 
and physical health characteristics that may have influenced the clinician’s decision to treat 
with a particular medication or potentially confound the relationship between treatment 
and adverse outcome. Despite including numerous variables in the PS, it is possible that 
residual confounding remained, especially as those prescribed lithium were older and were 
more likely to have taken the drug previously, perhaps reflecting a more chronic illness 
course. It may be that important patient or clinician features were not captured by the 
score, and despite the balance of observed covariates I cannot confirm balance of 
unobserved covariates (Austin et al., 2005, Stukel et al., 2007). I was also unable to consider 
dosage differences across the different treatment groups in this analysis. Periods of lithium 
toxicity may be particularly important with regards to developing renal failure and I was 
unable to capture this information from the available data.  Missing data can be a problem 
in studies utilising EHRs, especially as there may be a clinical reason why information is 
missing. Because of the way outcomes were defined, T2DM, CVD and diagnoses of 
hypertension had no missing data, and no covariates in the PS had missing values.  
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Patients prescribed lithium had no more physician contacts than those taking other mood 
stabiliser medication. In individuals that ever received tests during treatment exposure, 
testing frequency was similar in all study drugs for adjusted calcium, liver function and 
weight (Table 7.iv). Frequency of testing renal and thyroid function was higher in those 
taking lithium, which reflects the guidance for monitoring (National Institute for Health and 
Care Excellence, 2006). Patients prescribed lithium were also more likely to have at least 
one renal function, thyroid function, calcium or liver function test compared to patients 
taking other drugs. This is likely to be due to both drug related indications for monitoring, 
and the longer drug exposure seen in those taking lithium. IPTW sensitivity analysis to 
account for this difference did not alter my conclusions (Table 7.v). In the primary analysis 
the likely effect of this differential missingness would be to reduce the HRs for lithium 
compared to the other drugs, relative to their true values, as blood tests in the non-lithium 
group are more likely to be related to clinical symptoms than monitoring guidance (for 
instance, this is likely to represent an underestimation of the true hypercalcemia HR for 
lithium versus other drugs). The median number of weight measurements was similar in 
each group suggesting detection of weight gain was not related to differential monitoring. 
The sensitivity analyses including individual’s irrespective of blood tests produced similar 
adjusted HRs to the primary analyses for each outcome, but often with reduced incidence 
of the outcome in each treatment group (Table 7.v). These analyses may more accurately 
reflect testing occurring because of clinical indication. Further limitations that are general 
across all studies in the thesis are discussed in Chapter 9. 
7.5.4 Conclusions 
Lithium remains an important treatment option for individuals with BPD. However there is 
clear evidence that that its use is associated with a number of adverse events. These risks 
need to be offset with the potentially superior effectiveness and anti-suicidal benefits of 
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the drug compared to other treatment options (Cipriani et al., 2013a, Miura et al., 2014, 
Severus et al., 2014). It is also true that other recommended maintenance treatments can 
have serious side effects, often related to weight gain, and are not suitable for use in 
certain patient groups (such as the contraindication of valproate in women of childbearing 
potential (National Institute for Health and Care Excellence, 2014)). 
7.5.5 Implications of the findings of this study 
Assiduous monitoring of patients prescribed lithium should ameliorate some risk associated 
with effects on renal physiology and endocrine systems. Given the need to balance an array 
of risks and benefits, an individualised and collaborative approach to treatment choice is 
likely to be most appropriate. To achieve this, further research identifying patient 
characteristics that are risk factors for specific side effects and an understanding of the risks 
and benefits of stopping treatment in those who experience adverse effects is necessary. 
Implications for policy and practice are discussed comprehensively in Chapter 9. As a next 
step (in Study 4; Chapter 8), I go on to explore whether there are indeed anti-suicidal 
effects of lithium, which may offset some of the physical problems quantified in this 
chapter. 
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Chapter 8 Comparison of self-harm, 
accidental injury and suicide in 
individuals with bipolar disorder during 
treatment with different maintenance 
mood stabiliser medications for bipolar 
disorder 
8.1 Summary 
8.1.1 Objective 
To calculate and compare rates of self-harm, unintentional injury and suicide in individuals 
prescribed lithium, valproate, olanzapine and quetiapine, while accounting for propensity 
to be prescribed one of these mood stabilisers.  
8.1.2 Methods 
I conducted a propensity score adjusted and matched longitudinal cohort study in a 
nationally representative United Kingdom sample of electronic health record data collected 
January 1 1995 to December 31 2013. All patients diagnosed with BPD prescribed lithium 
(N=2148), valproate (N=1670), olanzapine (N=1477), or quetiapine (N=1376) as 
maintenance mood stabiliser treatment were included. The primary outcome was any 
record of self-harm. Secondary outcomes were accidental injury and suicide. 
8.1.3 Results 
Self-harm rates were lower in patients prescribed lithium (205 per 10,000 PYAR; 95% CI 175 
to 241) compared with those prescribed valproate (392 per 10,000 PYAR; 95% CI 334 to 
460), olanzapine (409 per 10,000 PYAR; 95% CI 345 to 483) or quetiapine (582 per 10,000 
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PYAR; 95% CI 489 to 692). This relationship was maintained after propensity score 
adjustment (valproate, olanzapine or quetiapine versus lithium; HR 1.40; 95% CI 1.12 to 
1.74) and matching (HR 1.51; 95% CI 1.21 to 1.88). After propensity score adjustment, 
accidental injury rates were lower in lithium compared to valproate (HR 1.32; 95% CI 1.10 
to 1.58) and quetiapine (HR 1.34; 95% CI 1.07 to 1.69), but not olanzapine. The suicide rate 
in the cohort was 14 per 10,000 PYAR (95% CI 9 to 21). Although this was lower in the 
lithium group than for other treatments, there were too few events to allow statistical 
comparison. 
8.1.4 Conclusions  
Patients taking lithium had reduced self-harm and accidental injury rates. This finding 
augments limited trial and smaller observational study results. It supports the hypothesis 
that lithium reduces impulsive aggression as well as stabilising mood. 
A modified version of this chapter was published as Hayes JF, Pitman A, Marston L, Walters 
K, Geddes JR, King M, Osborn DP. Self-harm, unintentional injury, and suicide in bipolar 
disorder during maintenance mood stabiliser treatment: a UK population-based 
electronic health records study. JAMA psychiatry. 2016; 73: 630-7 
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8.2 Introduction  
Self-harm is a major cause of morbidity in BPD (Singhal et al., 2014), and drug treatments 
that reduce suicidal and non-suicidal self-harm could improve quality of life for individuals 
with BPD and their families (Berghöfer, 2013). My mortality/morbidity cohort study (Study 
1: Chapter 4) found rates of self-harm in BPD to be 25 times higher than the general 
population. Furthermore, individuals who self-harm have a substantially increased suicide 
risk (Owens et al., 2002). My cohort study found BPD is associated with 13 times the rate of 
suicide (Chapter 4) and my systematic review demonstrated lifetime risk of suicide almost 
15 times greater (Chapter 3). RCTs of maintenance medication show that drugs such as 
lithium, valproate, olanzapine and quetiapine can stabilise mood compared to placebo 
(Chapter 5). However, balancing the relative benefits and potential risks (Chapter 7) of 
these medications is not straightforward; potential drug effects on self-harm have been 
under-examined in this regard.  
As trials often exclude those with a history of suicidal behaviour, drug effects on self-harm 
have been difficult to quantify due to low event rates (Perlis, 2011). A meta-analysis of 48 
trials suggested that suicide was less likely in people prescribed lithium than placebo or 
active comparator groups, but found no difference in self-harm rates (Cipriani et al., 
2013a). Observational studies have suggested that lithium may reduce fatal and non-fatal 
self-harm compared to maintenance treatment alternatives, most commonly 
anticonvulsant medication (Baldessarini et al., 2006b, Goodwin et al., 2003, Schou, 1998, 
Smith et al., 2009, Søndergård et al., 2008), but the findings are not always consistent 
(Ahearn et al., 2013, Bowden et al., 2000, Marangell et al., 2008). Following a warning from 
the United States Food and Drug Administration that anticonvulsant medications carry an 
increased risk of suicidal self-harm (US Food and Drug Administration, 2009), a number of 
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studies investigated this in BPD. A meta-analysis including only BPD patients (Redden et al., 
2011), and several observational studies (Arana et al., 2010, Leon et al., 2014, Reid, 2011) 
did not replicate this finding. There are relatively sparse data on the association between 
antipsychotic medication and self-harm. Small retrospective cohorts have shown no 
difference in suicidal self-harm in patients taking olanzapine or quetiapine (Koek et al., 
2012) and higher rates of suicide attempts in those prescribed SGAs compared to lithium or 
valproate (Ahearn et al., 2013, Yerevanian et al., 2007).  
Risk of accidental injury has also been understudied in BPD, despite deaths from accidents 
being around 6 times higher in BPD than in the general population (Hoang et al., 2011). 
Though accidents are often recorded in drug trials, they are rarely reported as important 
outcomes (Matson et al., 2006). Observational studies of drug treatments are even more 
limited (Elvik, 2013). It has been suggested that accidents are associated with (hypo)manic 
rather than depressive morbidity (Khalsa et al., 2008), in which case drugs with the 
strongest anti-accident properties may not be those with the strongest anti-suicidal effects. 
Three mechanisms for lithium’s potentially superior anti-suicidal effects have been 
proposed. Firstly, that lithium reduces risk through reducing depressive relapse, in which 
case drugs that also protect against depressive relapse should show comparable effects (for 
example quetiapine) (Cipriani et al., 2013a). Secondly, that there are specific serotonin-
mediated effects of lithium that result in reduced aggressive behaviour, risk-taking, and 
impulsivity (Fawcett, 2001, Kovacsics et al., 2009, Müller-Oerlinghausen and Lewitzka, 
2010), in which case one would also expect to see reductions in accidental injury in this 
group. Thirdly, that the close monitoring of patients taking lithium may provide 
psychosocial support lacking with other drug treatments, mitigating suicide risk (Tondo and 
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Baldessarini, 2009), in which case one would expect to see variability in service use across 
treatment groups. 
8.3 Method 
8.3.1 Study design, setting and participants 
This study used the same cohort as the adverse effects study (Chapter 7).  
8.3.2 Exposure 
Exposure to each of the study drugs, namely lithium, valproate, olanzapine or quetiapine 
was defined in the way described in Chapter 7.  
8.3.3 Outcomes 
The primary outcome of interest was emergency department or primary care attendance 
for self-harm during the period of drug exposure and the three months afterwards (both 
outcomes will be included in the EHR). This outcome included Read codes for intentional 
poisoning, intentional self-injurious behaviour, and self-harm acts of uncertain intent. The 
positive predictive value of this outcome in THIN has been shown to be 97% (Arana et al., 
2010). It was not possible to separate non-suicidal self-harm from self-harm with suicidal 
intent, or grade the event’s severity. However my unitary categorisation of non-suicidal and 
suicidal self-harm is consistent with UK research norms (Haw et al., 2015).  Secondary 
outcomes were accidental injury (such as falls or road traffic accidents) presenting to 
primary or secondary care, and a record of the patient’s suicide during this period, defined 
in line with previous research (Arana et al., 2010).20    
8.3.4 Propensity score estimation 
I developed a new PS model based on factors, decided a priori and based on existing 
research and clinical experience as described in Chapter 6 and Chapter 7. Variables in the 
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PS differed slightly from those in my previous studies, because of the recommendation that 
variables in a PS should be associated with the outcome, in this case self-harm (Rubin and 
Thomas, 1996).   Included variables were: sex, age at start of treatment with the study 
drug, year of entry to the cohort, ethnicity (grouped as White, Black, Asian, mixed, other, 
with missing values coded as White) (Chisholm, 1990), CVD diagnosis before baseline, 
hypertension, chronic kidney disease at baseline, history of hypo- or hyperthyroidism, 
history of liver disease, T2DM, epilepsy, alcohol use (grouped as none or low, moderate or 
heavy alcohol use, or dependence), history of illicit drug use, smoking status (grouped as 
never-smoker, ex-smoker, current smoker), BMI (grouped as healthy weight, overweight 
(BMI 25 to 30), obese (BMI over 30)), anxiety symptoms or diagnosis before baseline, 
depressive symptoms or diagnosis before baseline, sleep disturbance before baseline, 
treatment with study drug at or before baseline, history of previous self-harm. 
8.3.5 Statistical analysis 
A similar analysis to that described in Chapters 6 and 7 was performed. Cox regression 
analyses were conducted comparing the rates of self-harm, accidental injury and suicide in 
the four treatment groups. Time to adverse outcome was summarised by Kaplan-Meier 
curves. Analysis of Schoenfeld residuals was completed to test the assumption of 
proportional hazards (Schoenfeld, 1982). The PS was calculated by multinomial logistic 
regression using the covariates described as independent variables and drug treatment as 
the dependent variable. The PS was used as a linear term in a Cox regression analysis. A 
one-to-one PS matched analysis was also completed, with each patient in the valproate, 
olanzapine, or quetiapine group matched to a lithium patient with a 0.01 caliper, dropping 
all other patients from the analysis. As mentioned in Chapter 2 and Chapter 6, these two 
approaches to PS analysis have different strengths: the adjusted analysis may be more 
generalisable and is a more efficient use of the data (as no patients are dropped); the 
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matched analysis may provide a more valid estimate of treatment effect as only patients 
with similar observed characteristics are included (d’Agostino, 1998, Rosenbaum and Rubin, 
1985). Both adjusted and matched PS models were also adjusted for time-updated variables 
(age and calendar year) and clustering of patients by primary care practice.  
8.4 Results 
The key features of the cohort are described Section 7.4 and the flow diagram of included 
patients is shown in Figure 8.i. The characteristics of these patients important to this study 
are shown in Table 8.i. Of note, individuals prescribed lithium were less likely to have a 
history of self-harm prior to entry into the cohort. Individuals prescribed lithium had no 
more contacts with primary care services during follow-up than individuals prescribed other 
drugs. 
Figure 8.i Flow diagram of included patients 
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Table 8.i Patient characteristics 
 lithium valproate olanzapine quetiapine 
Total, N 2148 1670 1477 1376 
Female, N (%) 1287 (59.92) 911 (54.55) 791 (53.55) 959 (69.69) 
Age, median (IQR), years 46.28 (35.70-
60.67) 
42.31 (31.95-
54.80) 
41.01 (32.03-
53.08) 
38.08 (29.30-
48.71) 
Duration of drug exposure, median 
(IQR), years 
2.03 (0.77-
4.86) 
1.48 (0.65-
3.35) 
1.28 (0.59-
3.29) 
1.06 (0.56-
2.26) 
Non-white ethnic background, N (%) 55 (2.56) 85 (5.09) 78 (5.28) 43 (3.13) 
Primary care contacts per year, 
median (IQR) 
11.14 (7.36-
19.92) 
12.51 (7.36-
19.95) 
11.94 (7.08-
19.55) 
14.61 (9.21-
22.55) 
Physical health characteristics at 
baseline, N (%) 
    
CVD history 124 (5.77) 121 (7.25) 68 (4.60) 53 (3.85) 
Thyroid disease 234 (10.89) 130 (7.78) 92 (6.23) 87 (6.32) 
Liver disease 33 (1.54) 40 (2.40) 36 (2.44) 19 (1.38) 
T2DM  108 (5.03) 140 (8.38) 45 (3.05) 86 (6.25) 
Obesity (BMI>30) 896 (41.71) 716 (42.87) 509 (34.36) 609 (44.26) 
Hypertension 184 (8.57) 173 (10.36) 103 (6.97) 130 (9.45) 
Epilepsy 43 (2.00) 132 (7.90) 50 (3.39) 49 (3.56) 
Moderate/heavy alcohol use 1189 (57.00) 899 (54.75) 791 (54.82)  708 (52.21) 
Current smoker 711 (33.10) 652 (39.04) 632 (42.79) 567 (41.21) 
Illicit drug use history 93 (4.33) 148 (8.86) 179 (12.12) 160 (11.63) 
Mental health characteristics at 
baseline, N (%) 
    
Previous suicidal or non-suicidal self-
harm 
468 (22.44) 424 (25.82) 349 (24.19) 473 (34.88) 
Sleep problems 200 (9.59) 197 (12.00) 191 (13.24) 230 (16.96) 
Depression symptoms or diagnosis 1238 (57.64) 990 (59.28) 915 (61.95) 1015 (73.76) 
Anxiety symptoms or diagnosis 144 (6.70) 150 (8.98) 137 (9.28) 201 (14.61) 
Previous exposure to drug 1731 (80.59) 1157 (69.28) 886 (59.99) 847 (61.56) 
IQR, interquarti le range; CVD, cardiovascular d isease; T2DM, type 2 diabetes mellitus; BMI ,  
body mass index  
 
8.4.1 Self-harm 
The rate of self-harm reported to primary care physicians in individuals prescribed 
maintenance mood stabiliser medication for BPD was 340 per 10,000 PYAR (95% CI 313 to 
370 per 10,000 PYAR). In unadjusted analysis, self-harm rates were reduced in people 
taking lithium, compared to those taking valproate, olanzapine or quetiapine (Table 8.ii, 
Figure 8.ii). This was also the case after adjustment for PS, age, calendar year, and primary 
care practice (all other study drugs compared to lithium: HR 1.40; 95% CI 1.12 to 1.74). 
After one-to-one PS matching with lithium, rates of self-harm remained higher in 
individuals prescribed valproate (N=1,186; HR 1.31; 95% CI 1.01 to 1.70), olanzapine 
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(N=1,100; HR 1.33; 95% CI 1.01 to 1.75) and quetiapine (N=790; HR 1.51; 95% CI 1.21 to 
1.88). One-to-one matching of individuals taking lithium with those taking any other study 
drug showed higher self-harm rates in the non-lithium group  (N=1501; HR 1.51; 95% CI 
1.21 to 1.88). 
Table 8.ii Rates of self-harm, accidental injury, and suicide by mood stabiliser 
  Lithium Valproate  Olanzapine Quetiapine Valproate, 
olanzapine 
or 
quetiapine 
Self-harm       
 Events, N 146 152 137 128 417 
 PYAR 7106 3876 3353 2200 9430 
Rate, per 10,000 PYAR (95% 
CI) 
205  
(175-241) 
392  
(334-460) 
409  
(345-483) 
582  
(489-692) 
442  
(402-487) 
Unadjusted HR (95% CI) 1 [reference] 1.68  
(1.34-2.12) 
1.76  
(1.39-2.23) 
2.21  
(1.74-2.82) 
1.84  
(1.52-2.23) 
Model 1
a 
HR (95% CI) 1 [reference] 1.39  
(1.08-1.78) 
1.39  
(1.07-1.79) 
1.52  
(1.15-2.01) 
1.40  
(1.12-1.74) 
Model 2
b
 HR (95% CI) 1 [reference] 1.31  
(1.01-1.70) 
1.33  
(1.01-1.75) 
1.36  
(1.00-1.87) 
1.51  
(1.21-1.88) 
Accidental 
Injury 
      
 Events, N 388 255 190 154 599 
 PYAR 6615 3801 3366 2179 93.46 
Rate, per 10,000 PYAR (95% 
CI) 
583  
(528-644) 
669  
(592-757) 
569  
(494-655) 
705  
(602-825) 
641  
(592-694) 
Unadjusted HR (95% CI) 1 [reference] 1.18  
(1.01-1.39) 
1.00  
(0.84-1.19) 
1.29  
(1.06-1.56) 
1.13 
(1.00-1.29) 
Model 1
a 
HR (95% CI) 1 [reference] 1.32  
(1.10-1.58) 
1.14  
(0.95-1.37) 
1.34 (1.07-
1.69) 
1.26 (1.07-
1.47) 
Model 2
b
 HR (95% CI) 1 [reference] 1.34  
(1.09-1.65) 
1.17  
(0.94-1.47) 
1.44  
(1.09-1.91) 
1.19  
(1.01-1.41) 
Suicide
c
       
 Events, N 5 7 7 5 19 
 PYAR 7301 4043 3496 2308 9840 
Rate, per 10,000 PYAR (95% 
CI) 
7  
(3-16) 
17  
(8-36) 
20  
(9-42) 
22  
(9-52) 
19  
(12-32) 
Unadjusted HR (95% CI) 1 [reference] 2.35  
(0.74-7.46) 
2.73  
(0.86-8.64) 
2.85  
(0.81-10.06) 
2.60  
(0.96-7.03) 
Model 1
a 
HR (95% CI) 1 [reference] 2.71  
(0.75-9.80) 
3.18  
(0.86-11.73) 
3.01  
(0.68-13.38) 
2.86   
(0.88-9.26) 
PYAR, person-years at r isk; HR, hazard ratio; CI ,  conf idence interval .  aAdjusted for  propensity 
score, c luster ing by primary care practice,  age and calendar year ,  
b
Propensity score matched  
(pairwise matching with lithium) adjusted for cluster ing by primary care  practice,  age and 
calendar year,  
c
too few events for propensity score matched analysis  
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Figure 8.ii Cumulative self-harm rate in patients prescribed lithium vs. valproate, 
olanzapine or quetiapine (unadjusted, with 95% confidence intervals) 
 
8.4.2 Accidental injury 
The rate of accidental injury was 616 per 10,000 PYAR (95% CI 579 to 656 per 10,000 PYAR). 
Rates of accidental injury were lower in people taking lithium compared to those taking 
valproate and quetiapine, but not olanzapine in unadjusted, PS adjusted, and PS matched 
analyses (Table 8.ii). Individuals prescribed lithium had lower  accidental injury rates 
compared to those taking other study mood stabilisers, whether following adjustment for 
PS, calendar year, age and primary care practice (HR 1.26; 1.07 to 1.47), or following  one-
to-one PS matching with people taking valproate, olanzapine or quetiapine (HR 1.19; 95% CI 
1.01 to 1.41). 
8.4.3 Suicide 
The rate of suicide deaths in the cohort was 14 per 10,000 PYAR; 95% CI 9 to 21 per 10,000 
PYAR. The number of suicides was too low to show differences by individual drugs.  The HR 
  203 
point estimate for suicide was elevated for all other study drugs compared to lithium, but 
95% CIs overlapped unity, indicating no effect (unadjusted HR 2.60; 95% CI 0.96 to 7.03, 
and PS adjusted HR 2.86; 95% CI 0.88 to 9.26) (Table 8.ii).  
8.5 Discussion 
8.5.1 Main findings 
As far as I am aware this is the largest naturalistic longitudinal study of fatal and non-fatal 
self-harm rates in individuals with BPD treated with lithium, valproate, olanzapine or 
quetiapine. I found increased rates of self-harm in individuals prescribed valproate, 
olanzapine or quetiapine, compared to those prescribed lithium. I did not find differences 
in rates among valproate, olanzapine and quetiapine. This association remained after PS 
adjustment and matching. I also found reduced rates of accidental injury in those 
prescribed lithium, an important association that has not been widely investigated or found 
previously.  
8.5.2 Comparison with previous literature 
I did not find differences in rates of suicide because of the small number of suicides in the 
cohort. However, the point estimates for rates of suicide on lithium and valproate matched 
those found in the US retrospective cohort study by Goodwin et al. (7 per 10,000 PYAR and 
17 per 10,000 PYAR respectively) (Goodwin et al., 2003) and are similar to other studies 
(Smith et al., 2009).  
 
The lower rates of self-harm in those prescribed lithium may be due either to improved 
mood stabilisation compared to other treatments or specific effects on impulsive 
aggression and risk-taking. The similarity of the negative association between lithium and 
accidental injury and that between lithium and self-harm supports the latter hypothesis, as 
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there is little reason to expect that lower rates of depressive symptoms would reduce 
accidental injury (Khalsa et al., 2008). Also there is little evidence that lithium is superior to 
quetiapine in preventing depressive episode relapse (Miura et al., 2014). 
8.5.3 Strengths and limitations 
This study uses a large nationally representative sample to examine rates of fatal and non-
fatal self-harm and accidental injury. This is something that RCTs have struggled to do, 
because they tend to exclude suicidal individuals and event rates are often too low for 
statistical comparison. The use of EHR to capture those episodes of self-harm managed 
entirely in primary care, as well as those admitted to secondary care, captures the true 
burden of self-harm morbidity–both in the community and hospital-presenting. 
Consequently, rates of recorded self-harm in my study were slightly higher than in previous 
cohort studies (Gibbons et al., 2009, Goodwin et al., 2003). However, it was not possible to 
test if all secondary care self-harm presentations are appropriately coded in THIN. As in any 
analysis of health records, this study would have missed episodes of untreated and 
unreported self-harm: only population survey methods could capture these episodes, and 
estimates generated in this manner are prone to response biases. The number of suicides 
was low, so I was not able to examine differences in rates between drugs. It is possible that 
misclassification or non-recording of suicides occurred. However, similarities with other 
cohorts suggest this is not a major problem (Goodwin et al., 2003, Smith et al., 2009) – or it 
is a problem with all cohorts. There is no evidence to suggest misclassification of cause of 
death would differ by drug.  Exposure time was foreshortened because of both left 
truncation (for example, practices joining THIN later than 1995) and right censoring (for 
example, switch to or addition of another drug, patients leaving the primary care practice 
or dying of non-suicide causes). This censoring was equally distributed by exposure drug. 
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Potential biases relating to selection into the study should have been avoided by the use of 
contemporaneous, representative medical records, and information bias minimised by the 
use of THIN’s detailed and well recorded prescribing data as the exposure. However, 
exposure to the study drug is approximated through prescriptions issued, and may not 
reflect how the patient used the medication. It is possible that erratic adherence is more 
likely for drugs other than lithium (as lithium is more closely monitored through regular 
blood tests) and may have contributed to lithium’s perceived superiority. However these 
patients had no more physician contacts than those taking other medication, all individuals 
had to collect more than one prescription during their follow-up period (suggesting drug 
adherence), and other longitudinal cohort studies have not shown differential adherence 
(Sajatovic et al., 2007). As people taking lithium tended to be older, suicides could have 
occurred in this group prior to the start of follow-up, thus reducing the observed rate 
relative to other treatment groups. However, this should not be the case in the matched 
analysis. 
Through PS adjustment and matching, I attempted to account for potential confounding, 
including confounding by indication, and it is reassuring that both analyses produce similar 
results. Despite the numerous variables included in the PS, it is possible that residual 
confounding remained. It may be that important socio-demographic or clinical factors were 
not captured by the score, and I cannot confirm balance of unobserved covariates (Austin 
et al., 2005, Stukel et al., 2007). Notably, detailed information on educational level, 
individual socioeconomic status and social support is lacking from the database. However, 
although these covariates are likely to be associated with self-harm, accidental injury, and 
suicide, they should not be associated with treatment allocation. For these (or any) 
unmeasured covariates to have an important impact on the results they would have to be 
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strongly associated with exposure and outcome and be independent of covariates included 
in the PS (Psaty et al., 1999, Schneeweiss, 2006). 
Previously it has been shown that a combination of lithium and valproate was associated 
with the lowest rate of suicide attempt (Ahearn et al., 2013). This group (and other 
combinations) were excluded from my study, as I wanted to examine the association with 
monotherapy, and in fact this combination was rarely prescribed in THIN, despite 
recommendations for its use (Geddes et al., 2010).  
8.5.4 Conclusions 
In this representative UK study, individuals with BPD who were prescribed lithium had 
lower rates of self-harm and accidental injury than those with BPD taking other commonly 
prescribed maintenance treatments. Contrary to the FDA warning, I did not find higher self-
harm rates in those prescribed valproate than those taking other (non-lithium) 
maintenance drug treatments. These findings are important as they support and augment 
the existing evidence from RCT and smaller cohort studies. Self-harm, accidental injury and 
suicide are important outcomes in BPD that appear to be amenable to modification 
through appropriate drug treatment.  
8.5.5 Implications of the findings of this study 
Implications for policy and practice are discussed in Chapter 9. Lithium for Suicidal 
Behaviours in Mood Disorders (The Li+ Study) is an RCT that is currently recruiting from 
within the US Department of Veterans Affairs.  Participants will be patients with BPD or 
depression who have survived a recent episode of suicidal self-directed violence or were 
hospitalised specifically to prevent suicide. In theory, this impressive lithium plus treatment 
as usual versus treatment as usual trial will put pay to any doubt about the anti-suicidal 
properties of lithium (Smith and Attenburrow, 2016).   
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If lithium has anti-suicidal properties that are independent of mood stabilisation, then it 
may be appropriate to research its use in a wider range of diagnoses that are associated 
with self-harm and suicide. In particular, there is a paucity of evidence about the use of 
lithium in emotionally unstable personality disorder (Lieb et al., 2010, Rombold et al., 2014) 
and schizophrenia (Leucht et al., 2007), both of which have high rates of suicide and self-
harming behaviour (as demonstrated in Chapter 3 for schizophrenia).  
Apart from lithium, there are no pharmacological treatments that appear to have specific 
effects on self-harm or suicide (Saunders and Smith, 2016). A more comprehensive 
understanding of lithium’s mechanisms of action may lead to potential new drug 
development; this is further discussed in Section 9.7.4. 
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Chapter 9 Discussion, implications and 
conclusions 
9.1  Summary 
This chapter summarises the main findings of this thesis, and places them in the current 
research and clinical context.  It more fully explores the meaning, implications, strengths, 
and limitations of the completed studies and the routine data approaches used. Finally, 
future research and plans for dissemination are discussed. 
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9.2  Key findings 
The main objectives of this thesis were related to long-term outcomes in BPD and the 
effects of maintenance treatments:  
i) To summarise previous observational studies of long-term prognosis in individuals 
with a diagnosis of BPD by examining all-cause and cause specific mortality via 
systematic review and meta-analysis (Chapter 3) 
ii) To calculate recent time trends in all-cause mortality in the UK in individuals with 
BPD compared to individuals with schizophrenia and the general population (Study 
1: Chapter 4) 
iii) To determine relative rates of i) CVD deaths, ii) suicide, iii) CVD diagnoses, iv) self-
harm in individuals diagnosed with BPD or schizophrenia compared to the general 
population, while accounting for sociodemographic factors (Study 1: Chapter 4) 
iv) To determine relative efficacy of the four most commonly used maintenance mood 
stabiliser medications (lithium, valproate, olanzapine and quetiapine) via a network 
meta-analysis of all head-to-head and placebo controlled RCTs (Chapter 5) 
v) To assess comparative effectiveness and tolerability of the four most common 
mood stabilisers by calculating rates of time to cessation of treatment, or add-on of 
another psychotropic medication in individuals prescribed lithium, valproate, 
olanzapine and quetiapine, while accounting for propensity to be prescribed one of 
these mood stabilisers (Study 2: Chapter 6)   
vi)  To calculate rates of adverse events on these four mood stabilisers, specifically 
chronic renal, hepatic, endocrine and metabolic effects, accounting for propensity 
to be prescribed one of these mood stabilisers   (Study 3: Chapter 7)   
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vii) To determine rates of self-harm, unintentional injury and suicide on these four 
mood stabilisers, while accounting for propensity to be prescribed one of these 
mood stabilisers  (Study 4: Chapter 8)   
9.2.1 Mortality and morbidity in bipolar disorder 
9.2.1.1 All-cause mortality in bipolar disorder 
In my systematic review and meta-analysis of studies examining SMR (Chapter 3), all-cause 
mortality in BPD was 2.05 times that of the general population (95% CI 1.89 to 2.23) but 
heterogeneity was high (I2=96.2%) and could not be accounted for by study level factors, 
such as country or years of data collection. 
In my cohort study of 17,341 with BPD followed up between 2000 and 2014 (Chapter 4), 
all-cause mortality was elevated by 1.79 times (95% CI 1.67 to 1.88) compared to the 
general population (after adjustment for age, sex, calendar year, area level deprivation and 
ethnicity). For comparison, all-cause mortality in schizophrenia was elevated by 2.08 times 
(95% CI 1.98 to 2.19). However, the overall summary estimate for BPD masks a widening 
mortality gap between individuals with this diagnosis and the general population. Beginning 
in 2006 the HR increased by 0.14 per year (95% CI 0.10 to 0.19) until 2014. Similarly the 
mortality gap between those with schizophrenia diagnoses and the general population 
increased by 0.11 (95% CI 0.04 to 0.17) per year between 2004 and 2010, and from 2010 to 
2014 increased by 0.34 (95% CI 018 to 0.49). 
9.2.1.2 Cardiovascular disease mortality 
In my systematic review and meta-analysis of mortality in BPD, of all previous studies of 
mortality in BPD, 14 included estimates of mortality from circulatory disease (Chapter 3). 
The pooled SMR was 1.73 (95% CI 1.54 to 1.94).  There was no evidence that this differed 
by sex (men: 1.81; 95% CI 1.61 to 2.05, women: 1.72; 95% CI 1.46 to 2.03).  
  211 
In my mortality/morbidity cohort study (Chapter 4), using a more restricted definition of 
CVD (MI, CHD and CVE), there was no evidence of an increase in mortality after accounting 
for age, sex calendar year, area level deprivation, ethnicity and number of GP contacts (HR 
1.10; 955 CI 0.84-1.46). Again, there was no difference by sex or age group. However, 
stratification by 5 year calendar period found that rates were elevated from 2010-2014 (HR 
1.92; 95% CI 1.24-2.98). By way of comparison, CVD mortality in individuals with 
schizophrenia was elevated (HR 1.39; 95% CI 1.12 to 1.73), and dramatically so in those 
aged 50 or younger (HR 3.20; 95% CI 1.62 to 6.31).  Additional adjustment for traditional 
CVD risk factors (smoking, high cholesterol, high blood pressure, BMI, and T2DM) explained 
this association.   
9.2.1.3 Cardiovascular disease diagnoses 
Despite having no increase in CVD death rates compared to the general population, rates of 
CVD diagnosis were elevated in individuals with BPD diagnoses, after adjustment for age, 
sex, calendar period, area level deprivation, ethnicity and  primary care contacts (HR 1.41; 
95% CI 1.26 to 1.58). The rate of CVD diagnoses was similarly elevated in individuals with 
schizophrenia. Unlike CVD deaths, the relationship between SMI and CVD diagnosis was not 
fully explained by additional adjustment for CVD risk factors. In both diagnostic groups, it 
was men who had increased rates of CVD diagnoses, compared to men in the general 
population.  
9.2.1.4 Suicide 
Of the 31 studies included in the systematic review and meta-analysis, 15 reported SMRs 
for suicide in BPD, with a summary estimate of 14.44 (95% CI 12.43 to 16.78) (Chapter 3). 
There was no evidence that this was differentially elevated by sex. In my cohort study the 
HR for suicide in BPD comparted to the general population, after adjusting for age, sex 
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calendar year, area level deprivation, ethnicity and number of GP contacts was 12.66 (95% 
CI 7.79 to 20.58) (Chapter 4). There was no evidence of an interaction by sex, age group or 
calendar period.  Suicide rates in people with schizophrenia were similarly elevated, relative 
to the general population.  
9.2.1.5 Self-harm 
Elevated rates of self-harm compared to the general population were identified in those 
with BPD (adjusted HR 25.24; 95% CI 22.37 to 28.49) and rates were similarly elevated in 
those with schizophrenia (Chapter 4). Individuals aged 50 or younger in both diagnostic 
groups had markedly elevated self-harm rates (adjusted HR 55.74; 95% CI 45.35 to 68.53 in 
those with BPD and adjusted HR 52.07; 95% CI 42.43 to 63.92 in those with schizophrenia).  
9.2.2 Maintenance treatment for bipolar disorder 
9.2.2.1 Effectiveness and tolerability of the four most common maintenance mood 
stabiliser medications 
A NMA of RCTs examining any combination of lithium versus valproate versus olanzapine 
versus quetiapine versus placebo found no statistically significant difference between 
active drugs for effectiveness or tolerability (Chapter 5). All active drugs were superior to 
placebo for both outcomes. Ranking of active drugs suggested that olanzapine is potentially 
most effective, and quetiapine most well tolerated. Despite this, lithium is viewed 
favourably because of the results of a number of recent RCTs, which have been optimised 
for newer study drugs (such as quetiapine) and have used lithium as an active control. 
These RCTs have provided support for lithium’s mood stabilising properties beyond 
alternatives. 
In my cohort study of 5,089 patients, lithium monotherapy had a better effectiveness and 
tolerability profile (defined as stopping, swapping to an alternative mood stabiliser, or add-
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on of another psychotropic), than those prescribed valproate, olanzapine or quetiapine 
(Chapter 6). However, for all medications, time to monotherapy treatment failure was 
short (median 102 days for lithium, for example). Differences remained after accounting for 
clustering by GP practice, age, sex, calendar year and ethnicity. This was also true when I 
explored whether rate differences could be explained by variation between those 
prescribed each of the different drugs after PS adjustment and matching. In the matched 
analysis HRs were 1.20 (95% CI 1.10 to 1.32) for valproate, 1.17 (95% CI 1.07 to 1.29) for 
olanzapine and 1.32 (95% CI 1.20 to 1.45) for quetiapine, relative to lithium. Less strict 
definitions of treatment failure, and examining only those individuals stable for at least 
three months on medication did not alter these conclusions.  
9.2.2.2 Adverse effects of maintenance mood stabiliser medication  
In a cohort of 6,671 patients, those prescribed valproate, olanzapine and quetiapine had 
lower rates of ≥CKD stage 3 than those prescribed lithium, after accounting for PS, age, 
calendar year and clustering by GP practice (Chapter 7). HRs were 0.56 (95% CI 0.45 to 
0.69), 0.57 (95% CI 0.45 to 0.71) and 0.62 (95% CI 0.47 to 0.80) for valproate, olanzapine 
and quetiapine respectively. However, there was no difference in rates of more severe 
renal failure (≥CKD stage 4) between groups. 
In the fully adjusted analysis, rates of hypothyroidism were reduced in individuals taking 
valproate (HR 0.60; 95% CI 0.40 to 0.89) and olanzapine (HR 0.48; 95% CI 0.29 to 0.77), 
relative to those in the lithium treated group. Similarly, rates of hyperthyroidism and 
hypercalcemia were reduced in those taking alternatives to lithium.  
Conversely, rates of >7% and >15% weight gain were significantly elevated in groups 
treated with valproate, olanzapine or quetiapine, compared to those taking lithium. For 
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example in the fully adjusted PS analysis patients taking valproate (HR 1.62; 95% CI 1.31 to 
2.01), olanzapine (HR 1.84; 95% CI 1.47 to 2.30), and quetiapine (HR 1.67; 95% CI 1.24 to 
2.20) had elevated rates of >15% weight gain. I could find no significant difference in rates 
of CVD, T2DM or hepatotoxicity, but these outcomes were rare. A number of sensitivity 
analyses to address missing data did not alter these conclusions.  
9.2.2.3 Anti-suicidal effects of maintenance mood stabiliser medications  
In the same cohort as the previous study, rates of self-harm were lower in those individuals 
prescribed lithium, than those prescribed valproate, olanzapine or quetiapine, after 
adjusting for PS, age, calendar year and clustering by GP practice (Chapter 8). This was also 
true after one-to-one PS matching with lithium (valproate HR 1.31; 95% CI 1.01 to 1.70, 
olanzapine HR 1.33; 95% CI 1.01 to 1.75), and quetiapine HR 1.36; 95% CI 1.00 to 1.87). The 
number of suicides was too low to show differences by individual drugs (comparing lithium 
with other study drugs: PS-adjusted HR 2.86; 95% CI 0.88 to 9.26). Similarities between 
lower self-harm rates and lower accidental injury rates in those taking lithium suggested 
that lithium might have specific effects on impulsive aggression and risk taking that the 
other maintenance mood stabilisers do not. 
9.3 Implications of findings from my mortality and 
morbidity studies 
9.3.1 Key points for clinicians and patients 
i) Mortality is elevated in BPD relative to the general population 
ii) Mortality rates are decreasing in people with BPD and schizophrenia 
iii) Mortality rates are not decreasing in line with the general population – the 
mortality gap is widening 
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iv) From 2000, CVD mortality is not elevated in the group with BPD (except 2010-
2014), but CVD diagnosis is more frequent than in the general population 
v) Suicide and self-harm rates are dramatically elevated in people with BPD 
vi) Non-fatal self-harm presenting to emergency department or primary care may 
provide an opportunity for intervention and reduce the risk of suicide 
vii) Non-CVD causes of death contribute to the elevated natural mortality rate in BPD 
and also need to be monitored 
 
9.3.2 Key points for policy makers 
i) Mortality rates reflect the quality of psychiatric and physical healthcare provided to 
individuals 
ii) Current interventions and policies are not successfully addressing the mortality gap 
iii) With the expansion of EHRs tracking mortality in real time will become feasible 
iv) Policies to reduce CVD deaths in SMI are admirable, but measuring impact on 
mortality rates is challenging in short time periods  
v) The apparent increase in CVD mortality in BPD relative to the general population 
after 2010 needs to be monitored to see if this is a continuing trend; it may be a 
true elevation or it may reflect better/earlier CVD diagnosis in this group 
vi) There is a need for a clear and consistent message about primary care and 
psychiatrists’ responsibilities for their patients physical health monitoring 
vii) Increased rates of CVD diagnosis suggest CVD risk factor monitoring is occurring 
 
9.3.3 Key points for researchers 
i) The SMR is the most common measure of mortality, but does not account for 
important confounding factors. Life expectancy or years of life lost may be easier 
for patients, clinicians and policy makers to understand 
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ii) SMRs are highly heterogeneous by time, place, treatment setting and other 
unidentified covariates 
iii) Further research is necessary to better identify predictors of specific cause 
mortality, particularly suicide 
iv) Further research is necessary to understand the effects of behaviour, lifestyle and 
medication on mortality and morbidity in BPD, and not simply assume they are the 
same as in schizophrenia 
v) Disease processes beyond CVD require further investigation in BPD  
vi) Reasons for non-detection of CVD before a fatal event in schizophrenia should be 
investigated. For example: do people with schizophrenia potentially get assessed 
differently when they present with chest pain? Do they present with atypical 
symptoms (for example “black out”) more commonly? Why does this appear to be 
different in people with BPD? 
vii) There is a need to understand if, once diagnosed with non-fatal CVD, individuals 
with SMI receive equitable treatment and if risk factor management differs 
between SMI and non-SMI groups. My findings suggest this may be different for 
BPD and schizophrenia  
  
9.3.4 All-cause mortality in people with bipolar disorder 
The mortality rate is elevated in people with BPD relative to the general population, and 
this gap appears to be increasing (Chapter 4). Despite focus of UK policy on improving the 
health of individuals with schizophrenia (and SMI more generally), mortality for this group 
is also increasing relative to the general population (Schizophrenia Commission, 2012). This 
finding masks the fact that for both groups there has been a gradual decline in mortality 
rates since 2000.  Clearly, this reduction in all-cause mortality is important and should not 
be overlooked. However, it has been argued that reductions in health inequalities should 
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be a clinical priority, especially as in this case the inequality is likely to be largely avoidable 
and would provide cost effective benefits if addressed (Woodward and Kawachi, 2000). 
An over-all decline in mortality rate may suggest that some interventions in addressing SMI 
morbidity and disability have had an impact. It may also suggest that increased prescription 
of SGAs (Hayes et al., 2011, Verdoux et al., 2010) has not resulted in the increased mortality 
because of weight gain, metabolic abnormalities, T2DM and CVD that was anticipated 
(Kahn et al., 2008, Lieberman et al., 2005), though it may be too soon to observe this 
potential impact on mortality. From premature all-cause mortality we can extrapolate to 
more years lived with disability in individuals with BPD than the general population. More 
continuous monitoring of mortality in people with BPD and schizophrenia might guide us in 
evaluating the impact of interventions to manage physical comorbidity, reduce inequalities 
in medical care provision and prevent inequalities in their background risk factors. This sort 
of research becomes increasingly straightforward with the wider coverage of EHR and 
increasing availability of record linkages. Potentially this could become a semi-automated 
process that provided close-to-real-time information on mortality trends in different 
sociodemographic groups.  
9.3.5 Cause-specific mortality in people with bipolar disorder 
9.3.5.1 Cardiovascular disease mortality 
As with the general population, CVD is the commonest cause of death in individuals with 
BPD and schizophrenia but this is not necessarily reflected in elevated SMRs or HRs 
(National Institute for Health and Care Excellence, 2014). The pooled SMR for circulatory 
disorders in BPD (Chapter 3) was elevated. However, overall in the period 2000-2014, I 
found no evidence that CVD death was more common in individuals with BPD than in the 
general population (although it was higher in the period 2010-2014) (Chapter 4). This may 
  218 
suggest that since 2000 the elevated risk of death in the population with BPD is from other 
causes and that there is no CVD mortality gap to close. Certainly, this problem is not as 
marked in BPD as in individuals with schizophrenia, where CVD deaths in the 16-50 age 
group were more than three times as common as in the general population. Despite these 
differences in CVD mortality, diagnoses of CVD are similarly elevated in both BPD and 
schizophrenia relative to the general population. This suggests people with BPD are at 
increased risk of MI, CHD and CVE, but may either have better prognosis CVD events (e.g., 
non-ST elevation MIs) or receive better care that means these events are not fatal.   I did 
not explore potential reasons for this, but it does not seem to come from increased 
opportunity to receive a diagnosis because frequency of contact with primary care was 
similar in both groups. Risk factors for CVD were also comparable in both groups (apart 
from smoking, which was more common in individuals with schizophrenia). Adjustment for 
these risk factors did not fully explain the elevation in CVD above population baseline.   
9.3.5.2 Suicide 
Suicide is the cause of death that is consistently most elevated relative to the general 
population (Chapter 3 and Chapter 4). Rates appear to be similar in both BPD and 
schizophrenia, with point estimates tending to be higher in BPD (Chapter 4). Whilst it is 
hard to distinguish differences in suicide rate by age, self-harm is dramatically elevated in 
the younger (16-50) population. Suicide rates probably reflect the quality of care provided 
(both from primary and secondary care), the level of social support received by the patient, 
and the clustering of factors that increase risk (such as comorbid substance misuse or 
physical illness). Predicting who will  die by suicide remains a major challenge in psychiatry 
(Glenn and Nock, 2014). In BPD, risk factors tend to be similar to those in the general 
population. Beyond these, depressive or mixed episodes and rapid cycling appear to have 
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detrimental effects (Gonda et al., 2012). However, clinically applicable prediction models 
do not exist.  
9.3.5.3 Other causes of mortality in bipolar disorder 
All cause-specific SMRs in BPD are elevated (Chapter 3), and are comparable to those  for 
schizophrenia (Saha et al., 2007). Beyond CVD, in terms of natural causes, particular 
attention needs to be paid to potentially synergistic effects of metabolic abnormalities, 
inflammatory abnormalities, adverse health behaviours, early life experiences and lifestyle 
factors. It is likely that these factors cluster in a manner that increases all morbidity and 
mortality. Specifically with relation to unnatural deaths, little research has focused on the 
increased risk of accidental death (Chapter 8). Accidental injury, unlike suicide, is likely to 
be more common in the (hypo)manic phase of illness  (Khalsa et al., 2008) and therefore 
may be more amenable to treatment. 
9.3.6 Why is there a still “mortality gap”? 
A number of factors are likely to contribute to the increased mortality and morbidity in 
people with BPD. These include poor access to healthcare, lifestyle factors, social 
deprivation, the effects of psychiatric treatment and factors intrinsic to the disorder itself. 
9.3.6.1 Reduced access to healthcare compared to the general population 
Poor access to healthcare can occur through both healthcare system failures and failure of 
the patient to engage “appropriately” with the healthcare system.  Psychiatrists and other 
doctors may regard reporting of a physical symptom as a sign of mental illness (diagnostic 
overshadowing) (Jones et al., 2008). Clinicians may focus on the mental health issue at the 
expense of physical healthcare and may not possess the appropriate skills to diagnose the 
physical complaint. Resources for diagnosis and treatment may be lacking in a psychiatric 
setting. Physicians, surgeons and emergency department staff may be reticent to treat 
  220 
people with severe mental illness because engagement is complicated by the mental 
illness, because of stigmatising attitudes or because of issues with capacity, which they may 
feel less well versed in (Viron and Stern, 2010).  
Patients may actively avoid contact with general healthcare services (although this is not 
suggested from the baseline characteristics in my mortality and morbidity study (Study 1; 
Chapter 4). Poor general treatment adherence may also play a part. Some may have 
difficulty interpreting and communicating their physical health needs and problems in 
general, or may be unaware of physical health problems because of cognitive deficits or 
symptoms. Some patients may have difficulty undertaking tasks such as making 
appointments, comprehending healthcare or carrying out recommended lifestyle changes, 
without additional support.  
9.3.6.2 Negative health behaviours in individuals with bipolar disorder 
Individuals with BPD have been shown to engage in more unhealthy and high risk 
behaviours than the general population (Parks et al., 2006). They have been found to have 
poorer diets, exercise less frequently and smoke more than the general population (Kupfer, 
2005).  They are more likely to use illicit substances. They are less likely to practice safe sex. 
They are more at risk of coercion, exploitation and violence (Baxter et al., 2016). Many of 
these covariates are not well captured in primary care EHR and are a limitation of the data 
source (see Section 9.5.9). 
9.3.6.3 Medication effects on physical health 
Maintenance mood stabilisers (especially antipsychotics) cause weight gain (see Chapter 7), 
as do most antidepressants. This in turn can result in CVD, hyperlipidemia and T2DM. 
Medications also have side effects such as sedation or Parkinsonism that can contribute to 
reduced physical activity (Connolly and Kelly, 2005). 
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9.3.6.4 The direct effects of mental illness on physical health 
It has been shown that prior to the introduction of antipsychotic medication in the 1950s, 
individuals with schizophrenia were at increased risk of having high BMIs and T2DM (Green 
et al., 2000). Additionally there is evidence that drug naïve patients with schizophrenia 
have increased intra-abdominal fat, impaired fasting glucose tolerance, more insulin 
resistance than the general population (Ryan et al, 2003) and increased risk of metabolic 
syndrome (Vancampfort et al., 2013b). There is no similar evidence for BPD, because of a 
lack of research in this area. However, as with schizophrenia (Andreassen et al., 2013), 
there is now evidence of shared genetic risk for BPD, T2DM and elevated BMI (Winham et 
al., 2014). This suggests that there may be something intrinsic to the illness itself that 
reduces physical health, or that there is a common susceptibility to SMI and 
cardiometabolic disorders. 
9.3.7 What should be done to address the “mortality gap”? 
9.3.7.1 Physical health monitoring 
Worldwide there are multiple guidelines for the monitoring of physical health in SMI.  In 
the UK, two key guidelines are in place: the NICE BPD guidelines  (National Institute for 
Health and Care Excellence, 2014) and the QOF for primary care (Employers and 
Committee, 2012). The guidelines focus on the monitoring of BMI, blood pressure, HbA1c 
or glucose and the ratio of total cholesterol to high-density lipoprotein.  These guidelines 
do not state what comprises adequate frequency of testing, but NICE suggests monitoring 
physical health at least once a year. In addition, they state that it is primary care, rather 
than psychiatrists, who have responsibility for this monitoring, but that health professionals 
in secondary care should ensure this monitoring is happening. This has potentially led to 
some confusion about who takes responsibility for physical health issues and may have 
contributed to the increasing difference between mortality in BPD and the general 
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population. Some have therefore argued that mental health services should take 
responsibility for clearly understanding and monitoring the physical health problems of 
their patients, especially in relation to  potential adverse effects of the medication they are 
prescribing (Hasselt et al., 2015). There may be additional benefits to psychiatrists and 
other mental health staff being involved in the physical healthcare of people with BPD. It is 
clear that a whole range of chronic health problems have a significant effect on mental 
state and complicate the diagnosis and treatment of the disorders, so in identifying and 
treating patients physical complaints we may go some way to  improving their mental state. 
There is also the opportunity to strengthen the therapeutic alliance through addressing 
physical problems that the patient may feel have been neglected by other healthcare 
providers. There is evidence that routine monitoring via blood tests is not meeting 
standards set by guidelines (Chapter 7). In addition, there is some evidence that the 
increase in monitoring that has occurred has not had an effect on reducing the mortality 
gap (Chapter 4). 
9.3.7.2 Smoking cessation 
Considering the contribution of smoking to CVD, cancer and respiratory mortality, there is 
evidence that smokers lose at least 10 years of lifespan, and that stopping smoking before 
the age of 40 can prevent more than 90% of the excess mortality caused by continuing  
(Pirie et al., 2013). There is also evidence that generic smoking cessation programmes have 
been preferentially adopted by the non-SMI population (Lawrence and Kisely, 2010). This 
could partially explain the increasing HR seen in recent years (Chapter 4).  However, 
systematic reviews of RCTs confirm that treatment interventions based on 
behavioural support and pharmacotherapy that work in the general population are 
also (and approximately equally) effective in smokers with mental illness and do not 
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appear to worsen psychiatric symptoms (Banham and Gilbody, 2010, Ratschen et 
al., 2011).   
9.3.7.3 Exercise and healthy eating  
Strategies to help individuals with SMI manage their weight include restriction of caloric 
intake, pharmacological interventions, and behavioural interventions. Behavioural healthy 
eating programmes offer the best evidence for sustained change in the SMI population 
(Daumit et al., 2013). A review of healthy eating programmes in SMI patients suggests that 
basic approaches to caloric reduction can be as effective as more comprehensive efforts 
(Cabassa et al., 2010).  
Exercise interventions have been shown to be effective in increasing levels of physical 
activity in patients with SMI (Ussher et al., 2007). A simple intervention such as walking, 
either in the form of supervised walking groups or unsupervised, is one of the easiest, 
safest and most inexpensive types of exercise to promote. It is also one of the most popular 
forms of exercise for those with and without chronic illness (Siegel et al., 1995). 
9.3.7.4 Prescribing to reduce morbidity and mortality 
Controversy and uncertainty remain as to whether psychotropic prescribing increases 
overall mortality (Murray et al., 2016). Most of the literature is focused on high dose, long-
term prescribing of antipsychotics in schizophrenia, but these issues also apply to BPD. 
Recently it has been suggested that psychiatrists should 1) treat with the minimum 
necessary dose, 2) use a weight-sparing medications, 3) reduce to the lowest possible dose 
following recovery and 4) ensure access to non-pharmacological treatments (Murray et al., 
2016). However, this is further complicated in BPD because of the episodic nature of illness, 
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inherent risk of  different polarities of illness, potential for kindling effects and the limited 
evidence for effective psychological approaches (Goodwin et al., 2016, Oud et al., 2016).   
It may be that psychotropic medications reduce suicide (Torniainen et al., 2015) but 
increase CVD deaths (Saha et al., 2007), but again this is not clear-cut. We continue to know 
very little about the very long-term effects of maintenance treatment, and I have tried to 
address this in Chapter 7 and Chapter 8. However, these studies do not examine medicated 
vs. unmedicated  groups because taking medication is likely to be a surrogate marker for 
both illness severity and overall healthier behaviour (Mace et al., 2015). 
9.4 Implications of findings from my maintenance 
treatment studies 
9.4.1 Key points for clinicians and patients 
i) Individuals prescribed lithium are likely to remain on monotherapy for longer than 
those prescribed valproate, olanzapine or quetiapine, suggesting it is more effective 
and tolerable  
ii) Lithium should be considered the first-line treatment for BPD 
iii) Lithium is associated with increased rates of mild or moderate CKD, but not 
necessarily end-stage renal failure (although I cannot rule this out from my study 
results) 
iv) Lithium is associated with increased detection of hypothyroidism, hyperthyroidism 
and hypercalcemia 
v) Alternatives to lithium are associated with higher rates of weight gain 
vi) Patients taking olanzapine additionally have increased rates of hypertension 
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vii) Although CVD and T2DM diagnoses rates did not differ by drug type it is likely that 
increased weight gain, CKD and hypertension are major risk factors for these 
adverse events 
viii) Monitoring of physical health and blood test parameters is  necessary 
ix) In particular calcium is not monitored well in primary care, despite being part of 
NICE guidance 
x) If adverse events occur, a discussion about the risks and benefits of continued 
treatment should be initiated with the patient 
xi) Both self-harm and accidental injury rates are lower in patients prescribed lithium, 
this should be discussed as an additional potential benefit with patients 
 
9.4.2 Key points for policy makers 
i) Supporting clinicians to prescribe lithium may be necessary. Much like specialist 
clinics mitigate some of the risks and complications of prescribing clozapine, lithium 
clinics could allow better and safer prescribing 
ii) Improved documentation of physical health monitoring relating to specific 
prescribing choices may improve outcomes 
iii) Calcium monitoring should be added to QOF  
 
9.4.3 Key points for researchers 
i) It is unclear if individuals who have the best chance of responding to lithium can be 
identified in advance or early in treatment 
ii) Research into recovery from mood stabiliser adverse events is very limited, it is 
unclear whether (and at what point) clinicians should stop or alter medication 
iii) If lithium, beyond its mood stabiliser properties acts directly on impulsivity and 
aggression, then it may have therapeutic benefit in other psychiatric disorders 
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iv) A clearer understanding of lithium’s mechanism of action may advance our 
understanding of the pathophysiology of BPD and help identify drugs suitable for 
repurposing or targets for new drug development 
 
9.4.4 Effectiveness and tolerability of maintenance mood stabiliser medications 
A number of reviews and guidelines have aligned to suggest lithium should be the first-line 
prescribing choice for maintenance treatment in BPD (Goodwin et al., 2016, Miura et al., 
2014, National Institute for Health and Care Excellence, 2014, Severus et al., 2014). None of 
these were in existence at the time the studies in this thesis were conceived. It remains the 
case that RCTs and meta-analyses of these RCTs do not suggest that lithium is 
overwhelmingly superior to active comparators. However, lithium is the only drug that has 
been found to be efficacious and tolerable compared to active comparators under non-
enriched conditions (i.e., RCTs that are set up to favour the non-Lithium drug) (Licht, 2012, 
Miura et al., 2014, Chapter 5). Because the outcome measure in recent RCTs has been time 
to first relapse or recurrence, any treatment continued beyond this point is not evidence-
based. This also does not allow for the fact that a partial response may be clinically useful, 
and that mood stabilisers often require time to work (including dose optimisation) (Licht, 
2012).  My study (Chapter 6) robustly showed that individuals prescribed lithium took it for 
longer as monotherapy, before stopping medication, swapping to an alternative or having 
medication added to their treatment regimen. This outcome represents a combination of 
effectiveness and tolerability that has been widely used in RCTs (Miura et al., 2014). 
Stopping, swapping and add-on events were common with all drugs, but this is consistent 
with other naturalistic studies (Kessing et al., 2007, Schumann et al., 1999). It is reassuring 
that this study corroborates this treatment approach. However, in clinical practice, the 
perception that lithium is complicated to prescribe and associated with acute and long-
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term adverse effects constitutes a barrier to its effective prescription and management 
(these issues are discussed below and in Chapter 7). Additionally, it was not possible in the 
cohort from THIN to examine different effects of combination therapies, which are 
becoming increasingly common (Licht, 2012).  
9.4.5 Adverse events during maintenance mood stabiliser treatment 
The four commonly used mood stabiliser medications investigated are associated with a 
number of adverse effects (Chapter 7). Specifically, with regards to lithium the potential for 
irreversible long-term renal damage is likely to be the clinician’s greatest concern. With 
regards to all of the studied drugs, but particularly olanzapine and quetiapine, significant 
weight gain and the related cardiometabolic sequelae are a major concern. Neither of these 
adverse events had previously been quantified relative to other medications. I was able to 
examine these adverse events, and a number of others related to each drug.   
9.4.5.1 Renal impairment during maintenance mood stabiliser treatment 
That lithium is associated with mild or moderate renal impairment cannot be disputed. It is 
seen clinically, and has been shown in a number of longitudinal studies (Chapter 7). 
However, the implications of this are unclear. Previous studies have been hampered by lack 
of active comparator treatments and inability to appropriately manage potential 
surveillance bias. The study in this thesis addresses these previous limitations by comparing 
lithium with valproate, olanzapine and quetiapine and by completing an analysis accounting 
for the probability of having a blood test.  
≥CKD stage 3 was twice as common in those taking lithium. However, the majority of these 
cases will be at the mild end. Guidance for management of CKD stage 3 suggests active 
monitoring and lifestyle advice (unless there are signs of progression of renal disease such 
as  proteinuria or haematuria). I was not able to examine records of these events in THIN, 
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and often a finding of eGFR<60 ml/min/1.73m2 but >30 ml/min/1.73m2  will result in no 
change in management beyond that which would be received by people with SMI in 
general (i.e., lifestyle advice and additional monitoring) (Frankel et al., 2005, Levey and 
Coresh, 2012).  At this stage, however, there is already an approximately 40% increased risk 
of cardiovascular events (Go et al., 2004) but continuing lithium is not contraindicated 
(Werneke et al., 2012). Risk of progression from mild to end-stage CKD does not seem to be 
modified by continuing or stopping lithium (Bocchetta et al., 2015). Overall ≥CKD stage 4 
was rare in my cohort, such that it was not possible to discern differences in rates between 
those taking lithium and patients taking other mood stabilisers (Chapter 7). End-stage CKD 
has also been found to be rare in other recent cohort studies (Aiff et al., 2014a, b, Bendz et 
al., 2010). As such, the risks surrounding CKD in lithium treated patients who are 
maintained on a non-toxic, clinically therapeutic dose are likely to have been 
overestimated. I am not aware of methods for identifying patients at greatest risk of 
progression to end-stage renal failure from CKD stage 3 whilst taking lithium. This is an 
important future research focus. 
9.4.5.2 Thyroid disease during maintenance mood stabiliser treatment 
Hypothyroidism rates were elevated in lithium treated patients, compared to valproate or 
olanzapine treated patients. It was not possible to be certain that rates were higher than in 
those taking quetiapine, as CIs were wide and included unity. Hypothyroidism has long 
been recognised as a complication of lithium treatment. However, compared to alternative 
mood stabilisers the risk has not been quantified. In Study 2 in this thesis, rates of 
hypothyroidism during lithium treatment were less than double rates during treatment 
with alternatives. This is a lower relative risk than comparisons with the general population 
(McKnight et al., 2012) and potentially reflects the higher baseline risk of thyroid disease 
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associated with BPD itself (Kupka et al., 2002). The rate (approximately 2 per 100 PYAR) is 
ten times what is seen in general population studies (Garmendia Madariaga et al., 2014).  
Although hyperthyroidism is very rare, it was more common in those taking lithium, than 
those taking valproate or olanzapine (but not quetiapine).  As far as I am aware, this is the 
first study to be large enough to show definitive differences in hyperthyroidism rates 
between lithium and other drugs. Four previous case-control studies exist, with a pooled 
effect estimate overlapping no effect (McKnight et al., 2012) and one cohort study, with 
multiple limitations, also found no elevated risk in those taking lithium (Shine et al., 2015). 
Early identification and appropriate treatment of thyroid disease is vital in BPD as it can 
complicate the clinical picture and reduce the chance of recovery (Fagiolini et al., 2006). 
Even low but normal range thyroid function is associated with slower treatment response 
(Cole et al., 2002) Thyroid function monitoring is more common in individuals prescribed 
lithium than other drugs (75% vs 55%). However, given the increased risk to all patients 
with BPD, and the overlap in symptomatology, all of these patients should have been 
screened for thyroid abnormalities (National Institute for Health and Care Excellence, 
2014). 
9.4.5.3 Hypercalcemia during maintenance mood stabiliser treatment 
Clinically elevated levels of calcium were more than 4 times as common in individuals 
taking lithium than other mood stabilisers. However, the majority of individuals never 
received a calcium blood test during their exposure period. This suggests that this problem 
often goes unrecognised in clinical practice.  Other studies have found more elevated rates 
compared to the general population, but there are no active comparator studies (Grünfeld 
and Rossier, 2009, McKnight et al., 2012). As stated in Chapter 7 the HR reported is likely to 
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be an underestimation, due to missing data. In treatment with lithium, most hypercalcemia 
will be due to hyperparathyroidism.  
Detecting hypercalcemia is particularly important as some of the symptoms may be 
confused with side effects of lithium or signs of lithium toxicity, such as polyuria, polydipsia, 
dyspepsia, fatigue, nausea, cognitive impairment and muscle weakness  (Inzucchi, 2004).   
Hypercalcemia can be a causal factor in renal failure, and is also associated with 
arrhythmias and osteoporosis (Inzucchi, 2004).  
 
9.4.5.4 Weight gain during maintenance mood stabiliser treatment 
Weight gain was lowest in patients prescribed lithium. Point estimates for >7% and >15% 
weight gain were highest in the group taking olanzapine.  The rate of >15% weight gain was 
around 6 per 100 PYAR in patients taking alternatives to lithium. As far as I am aware, this is 
the first comparative study of weight gain during BPD treatment. Irrespective of medication 
effects, patients with BPD are at increased risk of being overweight or obese, relative to the 
general population (Keck and McElroy, 2003). This can be seen in the baseline 
characteristics of patients in my mortality/morbidity study (Study 1: Chapter 4). Weight 
gain is associated with increased mortality risk caused by CVD, T2DM, cancer and 
respiratory problems, but it also has psychological consequences such as low self-esteem 
and self-image, reduced socialisation and reduced activity (Torrent et al., 2008).  Weight 
gain is also likely to have an impact on medication adherence and consequently on illness 
course. It is therefore important that risks of weight gain be minimised, if possible, in these 
patients.  Additionally, although weight gain has been traditionally seen as an early event 
with regards to antipsychotic treatment (Sussman, 2001), in my study rates of >15% weight 
gain were stable over a 5 year follow-up period (Chapter 7).  Despite lithium having the 
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lowest propensity, of the drugs studied, to cause weight gain it is still associated with 
weight gain compared to placebo (McKnight et al., 2012). In contrast to risks of renal and 
endocrine adverse events, there is no tension between the preferential prescribing of 
lithium for preventing relapse or recurrence and the risk of weight gain.  
9.4.5.5 Cardiovascular disease and diabetes during maintenance mood stabiliser 
treatment 
Both weight gain and CKD increase the risk of CVD, therefore although we may hypothesise 
that olanzapine will be associated with more CVD, this may not necessarily be true. In Study 
3, I did not find differentially elevated rates of CVD by drug, although 95% CI were wide. I 
am not aware of any study that has been able to separate these medications in terms of 
CVD risk. Compared with the full BPD population (Chapter 4), rates of CVD in those treated 
with lithium, valproate, olanzapine or quetiapine were up to twice as high.  However, this 
cannot be not be taken as proof that these medications double the risk of CVD, as there are 
likely to be many other differences between individuals treated with these drugs and those 
who simply receive a BPD diagnosis.  I did not examine how these patients were treated 
following diagnosis of their CVD and this would have important implications for their 
mortality risk. 
T2DM is also a multifactorial disease that is associated with considerable illness burden. As 
with CVD, I was unable to find differences in rates by drug. I am aware of no literature that 
suggests that there is a direct link between lithium prescription and T2DM, but increased 
rates in this group are possible via weight gain, CKD and CVD risk increases. Conversely, 
olanzapine has been found to increase the risk of T2DM by more than 4 times that seen in 
untreated patients (Gianfrancesco et al., 2003) and appears to carry a direct risk that is 
independent of weight gain (Lean and Pajonk, 2003). Compared to the population who 
receive a diagnosis of BPD, individuals treated with these drugs clearly need increased 
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monitoring of cardiometabolic parameters to reduce the risk of morbidity and mortality 
from these diseases.   
9.4.5.6 Hepatotoxicity during maintenance mood stabiliser treatment 
I found no differences in rates of hepatotoxicity, but this outcome was extremely rare. 
Contrary to expectations, impaired liver function was not elevated in individuals taking 
valproate (Betrosian and Frantzeskaki, 2006). In the unadjusted analysis, it was elevated in 
those taking quetiapine. The potential risk of quetiapine induced liver damage remains 
limited to case-reports, the same is true of olanzapine (Sedky et al., 2012). Of all of the 
adverse events covered in this thesis, this is likely to be the rarest and should have least 
impact on prescribing choice, unless there is evidence of pre-existing liver impairment 
(Sedky et al., 2012). Co-prescribing of antipsychotic medications, anticonvulsant moods 
stabilisers and/or antidepressants may increase the risk of hepatotoxicity. Additionally 
alcohol and other drug use may have an impact on liver function, but this has not been 
widely investigated (Sedky et al., 2012). 
9.4.5.7 Other adverse effects  
I was unable to examine a number of acute side effects of these drugs, such as tremor and 
thirst with lithium. Whilst acute adverse effects such as these may be disturbing to patients 
and may reduce medication adherence, they are not life threatening and are unlikely to 
lead to a change in prescribing if occurring in isolation. I therefore focused on serious and 
potentially life threatening (direct or indirect) adverse effects. 
9.4.6 Self-harm, accidental injury and suicide during treatment with maintenance 
mood stabiliser medications 
Self-harm was less common in individuals taking lithium (Chapter 8) and this finding is 
supported by existing literature (Cipriani et al., 2013a). Accidental injury was also less 
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common in patients taking lithium. I found no evidence to support the FDA warning that 
valproate is associated with increased suicide risk (Busco, 2008). Whilst it is important to 
understand the risk of these adverse outcomes in and of themselves, Study 4 also 
attempted to further understand the potential mechanism by which lithium may display 
anti-suicidal properties.  
Three mechanisms have been proposed: 
1. Lithium requires closer monitoring, increasing psychosocial support and therefore 
reducing self-harm  
2. Lithium reduces depressive episodes, therefore reducing self-harm 
3. Lithium specifically reduces impulsive aggression, therefore reducing self-harm 
 
Mechanism 1 is unlikely to be correct as Study 4 showed that patients taking lithium had no 
extra primary care contacts than those taking other study drugs, additionally I would not 
necessarily expect accidental injury rates to be effected by closer monitoring. Mechanism 2 
is unlikely to be correct because lithium is not significantly better at preventing or 
shortening depressive episodes than other mood stabilisers such as quetiapine. In addition, 
I would not expect depressive episodes to be associated with risk of accidental injury (in 
fact accidental injury is associated with mood elevation (Khalsa et al., 2008)). If mechanism 
3 were correct then I would expect to see reduced rates of self-harm and accidental injury 
in patients prescribed lithium: and this is what was observed. The theory that lithium has 
specific serotonin-mediated effects, which reduce aggressive, risk-taking and impulsive 
behaviour is also supported by previous literature (Fawcett, 2001, Kovacsics et al., 2009, 
Müller-Oerlinghausen and Lewitzka, 2010). 
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The point estimate for suicide rate in those taking lithium was lower than in patients taking 
other medications, but the study was underpowered to be certain of this difference. That 
rates were similar to previous studies is reassuring (Goodwin et al., 2003, Smith et al., 
2009) and a meta-analysis of longitudinal studies may be an appropriate next step to 
investigate drug-specific suicide rates.   
Taking the evidence as a whole, there is a considerable argument for psychiatrists 
preferentially recommending lithium where self-harm is part of the clinical presentation.  
Potentially most benefit will come from starting lithium early in the illness course, where 
rates of self-harm and completed suicide are highest relative to the general population 
(Chapter 4). 
9.5 Strengths and limitations of studies making up this 
thesis 
Study specific strengths and limitations are discussed in each chapter. The more 
fundamental limitations are discussed here: 
9.5.1 Use of electronic health records 
Some of the strengths and limitations of using EHR for the studies in this thesis were 
discussed in Chapter 1 (section 1.6 and 1.7) and Chapter 2 (section 2.8 and 2.9). In the 
main, the questions addressed in this thesis were not ones that can, or will be adequately 
addressed by experimental studies or specially designed prospective cohort studies. 
However, EHR have a number of limitations that are particularly important and are linked 
to their use primarily as a clinician record, rather than a research tool.  Some of these 
limitations can be overcome by study design and analysis techniques, others cannot.  
Overcoming the limitations of EHR can mean relying on a number of assumptions, but often 
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these assumptions are based on the logical thinking that to be useful  to a treating clinician, 
data in EHR must be complete, correct, plausible, and display concordance (across records 
or other sources),  and that entries must also be appropriately timed (Weiskopf and Weng, 
2013). Additionally, we must assume that there is little risk of differential recording 
because of a particular state or trait, for example: GPs behave consistently and are just as 
likely to make a diagnosis of T2DM in the general population as they are in someone with 
BPD. In many instances in the studies in this thesis, this assumption will hold true.  In 
others, such as self-harm and suicide there may be more detection and coding in people 
with SMI compared to the general population, with evidence that EHRs tend to under-
record suicide in the general population (Thomas et al., 2013a). However, this should not 
be the case in the study comparing different maintenance medications (Chapter 8) as all 
individuals are considered high risk of suicide and rates appear similar to other cohort 
studies (Goodwin et al., 2003). In general, the HRs should be considered accurate, and the 
raw rates interpreted more cautiously.  
9.5.2 Diagnostic validity of bipolar disorder in THIN 
Diagnoses of BPD in THIN have not been directly validated. It has generally been considered 
that BPD is not a diagnosis that most GPs would make alone, and therefore the majority will 
be diagnosed in secondary care by a psychiatrist and will meet ICD criteria for the disorder 
(National Institute for Health and Care Excellence, 2014), however this heuristic approach is 
still vulnerable to error. I have previously shown that BPD incidence in THIN is similar to 
other European estimates, and shows expected age, sex and SES distributions (Hardoon et 
al., 2013). There may be potential for misdiagnosis, but attempts were made to minimise 
this by using the most recent diagnostic code in the patient record, at which point the 
treating clinician would have the most information about the patient’s illness course, and 
therefore be able to make the most accurate diagnosis. Clearly, misdiagnosis cannot be 
  236 
ruled out, but this would be the case in any situation where detailed research diagnostic 
criteria were not rigorously applied, with the added complication of the phasic nature of 
the illness in the case of BPD. The opportunity for misdiagnosis in BPD is potentially greater 
than in other mental illness. The psychotic episodes in mania and depression could be 
misdiagnosed as schizophrenia, schizoaffective disorder or other psychotic illness. BPD II 
symptoms could be misdiagnosed as unipolar depression or emotionally unstable 
personality disorder.  It has been reported that around 70% of BPD is initially misdiagnosed, 
with over one third waiting more than 10 years for a correct diagnosis (Hirschfeld and 
Vornik, 1899).  It is not possible to separate BPD I and II in THIN, and this may mean a 
heterogeneous group of individuals have been examined. Additionally, there may be 
diagnostic biases at play that lead to clinicians making a BPD, as opposed to alternative, 
diagnosis. These biases may exist because of baseline characteristics of the patients. For 
example, there has been a longstanding clinical (and historical research) belief that non-
White ethnicity and lower SES is more likely to be associated with schizophrenia than BPD 
(Eid et al., 2013, Garb, 1997),  having these prejudices in mind, along with a heuristic that 
interprets specific symptom clusters as definitely delineating one diagnosis from another, 
will lead to misdiagnosis.   
Within the mortality and morbidity studies, it is clear that, whether truly reflecting the 
illness state recognised as BPD, individuals who receive a code consistent with the diagnosis 
have a greatly elevated rate of all-cause mortality, CVD diagnosis, suicide and self-harm 
compared to the general population. These rates are comparable with other studies 
(Chapter 3) and comparable to people who receive a code consistent with a schizophrenia 
diagnosis (which is likely to be those at the severe end of psychotic illness, as there has 
been a move away from diagnosing schizophrenia specifically)(Hardoon et al., 2013). 
Within the maintenance medication studies it is likely that receiving a BPD diagnosis and 
  237 
being treated with a maintenance mood stabiliser increase the chance that the BPD 
diagnosis is valid.  
Beyond THIN, there is some evidence supporting the validity of BPD diagnosis in UK primary 
care records. A small CPRD study validated renal failure in patients with BPD treated with 
lithium and found that all those expected to have BPD fulfilled diagnostic criteria (Close et 
al., 2014).  In general, mental and behavioural disorders in CPRD are as well validated as 
other diagnoses, based on diagnostic algorithms, record checks and questionnaires sent to 
GPs  (Herrett et al., 2010). Previously psychotic illness has been validated in primary care 
records (Nazareth et al., 1993). Other EHR sources also display good case validity for BPD 
(Kessing, 1998, Sellgren et al., 2011). 
9.5.3 Comparing characteristics of my cohort of people with bipolar disorder with other 
cohort studies 
It is difficult to compare baseline sociodemographic and clinical characteristics (Table 4.i, 
Table 7.i) for people with BPD in this thesis with previous cohorts from the UK, because 
studies do not exist or do not report specific BPD characteristics. Internal comparisons with 
schizophrenia suggest individuals diagnosed with BPD are more likely to be female, White 
ethnicity and live in higher SES areas, as reported elsewhere (Laursen et al., 2007). Smoking 
prevalence is similar to that in patients recruited to the Stanley Research Program in the US 
(Dickerson et al., 2013). Compared to Danish population data, the sex and age distributions 
are similar, as is the all-cause mortality rate (Medici et al., 2015). In Study 2, 3 and 4 
baseline covariates were collected over specific time periods, with the most recent being 
used if there was more than one record. This approach minimises missing data, but may 
introduce bias because of failure to update records when a status changes. In these studies 
I would hope that this bias would be non-differential. However, there are cases where it 
may not be. For example, individuals commencing olanzapine may be more likely to have a 
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weight measure at the point of commencing the drug (because clinicians are concerned 
about the risk of weight gain). Whereas, if a drug with less recognised propensity to cause 
weight gain is commenced, weight may not be measured and therefore a more historical 
(i.e., inaccurate) weight may be used. 
9.5.4 Defining drug exposure using EHR 
Although most long-term prescribing for stable patients is likely to occur in primary care, 
prescriptions for mood stabilisers issued in secondary care, for example, in specialist 
psychiatric clinics or during inpatient care may not be recorded in THIN. Thus, drug 
exposure may be underestimated in these patients and may be at risk of ‘immeasurable 
time bias’. One previous CPRD study has suggested that lithium prescribing may be 
underestimated by primary care records (Close et al., 2014). However, there is no reason to 
believe that this would be differential by study drug, and therefore the study design used in 
this thesis minimises the potential impact of this problem. I also considered the issuing of a 
new prescription within 3 months of the previous predicted end date to signify a period of 
continuous prescribing to reduce the potential impact of this issue.  I am aware of no EHR 
that has better recording of medications than those that contain records from UK primary 
care. Additionally, in the case of the effectiveness/tolerability study (Study 2: Chapter 6) 
this move to psychiatrist prescribing or hospital care would reflect treatment failure and is 
therefore an outcome of interest.  
A larger issue is the patient’s potential non-adherence with medication. I aimed to minimise 
this threat to validity by only including patients with more than one prescription issued, and 
including a window of 3 months from the previous predicted end date in which a new 
prescription could be issued. Despite this, collecting a prescription can only be a proxy for 
taking a medication. Potentially, adherence is better in patients where medication levels 
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are measured, such as lithium and valproate. However, studies of cohorts with BPD have 
found that full and partial adherence rates are similar across groups prescribed lithium, 
valproate and SGAs (Sajatovic et al., 2007, Sajatovic et al., 2006). Adherence with any 
medication cannot be guaranteed, but non-adherence rates are similar in BPD populations 
and populations with other long-term health conditions (Horne et al., 2005). 
9.5.5 Using drug monotherapy to investigate effects 
To be able to understand the specific effects of drugs, studies 2, 3 and 4 included people 
prescribed monotherapy of one of lithium, valproate, olanzapine or quetiapine. Specific 
combinations of maintenance mood stabilisers could not be compared. This was due to 
relatively small numbers, the increasingly complex study design necessary, and the likely 
differences in patient characteristics related to adherence with a polypharmacy regimen. 
This study design therefore allows us to consider potential early/single drug treatment 
options for BPD, but may not be generalisable to situations where prescribing becomes 
more complicated. To put this limitation in context, in the UK (where prescribing is 
relatively conservative), there is evidence that for patients taking lithium, 20% take lithium 
alone, 45-50% take a second drug, about 30% a third and 5% a forth (Goodwin et al., 2016, 
Hayes et al., 2011). However, in each of these patients it is likely that they began with just 
one mood stabiliser prescribed; therefore it is important to understand which monotherapy 
has the best chance of keeping people well and the lowest risk of adverse events. In the 
case of adverse effects related to these drugs it remains unclear how combinations of 
mood stabilisers may interact.  
9.5.5.1 Considering the effects of drug dosage 
In addition to studying monotherapy only, I did not include drug dosage in any of the 
studies. This was too complex to add to this thesis, but is likely to be important for both 
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comparative effectiveness and adverse effect profiles. In effectiveness studies, an increase 
in drug dose may reflect treatment failure and in adverse effect studies, higher doses 
increase the risk of adverse effects.   
9.5.6 Follow-up time for patients with bipolar disorder in THIN 
Despite the potential for long follow-up time in THIN, the median follow-up time in the 
studies conducted in this thesis was relatively short. For example, in the 
mortality/morbidity study (Study 1: Chapter 4) patients with BPD had a median follow-up 
of 2.3 years and the general population comparator group 2.0 years. It is likely that this is 
due to more practices joining the database and coming up to agreed levels of data quality 
later during the study period, rather than high rates of de-registration from practices. There 
is some evidence that people with SMI are more likely to move accommodation than their 
healthy counterparts (McCarthy et al., 2007). However, this is not reflected in THIN data.  
Importantly, there does not appear to be differential follow-up by diagnosis (Chapter 4) or 
treatment group (Chapter 7, Chapter 8). In the study in Chapter 6, differential follow-up is 
the outcome of interest.  
9.5.7 Validity of outcomes used in this thesis 
The majority of outcomes examined in this thesis have been validated previously. Specific 
to studies examining THIN, all-cause mortality is well recorded, with >99% positive 
predictive value and sensitivity (Hall, 2009). Applying an algorithm for suicide gives a 
positive predictive value of 97% (Arana et al., 2010). CVD diagnoses have positive predictive 
values greater than 90% (Hammad et al., 2008, Ruigómez et al., 2010). Rates of CKD, 
hypertension, hypothyroidism, CVD and T2DM in THIN reflect UK national QOF prevalence 
(Blak et al., 2011). With regards to these outcomes in CPRD (a comparable system) the 
proportion of confirmed cases is: endocrine and metabolic, 88%; circulatory, 85%; and 
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injury and poisoning, 90% across multiple studies (Herrett et al., 2010). Despite these 
reassuring validation results, there remains the risk of potential misclassification when 
relying on algorithms rather than gold standard research criteria or death certificate 
information.   
In a number of studies, a more fine-grained definition of outcome would have been 
interesting to investigate. It would have been potentially informative to separate CVD into 
MI (ST and non-ST elevated MI), CHD and CVE (ischemic and haemorrhagic), but even in the 
full cohort of individuals with BPD this would have resulted in low power, because events 
were rare. Similarly, it would have been interesting to separate self-harm events into 
overdoses and other forms of self-harm, because of the different relationship these two 
types of acts might have with impulsivity and aggression. Again, this was not possible 
because of the rarity of the events. In Chapter 8, it would have been useful to be able to 
look at grades of blood test abnormalities. These limitations highlight the fact that very 
large datasets are required to answer a number of epidemiological and particularly 
pharmacoepidemiological questions, for example by combining data from several routinely 
collected data sources. 
9.5.8 Comparing bipolar disorder mortality with general population rates 
As well as GPs recording death, THIN relies on information being returned from the ONS 
about patient mortality. The accuracy of these data is checked regularly and, as discussed in 
Chapter 2, only practices with AMR contributed to this thesis. Although I would not 
necessarily expect the mortality in the healthy population comparison group in Study 1 to 
reflect exactly the UK population (because they were selected to match with BPD or 
schizophrenia patients rather than be representative of the general population), it should 
be similar. As such, SMRs for THIN general population vs. ONS general population should be 
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approximately 1.00. To check the generalisability of mortality recording for my cohort I 
generated annual SMRs (accounting for age group and sex) comparing my healthy 
population comparison group with ONS data at the start (2000) midpoint (2007) and end 
(2014) of the study. In 2000, the THIN SMR was 0.97 (95% CI 0.81 to 1.16). In 2007, the SMR 
was 1.13 (95% CI 1.03 to 1.22). In 2014, the SMR was 0.69 (95% CI 0.63 to 0.75). This 
suggests that there is general agreement between these data sources. By 2014, it appears 
that the THIN population had lower mortality than the general UK population, but this is 
potentially an error based on the large number of individuals in the THIN comparison group 
by this time (i.e., the 95% CI is likely to be too precise).  
9.5.9 Approach to handling missing data in THIN 
In general, I took a simple approach to missing data throughout this thesis, in line with 
previous EHR studies. In Study 1, I performed a complete case analysis, where the only 
missing data were considered to be quintiles of Townsend score (3% missing). Less than 5% 
missing data is considered unlikely to produce biased estimates (Bennett, 2001). As 
discussed in Chapter 2 all individuals with missing ethnicity data were considered White 
(Hippisley-Cox et al., 2008) and all individuals with missing smoking data were coded as 
non-smokers (Marston et al., 2014) in line with previous research. Other confounders in 
this study were coded as the worst ever recorded over follow-up (BMI, 
hypercholesterolemia, hypertension, T2DM). In Studies 2, 3 and 4 variables were dealt with 
similarly, but a number were only considered present if they were recorded before baseline 
(drug initiation).  The adverse events study (Study 3: Chapter 7), in particular, suffered from 
missing blood test recording, which was used to define the outcome. I attempted to 
overcome this limitation by conducting a number of sensitivity analyses (including IPTW).  
As discussed in Chapter 2, multiple imputation approaches for missing data are currently 
incompatible with PS analyses. However, in the case of the adverse effects study (Study 3), 
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using two-fold fully conditional multiple imputation (Welch et al., 2014) to impute missing 
blood tests and then attempting to identify the time points at which blood tests first 
became abnormal would have been a potentially interesting addition.   
Beyond the necessary simplification of variables that are recorded in THIN, a number of 
other variables that would enhance the quality of the completed work are not included in 
the EHR.  Illness and symptom severity is particularly difficult to quantify. For example, it 
could be argued that the observed lower rates of self-harm in individuals prescribed lithium 
are simply due to that group already having lower impulsivity (and therefore a clinician 
being happier to prescribe a potentially toxic drug). To be certain that this is not the case 
we would need everyone to receive a standardised measure of impulsivity, which clearly is 
not going to happen in clinical practice. All we can therefore draw on are covariates that 
are potential markers of impulsivity (for example: age, prior self-harm, smoking, alcohol 
and substance misuse) which suggest there are no dramatic differences by drug group.  
A major limitation of THIN in general for research purposes is the lack of information about 
individual level SES and other social factors (such as employment, education and 
relationships). In all UK primary care EHRs, SES is defined by an area level measure, either 
the Townsend score (see Section 2.3.3 and Section 2.9.5), or Index of Multiple Deprivation 
(IMD). These area level measures are considered suitable proxies for individual SES, but are 
clearly vulnerable to ecological fallacy (i.e that the SES of the group does not accurately 
reflect all individual SES in the group) (Galobardes et al., 2006). Townsend score, used in 
this thesis, is based on 2001 census data, and so may not adequately reflect the area by the 
end of cohort follow-up in 2014. IMD is a more recent measure of area SES and is now 
available in THIN. The problem is that there are different IMDs for each country of the UK, 
and these cannot be combined (Payne and Abel, 2012). Use of IMD would therefore have 
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reduced the cohort to individuals living in England (approximately 70%). Because of this, I 
decided to use Townsend score despite its limitations. Other data that would enhance the 
included studies would be measures of health behaviours, such as exercise and healthy 
eating, but again these would require some form of standardised longitudinal 
measurement as they are not routinely coded in primary care EHRs.  
9.5.9.1 How missing blood test results may have affected the results of maintenance 
treatment studies 
In the sensitivity analyses in the adverse events study (Study 3; Chapter 7), attempts were 
made to minimise the effects of potential surveillance bias in blood tests using IPTW. These 
results were consistent with the primary analysis. However, there remains the problem that 
GPs will complete blood tests when indicated, rather than at random, and it is unlikely that 
the effect of this indication can be totally overcome by statistical approaches. 
Interpretation of the potential effects of this on my results is complex. For example, GP 
will/should routinely complete renal function tests for people taking lithium. If people 
taking lithium have more tests, an abnormal result (especially mildly abnormal) is more 
likely to be detected. However, being on olanzapine is not necessarily an indication for 
testing renal function, and therefore when a test is completed there is likely to be a clinical 
(i.e., symptom related) reason for the test being completed. If there are clinical signs, a 
blood test is potentially more likely to be abnormal. In the case of calcium testing the 
effects are even more difficult to predict, because, in spite of guidelines recommending 
calcium monitoring for patients taking lithium it is only the minority of this group that 
receive tests. 
9.5.10 Unmeasured and residual confounding  
It remains impossible to rule out unmeasured and residual confounding in each of the 
completed studies, as it does in any observational research.  In the mortality/morbidity 
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study (Study 1: Chapter 4), this is potentially less important as the aim was to understand 
differences with relation to the general population accounting for a small number of 
potential confounders. In Studies 2, 3 and 4 the use of PS techniques goes beyond 
traditional multivariable regression approaches in terms of reducing confounding. For 
unmeasured confounders to have a dramatic impact on the results of any of these studies 
they would have to be strongly associated with drug-exposure and outcome and be 
independent of other confounders: it is unlikely that such covariates could be identified (Lin 
et al., 1998, Psaty et al., 1999). However to be more confident in this conclusion it may 
have been beneficial to have conducted an analysis to identify the strength of unmeasured 
or residual confounding that would be necessary to explain the observed association 
between drug-exposure and outcome, as suggested by Schneeweiss (Schneeweiss, 2006). 
9.5.10.1 Confounding by indication  
As discussed in Chapter 2 and the Potential limitations section of Chapters 6, 7, and 8, 
Studies 2, 3 and 4 may be at particular risk of confounding by indication. Although attempts 
were made to limit this via study and analysis design, it is impossible to rule out that there 
were unmeasured differences in patient groups that lead to treatment with one particular 
drug, rather than an alternative. In fact this type of bias may be an intractable threat to 
validity in all observational studies  (Bosco et al., 2010). It then becomes vital to show that 
results are consistent across “different persons, places, circumstances and time”(Hill, 1965). 
Certainly, this appears to be the case when comparing the results of the 
effectiveness/tolerability study (Study 2) with RCT results and the adverse events and 
suicide/self-harm studies (Studies 3 and 4) with other cohort studies. 
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9.5.11 Are propensity score approaches superior to traditional techniques? 
It has been argued that PSs are no better at managing confounding than traditional 
regression techniques (Biondi-Zoccai et al., 2011, Shah et al., 2005, Stukel et al., 2007). 
Even if this were the case, there are still fundamental benefits to PS analysis, beyond 
multivariable regression. The first benefit is the ability to synthesise succinctly several 
contributors of confounding together and to visualise the distribution of PSs across 
exposure statuses – this allows the researcher to understand how comparable two (or 
more) groups may be in terms of baseline characteristics. The second benefit is the ability 
to add more parameters to a model than multivariable regression and therefore adjust for 
more confounders without model instability. The third is their intuitive appeal as a quasi-
randomised adjustment method  (Biondi-Zoccai et al., 2011). Other authors still maintain 
that PS models outperform multivariable models. Simulation studies show that quintiles of 
PS give results closer to the true marginal treatment effect than logistic regression 
(Martens et al., 2008), and that PSs are less biased, more robust and more precise than 
logistic regression when the number of outcome events per confounder is low (Cepeda et 
al., 2003). 
9.5.12 Limitations related to study design 
The mortality/morbidity study (Study 1) used a classical regression approach to examine 
the morbidity and mortality in BPD. The other studies compared individuals treated with 
lithium, valproate, olanzapine or quetiapine monotherapy. Over the majority of the study 
period these medications were recommended as first-line treatments (National Institute for 
Health and Care Excellence, 2006). The main reason for designing the studies in this way 
was to minimise the potential for confounding by indication. Therefore I did not include a 
group receiving non-treatment or a group co-prescribed lithium and valproate, which 
would have been more likely to have underlying differences based on compliance and 
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illness severity (amongst other things). Additionally, at the point of designing these studies 
(before the NICE 2014 update (National Institute for Health and Care Excellence, 2014)), 
this was a real clinical dilemma facing psychiatrists and their patients: which drug to choose 
given that NICE considers them equal. A potential limitation of this approach, however, is 
that a large number of people with BPD are not prescribed monotherapy of one of these 
drugs, and thus their data were not included in any analysis. Additionally, to have large 
enough groups of individuals treated with each drug I had to start follow-up in 1995, which 
was before the first use of olanzapine and quetiapine for BPD (1997 and 1998 respectively) 
(Hayes et al., 2011). This means that clinical choice, and therefore clinical equipoise was not 
the same at the start and end of the study. It is unclear if clinician drug preference based on 
clinical presentation changed over this time; however, all of these factors (or their proxies) 
are included in the PS.    
9.6 Bipolar disorder now and in the future 
9.6.1 Is bipolar disorder becoming more common? 
It has been stated that in clinical practice the diagnosis of BPD has become more 
commonplace, that this is due to the introduction of BPD II (a new diagnosis in DSM-IV), 
and perhaps in part because of the marketing of SGAs and anticonvulsants as specific 
treatments for BPD (Ostacher et al., 2016). This is supported by studies showing rapid 
increases in rates of diagnosis in young people in the US (Moreno et al., 2007). However, 
Global Burden of Disease data do not endorse this argument and suggest that despite 
evidence of an approximately 50% increase in prevalent cases worldwide between 1990 
and 2013, the age-standardised prevalence remains stable at 0.7% (and all differences are 
explained by demographic shifts in population size and age composition) (Ferrari et al., 
2016). We previously found relatively stable incident recording of BPD in THIN (Hardoon et 
  248 
al., 2013).  Despite this, globally by 2013, years lived with disability in BPD was comparable 
with those of more prevalent conditions such as asthma or Alzheimer’s disease (over 100 
per 100,000) (Ferrari et al., 2016).  
What does seem apparent is that there is a growing interest in BPD from the general public 
and individuals experiencing mental health problems, with a lower level of stigma 
associated with BPD than other SMI (Chan and Sireling, 2010), perhaps related to the idea 
that BPD is associated with creativity (Kyaga et al., 2013, MacCabe et al., 2010). 
9.6.2 Underfunded and under researched 
In both clinical and research terms, BPD has been overlooked relative to other physical and 
mental health problems. In general, it is recognised that mental health problems receive a 
tiny proportion of global annual research budgets (Young, 2006).  
 
In relation to schizophrenia, Clement et al. found that for every one BPD publication on 
Medline there are 4.4 for schizophrenia.  When only trials are taken into account this ratio 
increases to 1:7.6 (Clement et al., 2003). More recently it has been shown that investment 
in BPD research his a tenth of that in schizophrenia (Goodwin and Geddes, 2007). It has 
been argued that this disparity may be due to clinicians’ and researchers’ perception of the 
seriousness of BPD. Historically there has been a feeling that schizophrenia represents a 
greater overall disease burden on individuals, highlighted by higher hospitalisation rates, 
poorer global functioning and greater economic costs (Craig et al., 2000, Das Gupta and 
Guest, 2002, Grossman et al., 1991). However, research that is more recent has suggested 
that this is not the case and reduced quality of life, healthcare costs and premature 
mortality are similar in both disorders (Dean et al., 2004, Hoang et al., 2013).  
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9.7 Future questions for bipolar disorder research  
9.7.1 Can early diagnosis improve functioning and reduce adverse long-term 
outcomes? 
Systematic, timely diagnosis of BPD remains a challenge. Potentially, an accurate diagnosis 
early in the illness course (ideally before the first episode of mania or hypomania) could 
help to prevent the long-term detrimental effects of the illness and inappropriate 
treatment. Changes to DSM-V and ICD-11 may help this (Phillips and Kupfer, 2013), as may 
the increased use of clinician and patient  rating scales, and more precise assessment of 
patients with depression for any symptoms or signs of (hypo)mania.   The potential impact 
of each of these approaches needs to be comprehensively assessed. Alternatives to 
categorical diagnostic approaches, such as Research Domain Criteria (Insel et al., 2010) and 
dimensional approaches (such as an affective disorders continuum)  (Angst, 2007) could 
feasibly redefine BPD in terms of pathophysiological processes (Vieta and Phillips, 2007). 
These approaches may enhance our understanding of the illness, suitable treatments and 
potential outcomes (Phillips and Kupfer, 2013). In particular, early and appropriate 
treatment could reduce the adverse outcomes studied in this thesis. 
9.7.2 Can staging models improve outcomes? 
Staging models, such as those developed for schizophrenia (incorporating prodrome, first 
episode and chronic phase) have only recently been proposed and developed for BPD 
(Grande et al., 2014, Vieta et al., 2011). Research has shown that psychosis staging is 
mirrored by anatomical brain and cognitive function changes and that treatment is 
improved by using stage specific strategies (McGorry et al., 2010).  For such models to be 
useful in BPD, they need to include occurrence of psychiatric comorbidities, medical 
disorders and risk factors. However, unlike schizophrenia, onset and longitudinal course of 
these elements remains poorly understood (Leboyer et al., 2012). Development and use of 
  250 
staging models, alongside stage specific treatment, has the potential to improve long-term 
outcomes.  
9.7.3 How do we better use the drugs that we have? 
As discussed in this thesis, pharmacological interventions have the potential to reduce the 
severity, and therefore disability in BPD. However, full lifetime remission is rare (American 
Psychiatric Association, 2013), and it has been estimated that even in a hypothetical 
situation where every individual with BPD received optimised evidence-based interventions 
only 40% of the burden would be averted (Andrews et al., 2004). This highlights the fact 
that although treatment strategies exist, these are far from ideal.  
There is now a body of evidence that suggests that lithium is the most effective mood 
stabiliser medication currently available. It has been argued that, with the exception of 
electroconvulsive therapy, lithium is the single most effective treatment in psychiatry 
(Shorter, 2009). However, naturalistic studies have shown that approximately 40% of those 
treated with lithium show no response, 30% will be partial responders and 30% excellent 
responders (Baldessarini and Tondo, 2000, Garnham et al., 2007). Currently there are no 
reliable ways of identifying responders early after drug initiation (Geoffroy et al., 2014). 
Complicating this is the reduction in use of a drug that requires clinician skill to be safely 
managed. Increasingly, trainees in psychiatry have become untutored in lithium use and are 
uncomfortable prescribing it (Healy, 2008). Whilst I hope the studies in this thesis will 
reassure clinicians and patients of the benefits of lithium, and that the risks are lower than 
previously thought, increasing the safe use of lithium is likely to require a cultural shift.  
This shift could be supported by increased education, systems support for monitoring of 
blood levels and potentially provision of tools for identifying likely responders and 
individuals at risk of adverse effects before they develop.  
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9.7.4 Could a better understanding of mechanism of lithium help develop new 
treatments? 
Lithium is also of interest to those considering the development of new drug treatments in 
BPD, because it remains uniquely effective in this condition (whereas other psychiatric drug 
treatments are effective across a range of disorders). As such, understanding its mechanism 
of action may be crucially important to the identification of pharmacological targets. Detail 
of lithium’s biochemical effects could be the focus of a thesis in itself, but it is interesting to 
consider the pharmacological properties of lithium that are not present in antipsychotic or 
anticonvulsant medications.  Lithium’s physiological effects are multiple, and it remains 
unclear which are vital for therapeutic efficacy. Additionally, studies of the action of lithium 
are also linked to studies of the pathophysiology of BPD.  
As it currently stands, lithium’s cellular level effects can be grouped onto: 1) Regulation of 
cell membrane transport, 2) regulation of ion distribution, 3) Regulation of cell membrane 
properties, 4) intracellular signalling regulation and, 5) neurotransmitter regulation. These 
properties interact as multilevel cascades (Alda, 2015). Perhaps, more usefully, we can 
consider the mechanisms that appear to mediate the relationship between molecular level 
and clinical level effects. These have been defined as neuroprotection, chronobiology and 
neuronal activity stabilisation (Alda, 2015). There is growing evidence that lithium is 
neurotropic, and that this suppresses stress effects and restores plasticity lost through 
illness (Gray and McEwen, 2013, Hajek et al., 2012, Moore et al., 2000). This has also led to 
research into the potential positive effects of lithium in individuals with dementia 
(Sutherland and Duthie, 2015) and neurodegenerative diseases such as multiple sclerosis, 
progressive supranuclear palsy and multiple system atrophy (Saccà et al., 2013). Sleep 
deprivation, jet lag and time zone shifts, and daytime light levels are associated with BPD 
relapse. Lithium modifies these biological rhythms, although mechanisms are not well 
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understood  (McCarthy and Welsh, 2012, Seggie et al., 1983). Finally, lithium is able to 
inhibit excessive neuronal activity whilst augmenting reduced activity, mostly via signal 
transduction and transcription factors (Jope, 1999). 
Additionally, work has begun on the task of identifying more immediate proxies for good 
lithium response, which could be employed in future drug development. The most 
promising target appears to be mood instability (Geddes and Miklowitz, 2013), but studies 
are also collecting measures of impulsivity, physical activity, sleep, gene expression and 
neural dynamics during magnetoencephalography and functional magnetic resonance 
imaging  (Saunders et al., 2016). 
9.8 Other research directions 
9.8.1 Study design 
PS studies are accessible and easy to communicate, they are likely to become increasingly 
important with the further expansion and linkage of EHR, where many covariates will be 
available. High-dimensional PS studies, using hundreds or thousands of covariates will 
become possible  (Schneeweiss et al., 2009) and PS models may be improved by machine 
learning techniques (Lee et al., 2010). However, these techniques are not without their 
problems. It is clear that even simpler PS approaches are not well defined (Chapter 2) and  
there is evidence that a wide range of estimates can result from apparently minor changes 
in model build and implementation strategy (Hill et al., 2011). Further statistical work that 
clarifies the possible impact of covariate inclusion/exclusion is necessary. Additionally, it is 
unclear how approaches that include as many potential confounders as possible in a PS sit 
with casual models which warn of the possibility of increase confounding through over 
adjustment (backdoor colliders) (Greenland et al., 1999). Currently there appears to be no 
literature on this likely contradiction or how it should be managed. In addition, there is no 
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agreed approach to combining multiple imputation and PS estimation. Missing data is a 
major problem in EHR and for full utility in research robust statistical techniques to 
combine these methods will be necessary. Some advances have been made in this field 
since I conduced the studies in this thesis (Leyrat et al., 2016, Mitra and Reiter, 2016).  
Other techniques for minimising confounding in observational studies exist and these may 
be useful in EHR studies. Nevertheless, these techniques also have methodological 
limitations and are potentially more complicated to apply and communicate. Instrumental 
variables have been used in a number of EHR studies, with GP prescribing practice used 
most frequently as an instrument (associated with exposure, only associated with outcome 
through its effect on the exposure and not associated with any confounding factors) (Davies 
et al., 2013, Thomas et al., 2013b). However, there is evidence that in some situations 
instrumental variable analysis will be more biased than traditional multivariable techniques 
(Davies, 2015, Garabedian et al., 2014) and in particular clinician prescribing preference can 
fail to perform effectively as an instrument, as there may be unidentified instrument-
outcome confounders (Garabedian et al., 2014, Kollhorst et al., 2016). Other approaches 
such as bootstrapping, exact methods, classification and regression tree analyses, mixed 
effect and Bayesian methods have been far less widely used (Biondi-Zoccai et al., 2011).  
9.8.2 Electronic health records 
Current EHR systems are primarily clinical in focus. This underestimates their true potential 
for research and advances in public health practice and policy, comparative effectiveness 
studies and trial recruitment and passive follow-up  (Haneuse and Daniels, 2016, Kukafka et 
al., 2007). There may be simple advances, which make them suitable for multiple research 
purposes, without compromising (and potentially improving) functionality. Widespread 
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linkage of data sources would improve validity and provide further detail about potential 
confounders. Linkage to genetic and imaging databanks would be particularly powerful.  
9.9  Dissemination  
At the time of completion of this thesis, modified versions of the following chapters had 
been published: 
i) A version of the meta-analysis in Chapter 3 had been published in Acta Psychiatrica 
Scandinavica (Appendix 4.1) 
ii) A version of the mortality/morbidity study (Study 1: Chapter 4) had been published 
in British Journal of Psychiatry  
iii) A version of the effectiveness/tolerability study (Study 2: Chapter 6) had been 
published in World Psychiatry (Appendix 4.2) 
iv) A version of the adverse effects study (Study 3: Chapter 7) had been published in 
PLoS Medicine (Appendix 4.3)  
v) A version of the suicide/self-harm study (Study 4: Chapter 8) had been published in 
JAMA Psychiatry (Appendix 4.4) 
 
Additionally I presented elements of this research at conferences internationally: 
i) A poster of the results of the meta-analysis (Chapter 3) was presented at the Royal 
College of Psychiatrists’ International Congress in July 2015, where I won Junior 
Researcher of the Year 
ii) The results of Study 2 (Chapter 6) and Study 3 (Chapter 7) were presented at 
Eleventh International Conference  of the European Network for Mental Health 
Service Evaluation in October 2015 
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iii) A poster of the results of Study 3 (Chapter 7) was presented at the 18th Annual 
Conference of the International Society for Bipolar Disorder in July 2016 
iv) An oral presentation of the results of Study 4 (Chapter 8) was presented at the 
Royal College of Psychiatrists’ International Congress in July 2016, where I won the 
Research prize 
v) An oral presentation of the results of Study 2, Study 3 and Study 4 was presented 
at the Royal College of Psychiatrists’ International Congress in June 2017 
 
Dissemination to a wider audience, including the members of the public included:   
i) Study 3 (Chapter 7) was the subject of an article in The Guardian (Appendix 5.1) 
and a news piece on BBC Radio Wales  
ii) The meta-analysis in Chapter 3 was the subject of a Mental Elf blog (Appendix 5.2) 
iii) Study 4 (Chapter 8) was the subject of a Mental Elf blog (Appendix 5.3) 
 
My aim is to continue to disseminate the findings of this thesis. I have been invited to join 
the International Group for the Study of Lithium Treated Patients and I will use this network 
to build future research collaborations and communicate these results.  
9.10  Conclusions 
This thesis set out to determine the impact of receiving a BPD diagnosis on mortality and 
morbidity, and the potential for outcomes to be modified by mood stabiliser medication. 
Included studies provide new evidence for a widening mortality gap between individuals 
with BPD and the general population, and highlight the persistent elevated risk of suicide 
and self-harm in this population. Additionally, I found that patients with BPD, unlike those 
with schizophrenia have no increase in CVD deaths, but increased rates of CVD diagnoses 
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relative to the general population. All other causes of death are elevated in BPD, relative to 
the general population. These findings should be used to further the argument that parity 
of esteem and parity of care is not yet a reality in the UK. 
Maintenance mood stabiliser medication has the potential to influence the risk of these 
adverse events, but before the studies in this thesis were completed the impact had not 
been well quantified. RCTs do not show resounding superiority of any one mood stabiliser. 
This thesis includes the first study to show that lithium monotherapy is potentially more 
effective and tolerable than valproate, olanzapine or quetiapine. I have quantified, for the 
first time: 1) the relative rates of renal impairment, thyroid disease and hypercalcemia; 
which are all elevated in individuals taking lithium relative to the other drugs examined,  2) 
the relative rates of severe CKD, T2DM, CVD and hepatotoxicity; which all occur at similar 
rates in people taking lithium, valproate, quetiapine or olanzapine, 3) the rate of 
hypertension; which is greater in those prescribed olanzapine, and 4) the relative rate of 
weight gain; which is greater in alternatives to lithium. Additionally, I examined the 
potential anti-suicidal effects of lithium and found that individuals prescribed this drug have 
lower rates of self-harm and accidental injury than patients taking other mood stabilisers.  I 
hope that this information can be used by clinicians, in collaboration with patients, to 
balance the potential risks and benefits of currently available and recommended treatment 
options.  
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2. Code lists for bipolar disorder and schizophrenia 
 
Diagnosis Description Read code 
Bipolar disorder Unspecified bipolar affective disorder E117.00 
 Unspecified bipolar affective disorder,severe with 
psychosis E117400 
 Manic psychoses E11..13 
 Recurrent manic episodes, severe without mention 
psychosis E111300 
 Mixed bipolar affective disorder E116.00 
 [X]Recurrent manic episodes Eu31y12 
 [X]Bipolar affective disorder, current episode mixed Eu31600 
 Bipolar affective disorder, currently manic, mild E114100 
 Recurrent manic episodes, partial or unspecified 
remission E111500 
 Other and unspecified manic-depressive psychoses E11y.00 
 [X]Manic episode Eu30.00 
 [X]Bipolar II disorder Eu31y11 
 [X]Bipolar affect disorder cur epi mild or moderate 
depressn Eu31300 
 Unspecified bipolar affective disorder, unspecified E117000 
 [X]Bipolar affect disorder cur epi manic wout 
psychotic symp Eu31100 
 Bipolar affective disorder, currently depressed, 
unspecified E115000 
 Mixed bipolar affective disorder, severe, without 
psychosis E116300 
 Mixed bipolar affective disorder, moderate E116200 
 Hypomanic psychoses E110.11 
 [X]Hypomania Eu30000 
 [X]Bipol aff disord, curr epis sev depress, no psychot 
symp Eu31400 
 Recurrent manic episode NOS E111z00 
 Manic-depressive - now depressed E115.11 
 Recurrent manic episodes, unspecified E111000 
 Unspecified bipolar affective disorder, NOS E117z00 
 Bipolar affective disorder, currently manic, full 
remission E114600 
 Single manic episode, moderate E110200 
 [X]Other bipolar affective disorders Eu31y00 
 Bipolar affective disorder, currently manic, 
moderate E114200 
 Other mixed manic-depressive psychoses E11y300 
 [X]Manic-depress psychosis,depressed 
type+psychotic symptoms Eu33312 
 Atypical manic disorder E11y100 
 [X]Bipolar affective disorder, unspecified Eu31z00 
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Bipolar disorder [X]Bipolar affective disorder, current episode 
hypomanic Eu31000 
 [X]Manic episode, unspecified Eu30z00 
 [X]Manic stupor Eu30213 
 [X]Bipolar disorder, single manic episode Eu30.11 
 Manic disorder, single episode NOS E110z00 
 Single manic episode in full remission E110600 
 Single manic episode in partial or unspecified 
remission E110500 
 Mixed bipolar affective disorder, unspecified E116000 
 Unspecified manic-depressive psychoses E11y000 
 Unspecified bipolar affect disord, partial/unspec 
remission E117500 
 Recurrent manic episodes E111.00 
 Bipolar affective disorder, now depressed, in full 
remission E115600 
 Manic-depressive - now manic E114.11 
 Single manic episode, severe without mention of 
psychosis E110300 
 Profile of mood states, bipolar ZRby100 
 Bipolar affect disord,currently manic, part/unspec 
remission E114500 
 Recurrent manic episodes, moderate E111200 
 Bipolar affect disord, now depressed, severe with 
psychosis E115400 
 [V]Personal history of manic-depressive psy ZV11112 
 [X]Mania with psychotic symptoms Eu30200 
 [X]Mania without psychotic symptoms Eu30100 
 [X]Mania with mood-congruent psychotic symptoms Eu30211 
 Recurrent manic episodes, mild E111100 
 Unspecified bipolar affective disorder, in full 
remission E117600 
 [X]Manic-depress psychosis,depressd,no psychotic 
symptoms Eu33213 
 Unspecified bipolar affective disorder, severe, no 
psychosis E117300 
 H/O: manic depressive disorder 146D.00 
 Bipolar affect disord, currently manic,severe with 
psychosis E114400 
 Bipolar affect disord, now depressed, part/unspec 
remission E115500 
 [X]Bipolar affect disorder cur epi manic with 
psychotic symp Eu31200 
 Bipolar affective disorder, currently depressed E115.00 
 Mixed bipolar affective disorder, NOS E116z00 
 Mixed bipolar affective disorder, severe, with 
psychosis E116400 
 Recurrent manic episodes, in full remission E111600 
 [X]Mania with mood-incongruent psychotic 
symptoms Eu30212 
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Bipolar disorder Bipolar affective disorder, currently manic, 
unspecified E114000 
 [X]Other manic episodes Eu30y00 
 Other and unspecified manic-depressive psychoses 
NOS E11yz00 
 Recurrent manic episodes, severe, with psychosis E111400 
 Bipolar affect disord, currently manic, severe, no 
psychosis E114300 
 [X]Bipolar affect dis cur epi severe depres with psyc 
symp Eu31500 
 Unspecified bipolar affective disorder, mild E117100 
 Mixed bipolar affective disorder, partial/unspec 
remission E116500 
 Single manic episode, unspecified E110000 
 Mixed bipolar affective disorder, in full remission E116600 
 Bipolar affective disorder, currently manic E114.00 
 Manic disorder, single episode E110.00 
 [X]Manic-depressive illness Eu31.11 
 Bipolar affective disorder, currently depressed, NOS E115z00 
 Mixed bipolar affective disorder, mild E116100 
 [V]Personal history of manic-depressive psy ZV11111 
 [X]Manic-depressive psychosis Eu31.12 
 Unspecified bipolar affective disorder, moderate E117200 
 [X]Mainc-depressive reaction Eu31.13 
 Bipolar affective disorder, currently manic, NOS E114z00 
 Bipolar affective disorder, currently depressed, mild E115100 
 [X]Bipolar affective disorder, currently in remission Eu31700 
 Bipolar affective disorder, currently depressed, 
moderate E115200 
 Bipolar affect disord, now depressed, severe, no 
psychosis E115300 
 Bipolar psychoses E11..11 
 Single manic episode, mild E110100 
 Single manic episode, severe, with psychosis E110400 
 [X]Bipolar affective disorder Eu31.00 
 [X]Mania NOS Eu30z11 
Schizophrenia  Acute exacerbation subchronic  schizophrenia E107300 
 Acute exacerbation of chronic paranoid 
schizophrenia E103400 
 Schizophrenic language ZS7C611 
 Cyclic schizophrenia E107.11 
 [X]Hebephrenic schizophrenia Eu20100 
 [X]Schizophrenifrm psychos NOS Eu20y13 
 [X]Schizophreniform disord NOS Eu20y12 
 Latent schizophrenia E105.00 
 Acute exacerbation of subchronic hebephrenic 
schizophrenia E101300 
 [X]Pseudoneurotic schizophrenia Eu21.16 
 [X]Schizophrenic reaction Eu23214 
 [X]Schizotypal personality disorder Eu21.18 
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Schizophrenia Hebephrenic schizophrenia in remission E101500 
 Other schizophrenia E10y.00 
 [X]Paraphrenia - late Eu22013 
 [V]Personal history of schizophrenia ZV11000 
 Latent schizophrenia in remission E105500 
 Other schizophrenia NOS E10yz00 
 Schizophrenic disorders E10..00 
 Simple schizophrenia NOS E100z00 
 [X]Simple schizophrenia Eu20600 
 Simple schizophrenia E100.00 
 [X]Undifferentiated schizophrenia Eu20300 
 Paranoid schizophrenia NOS E103z00 
 [X]Prepsychotic schizophrenia Eu21.14 
 Chronic latent schizophrenia E105200 
 [X]Mixed schizophrenic and affective psychosis Eu25212 
 [X]Disorganised schizophrenia Eu20111 
 Chronic paranoid schizophrenia E103200 
 Paranoid schizophrenia E103.00 
 [X]Pseudopsychopathic schizophrenia Eu21.17 
 Latent schizophrenia NOS E105z00 
 Unspecified latent schizophrenia E105000 
 [X]Restzustand schizophrenic Eu20512 
 [X]Latent schizophrenia Eu21.13 
 Schizophrenia NOS E10z.00 
 H/O: schizophrenia 1464 
 [X]Paranoid schizophrenia Eu20000 
 [X]Residual schizophrenia Eu20500 
 [X]Schizophrenia, schizotypal and delusional 
disorders Eu2..00 
 [X]Schizophrenic catalepsy Eu20212 
 Atypical schizophrenia E10y000 
 [X]Schizophrenic catatonia Eu20213 
 Acute exacerbation of subchronic latent 
schizophrenia E105300 
 Subchronic paranoid schizophrenia E103100 
 Acute exacerbation of chronic catatonic 
schizophrenia E102400 
 [X]Cycloid psychosis with symptoms of schizophrenia Eu23112 
 [X]Other schizophrenia Eu20y00 
 [X]Chronic undifferentiated schizophrenia Eu20511 
 [X]Borderline schizophrenia Eu21.12 
 Cenesthopathic schizophrenia E10y.11 
 [X]Catatonic schizophrenia Eu20200 
 Hebephrenic schizophrenia E101.00 
 Subchronic schizophrenia E100100 
 [X]Atypical schizophrenia Eu20311 
 [X]Schizophreniform psychosis, manic type Eu25012 
 Acute exacerbation of chronic latent schizophrenia E105400 
 Acute exacerbation of chronic hebephrenic 
schizophrenia E101400 
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Schizophrenia [X]Prodromal schizophrenia Eu21.15 
 Catatonic schizophrenia in remission E102500 
 [X]Latent schizophrenic reaction Eu21.11 
 [X]Schizophrenia, unspecified Eu20z00 
 [X]Paraphrenic schizophrenia Eu20011 
 Restzustand - schizophrenia E106.11 
 Acute exacerbation of subchronic paranoid 
schizophrenia E103300 
 Acute exacerbation of subchronic catatonic 
schizophrenia E102300 
 Acute schizophrenic episode E104.00 
 Coenesthopathic schizophrenia E10y100 
 Schizo-affective schizophrenia NOS E107z00 
 Catatonic schizophrenia NOS E102z00 
 Acute exacerbation of subchronic schizophrenia E100300 
 [X]Cyclic schizophrenia Eu25211 
 Chronic schizophrenic E100200 
 [X]Cenesthopathic schizophrenia Eu20y11 
 [X]Schizophrenic flexibilatis cerea Eu20214 
 Residual schizophrenia E106.00 
 Unspecified hebephrenic schizophrenia E101000 
 Hebephrenic schizophrenia NOS E101z00 
 [X]Schizophreniform psychosis, depressive type Eu25112 
 Catatonic schizophrenia E102.00 
 Paranoid schizophrenia in remission E103500 
 Subchronic catatonic schizophrenia E102100 
 Unspecified paranoid schizophrenia E103000 
 Unspecified schizophrenia E100000 
 Unspecified catatonic schizophrenia E102000 
 Schizophrenia in remission E100500 
 Chronic catatonic schizophrenia E102200 
 [X]Post-schizophrenic depression Eu20400 
 Chronic hebephrenic schizophrenia E101200 
 Subchronic hebephrenic schizophrenia E101100 
 [X]Schizophrenia Eu20.00 
 Schizophrenia simplex E100.11 
 Acute exacerbation of chronic schizophrenia E100400 
 Subchronic latent schizophrenia E105100 
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3. Meta-analysis search terms  
3.1 A systematic review and meta-analysis of mortality in individuals with bipolar 
disorder 
Search in PsychINFO, Medline and EMBASE on 30.7.14 
**All MeSH terms auto exploded 
Medline (OVID version) 
Exposure: BIPOLAR DISORDER (MeSH) or “bipolar illness” “manic depression” “bipolar 
disorder” “bipolar affective disorder” “manic” “mania” “hypomania” (keyword) 
AND 
Outcome: MORTALITY, LIFE EXPECTANCY, “CAUSE OF DEATH”,  DEATH (MeSH) or “life 
expectancy” “mortality” “death” “mortality rate” “standardised mortality ratio 
““standardized mortality ratio “ (keyword) 
N=699 
 
Embase (including Embase classic) 
Exposure: BIPOLAR DISORDER, BIPOLAR MANIA, MANIA, “MIXED MANIA  AND 
DEPRESSION” (MeSH) or “bipolar illness” “manic depression” “bipolar disorder” “bipolar 
affective disorder” “mania” “hypomania” “manic” (keyword) 
AND 
Outcome: MORTALITY, LIFE EXPECTANCY, DEATH, STANDARDIZED MORTALITY RATIO, 
(MeSH) or “life expectancy” “mortality” “death” “mortality rate” “standardised mortality 
ratio ““standardized mortality ratio “ (keyword) 
N=611 
 
Psychinfo 
Exposure: BIPOLAR DISORDER, MANIA, HYPOMANIA (MeSH) or “bipolar illness” “manic 
depression” “bipolar disorder” “bipolar affective disorder” “manic” “mania” “hypomania 
(keyword) 
AND 
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Outcome: MORTALITY, LIFE EXPECTANCY, “DEATH AND DYING”, MORTALITY RATE (MeSH) 
or “life expectancy” “mortality” “death” “standardised mortality ratio“ “standardized 
mortality ratio “ (keyword) 
N=3196 
 
After combining databases and removal of duplicates N=3522 
 
3.2 Systematic review and network meta-analysis comparing the effectiveness and 
tolerability of lithium, valproate, olanzapine and quetiapine as maintenance medication 
in bipolar disorder 
Search in the Cochrane Central Register of Controlled Trials on 9.4.2015: 
 
#1 MeSH descriptor: [Bipolar Disorder] explode all trees (N=1624) 
 
#2 (((bipolar or bi?polar or bi polar) near/5 (disorder* or depress*)) or ((cyclothymi* or 
rapid or ultradian) near/5 cycl*) or hypomani* or mania* or manic* or "mixed episode*" or 
rcbd):ti or (((bipolar or bi?polar or bi polar) near/5 (disorder* or depress*)) or ((cyclothymi* 
or rapid or ultradian) near/5 cycl*) or hypomani* or mania* or manic* or "mixed episode*" 
or rcbd):ab (N=3499) 
 
#3 #1 or #2 (N=3865) 
#4 (continuation or "long term" or maintenance or prevent* or prophylactic or prophylaxis 
or recurrence or relapse or relapses):ti or ("long term" or maintenance or prevent* or 
prophylaxis or recurrence or relapse or relapses):ab (N=153959) 
 
#5 ("valproic acid" or "2 propylpentanoate" or "2 propylpentanoic acid" or "2 
propylpentanoic acid" or "2 propylvalerate sodium" or "2 propylvaleric acid" or "2 
propylvaleric acid sodium" or "alpha propylvaler*" or apilepsin* or convulex or 
convulsofin* or depacon or depakene or depakin* or depakote or deprakin* or "di n 
propylacetat*" or "di n propylacetat* sodium" or "di n propylacetic acid" or "dipropyl 
acetate" or "dipropyl acetic acid" or dipropylacetat* or dipropylacetatic or diprosin* or 
divalproate or divalproex or epilim or epival or ergenyl or everiden* or goilim or labazen* 
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or leptilan* or leptilanil* or mylproin* or "myproic acid" or "n dipropylacetic acid" or orfiril 
or orlept or propymal* or "sodium 2 propylpentanoat*" or "sodium 2 propylvalerat*" or 
"sodium di n propyl acetate" or "sodium di n propylacetat*" or "sodium dipropyl acetate" 
or "sodium dipropylacetate" or "sodium n dipropylacetate" or valerin* or valparin* or 
valpro or valproate or vupral) (N=1948) 
 
#6 (olanzapin* or lanzac or midax or olansek or olzapin or rexapin or zalasta or zolafren or 
zydis or zypadhera or zyprex*) (N=2560) 
 
#7 (lithium* or camcolit or candamid* or carbolith or carbolitium or cibalith or contemnol* 
or dilithium or eskalith or hypnorex or "li salt" or limas or linthane or liskonium or liskonum 
or litarex or lithane or lithiofor or lithionit or lithiophor or lithobid or lithocarb or lithonate 
or lithotabs or maniprex or mesin or micalith or neurolepsin or neurolithium or plenur or 
priadel or quilinormretard or quilonorm or quilonum or teralithe or theralite or 
theralithe):ti,ab,kw (N=2088) 
#8  (quetiapine* or ketipinor or quepin or seroquel or tienapin*).ti,ab.  (N=1310) 
#9 #3 and #4 (N=835) 
#10 #5 or #6 or #7 or #8 (N=6600) 
#11 #9 and #10 (N=458) 
After removal of non-RCTs, N=396, After removal of duplicates N= 382 
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4.3 Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood 
Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study 
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5. Media 
5.1 The Guardian (online 14.8.2016, print 15.8.2016) – Lithium should be more widely 
used for bipolar disorder, researchers say 
 
 
…The lead author behind the research told the Guardian that widespread “lithium stigma” 
among patients is leading to them receiving the wrong treatment and ending up admitted 
to hospital unnecessarily because their condition is not as well controlled as it could be. 
 
“Lithium is a drug with a bad reputation. It is seen by patients, and some psychiatrists, as a 
dangerous drug. People rightly have suspicions about it. Patients say that the downsides 
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include emotional numbing – feeling that you aren’t connected with your feelings – as well 
as tremors,” said Dr Joseph Hayes, a psychiatrist at University College London. 
 
But lithium’s reputation is largely misplaced and based on the experiences of patients from 
the 1960s to the 1980s who were given too large a dose of the drug, he added. The new 
research, published in the medical journal PLOS Medicine, found that the side-effects of the 
mood-stabilising alternatives used by most patients are either the same as or worse than 
lithium, Hayes said. 
 
The paper, co-written by Hayes and four colleagues from UCL and Oxford University, 
concluded that: “Lithium remains an important treatment for individuals with bipolar 
disorder.” It accepts that “there is clear evidence that its use is associated with a number of 
a owever, it adds: “These risks need to be offset with the potentially superior effectiveness 
and anti-suicidal benefits of the drug compared to other treatment options.” 
 
The researchers studied a nationally representative sample of 6,671 patients across the UK 
who were treated for bipolar disorder between 1995 and 2013. Of those, 2,148 had taken 
lithium, 1,670 had used valproate, 1,477 had been on olanzapine and 1,376 had taken 
quetiapine. They experienced side-effects including chronic kidney disease, thyroid disease, 
weight gain and high blood pressure. 
 
The researchers’ analysis bore out one of the two main criticisms of lithium, but found the 
other to be baseless. They found that patients on lithium had a higher risk of suffering 
kidney function problems and developing hypothyroidism or hyperthyroidism and also 
hypercalcemia. However, none of the drugs caused more severe kidney problems. 
 
Meanwhile, lithium patients were less likely to put on weight than patients on the other 
drugs. While 15%-20% of those on the three other drugs were more likely to gain more 
than 15% of their body weight, just 10% of those on lithium put on the same amount of 
extra pounds. Those on olanzapine added the most weight and experienced high blood 
pressure as a result. 
 
Separate research has shown that patients on the other three medications are 40% more 
likely to harm themselves than those on lithium. Bipolar disorder carries one of the highest 
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rates of suicide of any mental illness, alongside schizophrenia and alcohol and drug 
addiction. 
 
The very limited use of lithium is despite the National Institute for Health and Care 
Excellence (Nice) advising in 2014 that it should be the standard treatment for bipolar 
disorder, which is also known as manic depression and is characterised by manic highs and 
bouts of depression. That superseded its previous view, outlined in 2006, that any of the 
four drugs were useful first lines of treatment for the condition, which affects about one in 
100 people. 
 
“Lithium stigma, which includes some people in the psychiatric community, leads to people 
using drugs that are less effective [than lithium]. To me as a doctor that’s a big worry 
because my main aim is to help people to be well and if you aren’t doing that with the best 
“I think that many patients are missing out quite commonly on the best available 
treatment. That means that people end up in hospital more often than they need to and 
end up achieving less in their lives than they could do if they were on lithium. The high 
suicide rate with bipolar disorder should encourage greater use of lithium. There should be 
more sensible use of it.” 
 
Stephen Buckley, head of information at the charity Mind, said: “We welcome research 
which adds to our understanding of treatments and medications for people experiencing 
mental health problems, including bipolar disorder. But as with all areas of mental health 
there is still more research to be done. 
 
“Different people will find that different treatments help with managing their mental health 
problems. This may be medication, talking therapies, or a mixture of both.” 
 
 
5.2 The Mental Elf (online 2.6.15) – Premature mortality in bipolar disorder  
People with bipolar disorder are more likely to die at a younger age compared with the 
general population (Crump et al 2013; Hoang et al 2013). This is often due to high rates of 
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suicide and violent crime, which I blogged about last year, but may also be attributed to a 
heightened risk for physical health problems. 
 
In 2013, Rethink published a report (PDF) outlining a number of common factors which can 
lead to medical illnesses in this population such as smoking, side effects from antipsychotic 
medication, as well as poor physical health monitoring and stigma. 
 
Hayes and colleagues (2015) conducted a systematic review and meta-analysis of large 
observational studies to estimate the mortality rate of people with bipolar disorder 
compared with the general population. They looked at a range of different reasons for 
mortality which included unnatural causes, such as suicide and violent crime, as well as 
natural causes, such as circulatory and respiratory problems. 
 
Methods 
The authors looked for eligible articles by searching three electronic databases, scanning 
reference lists of included studies and tracking citations using the Cochrane Database of 
Systematic Reviews and Google Scholar. 
 
Studies were included if they reported data on deaths of people with a diagnosis of bipolar 
disorder (any criteria were accepted), due to any reason (all-cause mortality) or deaths due 
to specific reasons (cause-specific mortality) including: 
 Natural deaths 
 Unnatural deaths 
 Suicide 
 Other violent deaths 
 Infection 
 Neoplasm 
 Respiratory 
 Circulatory system disease 
Studies were excluded if they had fewer than 50 participants or were not standardised by 
age. 
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Standardised mortality ratios (SMRs) with their 95% confidence intervals were used to 
calculate the ratio of participants with bipolar disorder who died for each reason compared 
with the general population. SMRs greater than 1 indicate increased mortality in people 
with bipolar disorder compared with the general population, whereas those smaller than 1 
indicate decreased mortality in this population. 
 
Heterogeneity within each meta-analysis was assessed using the I2 index and chi-square 
test. Additionally a number of meta-regressions were carried out for all-cause mortality 
controlling for: decade of publication, cohort size, geographical region, mid-decade of 
cohort data collection and population type (inpatient or community based). Subgroup 
analyses where also performed for geographical region of study, patient population type 
and decade of the middle year of patient observation. 
 
Results 
In total, 31 studies of 305,859 people with bipolar disorder met the inclusion criteria. 
Studies were mainly inpatient cohorts (64%) and a large proportion were conducted in 
Scandinavian countries (45%). 
 
All-cause mortality 
The SMR for all-cause mortality was 2.05 (95% CI 1.98 to 2.23), ranging from 1.24 (95% CI 
0.83 to 1.17) to 4.65 (95% CI 1.27 to 11.91). Heterogeneity between studies was significant 
and high (p < 0.001, I2 =96.2%). 
 
Cause-specific mortality 
SMRs indicated increased rates of death for people with bipolar disorder for all cause-
specific mortality categories. Estimates were highest for death due to suicide (SMR=14.44) 
and unnatural causes (SMR=7.42). As for all-cause mortality, heterogeneity was significant 
and high for most categories except for infection and neoplasm which were relatively 
homogenous. 
 
Meta-regression and sub-group analyses 
Meta-regression analyses revealed that none of the following variables could account for 
the heterogeneity in findings: decade of publication, cohort size, geographical region, mid-
decade of cohort data collection or population type. Subgroup analyses also did not find 
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any effect on heterogeneity when stratifying for geographical region, population type and 
mid-decade of study. 
 
Strengths and limitations 
The authors carried out a thorough search strategy using multiple databases and tracking 
citations from reference lists of included studies. The Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement and the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) proposal for reporting were also followed. 
However, despite being an item in both reporting checklists, the authors did not carry out 
an assessment of study quality, which may have played a role in the high levels of 
heterogeneity found. 
 
Another limitation in this review is the fact that included studies only adjusted SMRs for age 
and gender. It therefore was not possible to assess whether other factors may have 
accounted for the increased rate of deaths or heterogeneity in findings. For example, 
people with a serious mental illness are more likely to smoke which may have had a 
significant impact on deaths due to respiratory problems. 
 
Summary 
Overall this review provides evidence that people with bipolar disorder have increased 
mortality rates compared with the general population. 
 
For all-cause mortality, there was a two-fold increase, whereas for suicide the SMR was as 
high as 14, which reflects previous results from large cohort studies. Although there was 
considerable heterogeneity in the summary estimate, all studies showed an increased risk 
for all-cause mortality of which only 4 out of 31 showed confidence intervals which crossed 
the line of no effect. These studies were all relatively small (74-440 participants) which 
explains the large confidence intervals. This finding indicates that we can be fairly certain 
that a true increased risk exists, although the precise estimate is still uncertain. 
 
An interesting finding was that when controlling for year of publication, there was no effect 
on estimates indicating no change in mortality ratios from 60 years ago with those 
completed recently. This highlights the need for improvements in physical and mental 
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health monitoring, smoking cessation programmes and the provision of clear information 
about side effects of medication. 
 
5.3 The Mental Elf (online 18.8.16) – Lithium for bipolar disorder: the best maintenance 
mood stabiliser protection against self-harm and suicide? 
The prevention of self-harm and suicide is one of the primary goals of treatment across all 
psychiatric disorders. Bipolar disorder has particularly high rates of completed suicides, so 
prevention of suicide is especially important for this disorder. The question of whether 
lithium (or another medical treatment) best prevents suicide in bipolar disorder has long 
been asked, and the preponderance of indirect evidence suggests that it does, although 
there is great uncertainty about the relative benefit of lithium compared to other drugs 
when the goal is to prevent self-harm, injury and suicide. 
 
The study under consideration here uses a different approach to answering the question 
about the relative benefit of different common treatments for bipolar disorder. It examines 
a large dataset derived from electronic health records (EHR) to determine whether 
exposure to lithium results in improved outcomes compared to sodium valproate, 
olanzapine or quetiapine, three commonly used acute and maintenance treatments for 
bipolar disorder. The authors used a propensity score to adjust for baseline clinical 
characteristics to try to make the study groups comparable. 
 
The great strength to this approach is that it examines real patients, not those selected for 
participation in a randomised trial. There is a possibility of bias, however, that may make 
results from EHR studies difficult to interpret. Confounding by indication (the fact that 
certain treatments tend to look harmful because they are given to sicker patients, or visa 
versa) is the biggest barrier to knowing whether the results of this study are biased. 
Perhaps the patients in one group were inherently different from those in the other groups 
and therefore a medication was chosen for that reason (rather than that the medication 
itself caused the difference). Let’s have a look at the study and its results. 
 
Methods 
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Cohort study using primary care EHRs (electronic health records) data collected between 
January 1, 1995, and December 31, 2013, by The Health Improvement Network (THIN) 
system. 
 
Individuals (aged 16 and older) with diagnoses of bipolar disorder were included in the 
study if they received 2 or more consecutive prescriptions for treatment lasting 28 days or 
longer of lithium, valproate, olanzapine or quetiapine. 
 
Patients were followed from the time of first prescription to 3 months after medication 
discontinuation (if that occurred). Patients prescribed any of the medications concurrently 
were excluded from the analyses. 
 
 Outcomes 
The primary outcome of interest was emergency department or primary care attendance 
for self-harm during the period of drug exposure and the 3 months afterward (including 
intentional poisoning, intentional self- injurious behaviour, and self-harm acts of uncertain 
intent). Secondary outcomes were unintentional injury (e.g., falls or motor vehicle crashes) 
seen in primary or secondary care or a record of the patient’s suicide during this period. 
 
 Propensity score 
Propensity score (PS) adjustment for sex, age at the start of treatment with the study drug, 
year of entry to the cohort, race/ethnicity, cardiovascular disease diagnosis before baseline, 
hypertension, chronic kidney disease at baseline, history of hypothyroidism or 
hyperthyroidism, history of liver disease, type 2 diabetes mellitus, epilepsy, alcohol use 
(grouped as none or low, moderate or heavy, or dependence), history of illicit drug use, 
smoking status, body mass index, anxiety symptoms or diagnosis before baseline, 
depressive symptoms or diagnosis before baseline, sleep disturbance before baseline, 
treatment with the study drug at or before baseline, and history of previous self-harm. 
 
Results 
The authors found a strong association between lithium prescribing and lower risk of self 
harm: 
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Of 14,396 individuals with a diagnosis of bipolar disorder, 6,671 were included in the 
cohort, with: 
 2,148 prescribed lithium 
 1,670 prescribed valproate 
 1,477 prescribed olanzapine 
 1,376 prescribed quetiapine 
 
Self-harm rates were lower in patients prescribed lithium compared with the other drugs: 
 Lithium (205; 95% CI, 175 to 241 per 10,000 person-years at risk [PYAR]) 
 Valproate (392; 95% CI, 334 to 460 per 10,000 PYAR) 
 Olanzapine (409; 95% CI, 345 to 483 per 10,000 PYAR) 
 Quetiapine (582; 95% CI, 489-692 per 10,000 PYAR). 
 
The authors also report: 
People prescribed lithium tended to be older than those taking other study drugs, with 
more years of follow-up data. These individuals were less likely to have records of 
depression, anxiety, or self-harm before entry into the cohort. Individuals prescribed 
lithium had no more contacts with primary care services during follow-up than individuals 
prescribed other drugs. 
 
This association [between lithium and self-harm] was maintained after PS adjustment 
(hazard ratio [HR], 1.40; 95% CI, 1.12 to 1.74 for valproate, olanzapine, or quetiapine vs 
lithium) and PS matching (HR, 1.51; 95% CI, 1.21 to 1.88). After PS adjustment, 
unintentional injury rates were lower for lithium compared with valproate (HR, 1.32; 95% 
CI, 1.10 to 1.58) and quetiapine (HR, 1.34; 95% CI, 1.07 to 1.69) but not olanzapine. The 
suicide rate in the cohort was 14 (95% CI, 9-21) per 10,000 PYAR. Although this rate was 
lower in the lithium group than for other treatments, there were too few events to allow 
accurate estimates. 
 
Is lithium viewed as a risky drug? 
Consistent with what has been reported in the literature, lithium is associated with lower 
rates of self-harm in patients with bipolar disorder compared to the rates found in patients 
treated with valproate, olanzapine, or quetiapine. There remains a great deal of 
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uncertainty, though, about all the differences as to why drugs were differentially prescribed 
and whether adjusting for them using propensity scores is adequate to statistically create 
groups that are as unbiased as those that would be arrived at through randomisation. 
 
Clinicians likely make very complex determinations of risk and benefit when making 
prescribing decisions. It is quite possible, though, that prescribers view lithium as a risky 
drug (because of its risk of both accidental and intentional overdose) compared to the 
other drugs examined in this study (whose risks in overdose are considerably lower), and 
therefore are prescribing lithium to lower risk patients to begin with. 
 
There certainly may be reasons for this. Lithium has a very narrow therapeutic window and 
must be monitored closely in the context of other medications (NSAIDs and diuretics, for 
example) and medical problems. Even if lithium is a drug that (as the authors suggest) 
reduces impulsive aggression, it is not likely being prescribed as readily to patients who are 
perceived by clinicians to have that problem in the first place. The baseline characteristics 
of the sample suggest as much: the sample, among other things, is older (younger people 
tend to be more impulsive), less likely to have had prior self-harm (in spite of being older 
and therefore having extra years before treatment to have harmed themselves), less likely 
to be cigarette smokers (itself associated with impulsiveness), and less likely to be anxious 
or depressed. 
 
All of this suggests that lithium is being prescribed to a lower risk group to begin, and 
makes it very difficult (even with propensity score matching) to conclude that it is the 
lithium itself, rather than baseline differences in groups, that is reducing the risk. The 
propensity score matching markedly reduces the differences in risk between the lithium 
group and the others, and it is difficult to know whether the differences would be even 
further diminished (towards the null) if all factors actually involved in prescribing 
differences (such as actual measures of impulsiveness) were included in the propensity 
score. 
 
Conclusion 
The authors conclude that: Lower rates of self-harm in those prescribed lithium may be due 
either to improved mood stabilization compared with other treatments or specific effects 
on impulsive aggression and risk taking. An alternative conclusion, not addressed by the 
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authors, is that even at baseline, lithium is being preferentially prescribed to a lower risk 
group. 
 
Implications 
How this study might be most appropriately used is to increase the dissemination of 
evidence about the importance of more widespread lithium use. I, for one, am for more 
lithium prescribing. There is much more randomised data supporting its use in general in 
bipolar disorder than for many other drugs, and its prescribing is, contrary to what the 
evidence might necessitate, declining. People are afraid of it. There are no data, in fact, to 
support its being associated with more death from all causes; to the contrary, the opposite 
is true. 
 
Lithium, in this cohort, is clearly being preferentially kept from more severely ill patients 
with higher risk of self-harm (as the baseline characteristics confirm), but much indirect 
evidence suggest that the converse should be true. Even if this study is not definitive, the 
preponderance of the evidence suggests that lithium mitigates risk of self-harm and suicide, 
and none, most importantly, suggests that it increases such risk. Continued education 
about lithium prescribing, the absolute and relative risks to patients of its use, and support 
to practitioners and patients alike must be stressed. 
 
There is also a call to actually do comparative trials. The Veterans Administration, in the 
United States, is currently undertaking the largest randomised trial of lithium for suicide 
prevention ever undertaken, expecting to randomise 1,862 Veterans with depression (from 
both bipolar disorder and major depressive disorder) to either adjunctive lithium or 
placebo, and to follow them for up to a year. When completed, this study has the potential 
to add considerable information regarding just the question we are asking today. 
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